<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="author" content="Tim Woelfle" />

<meta name="date" content="2024-04-21" />


<title>PRISMA &amp; AMSTAR in Cullis 2017: LLM (Claude-2) vs Human Consensus</title>

<meta property="og:title" content="PRISMA &amp; AMSTAR in Cullis 2017: LLM (Claude-2) vs Human Consensus" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script id="flexdashboard-navbar" type="application/json">
[{"title":"Home","href":"../index.html"},{"title":"Source Code","icon":"fa-github","href":"https://github.com/timwoelfle/Research-Assessment-AI/","align":"right"}]
</script>
<script src="lib/header-attrs-2.21/header-attrs.js"></script>
<script src="lib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="lib/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="lib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="lib/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<link href="lib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="lib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<link href="lib/value-box-accent-static-0.6.1/theme-cosmo-value-box.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/flexdashboard.min.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/theme-cosmo.css" rel="stylesheet" />
<script src="lib/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<link href="lib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="lib/datatables-binding-0.28/datatables.js"></script>
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="lib/dt-core-1.13.4/js/jquery.dataTables.min.js"></script>
<link href="lib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="lib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<style type="text/css">
/*
  CSS for flexdashboard.js' use of Sly(). The sizing/position of this CSS needs to be
  applied _before_ flexdashboard.js initializes, which is why this CSS has been pulled
  out from flexdashboard.scss and inlined in the document's head.
*/

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  text-align: left;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.sbframe-commentary {
  width: 300px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}
@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  PRISMA &amp; AMSTAR in Cullis 2017: LLM (Claude-2) vs Human Consensus
  <span class="navbar-author">
    Tim Woelfle &mdash; 2024-04-21
    </span>
</span>

<button id="navbar-button" type="button" class="navbar-toggle collapsed pull-right" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false,
      resize_reload: true
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.append(h1.contents());
        h3.insertBefore(h1);
        h1.detach();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if resize_reload is set to true and it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    if (_options.resize_reload) {
      $(window).on('resize', function() {
        if (_options.isMobile !== isMobilePhone() ||
            _options.isPortrait !== isPortrait()) {
          window.location.reload();
        }
      });
    } else {
      // if in desktop mode and resizing to mobile, make sure the heights are 100%
      // This enforces what `fillpage.css` does for "wider" pages.
      // Since we are not reloading once the page becomes small, we need to force the height to 100%
      // This is a new situation introduced when `_options.resize_reload` is `false`
      if (! _options.isMobile) {
        // only add if `fillpage.css` was added in the first place
        if (_options.fillPage) {
          // fillpage.css
          $("html,body,#dashboard").css("height", "100%");
        }
      }
    }
    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          var a = navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target);
          a.removeClass("nav-link").addClass("dropdown-item");
          li.append(a);
          menu.append(li);
        }
      } else {
        var li = $('<li class="nav-item"></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li class="nav-item"></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('data-bs-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover its inner contens, then detach it
    var h1 = wrapper.find('h1').first();
    var title = h1.contents();
    h1.detach();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      li.find("> a").removeClass("nav-link").addClass("dropdown-item");
      menu.append(li);
    } else {
      li.addClass("nav-item")
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a class="nav-link"></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = null;
      var iconSplit = icon.split(" ");
      if (iconSplit.length > 1) {
        iconSet = iconSplit[0];
        icon = iconSplit.slice(1).join(" ");
      } else {
        iconSet = icon.substring(0, dashPos);
      }
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.append(h2.contents());
      h3.insertBefore(h2);
      h2.detach();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.append(h3.contents());
      h3.detach();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.append(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingDom = heading.contents();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab" class="nav-link"></a>');
      a.append(headingDom);
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation" class="nav-item"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children()[activeTab]).tab("show");
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.contents();
    h3.detach();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.empty().append(blockquote.children('p:first-child').contents());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.empty().append(caption.contents());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.decodeURIComponent(window.location.hash);
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.decodeURIComponent(window.location.hash);
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from currently active tabs
    $('.navbar ul.nav .active').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").tab("show");
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.append(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var iconSplit = chartIcon.split(" ");
      if (iconSplit.length > 1) {
        iconLib = iconSplit[0];
        chartIcon = iconSplit.slice(1).join(" ");
      } else {
        var components = chartIcon.split("-");
        if (components.length > 1)
          iconLib = components[0];
      }
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // If valueBox(color=) was an accent color, this attr should
      // be populated with the accent color and the relevant CSS comes
      // in through HTML dependencies
      var dataColorAccent = valueOutput.attr('data-color-accent');
      var valueBoxClasses = "value-box-" + (["primary", "info", "danger", "warning", "success"].join(" value-box-"));
      if (dataColorAccent) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.addClass('value-box-' + dataColorAccent);
      }

      // If valueBox(color=) was a CSS color, these other data-color-*
      // attrs will be populated
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.css('background-color', dataColor);
      }
      var dataColorText = valueOutput.attr('data-color-text');
      if (dataColorText) {
        valueBox.find(".inner").css('color', dataColorText);
      }
      var dataColorIcon = valueOutput.attr('data-color-icon');
      if (dataColorIcon) {
        valueBox.find(".icon").css('color', dataColorIcon);
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});
</script>

<div id="dashboard-container">

<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<style type="text/css">
table {
  margin: auto;
  border-top: 1px solid #666;
  border-bottom: 1px solid #666;
}
table thead th { border-bottom: 1px solid #ddd; }
th, td { padding: 5px; }

pre {
  white-space: pre-wrap;
  word-break: keep-all;
}

/* Hack to make prompt-tab scrollable again */
div.level3.tab-pane .chart-stage {
  overflow: scroll;
}
</style>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="column" class="section level2" data-width="55">
<h2>Column</h2>
<div id="score-comparisons-of-112-publications" class="section level3">
<h3>Score comparisons of 112 publications</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-8e67fba7f623d78dcce2" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-8e67fba7f623d78dcce2">{"x":{"filter":"none","vertical":false,"fillContainer":true,"data":[["61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172"],["<a href='#61' title='Jump to individual results on the right'>Aikenhead 2011<\/a>","<a href='#62' title='Jump to individual results on the right'>Al-Hozaim 2010<\/a>","<a href='#63' title='Jump to individual results on the right'>Allen 2015<\/a>","<a href='#64' title='Jump to individual results on the right'>Allin 2015<\/a>","<a href='#65' title='Jump to individual results on the right'>Alzahem 2011<\/a>","<a href='#66' title='Jump to individual results on the right'>Apelt 2013<\/a>","<a href='#67' title='Jump to individual results on the right'>Aworanti 2014<\/a>","<a href='#68' title='Jump to individual results on the right'>Baker 2015<\/a>","<a href='#69' title='Jump to individual results on the right'>Berger 2012<\/a>","<a href='#70' title='Jump to individual results on the right'>Billingham 2010<\/a>","<a href='#71' title='Jump to individual results on the right'>Black 2013<\/a>","<a href='#72' title='Jump to individual results on the right'>Borruto 2010<\/a>","<a href='#73' title='Jump to individual results on the right'>Castagnetti 2010<\/a>","<a href='#74' title='Jump to individual results on the right'>Castagnetti 2016<\/a>","<a href='#75' title='Jump to individual results on the right'>Chan 2014 (Pediatr Surg Int)<\/a>","<a href='#76' title='Jump to individual results on the right'>Chan 2014 (J Pediatr Surg)<\/a>","<a href='#77' title='Jump to individual results on the right'>Chang 2015<\/a>","<a href='#78' title='Jump to individual results on the right'>Chen 2013<\/a>","<a href='#79' title='Jump to individual results on the right'>Corbett 2015<\/a>","<a href='#80' title='Jump to individual results on the right'>Cullis 2016<\/a>","<a href='#81' title='Jump to individual results on the right'>Cundy 2014 (BJU Int)<\/a>","<a href='#82' title='Jump to individual results on the right'>Cundy 2014 (J Pediatr Surg)<\/a>","<a href='#83' title='Jump to individual results on the right'>Cundy 2014 (Eur J Pediatr Surg)<\/a>","<a href='#84' title='Jump to individual results on the right'>Ding 2013<\/a>","<a href='#85' title='Jump to individual results on the right'>Dingemann 2014<\/a>","<a href='#86' title='Jump to individual results on the right'>Dingemann 2013<\/a>","<a href='#87' title='Jump to individual results on the right'>Ells 2015<\/a>","<a href='#88' title='Jump to individual results on the right'>Elyas 2010<\/a>","<a href='#89' title='Jump to individual results on the right'>Esposito 2014<\/a>","<a href='#90' title='Jump to individual results on the right'>Feng 2016<\/a>","<a href='#91' title='Jump to individual results on the right'>Feng 2015<\/a>","<a href='#92' title='Jump to individual results on the right'>Friedmacher 2011<\/a>","<a href='#93' title='Jump to individual results on the right'>Friedmacher 2012<\/a>","<a href='#94' title='Jump to individual results on the right'>Frongia 2013<\/a>","<a href='#95' title='Jump to individual results on the right'>Gallo 2012<\/a>","<a href='#96' title='Jump to individual results on the right'>Gosemann 2013<\/a>","<a href='#97' title='Jump to individual results on the right'>Graziano 2015<\/a>","<a href='#98' title='Jump to individual results on the right'>Guo 2011<\/a>","<a href='#99' title='Jump to individual results on the right'>Hall 2011<\/a>","<a href='#100' title='Jump to individual results on the right'>Healy 2015<\/a>","<a href='#101' title='Jump to individual results on the right'>Healy 2016<\/a>","<a href='#102' title='Jump to individual results on the right'>Heloury 2012<\/a>","<a href='#103' title='Jump to individual results on the right'>Huang 2015<\/a>","<a href='#104' title='Jump to individual results on the right'>Ishii 2014<\/a>","<a href='#105' title='Jump to individual results on the right'>Ishii 2015<\/a>","<a href='#106' title='Jump to individual results on the right'>Ito 2014<\/a>","<a href='#107' title='Jump to individual results on the right'>Jia 2011<\/a>","<a href='#108' title='Jump to individual results on the right'>Kapralik 2016<\/a>","<a href='#109' title='Jump to individual results on the right'>Kunz 2013<\/a>","<a href='#110' title='Jump to individual results on the right'>Landisch 2015<\/a>","<a href='#111' title='Jump to individual results on the right'>Lane 2010<\/a>","<a href='#112' title='Jump to individual results on the right'>Lansdale 2010<\/a>","<a href='#113' title='Jump to individual results on the right'>Lee 2010<\/a>","<a href='#114' title='Jump to individual results on the right'>LeeVan 2016<\/a>","<a href='#115' title='Jump to individual results on the right'>Liang 2011<\/a>","<a href='#116' title='Jump to individual results on the right'>Lishuang 2015<\/a>","<a href='#117' title='Jump to individual results on the right'>Livingston 2015<\/a>","<a href='#118' title='Jump to individual results on the right'>Mauritz 2013<\/a>","<a href='#119' title='Jump to individual results on the right'>Mauritz 2011<\/a>","<a href='#120' title='Jump to individual results on the right'>Mei 2011<\/a>","<a href='#121' title='Jump to individual results on the right'>Mullassery 2014<\/a>","<a href='#122' title='Jump to individual results on the right'>Nagler 2011<\/a>","<a href='#123' title='Jump to individual results on the right'>Narayanan 2013<\/a>","<a href='#124' title='Jump to individual results on the right'>Nasr 2010<\/a>","<a href='#125' title='Jump to individual results on the right'>Nasr 2013<\/a>","<a href='#126' title='Jump to individual results on the right'>Nataraja 2013<\/a>","<a href='#127' title='Jump to individual results on the right'>Nicolau 2011<\/a>","<a href='#128' title='Jump to individual results on the right'>Oliveira 2016<\/a>","<a href='#129' title='Jump to individual results on the right'>Oomen 2012<\/a>","<a href='#130' title='Jump to individual results on the right'>Parolini 2016<\/a>","<a href='#131' title='Jump to individual results on the right'>Parolini 2014<\/a>","<a href='#132' title='Jump to individual results on the right'>Peters 2013<\/a>","<a href='#133' title='Jump to individual results on the right'>Peycelon 2014<\/a>","<a href='#134' title='Jump to individual results on the right'>Pfistermuller 2015<\/a>","<a href='#135' title='Jump to individual results on the right'>Puligandla 2015<\/a>","<a href='#136' title='Jump to individual results on the right'>Reddy 2010<\/a>","<a href='#137' title='Jump to individual results on the right'>Romao 2012<\/a>","<a href='#138' title='Jump to individual results on the right'>Ross 2015<\/a>","<a href='#139' title='Jump to individual results on the right'>Ruttenstock 2010<\/a>","<a href='#140' title='Jump to individual results on the right'>Rynja 2011<\/a>","<a href='#141' title='Jump to individual results on the right'>Saldaa 2013<\/a>","<a href='#142' title='Jump to individual results on the right'>Sauerland 2010<\/a>","<a href='#143' title='Jump to individual results on the right'>Scholfield 2016<\/a>","<a href='#144' title='Jump to individual results on the right'>Sharp 2015<\/a>","<a href='#145' title='Jump to individual results on the right'>Shawyer 2014<\/a>","<a href='#146' title='Jump to individual results on the right'>Shawyer 2015<\/a>","<a href='#147' title='Jump to individual results on the right'>Shen 2015<\/a>","<a href='#148' title='Jump to individual results on the right'>Siddiqui 2011<\/a>","<a href='#149' title='Jump to individual results on the right'>Siminas 2015<\/a>","<a href='#150' title='Jump to individual results on the right'>Sklar 2014<\/a>","<a href='#151' title='Jump to individual results on the right'>Sola 2010<\/a>","<a href='#152' title='Jump to individual results on the right'>Symeonidis 2016<\/a>","<a href='#153' title='Jump to individual results on the right'>Tan 2016<\/a>","<a href='#154' title='Jump to individual results on the right'>Terui 2015<\/a>","<a href='#155' title='Jump to individual results on the right'>Thomson 2015<\/a>","<a href='#156' title='Jump to individual results on the right'>Thyoka 2013<\/a>","<a href='#157' title='Jump to individual results on the right'>van Dalen 2015<\/a>","<a href='#158' title='Jump to individual results on the right'>Vanden Berg 2016<\/a>","<a href='#159' title='Jump to individual results on the right'>van den Hondel 2014<\/a>","<a href='#160' title='Jump to individual results on the right'>Vernon-Roberts 2013<\/a>","<a href='#161' title='Jump to individual results on the right'>Wang 2013<\/a>","<a href='#162' title='Jump to individual results on the right'>Wayne 2015<\/a>","<a href='#163' title='Jump to individual results on the right'>Weih 2012<\/a>","<a href='#164' title='Jump to individual results on the right'>Wenk 2015<\/a>","<a href='#165' title='Jump to individual results on the right'>Wilkinson 2012<\/a>","<a href='#166' title='Jump to individual results on the right'>Wright 2013<\/a>","<a href='#167' title='Jump to individual results on the right'>Yang 2011<\/a>","<a href='#168' title='Jump to individual results on the right'>Yang 2013<\/a>","<a href='#169' title='Jump to individual results on the right'>Youssef 2016<\/a>","<a href='#170' title='Jump to individual results on the right'>Zani 2015<\/a>","<a href='#171' title='Jump to individual results on the right'>Zhao 2015<\/a>","<a href='#172' title='Jump to individual results on the right'>Zhu 2016<\/a>"],[0.814814814814815,0.666666666666667,0.740740740740741,0.777777777777778,0.62962962962963,0.851851851851852,0.851851851851852,0.740740740740741,0.740740740740741,0.592592592592593,0.666666666666667,0.555555555555556,0.740740740740741,0.481481481481481,0.814814814814815,0.555555555555556,0.407407407407407,0.703703703703704,0.740740740740741,0.740740740740741,0.666666666666667,0.703703703703704,0.777777777777778,0.666666666666667,0.740740740740741,0.777777777777778,0.851851851851852,0.740740740740741,0.666666666666667,0.592592592592593,0.777777777777778,0.407407407407407,0.666666666666667,0.888888888888889,0.740740740740741,0.592592592592593,0.740740740740741,0.740740740740741,0.666666666666667,0.703703703703704,0.814814814814815,0.925925925925926,0.518518518518518,0.740740740740741,0.851851851851852,0.592592592592593,0.62962962962963,0.777777777777778,0.481481481481481,0.888888888888889,0.777777777777778,0.666666666666667,0.814814814814815,0.777777777777778,0.740740740740741,0.296296296296296,0.555555555555556,0.777777777777778,0.703703703703704,0.62962962962963,0.777777777777778,0.62962962962963,0.814814814814815,0.777777777777778,0.592592592592593,0.703703703703704,0.777777777777778,0.777777777777778,0.777777777777778,0.777777777777778,0.851851851851852,0.777777777777778,0.703703703703704,0.555555555555556,0.666666666666667,0.777777777777778,0.740740740740741,0.666666666666667,0.555555555555556,0.777777777777778,0.703703703703704,0.925925925925926,0.592592592592593,0.666666666666667,0.814814814814815,0.518518518518518,0.592592592592593,0.740740740740741,0.62962962962963,0.62962962962963,0.555555555555556,0.740740740740741,0.814814814814815,0.518518518518518,0.592592592592593,0.851851851851852,0.740740740740741,0.62962962962963,0.777777777777778,0.851851851851852,0.555555555555556,0.851851851851852,0.777777777777778,0.555555555555556,0.62962962962963,0.592592592592593,0.518518518518518,0.888888888888889,0.555555555555556,0.777777777777778,0.592592592592593,0.814814814814815],[0.703947368421053,0.5,0.608695652173913,0.509090909090909,0.395973154362416,0.774530271398747,0.766738660907127,0.432432432432432,0.590909090909091,0.355748373101952,0.337874659400545,0.217391304347826,0.604602510460251,0.12093023255814,0.678571428571429,0.244755244755245,0.111111111111111,0.497674418604651,0.580931263858093,0.568493150684932,-0.0800000000000001,0.307692307692308,0.638392857142857,0.259146341463415,0.598726114649682,0.661087866108787,0.666666666666667,0.407523510971787,0.505091649694501,0.331081081081081,0.608695652173913,0.116564417177914,0.446469248291572,0.823144104803493,0.559440559440559,0.372093023255814,0.624254473161034,0.411214953271028,0.503067484662577,0.382857142857143,0.71875,0.857519788918206,0.135467980295567,0.604602510460251,0.758389261744966,0.341463414634146,0.293193717277487,0.406593406593407,0.180043383947939,0.817155756207675,0.6,0.343243243243243,0.703296703296703,0.664596273291925,0.407523510971787,-0.0490797546012274,0.217391304347826,0.479099678456592,0.552795031055901,0.358669833729216,0.504587155963303,0.0816326530612244,0.642857142857143,0.582474226804124,0.348684210526316,0.478260869565217,0.653846153846154,0.650862068965517,0.608695652173913,0.653846153846154,0.758928571428571,0.664596273291925,0.503448275862069,0.346774193548387,0.481876332622601,0.61520190023753,0.574324324324324,0.387909319899244,0.316455696202532,0.665289256198347,0.553719008264463,0,0.355748373101952,0.4375,0.6875,0.181818181818182,0.326530612244898,0.359322033898305,0.465346534653465,0.380733944954128,0.175572519083969,0.568493150684932,0.680851063829787,0.22,0.139130434782609,0.766738660907127,0.522727272727273,0.419354838709677,0.63431151241535,0.675675675675676,0.10989010989011,0.733990147783251,0.649350649350649,0.213592233009709,0.431578947368421,0.329571106094808,0.22,0.824675324675325,0.151832460732984,0.649350649350649,0.272058823529412,0.677033492822966],[0.727272727272727,0.727272727272727,0.636363636363636,0.636363636363636,0.909090909090909,0.545454545454545,0.727272727272727,0.636363636363636,0.818181818181818,0.909090909090909,0.727272727272727,0.636363636363636,0.454545454545455,0.181818181818182,0.818181818181818,0.545454545454545,0.454545454545455,0.545454545454545,0.636363636363636,0.545454545454545,0.636363636363636,0.818181818181818,0.818181818181818,0.545454545454545,0.636363636363636,0.636363636363636,0.909090909090909,0.454545454545455,0.636363636363636,0.636363636363636,0.454545454545455,0.727272727272727,0.727272727272727,0.636363636363636,0.818181818181818,0.545454545454545,0.545454545454545,0.363636363636364,0.636363636363636,0.727272727272727,0.727272727272727,0.818181818181818,0.454545454545455,0.636363636363636,0.636363636363636,0.454545454545455,0.363636363636364,0.545454545454545,0.454545454545455,0.545454545454545,0.818181818181818,0.545454545454545,0.636363636363636,0.636363636363636,0.727272727272727,0.454545454545455,0.454545454545455,0.545454545454545,0.454545454545455,0.545454545454545,0.727272727272727,0.818181818181818,0.818181818181818,0.545454545454545,0.636363636363636,0.545454545454545,0.454545454545455,0.727272727272727,0.636363636363636,0.636363636363636,0.454545454545455,0.545454545454545,0.636363636363636,0.363636363636364,0.727272727272727,0.727272727272727,0.636363636363636,0.636363636363636,0.363636363636364,0.636363636363636,0.636363636363636,0.909090909090909,0.545454545454545,0.545454545454545,0.636363636363636,0.545454545454545,0.636363636363636,0.636363636363636,0.727272727272727,0.818181818181818,0.454545454545455,0.818181818181818,0.818181818181818,0.363636363636364,0.545454545454545,0.636363636363636,1,0.727272727272727,0.636363636363636,0.909090909090909,0.454545454545455,0.727272727272727,0.636363636363636,0.363636363636364,0.727272727272727,0.545454545454545,0.636363636363636,0.818181818181818,0.545454545454545,0.727272727272727,0.818181818181818,0.636363636363636],[0.56,0.521739130434783,0.333333333333333,0.333333333333333,0.813559322033898,0.36046511627907,0.521739130434783,0.3125,0.576923076923077,0.819672131147541,0.492307692307692,0,-0.03125,-0.164705882352941,0.698630136986301,0.191176470588235,0.108108108108108,0.256756756756757,0.405405405405405,0.345238095238095,0.185185185185185,0.702702702702703,0.702702702702703,0.153846153846154,0.371428571428571,0.421052631578947,0.755555555555556,-0.081967213114754,0.333333333333333,0.278688524590164,0.0434782608695653,0.459016393442623,0.440677966101695,0.443037974683544,0.639344262295082,0.17910447761194,0.30379746835443,-0.203125,0.266666666666667,0.377358490566038,0.541666666666667,0.576923076923077,0.142857142857143,0.333333333333333,0.333333333333333,0,-0.0266666666666668,0.140625,0.142857142857143,0.30379746835443,0.576923076923077,0.17910447761194,0.36231884057971,0.333333333333333,0.440677966101695,0.175,0.0294117647058825,0.166666666666667,0.142857142857143,0.285714285714286,0.5,0,0.666666666666667,0.202898550724638,0.413333333333333,0.126984126984127,0.0434782608695653,0.440677966101695,0.323076923076923,0.333333333333333,0.12,0.266666666666666,0.185185185185185,2.22044604925031e-16,0.554054054054054,0.541666666666667,0.388888888888889,0.323076923076923,-0.0405405405405406,0.371428571428571,0.36231884057971,0,0.166666666666667,0.256756756756757,0.413333333333333,0.166666666666667,0.301587301587302,0.241379310344828,0.576923076923077,0.645161290322581,0.0704225352112676,0.721518987341772,0.65625,-0.166666666666667,0.0983606557377049,0.333333333333333,1,0.582278481012658,0.405405405405405,0.833333333333333,0.142857142857143,0.535211267605634,0.371428571428571,0.0493827160493827,0.45,0.166666666666667,0.343283582089552,0.65625,0.202898550724638,0.440677966101695,0.639344262295082,0.333333333333333]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th>Ref.<\/th>\n      <th>Author & Year<\/th>\n      <th>PRISMA agreement<\/th>\n      <th>PRISMA <\/th>\n      <th>AMSTAR agreement<\/th>\n      <th>AMSTAR <\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"t","order":[[0,"asc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":5,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"targets":4,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[2,3,4,5]}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render","options.columnDefs.3.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="score-heatmaps-prisma-amstar" class="section level3"
data-height="720">
<h3>Score heatmaps
(<a onclick="$('p.image-container')[0].style = 'background: url(&quot;../prisma_amstar/claude2_prisma_amstar/results/human_consensus_27_items.png&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = &quot;../prisma_amstar/claude2_prisma_amstar/results/human_consensus_27_items.png&quot;;" style="cursor: pointer">PRISMA</a>
/
<a onclick="$('p.image-container')[0].style = 'background: url(&quot;../prisma_amstar/claude2_prisma_amstar/results/human_consensus_11_items.png&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = &quot;../prisma_amstar/claude2_prisma_amstar/results/human_consensus_11_items.png&quot;;" style="cursor: pointer">AMSTAR</a>)</h3>
<p><img data-figure-id="fig1" src="../prisma_amstar/claude2_prisma_amstar/results/human_consensus_27_items.png" width="1536" onclick="window.open(this.src)" style="cursor: pointer"></p>
</div>
</div>
<div id="column-1" class="section level2 tabset" data-width="45">
<h2 class="tabset">Column</h2>
<div id="individual-results" class="section level3">
<h3>Individual results</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><a name='61'></a></p>
<div
id="aikenhead-2011-effectiveness-and-cost-effectiveness-of-paediatric-bariatric-surgery-a-systematic-review"
class="section level4">
<h4>61.
<a href='https://doi.org/10.1111/J.1758-8111.2010.00003.X' title='Open publication'>Aikenhead
2011: <i>Effectiveness and cost-effectiveness of paediatric bariatric
surgery: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 89.5%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">2
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span> The research question and inclusion criteria are clearly stated in the Methods section.

A2. "[No]"  
There is no mention of duplicate study selection or data extraction.

A3. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).&quot;</span> The authors searched PubMed, Embase, ISI Web of Science and the Cochrane Library. 

A4. "[Yes]" 
The authors state <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.5%):

Hand-searching of the bibliographies of articles and reviews identified was also conducted to ensure c' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Hand-searching of the bibliographies of articles and reviews identified was also conducted to ensure completeness of the initial electronic searches.&quot;</span>

A5. "[No]"
No list of included and excluded studies is provided.

A6. "[Yes]" 
Characteristics of included studies are provided in Appendix 3, Tables A1-A3.

A7. "[No]"
The methodological quality of included studies was not assessed.

A8. "[NA]"
Since quality was not assessed, it was not used in formulating conclusions.

A9. "[NA]"
No meta-analysis was performed. 

A10. "[No]"
Publication bias was not assessed.

A11. "[No]"
No statement about conflicts of interest is provided.

P1. "[Yes]"
The title <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Effectiveness and cost-effectiveness of paediatric bariatric surgery: a systematic review&quot;</span> identifies the report as a systematic review.

P2. "[Yes]" 
The abstract provides relevant background, objectives, eligibility criteria, data sources, study selection process, results, and conclusions. 

P3. "[Yes]"
The introduction describes the rationale in context of childhood obesity prevalence and lack of prevention/treatment options.

P4. "[Yes]"
The objectives state: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This systematic review examines the evidence on effectiveness of surgical interventions to treat obese children and adolescents, and whether they are cost-effective.&quot;</span>

P5. "[No]"
No protocol registration is mentioned.

P6. "[Yes]"  
Eligibility criteria regarding population, interventions, outcomes, and study designs are described.

P7. "[Yes]"
The information sources section describes the databases searched and date ranges.

P8. "[Yes]"
The search strategy for PubMed is provided in Appendix 1.

P9. "[Yes]" 
The study selection process is described and depicted in a flow diagram. 

P10. "[No]"
No details are provided on the data collection process.

P11. "[No]" 
The data items for which information was sought are not listed or defined.

P12. "[No]"
No assessment of risk of bias in individual studies is described.

P13. "[NA]" 
No meta-analysis was performed.

P14. "[NA]"
No meta-analysis was performed. 

P15. "[NA]" 
No meta-analysis was performed.

P16. "[NA]"
No additional analyses were performed.

P17. "[Yes]"
Numbers of studies screened, assessed, and included are provided in the flow diagram. Reasons for exclusions are stated.

P18. "[No]"
No summary table of study characteristics is provided.

P19. "[No]"
No assessment of risk of bias is presented.

P20. "[Yes]" 
Key findings of individual studies are summarized in the Results section and tables.

P21. "[NA]" 
No meta-analysis was performed.

P22. "[NA]"
No meta-analysis was performed.

P23. "[NA]"
No additional analyses were performed. 

P24. "[Yes]"
The main findings are summarized in the Discussion section.

P25. "[Yes]"
Limitations are discussed.

P26. "[Yes]"
Conclusions are provided regarding the implications of the evidence.

P27. "[No]"
No statement about sources of funding is provided.</pre>
<p><a name='62'></a></p>
</div>
<div
id="al-hozaim-2010-laparoscopic-assisted-anorectal-pull-through-for-anorectal-malformations-a-systematic-review-and-the-need-for-standardization-of-outcome-reporting"
class="section level4">
<h4>62.
<a href='https://doi.org/10.1016/J.JPEDSURG.2009.12.001' title='Open publication'>Al-Hozaim
2010: <i>Laparoscopic-assisted anorectal pull-through for anorectal
malformations: a systematic review and the need for standardization of
outcome reporting</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted.&quot;</span> The review had an a priori design with predefined inclusion/exclusion criteria.

A2. [No] The review does not mention duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The search terms used were laparoscopic, pull-through, anorectal malformation, and imperforate anus. In addition, a manual search of 4 surgical journals from the same period was performed.&quot;</span> At least two electronic sources were searched. 

A4. [No] The review does not mention searching for or including grey literature.

A5. [No] The review does not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The studies included 124 patients96 males (77.4%) and 28 females (22.6%).&quot;</span> Characteristics of included studies are provided in aggregated form.

A7. [No] The review does not mention assessing study quality.

A8. [NA] Study quality was not assessed.

A9. [NA] No quantitative synthesis was performed. 

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported.

P1. [Yes] The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale for the review.

P4. [No] The objectives do not explicitly mention PICOS elements.

P5. [No] The review does not mention a protocol. 

P6. [Yes] The methods section specifies eligibility criteria.

P7. [Yes] The information sources are described.

P8. [No] The full search strategy is not provided.

P9. [No] The study selection process is not described. 

P10. [No] The data collection process is not described.

P11. [No] Data items sought are not listed or defined.

P12. [NA] Risk of bias assessment was not done.

P13. [NA] No quantitative synthesis was performed.

P14. [NA] No quantitative synthesis was performed. 

P15. [NA] No quantitative synthesis was performed.

P16. [NA] No additional analyses were done.

P17. [No] A flow diagram of study selection is not provided.

P18. [Yes] Study characteristics are presented.

P19. [NA] Risk of bias was not assessed.

P20. [No] Results of individual studies are not presented.

P21. [NA] No quantitative synthesis was performed.

P22. [NA] No quantitative synthesis was performed.

P23. [NA] No additional analyses were done.

P24. [Yes] Main findings are summarized.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='63'></a></p>
</div>
<div
id="allen-2015-pediatric-emergency-department-thoracotomy-a-large-case-series-and-systematic-review"
class="section level4">
<h4>63.
<a href='https://doi.org/10.1016/J.JPEDSURG.2014.10.042' title='Open publication'>Allen
2015: <i>Pediatric emergency department thoracotomy: A large case series
and systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">12 quote(s)
from the LLM prompt briefing</span> (mean similarity 100%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
[Yes]
The introduction states the rationale and objectives clearly.

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>  
[No]
The methods do not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).&quot;</span>
[Yes]
The methods state: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;These reports were obtained from a Medline search for all publications regarding EDT in the pediatric population for the past 40 year using the keywords thoracotomy, emergency, trauma, resuscitation, pediatrics, and children.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The authors should state that they searched for reports regardless of their publication type.&quot;</span>
[No] 
Grey literature was not mentioned.

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;A list of included and excluded studies should be provided.&quot;</span>
[No]
No lists of included or excluded studies were provided.

A6. Were the characteristics of the included studies provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
[Yes]
Table 1 provides aggregated data on the included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;A priori methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span> 
[No]
The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span>
[NA] 
The quality of studies was not assessed (A7).

A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
[NA]
The results were not combined quantitatively.

A10. Was the likelihood of publication bias assessed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span> 
[No]
Publication bias was not assessed.

A11. Was the conflict of interest included?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
[No]
Conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. 
[Yes]
The title states <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;systematic review&quot;</span>.

P2. Provide a structured summary.
[Yes] 
The abstract provides a structured summary.

P3. Describe the rationale for the review. 
[Yes]
The introduction describes the rationale.

P4. Provide an explicit statement of questions being addressed.
[Yes]
The introduction states: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;we reviewed our experience at a level 1 trauma center and report the largest analysis over the past 25 years. In conjunction, we performed a systematic review of all published reports regarding pediatric EDT to help identify the factors associated with morbidity and mortality.&quot;</span>

P5. Indicate if a review protocol exists and provide registration information.
[No]
A protocol was not mentioned. 

P6. Specify study characteristics and report characteristics.
[Yes]
The methods describe the study selection criteria. 

P7. Describe information sources and dates last searched.
[Yes] 
The methods state: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;These reports were obtained from a Medline search for all publications regarding EDT in the pediatric population for the past 40 year using the keywords thoracotomy, emergency, trauma, resuscitation, pediatrics, and children.&quot;</span>

P8. Present full electronic search strategy. 
[No]
The full search strategy was not presented.

P9. State the process for selecting studies.
[Yes]
The methods describe the study selection process.

P10. Describe method of data extraction.
[No] 
The data extraction process was not described.

P11. List and define all variables for which data were sought.
[Yes]
Table 4 lists the variables that were extracted.

P12. Describe methods for assessing risk of bias. 
[NA]
Risk of bias was not assessed.

P13. State the principal summary measures.
[NA] 
Quantitative synthesis was not done. 

P14. Describe the methods of handling data and combining results.
[NA]
Quantitative synthesis was not done.

P15. Specify any assessment of risk of bias across studies.
[NA]
Risk of bias across studies was not assessed.

P16. Describe methods of additional analyses.
[NA]
No additional analyses were done.

P17. Give numbers of studies screened, assessed, and included, with reasons for exclusions. 
[No]
The number of studies screened and excluded was not provided.

P18. For each study, present characteristics and provide citations.
[Yes]
Table 1 provides aggregated characteristics and citations for each included study.

P19. Present data on risk of bias for each study. 
[NA] 
Risk of bias was not assessed.

P20. For each study, present simple summary data for each intervention group, effect estimates, and confidence intervals.
[No]
Outcome data for each study was not presented. 

P21. Present results of each meta-analysis, including confidence intervals and measures of consistency. 
[NA]
No meta-analysis was done.

P22. Present results of any assessment of risk of bias across studies.
[NA] 
Risk of bias across studies was not assessed.

P23. Give results of additional analyses.
[NA]
No additional analyses were done. 

P24. Summarize the main findings and discuss relevance to key groups.
[Yes] 
The discussion summarizes the main findings and their relevance.

P25. Discuss limitations at study and outcome level and at review level.
[Yes]
The discussion describes limitations at the study and review level.

P26. Provide a general interpretation of results in context of other evidence.
[Yes]
The discussion interprets the findings in the context of other evidence.

P27. Describe sources of funding and role of funders.
[No]
Sources of funding were not reported.</pre>
<p><a name='64'></a></p>
</div>
<div
id="allin-2015-challenges-of-improving-the-evidence-base-in-smaller-surgical-specialties-as-highlighted-by-a-systematic-review-of-gastroschisis-management"
class="section level4">
<h4>64.
<a href='https://doi.org/10.1371/JOURNAL.PONE.0116908' title='Open publication'>Allin
2015: <i>Challenges of Improving the Evidence Base in Smaller Surgical
Specialties, as Highlighted by a Systematic Review of Gastroschisis
Management</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The review was conducted according to a pre-specified protocol.&quot;</span>
They had a pre-specified protocol.

A2. [No] There is no mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Multiple search strategies were used to identify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google scholar.&quot;</span>
They searched multiple databases.  

A4. [No] There is no mention of including or excluding based on publication status.

A5. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;One Spanish paper was translated. Unpublished data were obtained from two authors [2, 9].&quot;</span> And Figure 1 shows a flow diagram of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data from included articles were extracted independently by the same two investigators (BA and WT), and any differences resolved by discussion.&quot;</span> And Table 2 provides characteristics of included studies.

A7. [No] There is no mention of assessing quality or risk of bias of individual studies.

A8. [NA] This is not applicable since quality of studies was not assessed.

A9. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The chi-squared test for heterogeneity was used to assess the extent to which the results of the studies were in agreement. Using a conservative cut-off of p<0.01, no statistical heterogeneity was detected and therefore fixed-effect methods were used throughout.&quot;</span>

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Challenges of Improving the Evidence Base in Smaller Surgical Specialties, as Highlighted by a Systematic Review of Gastroschisis Management&quot;</span>

P2. [Yes] The abstract provides relevant details.

P3. [Yes] The introduction describes the rationale.

P4. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this study, therefore, was to perform a systematic review of the literature comparing outcomes of infants with simple gastroschisis following either OPFC or SR.&quot;</span>

P5. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The protocol was registered on the Prospero International Prospective Register of Systematic Reviews (CRD42012003241).&quot;</span>

P6. [Yes] The eligibility criteria are described. 

P7. [Yes] The information sources are described.

P8. [No] The full search strategy is not provided.

P9. [Yes] The study selection process is described and Figure 1 shows a flow diagram.

P10. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data from included articles were extracted independently by the same two investigators (BA and WT), and any differences resolved by discussion.&quot;</span>

P11. [Yes] The data items sought are listed in the Outcome Measures section. 

P12. [NA] Risk of bias was not assessed for individual studies.

P13. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

Dichotomous outcomes were meta-analysed using MantelHaenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were metaanalysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Dichotomous outcomes were meta-analysed using MantelHaenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were meta-analysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.&quot;</span>

P14. [NA] There was no meta-analysis. 

P15. [NA] There was no meta-analysis.

P16. [NA] There were no additional analyses.

P17. [Yes] Figure 1 shows the study selection flow diagram. 

P18. [Yes] Table 2 provides characteristics of included studies.

P19. [NA] Risk of bias was not assessed.

P20. [Yes] Results for individual studies are presented in the text, tables, and forest plots.

P21. [Yes] Where meta-analyses were done, results are presented with confidence intervals and measures of consistency.

P22. [NA] No assessment of risk of bias across studies was done.

P23. [NA] No additional analyses were done.

P24. [Yes] The Discussion summarizes the main findings and their relevance.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided along with implications for future research.

P27. [Yes] Funding is described.</pre>
<p><a name='65'></a></p>
</div>
<div
id="alzahem-2011-laparoscopic-versus-open-inguinal-herniotomy-in-infants-and-children-a-meta-analysis"
class="section level4">
<h4>65.
<a href='https://doi.org/10.1007/S00383-010-2840-X' title='Open publication'>Alzahem
2011: <i>Laparoscopic versus open inguinal herniotomy in infants and
children: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
unsolicited-ranges</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
"[No]" The research question and inclusion criteria are not explicitly stated before the conduct of the review.

A2. Was there duplicate study selection and data extraction?
"[Yes]" Two authors independently abstracted data on patients, intervention, control, outcomes and methodological quality.

A3. Was a comprehensive literature search performed?
"[Yes]" Multiple databases were searched without language restrictions and supplementary searches were done.

A4. Was the status of publication used as an inclusion criterion?  
"[No]" The authors do not state whether unpublished studies or grey literature were sought.

A5. Was a list of studies (included and excluded) provided?
"[No]" A list of excluded studies is not provided.

A6. Were the characteristics of the included studies provided?
"[Yes]" Characteristics of included studies are summarized in Table 1. 

A7. Was the scientific quality of the included studies assessed and documented?
"[Yes]" The methodological quality of included studies was assessed using standard tools.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[Yes]" The limitations due to study quality are acknowledged in the discussion.

A9. Were the methods used to combine the findings of studies appropriate?
"[Yes]" Fixed and random effects models were used as appropriate based on heterogeneity.

A10. Was the likelihood of publication bias assessed?
"[No]" Publication bias was not assessed.

A11. Was the conflict of interest included?
"[No]" Sources of support are not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. 
"[Yes]" The title identifies it as a meta-analysis.

P2. Structured summary 
"[Yes]" The abstract provides a structured summary.

P3. Describe the rationale for the review
"[Yes]" The introduction describes the rationale.

P4. Provide an explicit statement of questions being addressed 
"[Yes]" The objectives relate to comparing laparoscopic and open repair.

P5. Indicate if a review protocol exists
"[No]" A protocol is not mentioned.

P6. Specify study characteristics used as criteria  
"[Yes]" Inclusion criteria relating to population, intervention, comparator are described.

P7. Describe information sources  
"[Yes]" Databases and dates searched are reported.

P8. Present full electronic search strategy
"[No]" The full search strategy is not provided.

P9. State process for selecting studies
"[Yes]" Study selection process is described and shown in a flow diagram.

P10. Describe method of data extraction
"[Yes]" Data extraction by two authors is described. 

P11. List and define all variables for which data were sought
"[Yes]" Outcomes analyzed are listed.

P12. Describe methods for assessing risk of bias
"[Yes]" Quality assessment using standard tools is described.

P13. State principal summary measures  
"[Yes]" Odds ratio, mean difference etc. are stated.

P14-P23. [NA] Related to quantitative synthesis methods which were not done.

P24. Summarize the main findings including the strength of evidence
"[Yes]" Main findings are summarized in the discussion.

P25. Discuss limitations at study and outcome level   
"[Yes]" Limitations due to study quality are discussed.

P26. Provide a general interpretation of results in context of other evidence
"[Yes]" Results are interpreted in the context of other evidence. 

P27. Describe sources of funding for the review
"[No]" Sources of funding are not reported.</pre>
<p><a name='66'></a></p>
</div>
<div
id="apelt-2013-laparoscopic-treatment-of-intussusception-in-children-a-systematic-review"
class="section level4">
<h4>66.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.024' title='Open publication'>Apelt
2013: <i>Laparoscopic treatment of intussusception in children: A
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">19 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic review of all publications on the laparoscopic treatment of pediatric intussusception from January 1990 to April 2012 was performed.&quot;</span>
2. The review had predefined objectives and eligibility criteria.
[Yes]

A2.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Results were confirmed by a second independent search by a different member of the team using matching search strings and databases.&quot;</span>
2. Two reviewers performed study selection. 
[Yes]

A3.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An online database search for all English language articles on pediatric small bowel obstruction, intussusception and laparoscopy in PubMed, Medline and Ovid from January 1990 to April 2012 was performed.&quot;</span>
2. At least two databases were searched.
[Yes]

A4.
[NA] 

A5.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Fig. 1 shows the selection algorithm for the studies included.&quot;</span>
2. A list of included and excluded studies was provided.
[Yes]

A6.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Table 1 provides specific details on the selected studies.&quot;</span> 
2. Characteristics of included studies were provided.
[Yes]

A7.  
[No]

A8.  
[No] 

A9. 
[NA]

A10.  
[NA]

A11. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Received 9 December 2012; revised 21 April 2013; accepted 21 May 2013&quot;</span>
2. No statement on conflicts of interest.
[No]

P1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic treatment of intussusception in children: A systematic review&quot;</span>
2. Identified as a systematic review.  
[Yes]

P2.  
1. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
2. Structured abstract provided.
[Yes]  

P3.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Idiopathic intussusception is the single most common cause of small bowel obstruction in children younger than 5 years [1,2].&quot;</span>
2. Provided background and rationale.
[Yes]

P4. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;we aimed to establish whether laparoscopy should be the primary technique in the surgical reduction of intussusception.&quot;</span>
2. Objectives stated.
[Yes]  

P5.  
[No]

P6.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Exclusion criteria were non-English language articles, case reports, laparoscopic-assisted enema reduction and mixed pediatric and adult populations (age cutoff 18 years).&quot;</span>
2. Inclusion/exclusion criteria described.  
[Yes]

P7. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An online database search for all English language articles on pediatric small bowel obstruction, intussusception and laparoscopy in PubMed, Medline and Ovid from January 1990 to April 2012 was performed.&quot;</span>
2. Information sources described.
[Yes]

P8.  
[No]

P9. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Fig. 1 shows the selection algorithm for the studies included.&quot;</span>
2. Study selection process described.
[Yes]

P10.  
[No] 

P11.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following variables were analyzed: age, laparoscopic success rate, reason for conversion, enterotomy rate, operative time, complications, and length of stay (LOS).&quot;</span>
2. Data items listed.
[Yes]

P12.  
[No]

P13.  
[NA]

P14.  
[NA]

P15. 
[NA]

P16.  
[NA] 

P17.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Fig. 1 shows the selection algorithm for the studies included.&quot;</span>
2. Study selection flow diagram provided.
[Yes]

P18. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Table 1 provides specific details on the selected studies.&quot;</span>
2. Study characteristics presented.
[Yes]  

P19.  
[No]

P20.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Table 2 Laparoscopic outcome data for intussusception.&quot;</span>
2. Summary results for each intervention presented.
[Yes]

P21. 
[NA]

P22.  
[NA]

P23.  
[NA]

P24.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Conclusion: Laparoscopy is safe and effective in the treatment of pediatric intussusception.&quot;</span> 
2. Main findings and implications summarized.
[Yes]

P25. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

ver, the main limitation of the present study includes the lack of prospective randomized controlled trials (RCT) comparing laparoscopic vs. open reduction of pediatric intussusception.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;However, the main limitation of the present study includes the lack of prospective randomized controlled trials (RCT) comparing laparoscopic vs. open reduction of pediatric intussusception.&quot;</span>
2. Limitations discussed.
[Yes]

P26.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;These results call for a change in the traditional pediatric surgical management of intussusception. We advocate for laparoscopy to be considered the primary interventional technique for intussusception in tertiary centers with advanced pediatric minimally invasive skills [26].&quot;</span>
2. Conclusions and implications described.
[Yes]

P27.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Received 9 December 2012; revised 21 April 2013; accepted 21 May 2013&quot;</span>
2. No statement on funding sources. 
[No]</pre>
<p><a name='67'></a></p>
</div>
<div
id="aworanti-2014-management-of-recurrent-tracheoesophageal-fistulas-a-systematic-review"
class="section level4">
<h4>67.
<a href='https://doi.org/10.1055/S-0034-1370780' title='Open publication'>Aworanti
2014: <i>Management of Recurrent Tracheoesophageal Fistulas: A
Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 98.2%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">7
quote(s) from the LLM prompt briefing</span> (mean similarity 94.9%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
Explanation: The review states that inclusion criteria should be pre-determined.
[Yes]

A2. Was there duplicate study selection and data extraction?
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
Explanation: The review does not mention duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed?
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched.&quot;</span> <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;All searches should be supplemented by&quot;</span> [...] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;reviewing the references in the studies found.&quot;</span>
Explanation: The review searched Medline, Embase, Web of Science, and references of included studies. 
[Yes]

A4. Was the status of publication used as an inclusion criterion?
Quotes: N/A
Explanation: Grey literature was not discussed.
[No]

A5. Was a list of studies (included and excluded) provided?
Quotes: N/A
Explanation: A list of included/excluded studies was not provided.
[No] 

A6. Were the characteristics of the included studies provided?
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> 
Explanation: Tables 1 and 2 provide characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quotes: N/A
Explanation: The quality of included studies was not assessed.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
Quotes: N/A
Explanation: Study quality was not assessed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
Quotes: N/A
Explanation: No quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
Quotes: N/A
Explanation: Publication bias was not assessed.
[No]

A11. Was the conflict of interest included?
Quotes: N/A  
Explanation: Conflicts of interest were not reported.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 91%):

Management of Recurrent Tracheoesophageal Fistulas: A Systematic Review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Title: Management of Recurrent Tracheoesophageal Fistulas: A Systematic Review&quot;</span>
Explanation: The title identifies the report as a systematic review.
[Yes]

P2. Structured summary.
Quotes: N/A
Explanation: No structured abstract provided.
[No]

P3. Describe the rationale for the review. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The management of a recurrent tracheoesophageal fistula (RTEF) includes either open surgery (OS) or an endoscopic treatment (ET); the ideal option is unclear. We aim to comparatively review all published treatment options, and outcomes, for managing RTEF.&quot;</span>
Explanation: Provides background and rationale.
[Yes]

P4. Provide objectives with PICOS.
Quotes: N/A
Explanation: Does not explicitly state PICOS objectives.
[No]

P5. Indicate protocol and registration.
Quotes: N/A
Explanation: Does not mention a protocol or registration.
[No]

P6. Specify study characteristics and rationale.
Quotes: N/A
Explanation: Does not describe eligibility criteria.
[No] 

P7. Describe information sources and searches.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A Medline, Embase, and web of science searches were performed using the keywords recurrent tracheoesophageal fistula. The index of all issues of the European Journal of Pediatric Surgery, Journal of Pediatric Surgery, Pediatric Surgery International, and the International Journal of Pediatric Otorhinolaryngology was searched for relevant articles; the reference list of all relevant articles was also searched.&quot;</span>
Explanation: Describes sources searched.
[Yes]

P8. Present search strategy. 
Quotes: N/A
Explanation: Does not provide full search strategy.
[No]

P9. State process for selection studies.
Quotes: N/A
Explanation: Does not describe study selection process. 
[No]

P10. Describe data collection process.
Quotes: N/A
Explanation: Does not describe data extraction process.
[No]

P11. List and define data items sought.
Quotes: N/A
Explanation: Does not list or define data sought.
[No]

P12. Assess risk of bias in individual studies.
Quotes: N/A
Explanation: Does not assess risk of bias.
[No]

P13. State principal summary measures.
Quotes: N/A
Explanation: No quantitative synthesis performed.
[NA]

P14. Synthesis of results.
Quotes: N/A
Explanation: No quantitative synthesis performed.
[NA] 

P15. Risk of bias across studies.
Quotes: N/A
Explanation: No assessment of risk of bias across studies.  
[NA]

P16. Additional analyses. 
Quotes: N/A
Explanation: No additional analyses performed.
[NA]

P17. Give numbers of studies at each stage. 
Quotes: N/A
Explanation: Does not report number of studies at each stage.
[No]

P18. Present study characteristics.
Quotes: <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.4%):

e characteristics of the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;Tables 1 and 2 provide characteristics of included studies.&quot;</span>
Explanation: Provides some characteristics in tables.
[Yes]

P19. Present risk of bias within studies. 
Quotes: N/A
Explanation: Does not assess risk of bias within studies.
[No]

P20. Results of individual studies.
Quotes: N/A 
Explanation: Does not provide results for each study.
[No]

P21. Present results of syntheses.
Quotes: N/A
Explanation: No quantitative syntheses performed.
[NA]

P22. Present risk of bias across studies.
Quotes: N/A
Explanation: Did not assess risk of bias across studies.
[NA]

P23. Give additional analyses.
Quotes: N/A
Explanation: No additional analyses performed.
[NA]

P24. Summarize evidence.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, based on our findings on 165 published cases, OS for the repair of recurrent TEF has a low morbidity, mortality, and re-fistulation rate particularly when an interposition tissue is placed between the trachea and esophagus. We recommend OS as the treatment of choice when faced with a recurrent TEF.&quot;</span>
Explanation: Summarizes main findings and conclusions.
[Yes]

P25. Discuss limitations.
Quotes: N/A
Explanation: Does not discuss limitations.
[No] 

P26. Provide general interpretation.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, based on our findings on 165 published cases, OS for the repair of recurrent TEF has a low morbidity, mortality, and re-fistulation rate particularly when an interposition tissue is placed between the trachea and esophagus. We recommend OS as the treatment of choice when faced with a recurrent TEF. Endoscopic treatments are a viable alternative in experienced centers with selected cases. Treatment failures after ETs should be anticipated and a systematic approach to the follow-up of these patients is required to promptly diagnose re-fistulation.&quot;</span>
Explanation: Provides interpretation of results.
[Yes]

P27. Describe sources of funding.
Quotes: N/A
Explanation: Does not describe sources of funding.
[No]</pre>
<p><a name='68'></a></p>
</div>
<div
id="baker-2015-a-systematic-review-and-meta-analysis-of-gastrostomy-insertion-techniques-in-children"
class="section level4">
<h4>68.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.021' title='Open publication'>Baker
2015: <i>A systematic review and meta-analysis of gastrostomy insertion
techniques in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
unsolicited-ranges</i></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">3
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span> The authors state the objective and inclusion criteria in the abstract. 

A2. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span> The authors state <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Screening of eligible studies, data extraction, and assessment of methodological quality were conducted independently by two reviewers.&quot;</span>

A3. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched.&quot;</span> The authors searched MEDLINE, EMBASE, CINAHL, Scopus and Cochrane Library.

A4. [No] The authors do not state whether they searched for or included grey literature.

A5. [No] The authors do not provide a list of included and excluded studies. 

A6. [Yes] Table 1 provides characteristics of the included studies.

A7. [Yes] The authors used the MINORS tool to assess study quality.

A8. [Yes] The authors consider study limitations in the discussion.

A9. [Yes] The authors assessed heterogeneity using I2 and used fixed and random effects models appropriately.

A10. [No] Publication bias was not assessed.

A11. [NA] No information on funding sources was provided.

P1. [Yes] The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The objective and inclusion criteria are stated in the abstract. 

P5. [No] The authors do not mention a review protocol.

P6. [Yes] Inclusion criteria are described in the methods.

P7. [Yes] The information sources and dates searched are described. 

P8. [Yes] The full search strategy is provided in the appendix.

P9. [Yes] The study selection process is described and shown in the flow diagram.

P10. [Yes] Data extraction by two independent reviewers is described. 

P11. [Yes] Outcomes extracted are described in the methods.

P12. [NA] Risk of bias assessment for individual studies is not applicable for this type of review.

P13. [Yes] Summary measures are described.

P14-P16. [NA] Not applicable as no meta-regression or subgroup analyses were done.

P17. [Yes] Study selection is shown in the flow diagram. 

P18. [Yes] Study characteristics are presented in Table 1.

P19. [NA] Not applicable as no risk of bias assessment was done.

P20. [Yes] Results for major complications are shown in the forest plots.

P21-P23. [NA] Not applicable as no meta-regression or subgroup analyses were done. 

P24. [Yes] Main findings are summarized in the discussion.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='69'></a></p>
</div>
<div
id="berger-2012-mitomycin-c-in-the-therapy-of-recurrent-esophageal-strictures-hype-or-hope"
class="section level4">
<h4>69.
<a href='https://doi.org/10.1055/S-0032-1311695' title='Open publication'>Berger
2012: <i>Mitomycin C in the Therapy of Recurrent Esophageal Strictures:
Hype or Hope?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
"[No]"
No protocol or pre-determined objectives mentioned.

A2. Was there duplicate study selection and data extraction?
"[No]"  
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[No]"
Only PubMed mentioned, no details on search strategy provided.

A4. Was the status of publication used as an inclusion criterion?  
"[No]"
No mention of including or excluding based on publication status. 

A5. Was a list of studies (included and excluded) provided?
"[No]"
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided?
"[Yes]"
Relevant characteristics summarized in Tables 2 and 3.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]" 
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]" 
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed?
"[No]"
No assessment of publication bias mentioned.

A11. Was the conflict of interest included?
"[No]"
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
Title identifies it as a systematic review.

P2. Structured summary 
"[No]" 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"
Introduction describes rationale and background.

P4. Provide an explicit statement of questions being addressed. 
"[No]"
No explicit objectives or questions stated.

P5. Indicate if a review protocol exists.
"[No]" 
No protocol mentioned.

P6. Specify study characteristics used as criteria for eligibility.
"[No]"
Inclusion/exclusion criteria not specified.

P7. Describe information sources in the search.
"[No]" 
Only mentions PubMed, no details on search provided.

P8. Present full electronic search strategy.
"[No]"
No search strategy presented.

P9. State the process for selecting studies.
"[No]"
No details provided on study selection process. 

P10. Describe method of data extraction. 
"[No]"
No data extraction process described.

P11. List and define all variables for which data were sought.
"[No]"
No list of data items provided.

P12. Describe methods for assessing risk of bias of individual studies. 
"[No]"
No risk of bias assessment described.

P13. State the principal summary measures.
"[NA]"
No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results.
"[NA]" 
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias across studies.
"[NA]"
No quantitative synthesis performed.

P16. Describe methods of additional analyses.
"[NA]"
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. 
"[No]"
No flow diagram or details on study selection process provided.

P18. For each study, present characteristics and provide citations. 
"[Yes]" 
Study characteristics presented in Tables 2 and 3. 

P19. Present data on risk of bias for each study.
"[No]"
No risk of bias assessment presented.

P20. For each study, present simple summary data for each intervention group.
"[Yes]"
Relevant data extracted and summarized for each study in Table 3.

P21. Present results of each meta-analysis done.
"[NA]" 
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies.
"[NA]"
No assessment of publication bias mentioned.

P23. Give results of additional analyses.
"[NA]"
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome.
"[Yes]" 
Main findings summarized in discussion.

P25. Discuss limitations at study and outcome level and at review-level.
"[Yes]"
Limitations discussed in discussion.

P26. Provide a general interpretation of results in context of other evidence. 
"[Yes]"
Results interpreted in discussion.

P27. Describe sources of funding for the review.
"[No]"
No statement about sources of funding.</pre>
<p><a name='70'></a></p>
</div>
<div
id="billingham-2010-pediatric-surgical-technique-laparoscopic-or-open-approach-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>70.
<a href='https://doi.org/10.1055/S-0029-1241871' title='Open publication'>Billingham
2010: <i>Pediatric Surgical Technique: Laparoscopic or Open Approach? A
systematic Review and Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
[Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The objectives section clearly states the research question and inclusion criteria before describing the methods.

A2. Was there duplicate study selection and data extraction?
[No] 
The methods do not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A computerized comprehensive search supplemented by a manual review of the literature was performed for all peer-reviewed publications comparing laparoscopic and open appendectomy, fundoplication and hernia repair cohorts.&quot;</span>
The search included multiple databases and supplementary strategies.

A4. Was the status of publication used as an inclusion criterion?
[No]
The inclusion/exclusion criteria do not mention use of grey literature or language restrictions. 

A5. Was a list of studies (included and excluded) provided?
[No]
A list of included studies is provided in Table 1, but no excluded studies are listed.

A6. Were the characteristics of the included studies provided?
[Yes] 
Table 1 provides the study design, quality, and group sizes for all included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
[Yes]
The methods describe assigning a level of evidence to each study using standard criteria.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
[Yes]
The discussion mentions limitations related to study quality.

A9. Were the methods used to combine the findings of studies appropriate?
[Yes] 
The meta-analysis methods are described and appropriate tests for heterogeneity were used.

A10. Was the likelihood of publication bias assessed?
[No]
Publication bias was not assessed.

A11. Was the conflict of interest included?
[No] 
No statement about conflicts of interest is provided.

P1. Identify the report as a systematic review, meta-analysis, or both. 
[Yes]
The title identifies it as a systematic review and meta-analysis.

P2. Structured summary.
[Yes] 
The abstract provides appropriate background, objectives, data sources, eligibility criteria, methods, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known.
[Yes]  
The introduction describes the rationale and background.

P4. Provide an explicit statement of questions being addressed. 
[Yes]
The objectives section explicitly states the question being addressed.

P5. Indicate if a review protocol exists and provide registration information.
[No] 
A protocol is not mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. 
[Yes]  
The inclusion/exclusion criteria specify appropriate study characteristics.

P7. Describe all information sources in the search and date last searched.
[Yes]
The search strategy is described including databases searched. 

P8. Present full electronic search strategy for at least one database, including any limits used.
[No] 
The search strategy is not provided.

P9. State the process for selecting studies.
[Yes]  
The study selection process is described.

P10. Describe method of data extraction from reports. 
[No]  
The data extraction process is not described.

P11. List and define all variables for which data were sought.
[Yes]
The outcomes extracted are listed and defined.

P12. Describe methods used for assessing risk of bias of individual studies.
[Yes] 
The use of evidence grading criteria to assess study quality is described.

P13. State the principal summary measures.
[Yes] 
The use of weighted mean differences is stated for continuous outcomes.

P14. Describe the methods of handling data and combining results of studies.
[Yes]
The meta-analysis methods are described. 

P15. Specify any assessment of risk of bias across studies.
[NA]
Not applicable since no meta-analysis was performed.

P16. Describe methods of additional analyses.
[NA]  
Not applicable since no additional analyses were performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, ideally with a flow diagram.
[No]
The number of studies screened and assessed is not provided.

P18. For each study, present characteristics for which data were extracted.
[Yes] 
Table 1 presents relevant characteristics of the included studies.

P19. Present data on risk of bias of each study. 
[Yes]
Table 1 provides the study quality/risk of bias assessments.

P20. For each study, present simple summary data for each intervention group.
[No] 
Individual study data are not presented, only meta-analysis results.  

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
[Yes]
The meta-analysis results include confidence intervals and heterogeneity measures.

P22. Present results of any assessment of risk of bias across studies.
[NA] 
Not applicable since no assessment of publication bias was performed.

P23. Give results of additional analyses, if done.
[NA]
No additional analyses were performed.

P24. Summarize the main findings including the strength of evidence for each main outcome.
[Yes] 
The discussion summarizes the main findings and limitations.

P25. Discuss limitations at study and outcome level and at review-level.
[Yes]  
Limitations at the study and review level are discussed.

P26. Provide a general interpretation of the results in the context of other evidence.
[Yes]
The results are interpreted in the context of previous evidence.

P27. Describe sources of funding for the systematic review. 
[No]
Sources of funding are not described.</pre>
<p><a name='71'></a></p>
</div>
<div
id="black-2013-bariatric-surgery-for-obese-children-and-adolescents-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>71.
<a href='https://doi.org/10.1111/OBR.12037' title='Open publication'>Black
2013: <i>Bariatric surgery for obese children and adolescents: a
systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.7%)</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

systematic literature search (19552013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[A] systematic literature search (19552013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.&quot;</span> The review had an a priori design with predefined inclusion criteria. [Yes]

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;</span> There was duplicate study selection and data extraction. [Yes]  

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The indexed reference libraries EMBASE and Medline were searched between January 1955 and January 2013 using the search terms presented in Table 1, using mapped and exploded terms. Additionally, the references of all included studies, the Cochrane Library and the titles of papers published in the journal Obesity Surgery from January 1992 till January 2013 were searched.&quot;</span> At least two electronic sources were searched along with supplementary strategies. [Yes]

A4. The authors do not mention whether grey literature was included or excluded. [No] 

A5. Table 2 provides a list of included and excluded studies. [Yes]

A6. Table 2 provides aggregated participant characteristics for the included studies. [Yes]

A7. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;It was not possible to provide a summary estimate of the number of complications as studies defined complications in different ways and expressed complications as a count of events or described case-specific complications (Table 3).&quot;</span> The methodological quality of included studies was assessed but not incorporated in the analysis. [No]

A8. The quality assessment was not used to formulate conclusions. [No] 

A9. Heterogeneity was assessed using I2 and chi-squared tests. A random effects model was used for the meta-analysis. [Yes]

A10. Publication bias was assessed visually with funnel plots and statistically with Egger's test. [Yes]

A11. Sources of support were not reported for the included studies. [No]

P1. The title identifies the report as a systematic review and meta-analysis. [Yes]

P2. The abstract provides a structured summary. [Yes]

P3. The introduction describes the rationale and context. [Yes] 

P4. The introduction states the objectives related to participants, interventions, comparisons, outcomes, and study design. [Yes]

P5. The authors do not mention whether a review protocol exists. [No]

P6. The methods specify eligibility criteria. [Yes]

P7. The methods describe the information sources and dates searched. [Yes]

P8. The full search strategy is provided for one database. [Yes]

P9. The methods describe the study selection process. [Yes] 

P10. The methods state that standard data extraction was used but do not describe confirmation. [No]

P11. The methods list the data items sought. [Yes]

P12. The methods do not describe the assessment of risk of bias. [No]

P13. The methods state that mean BMI difference was the summary measure. [Yes]

P14. Not applicable - no meta-analysis synthesis methods. [NA]

P15. Not applicable - no assessment of risk of bias across studies. [NA] 

P16. Not applicable - no additional analyses mentioned. [NA]

P17. Figure 1 shows the study selection flow diagram. [Yes]

P18. Table 2 provides study characteristics. [Yes]

P19. The results state that risk of bias was not assessed. [No]

P20. The results provide summary data and effect estimates for each study. [Yes]

P21. Figure 2 shows the meta-analysis results. [Yes]

P22. Not applicable - no assessment of risk of bias across studies. [NA]

P23. Not applicable - no additional analyses mentioned. [NA]

P24. The discussion summarizes the main findings and considers their relevance. [Yes]

P25. The discussion examines limitations at the study and outcome level. [Yes]

P26. The conclusion provides an overall interpretation and implications. [Yes]

P27. The authors state that there were no conflicts of interest. [Yes]</pre>
<p><a name='72'></a></p>
</div>
<div
id="borruto-2010-laparoscopic-vs-open-varicocelectomy-in-children-and-adolescents-review-of-the-recent-literature-and-meta-analysis"
class="section level4">
<h4>72.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.07.007' title='Open publication'>Borruto
2010: <i>Laparoscopic vs open varicocelectomy in children and
adolescents: review of the recent literature and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [No] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A literature search was performed, using Medline and Pubmed database, on all articles published during the last 10 years (2000-2009), reporting on varicocele treatments.&quot;</span> The review did not mention an a priori design.
The review did not mention having an a priori design.

A2. [No] There is no mention of duplicate study selection or data extraction.
Duplicate study selection and data extraction are not mentioned. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following key words were used: varicocele, treatment, and adolescent. Searches were also performed using the following as limits: last 10 years, adolescent, clinical trials, randomized controlled trials, meta-analysis, and multicenter retrospective and prospective studies.&quot;</span> The review searched Medline and PubMed and used keywords, limits, and supplementary strategies.

A4. [No] The review did not mention searching for or using unpublished literature/grey literature. 
Use of grey literature is not mentioned.

A5. [No] The review mentioned screening studies and excluding some based on relevance and population criteria, but did not provide a list of included/excluded studies.
A list of included/excluded studies is not provided.

A6. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

We first considered all studies that showed a population of 1443 children and adolescents (age, 6-17 years; mean age, 14.62 years) who underwent varicocelectomy by laparoscopic (LS) and open techniques (OS)' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We first considered all studies that showed a population of 1443 children and adolescents (age, 6-17 years; mean age, 14.62 years) who underwent varicocelectomy by laparoscopic (LS) and open techniques (OS).&quot;</span> Study characteristics like sample size, age, and interventions are described in aggregate.

A7. [No] The review does not mention assessing study quality or using it in conclusions.
Assessment of study quality is not mentioned.

A8. [NA] Study quality assessment was not performed so using it in formulating conclusions is not applicable.
Study quality was not assessed.

A9. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Statistical analysis for categorical variables was carried out using the odds ratio as the summary statistic.&quot;</span> The review used appropriate methods to combine findings across studies in the meta-analyses. 

A10. [No] The review did not assess likelihood of publication bias.
Publication bias assessment is not mentioned.

A11. [No] The review did not report on conflicts of interest in the included studies.
Conflicts of interest are not reported for included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic vs open varicocelectomy in children and adolescents: review of the recent literature and meta-analysis&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [No] The abstract does not contain a structured summary.
The abstract is not structured.

P3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Varicocele is generally considered the most common correctable cause of male infertility [1,2].&quot;</span> The introduction describes the rationale and context for the review.

P4. [No] The objectives are not explicitly stated with PICOS elements.
Objectives are not stated with PICOS.

P5. [No] The review does not mention whether a protocol exists.
A protocol is not mentioned.

P6. [No] Eligibility criteria are not specified.
Eligibility criteria are not specified.  

P7. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A literature search was performed, using Medline and Pubmed database, on all articles published during the last 10 years (2000-2009), reporting on varicocele treatments.&quot;</span> The information sources and dates searched are described.

P8. [No] The full search strategy is not presented for any database.
The full search strategy is not presented.

P9. [No] The study selection process is not described.
The study selection process is not described.

P10. [No] The data collection process is not described.
The data collection process is not described. 

P11. [No] The variables extracted are not listed or defined.
Extracted variables are not listed.

P12. [No] Risk of bias assessment for individual studies is not described. 
Risk of bias assessment is not described.

P13. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Statistical analysis for categorical variables was carried out using the odds ratio as the summary statistic.&quot;</span> The summary measures are stated.

P14. [NA] Quantitative synthesis methods are not applicable since this review did not perform meta-analysis across all studies.

P15. [NA] Assessment of risk of bias across studies is not applicable since this review did not perform meta-analysis across all studies.  

P16. [NA] Additional analyses are not applicable since this review did not perform meta-analysis across all studies.

P17. [No] A flow diagram of study selection is not provided.
A flow diagram is not provided.

P18. [No] Study characteristics are not presented in a table or list of citations.
Study characteristics are not presented in a table.

P19. [No] Risk of bias within studies is not presented.
Risk of bias within studies is not presented.

P20. [No] Results for each study are not presented.
Results for each study are not presented.

P21. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta-analysis showed that there was no statistical difference between laparoscopic surgery and open surgery in recurrence rate and postoperative hydrocele rate.&quot;</span> Meta-analysis results are presented with confidence intervals.

P22. [NA] Assessment of risk of bias across studies is not applicable since this review did not perform meta-analysis across all studies.

P23. [NA] Additional analyses are not applicable since this review did not perform meta-analysis across all studies.

P24. [No] The main findings and strengths of evidence are not summarized.
Main findings and strength of evidence are not summarized.

P25. [No] Limitations are not discussed at the study and outcome level.
Limitations are not discussed.

P26. [No] The results are not interpreted in the context of other evidence and implications for future research are not discussed.
Results are not interpreted in context of other evidence.

P27. [No] Sources of funding and role of funders are not described.
Funding sources are not described.</pre>
<p><a name='73'></a></p>
</div>
<div
id="castagnetti-2010-surgical-management-of-primary-severe-hypospadias-in-children-systematic-20-year-review"
class="section level4">
<h4>73.
<a href='https://doi.org/10.1016/J.JURO.2010.06.044' title='Open publication'>Castagnetti
2010: <i>Surgical Management of Primary Severe Hypospadias in Children:
Systematic 20-Year Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.3%)</i></p>
<pre>
A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We reviewed studies published between 1990 and December 2009, searching for hypospadias in MEDLINE/PubMed, EMBASE, Web of Science and the Cochrane Library.]&quot;</span>
The review had predefined inclusion criteria based on searching for studies on <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;hypospadias&quot;</span> within a specified timeframe. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Three doctors reviewed the abstracts. Articles relevant to the topic of the review were selected by consensu' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Three doctors reviewed the abstracts. Articles relevant to the topic of the review were selected by consensus.]&quot;</span>
Multiple reviewers were involved in study selection. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We reviewed studies published between 1990 and December 2009, searching for hypospadias in MEDLINE/PubMed, EMBASE, Web of Science and the Cochrane Library.]&quot;</span>
The search included multiple databases within a defined timeframe. [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
No mention of including or excluding grey literature. [No]  

A5. Was a list of studies (included and excluded) provided?
No list of included or excluded studies provided. [No]

A6. Were the characteristics of the included studies provided?
Table provides complication rates for different techniques but no other study characteristics. [No]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[These studies were generally of low quality (69.5% surgical series). Even the 18 controlled studies were fraught with several methodological flaws, limiting their validity.]&quot;</span>
The quality of included studies was discussed but not formally assessed. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The low quality of studies was acknowledged as a limitation but quality was not used to interpret results. [No]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias. [No]  

A11. Was the conflict of interest included?
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]

P2. Structured summary including key elements. [Yes]

P3. Describe the rationale for the review. [Yes] 

P4. Provide objectives with PICOS elements. [No]

P5. Indicate protocol and registration. [No] 

P6. Specify eligibility criteria. [Yes]

P7. Describe information sources including dates. [Yes]

P8. Present search strategy. [No]

P9. State process for study selection. [Yes] 

P10. Describe data collection process. [No] 

P11. List and define data items sought. [No]

P12. Assess risk of bias in studies. [No] 

P13. State summary measures. [NA]

P14. Synthesis methods. [NA]

P15. Risk of bias across studies. [NA]

P16. Describe additional analyses. [NA]

P17. Give study selection flow diagram. [No]

P18. Study characteristics. [No]

P19. Present risk of bias assessments. [No]

P20. Results for each study. [No]

P21. Synthesis results. [NA] 

P22. Risk of bias across studies. [NA]

P23. Additional analysis results. [NA]

P24. Summary of evidence. [Yes]

P25. Discuss limitations. [Yes]

P26. Interpret results and implications. [Yes]

P27. Describe sources of funding. [No]</pre>
<p><a name='74'></a></p>
</div>
<div
id="castagnetti-2016-does-preputial-reconstruction-increase-complication-rate-of-hypospadias-repair-20-year-systematic-review-and-meta-analysis"
class="section level4">
<h4>74.
<a href='https://doi.org/10.3389/FPED.2016.00041' title='Open publication'>Castagnetti
2016: <i>Does Preputial Reconstruction Increase Complication Rate of
Hypospadias Repair? 20-Year Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):

A systematic review of the literature published after June 1995 was performed in June 2015 in agreement with the PRISMA statement (3).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A systematic review of the literature published after 06/1995 was performed in 06/2015 in agreement with the PRISMA statement (3).&quot;</span> [Yes] Reports an a priori design with predefined objectives.

A2: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three doctors reviewed separately the abstracts.&quot;</span> [Yes] Reports duplicate study selection. 

A3: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three databases, namely, MEDLINE/PubMed, Scopus, and The Cochrane library, were searched for using the free text hypospadias repair&quot;</span> [...] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For MEDLINE/PubMed search, English, Humans, Males, and Publication date from June 1995 to June 2015 were considered, as limits.&quot;</span> [Yes] Reports searching at least two databases plus supplementary strategies.

A4: [NA] Does not mention searching for grey literature.

A5: Figure 1 shows a flow diagram with included and excluded studies. [Yes] 

A6: Table 1 reports characteristics of included studies. [Yes]

A7: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We included only studies reporting data on complications of PR (dehiscence of reconstructed prepuce and phimosis), on urethroplasty complications (fistula formation), and on reoperation rates in patients undergoing hypospadias repair with preservation of the prepuce.&quot;</span> [Yes] Reports assessing quality related to the research question.

A8: [NA] Does not synthesize study findings.

A9: [NA] No meta-analysis performed.

A10: [NA] No meta-analysis performed.  

A11: [NA] No meta-analysis performed.

P1: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Does Preputial reconstruction increase complication rate of hypospadias repair? 20-Year systematic review and Meta-analysis&quot;</span> [Yes] Identifies as a systematic review and meta-analysis.

P2: The abstract provides a structured summary. [Yes]

P3: The introduction describes the rationale and context. [Yes] 

P4: The introduction states the objective to determine complications of PR and influence on fistula and reoperation rate. [Yes]

P5: [NA] Does not mention a protocol.

P6: The methods specify inclusion criteria. [Yes]

P7: The methods describe the literature search. [Yes] 

P8: The methods provide the full search strategy. [Yes]

P9: The methods describe the selection process and Figure 1 shows a flow diagram. [Yes] 

P10: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three doctors reviewed separately the abstracts.&quot;</span> [Yes] Describes that data extraction was done in duplicate.

P11: Table 1 lists characteristics extracted. [Yes]

P12: [NA] Does not assess risk of bias in individual studies.

P13: [NA] No meta-analysis performed.

P14: [NA] No meta-analysis performed.

P15: [NA] No meta-analysis performed. 

P16: [NA] No additional analyses mentioned.

P17: Figure 1 provides a flow diagram of study selection. [Yes]

P18: Table 1 provides characteristics of included studies. [Yes]

P19: [NA] Does not assess risk of bias within studies.

P20: [NA] No meta-analysis results presented.

P21: [NA] No meta-analysis performed.

P22: [NA] No meta-analysis performed.

P23: [NA] No additional analyses mentioned.

P24: The discussion summarizes the main findings. [Yes]

P25: The limitations are discussed. [Yes]

P26: The conclusion provides an overall interpretation. [Yes]

P27: [No] Does not report on sources of funding.</pre>
<p><a name='75'></a></p>
</div>
<div
id="chan-2014-pediatr-surg-int-ideal-timing-of-orchiopexy-a-systematic-review"
class="section level4">
<h4>75.
<a href='https://doi.org/10.1007/S00383-013-3429-Y' title='Open publication'>Chan
2014 (Pediatr Surg Int): <i>Ideal timing of orchiopexy: a systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), Embase (1980 onwards), and CINAHL (1982 onwards) to find relevant articles.]&quot;</span>
This indicates that the review protocol was established before conducting the review. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two researchers independently performed each level of screening, comparing the selected studies to reach a consensus. If a consensus could not be reached, they consulted a third researcher.&quot;</span> 
This indicates that there was duplicate study selection. [Yes] 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), Embase (1980 onwards), and CINAHL (1982 onwards) to find relevant articles.]&quot;</span>
At least two electronic sources were searched. [Yes]

A4. Was the status of publication used as an inclusion criterion? 
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
No list of included/excluded studies provided. [No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two researchers independently assessed each study, comparing the scores for each item on each tool to reach a consensus.&quot;</span>
Quality was assessed using standard tools. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results and conclusions focus on the highest quality studies based on the quality assessment. [Yes] 

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included?
No mention of conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In this systematic review, we assessed the quality of all studies pertaining to this topic and developed recommendations based on the highest quality evidence.&quot;</span> [Yes]

P2. Structured summary.
The abstract provides a structured summary. [Yes]

P3. Describe the rationale for the review. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To address this problem, we conducted a systematic evaluation of orchiopexy research, focusing on fertility and testicular malignancy outcomes, and assessing the quality of each study.&quot;</span> [Yes]

P4. Provide objectives with PICOS.
Objectives provided in introduction: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;From there, we were able to reach a conclusion regarding the ideal timing of orchiopexy in cryptorchid children, based on the highest quality research available.&quot;</span> [Yes] 

P5. Indicate if a review protocol exists.
No mention of a review protocol. [No]

P6. Specify study characteristics used as criteria.
Inclusion criteria described in methods. [Yes]

P7. Describe information sources and dates last searched. 
Information sources and dates described. [Yes]

P8. Present full electronic search strategy.
Full search strategy not provided. [No]

P9. State process for selecting studies.
Study selection process described. [Yes]

P10. Describe method of data extraction.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;One researcher extracted data from each of the included studies, and a second researcher checked the data for accuracy and completeness.&quot;</span> [Yes]

P11. List and define all variables extracted.
Outcomes described in Table 1. [Yes] 

P12. Describe methods for assessing risk of bias. 
Quality assessment tools described. [Yes]

P13. State principal summary measures.
No quantitative synthesis performed. [NA]

P14. Describe methods of handling and combining data.
No quantitative synthesis performed. [NA] 

P15. Specify assessment of risk of bias across studies.
No assessment of risk of bias across studies. [NA]

P16. Describe additional analyses. 
No additional analyses mentioned. [NA]

P17. Give numbers of studies at each stage. 
Figure 1 provides numbers of studies at each stage. [Yes]

P18. Present characteristics of included studies.
Table 1 presents characteristics of included studies. [Yes]

P19. Present risk of bias within studies.
Table 1 includes quality assessment scores. [Yes]

P20. Present results for each study. 
Table 1 summarizes key results. [Yes]

P21. Present results of meta-analyses. 
No meta-analysis performed. [NA]

P22. Present assessment of risk of bias across studies.
No assessment of risk of bias across studies. [NA] 

P23. Give results of additional analyses.
No additional analyses mentioned. [NA]

P24. Summarize evidence.
Key findings are summarized in the discussion. [Yes]

P25. Discuss limitations at study and outcome level.
Limitations are discussed. [Yes]

P26. Provide general interpretation of results.
Results are interpreted in the context of existing evidence. [Yes]

P27. Describe sources of funding.
Sources of funding are not described. [No]</pre>
<p><a name='76'></a></p>
</div>
<div
id="chan-2014-j-pediatr-surg-minimally-invasive-versus-open-repair-of-bochdalek-hernia-a-meta-analysis"
class="section level4">
<h4>76.
<a href='https://doi.org/10.1016/J.JPEDSURG.2014.02.049' title='Open publication'>Chan
2014 (J Pediatr Surg): <i>Minimally invasive versus open repair of
Bochdalek hernia: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 98.7%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis]&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Our objective was to compare the outcomes of these procedures in a systematic review and meta-analysis.]&quot;</span>
The objective indicates this is a systematic review. [Yes]

A2. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two researchers independently assessed each study and compared their scores for each item to reach a consensus. If an agreement could not be reached, they consulted a third researcher.&quot;</span>
Duplicate study selection and data extraction were done. [Yes]

A3.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To identify all studies comparing MIS with open surgery for CDH repair, we conducted an electronic search of MEDLINE (1966 onwards), Embase (1980 onwards), and the Cochrane Central Register of Controlled Trials (CENTRAL). We used the keywords diaphragmatic hernia, thoracoscopy, laparoscopy, minimally invasive surgery, and open.&quot;</span>
At least 2 databases were searched. [Yes]

A4.  
No mention of including or excluding based on publication status. [No] 

A5.  
Figure 1 shows a flow diagram of included and excluded studies. [Yes]

A6.  
Table 1 provides characteristics of included studies. [Yes]

A7.  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):

Methodological Index for Non-Randomized Studies (MINORS) [5]: We used this index to assess the quality of nonrandomized studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;We used the Methodological Index for Non-Randomized Studies (MINORS) [5] to assess the quality of nonrandomized studies.&quot;</span> 
The MINORS criteria are described. [Yes]

A8.  
The results and limitations sections mention issues like selection bias in the studies. [Yes]

A9. [NA]

A10.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To address the risk of publication bias, we created a funnel plot for the recurrence outcome (Fig. 2).&quot;</span>
Publication bias was assessed with a funnel plot. [Yes]

A11. [NA]

P1. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis]&quot;</span>
The title identifies this as a systematic review/meta-analysis. [Yes]

P2.  
The abstract provides a structured summary including objectives, data sources, eligibility criteria, results, and conclusions. [Yes] 

P3.  
The introduction describes the rationale and background. [Yes]

P4.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our objective was to conduct a systematic review and meta-analysis of all published literature comparing surgical repair techniques for CDH. We compared MIS versus open surgery for Bochdalek-type CDH, examining perioperative and postoperative outcomes.&quot;</span>
The objective specifies the participants, interventions, comparisons, and outcomes. [Yes]

P5. [NA] 

P6.  
The methods section specifies study characteristics like study design, participants, interventions used. [Yes]

P7.  
The methods describe the databases searched and date ranges. [Yes]

P8.  
The full search strategy is not provided. [No]

P9.  
Figure 1 shows the study selection process. [Yes] 

P10.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two researchers independently assessed each study for methodological quality using MINORS.&quot;</span>
Duplicate data extraction is mentioned. [Yes]

P11.  
Outcomes like recurrence, operative time, length of stay, etc. are defined. [Yes]

P12. [NA]

P13. [NA] 

P14. [NA]

P15. [NA]

P16. [NA]

P17.  
Figure 1 provides a flow diagram of studies screened, assessed, and included/excluded. [Yes]

P18. 
Table 1 provides characteristics of included studies. [Yes]

P19. [NA]

P20. [NA] 

P21. [NA] 

P22. [NA]

P23. [NA]

P24.  
The discussion summarizes the main findings. [Yes]

P25.  
The discussion mentions limitations like selection bias, heterogeneity, and potential publication bias. [Yes]

P26.  
The conclusion provides an interpretation of the results and implications. [Yes]

P27. [No]</pre>
<p><a name='77'></a></p>
</div>
<div
id="chang-2015-comparing-the-efficacy-and-safety-between-robotic-assisted-versus-open-pyeloplasty-in-children-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>77.
<a href='https://doi.org/10.1007/S00345-015-1526-3' title='Open publication'>Chang
2015: <i>Comparing the efficacy and safety between robotic-assisted
versus open pyeloplasty in children: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for AMSTAR and PRISMA:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We used the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement to report our findings.&quot;</span> The review protocol is described.

A2. [No] There is no mention of duplicate study selection or data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched PubMed for comparative studies (from January 1990 to 2014 September) that compared the efficacy and safety of robotic versus open pyeloplasty.&quot;</span> At least two electronic sources were searched.

A4. [No] The status of publication was not used as an inclusion criterion.

A5. [No] A list of included and excluded studies was not provided. 

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The enrolled trials revealed that RP was more frequently performed in older children, required longer operative time, and shorter hospital stay.&quot;</span> Characteristics of included studies are provided in aggregated form.

A7. [No] The scientific quality of included studies was not formally assessed.

A8. [NA] Scientific quality was not assessed so it was not used in formulating conclusions.

A9. [NA] Methods to combine study findings were not described. 

A10. [NA] Assessment of publication bias was not performed.

A11. [No] Sources of support and conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Comparing the efficacy and safety between roboticassisted versus open pyeloplasty in children: a systemic review and metaanalysis&quot;</span> The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] The objectives state the participants, interventions, comparisons, and outcomes. 

P5. [No] A review protocol is not mentioned.

P6. [Yes] Eligibility criteria are described including characteristics and sources.

P7. [Yes] The information source (PubMed) is described including dates searched. 

P8. [No] The full search strategy is not provided.

P9. [No] The study selection process is not described.

P10. [No] Methods for data collection are not described.

P11. [No] Variables extracted are not listed and defined.

P12. [NA] Risk of bias assessment was not done.

P13. [NA] Summary measures were not described. 

P14. [NA] Synthesis methods were not described.

P15. [NA] Assessment of bias across studies was not done.

P16. [NA] No additional analyses were done.

P17. [No] A flow diagram of study selection is not provided.

P18. [Yes] Study characteristics are presented in the tables.

P19. [NA] Risk of bias within studies was not presented.

P20. [No] Results for each study are not presented. 

P21. [NA] Results of syntheses are not presented. 

P22. [NA] Risk of bias across studies was not presented.

P23. [NA] No additional analyses were done.

P24. [Yes] Main findings are summarized including strength of evidence.

P25. [No] Limitations are not thoroughly discussed.

P26. [Yes] Conclusions are provided with implications for research.

P27. [No] Sources of funding are not described.</pre>
<p><a name='78'></a></p>
</div>
<div
id="chen-2013-transanal-endorectal-pull-through-versus-transabdominal-approach-for-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>78.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.12.036' title='Open publication'>Chen
2013: <i>Transanal endorectal pull-through versus transabdominal
approach for Hirschsprungs disease: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 98.5%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 89.6%):

We searched all publications from August 1998 to March 2012 in the MEDLINE, EMBASE and Cochrane library databases and the Cochrane Controlled Trials Register using different combinations of the following terms: Hirschsprung&#39;s disease, transanal, perineal approach, transabdominal and pull-through.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Original articles published from 1998 to 2012 were searched from Medline, Embase, and Cochrane databases and the Cochrane Controlled Trials Register using different combinations of the following terms: Hirschsprung's disease, transanal, perineal approach, transabdominal and pull-through.&quot;</span>
- The review had predefined inclusion criteria.
- [Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each included study was independently appraised by 3 reviewers (C.Y., S.N., N.K.L.) and data were extracted and entered into a database.&quot;</span>  
- There were at least 2 independent data extractors.
- [Yes]

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched all publications from August 1998 to March 2012 in the MEDLINE, EMBASE and Cochrane library databases and the Cochrane Controlled Trials Register using different combinations of the following terms: Hirschsprung's disease, transanal, perineal approach, transabdominal and pull-through. The reference lists of the full articles were also manually searched to identify additional eligible studies.&quot;</span>
- At least 2 databases were searched along with supplementary methods.
- [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
- No mention of searching for grey literature.
- [No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows a flow diagram of included and excluded studies.
- [Yes] 

A6. Were the characteristics of the included studies provided?
- Table 1 provides characteristics of the included studies.
- [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No quality assessment of included studies is described.
- [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Since quality of studies was not assessed (A7), it could not be used in formulating conclusions.
- [No]

A9. Were the methods used to combine the findings of studies appropriate?  
- Not applicable since no meta-analysis was performed.
- [NA]

A10. Was the likelihood of publication bias assessed?
- Not applicable since no meta-analysis was performed.
- [NA]

A11. Was the conflict of interest included?
- No mention of conflicts of interest.
- [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Transanal endorectal pull-through versus transabdominal approach for Hirschsprung's disease: A systematic review and meta-analysis&quot;</span>
- [Yes]

P2. Structured summary.
- The abstract provides a structured summary.
- [Yes]

P3. Describe rationale for review. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To compare the clinical outcomes of TERPT and TAB, we performed a systematic review and comprehensive meta-analysis from indexed published literature.&quot;</span>
- [Yes]

P4. Provide objectives with PICOS.
- The objective to compare TERPT and TAB is stated, but no PICOS provided.  
- [No]

P5. Indicate protocol and registration.
- No protocol or registration mentioned.
- [No] 

P6. Specify study eligibility criteria.
- Inclusion criteria specified as studies comparing TERPT and TAB.
- [Yes]

P7. Describe information sources.
- Databases and dates searched are reported.
- [Yes]

P8. Present search strategy.
- Search terms provided but not the full search strategy.
- [No]

P9. State process for selection.
- Study selection process described and shown in Figure 1.
- [Yes]

P10. Describe data collection process.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each included study was independently appraised by 3 reviewers (C.Y., S.N., N.K.L.) and data were extracted and entered into a database.&quot;</span>
- [Yes]

P11. List and define data items.
- Outcomes evaluated are listed but not defined.
- [No] 

P12. Assess risk of bias in studies.
- No risk of bias assessment described. 
- [No]

P13. State summary measures.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Pooled odds ratios (OR) were calculated for dichotomous variables; pooled mean differences (MD) were measured for continuous variables.&quot;</span>
- [Yes]

P14. Synthesis methods.
- Not applicable since no meta-analysis was done.
- [NA]

P15. Risk of bias across studies.
- Not applicable since no meta-analysis was done.
- [NA] 

P16. Additional analyses.
- Not applicable since no meta-analysis was done.
- [NA]

P17. Study selection results. 
- The number of studies screened, assessed, and included at each stage is presented in Figure 1.
- [Yes]

P18. Study characteristics.
- Table 1 provides relevant characteristics of the included studies.
- [Yes]

P19. Risk of bias in studies.
- No assessment of risk of bias.
- [No]

P20. Results of individual studies.
- Table 2 reports results for each study.
- [Yes]

P21. Synthesis results. 
- Not applicable since no meta-analysis was done.
- [NA]

P22. Risk of bias across studies.
- Not applicable since no meta-analysis was done.  
- [NA]

P23. Additional analysis.
- Not applicable since no meta-analysis was done.
- [NA]

P24. Summary of evidence.
- The discussion summarizes the main findings.
- [Yes]

P25. Limitations.
- Limitations are discussed.
- [Yes]

P26. Conclusions.
- Conclusions are provided considering limitations and implications.
- [Yes]

P27. Funding. 
- No funding reported.
- [No]</pre>
<p><a name='79'></a></p>
</div>
<div
id="corbett-2015-outcomes-of-endopyelotomy-for-pelviureteric-junction-obstruction-in-the-paediatric-population-a-systematic-review"
class="section level4">
<h4>79.
<a href='https://doi.org/10.1016/J.JPUROL.2015.08.014' title='Open publication'>Corbett
2015: <i>Outcomes of endopyelotomy for pelviureteric junction
obstruction in the paediatric population: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">2
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Medline and Embase databases were searched using relevant key terms to identify reports of paediatric endoplyelotomy.&quot;</span> The review had an a priori design with predefined inclusion/exclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The inclusion of publications was decided by both the study authors and data were extracted independently by both study authors.&quot;</span> There was duplicate study selection and data extraction.  

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Medline and Embase databases were searched using relevant key search terms&quot;</span> [...] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span> At least two databases were searched along with supplementary strategies.

A4. [No] The review did not mention searching for or including grey literature. 

A5. [No] The review did not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> Tables 1 and 2 provide characteristics of included studies.

A7. [No] The review did not describe assessing methodological quality/risk of bias of included studies.

A8. [NA] Not applicable since quality assessment was not done.

A9. [NA] Not applicable since there was no meta-analysis. 

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] The title identifies the report as a systematic review. 

P2. [Yes] The abstract provides a structured summary including objectives, eligibility criteria, data sources, study selection/data extraction methods, results, and conclusions.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The introduction states the objective to systematically analyze published literature to determine the success rate of endopyelotomy in children. 

P5. [No] A protocol was not mentioned.

P6. [Yes] The methods specify inclusion/exclusion criteria. 

P7. [Yes] The methods state the literature sources searched.

P8. [No] A full search strategy was not provided.

P9. [Yes] The methods describe the process of study screening, eligibility, and inclusion. 

P10. [Yes] The methods state that data extraction was done independently in duplicate. 

P11. [Yes] The data extracted from studies are listed in Tables 1 and 2.

P12. [NA] Risk of bias assessment was not done.

P13. [NA] Not applicable since no meta-analysis was done.

P14. [NA] Not applicable since no meta-analysis was done. 

P15. [NA] Not applicable since no meta-analysis was done.

P16. [NA] Not applicable since no additional analyses were done.

P17. [No] A flow diagram of study selection was not provided.

P18. [Yes] Tables 1 and 2 provide characteristics of included studies.

P19. [NA] Risk of bias assessment was not done. 

P20. [Yes] Tables 1 and 2 provide results for each included study.

P21. [NA] Not applicable since no meta-analysis was done.

P22. [NA] Not applicable since no meta-analysis was done.

P23. [NA] Not applicable since no additional analyses were done. 

P24. [Yes] The discussion summarizes the main findings and conclusions.

P25. [Yes] The discussion considers limitations at the review level.

P26. [Yes] The conclusion provides an overall interpretation of results and implications.

P27. [No] Sources of funding were not reported.</pre>
<p><a name='80'></a></p>
</div>
<div
id="cullis-2016-is-screening-of-intestinal-foregut-anatomy-in-heterotaxy-patients-really-necessary"
class="section level4">
<h4>80.
<a href='https://doi.org/10.1097/sla.0000000000001563' title='Open publication'>Cullis
2016: <i>Is Screening of Intestinal Foregut Anatomy in Heterotaxy
Patients Really Necessary?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 67.9%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">23 quote(s)
from the LLM prompt briefing</span> (mean similarity 68.6%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.8%):

review protocol was established.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] The review protocol was not mentioned.&quot;</span>

A2. Was there duplicate study selection and data extraction?  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

hed. Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Yes] Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.&quot;</span>

A3. Was a comprehensive literature search performed?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.4%):

A systematic search of the English language literature was conducted using a keyword algorithm (Supplemental Figure 1, http:// links.lww.com/SLA/A928). The search was conducted using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] A systematic search of the English language literature was conducted using a keyword algorithm (Supplemental Figure 1, http://links.lww.com/SLA/A928). The search was conducted using the indexed databases: CINAHL, EMBASE, Medline, and Cochrane Databases, from inception to January 11, 2015.&quot;</span>

A4. Was the status of publication used as an inclusion criterion?
<span title='Moderate quote deviation. Best match in prompt (Similarity 80%):

the status of publication (i.e. grey literature) used as an inclusion criterion?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] The status of publication was not mentioned as an inclusion criterion.&quot;</span> 

A5. Was a list of studies (included and excluded) provided?
<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):

? A list of included and excluded studies should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] A list of included and excluded studies was not provided.&quot;</span>

A6. Were the characteristics of the included studies provided?  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):

Table 2 summarizes the main characteristics of the 19 included studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Table 2 summarizes the main characteristics of the 19 included studies.&quot;</span>

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.5%):

the scientific quality of the included studies assessed and' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] The quality of included studies was not assessed beyond MINORS criteria applied later.&quot;</span>

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Moderate quote deviation. Best match in prompt (Similarity 79.5%):

the scientific quality of the included studies used appropriately in formulating conclusions?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] The quality of studies was not discussed in formulating conclusions.&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.9%):

nor were any designed to compare those managed conservatively' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] The findings were not combined quantitatively.&quot;</span>

A10. Was the likelihood of publication bias assessed?
<span title='Moderate quote deviation. Best match in prompt (Similarity 82.1%):

publication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] Publication bias was not assessed.&quot;</span>

A11. Was the conflict of interest included?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.2%):

ns, Collins 34 found that 4% were reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] Conflicts of interest were not reported.&quot;</span>

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.4%):

Title: Identify the report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The title identifies it as a systematic review.&quot;</span>

P2. Structured summary.
<span title='Moderate quote deviation. Best match in prompt (Similarity 81.6%):

Abstract / Structured summary: Provide a structured summary' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The abstract provides a structured summary.&quot;</span>

P3. Describe the rationale for the review. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.5%):

Introduction / Rationale: Describe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The introduction describes the rationale in context of existing knowledge.&quot;</span>

P4. Provide an explicit statement of questions being addressed.
<span title='Moderate quote deviation. Best match in prompt (Similarity 76.6%):

Introduction / Objectives: Provide an explicit statement of questions being addressed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The introduction states the two questions being addressed.&quot;</span>

P5. Indicate if a review protocol exists and provide registration information.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.9%):

review protocol was established.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] A review protocol was not mentioned.&quot;</span> 

P6. Specify study characteristics used as criteria for eligibility.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.7%):

. Inclusion and Exclusion Criteria' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Inclusion and exclusion criteria are specified in Table 1.&quot;</span>

P7. Describe information sources and dates last searched.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.3%):

Methods / Information sources: Describe all information sources (e.g., databases' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The methods section describes the information sources and dates searched.&quot;</span>

P8. Present full electronic search strategy.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.1%):

(Supplemental Figure 1, http:// links.lww.com/SLA/A928). The search' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Supplemental Figure 1 shows the full search strategy.&quot;</span>

P9. State process for selecting studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.2%):

Methods / Study selection: State the process for selecti' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The methods section describes the process for study selection.&quot;</span>

P10. Describe method of data extraction and confirmation. 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.2%):

Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] The methods state two reviewers extracted data independently.&quot;</span>

P11. List and define variables for which data were sought.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.4%):

s / Data items: List and define' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Data items sought were not explicitly listed and defined.&quot;</span>

P12. Describe methods for assessing risk of bias.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61%):

methods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Methods for assessing risk of bias were not described.&quot;</span> 

P13. State principal summary measures.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 50.9%):

were any designed to compare those managed conservatively' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Summary measures were not combined quantitatively.&quot;</span>

P14. Describe methods of handling and combining data.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.5%):

combining data in quantitative' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] Data were not combined quantitatively.&quot;</span>

P15. Specify assessment of risk of bias across studies.
<span title='Moderate quote deviation. Best match in prompt (Similarity 80%):

/ Risk of bias across studies: Specify any assess' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[NA] Risk of bias across studies was not assessed.&quot;</span>

P16. Describe additional analyses.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.1%):

additional analyses, if done' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] No additional analyses were done.&quot;</span>

P17. Give numbers of studies screened, assessed, and included. 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.3%):

, the number of individual patients reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] The number of studies at each stage was not reported.&quot;</span>

P18. For each study, present characteristics and provide citations.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78%):

TABLE 2. Characteristics of Included Studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Table 2 presents characteristics of included studies.&quot;</span> 

P19. Present data on risk of bias for each study.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61%):

risk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Risk of bias was not presented for individual studies.&quot;</span>

P20. For each study, present simple summary data for each intervention group.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.5%):

) simple summary data for each' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Simple summary data were not presented for each study.&quot;</span>

P21. Present results of meta-analyses done.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.7%):

s (meta-analysis was therefore not' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Meta-analyses were not done.&quot;</span>

P22. Present results of assessment of risk of bias across studies.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.7%):

assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] Assessment of risk of bias across studies was not done.&quot;</span>

P23. Give results of additional analyses.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.1%):

additional analyses, if done' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] No additional analyses were done.&quot;</span>

P24. Summarize the main findings and discuss relevance to key groups.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61.7%):

Discussion / Summary of evidence: Summarize the main findings in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The discussion summarizes main findings and relevance.&quot;</span>

P25. Discuss limitations at study and outcome level and at review level.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.1%):

limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Limitations at the study and review levels are discussed.&quot;</span>

P26. Provide a general interpretation of results and implications for future research.
<span title='Moderate quote deviation. Best match in prompt (Similarity 87.2%):

Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The discussion provides an interpretation and implications for research.&quot;</span>

P27. Describe sources of funding and role of funders.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.2%):

sources of funding for' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Sources of funding were not described.&quot;</span></pre>
<p><a name='81'></a></p>
</div>
<div
id="cundy-2014-bju-int-meta-analysis-of-robot-assisted-vs-conventional-laparoscopic-and-open-pyeloplasty-in-children"
class="section level4">
<h4>81.
<a href='https://doi.org/10.1111/bju.12683 ' title='Open publication'>Cundy
2014 (BJU Int): <i>Meta-analysis of robot-assisted vs conventional
laparoscopic and open pyeloplasty in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, reasoning, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The search was conducted up to December 2013.]&quot;</span>
The review protocol was registered prior to conducting the review. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently undertook literature searches, screened abstracts, and assessed eligible articles against inclusion criteria (T.P.C., A.H.H.).&quot;</span>
Two authors independently performed study selection and data extraction. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic literature searches were undertaken of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Ovid Medline and EMBASE electronic databases using the following search strategy using the following Medical Subject Headings (MeSH): (Surgery, Computer-Assisted OR robotics OR da Vinci OR telerobotic OR telesurgery OR robotic surgery) AND (Pediatrics OR Infant OR Child OR Adolescent) AND (Kidney OR Pelvi-ureteric Junction Obstruction OR Pyeloplasty).&quot;</span>
At least two electronic databases were searched along with supplementary sources. [Yes]

A4. Was the status of publication used as an inclusion criterion?  
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Table 1 lists the included studies. The excluded studies are not listed. [No]

A6. Were the characteristics of the included studies provided? 
Table 1 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total out of 15).&quot;</span> [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The quality of studies was considered in the discussion. [Yes]  

A9. Were the methods used to combine the findings of studies appropriate? [NA]

A10. Was the likelihood of publication bias assessed? [NA]

A11. Was the conflict of interest included? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;None disclosed.&quot;</span> [Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]

P2. Structured summary. [Yes]

P3. Describe rationale for review. [Yes]  

P4. Provide objectives with PICOS. [Yes]

P5. Indicate protocol and registration. [Yes]

P6. Specify eligibility criteria. [Yes] 

P7. Describe information sources including dates. [Yes]

P8. Present search strategy. [Yes]

P9. State process for selection studies. [Yes]

P10. Describe data collection process. [Yes] 

P11. List and define data items sought. [Yes]

P12. Assess risk of bias in individual studies. [Yes] 

P13. State summary measures. [Yes]

P14. Describe synthesis methods. [NA]

P15. Assess risk of bias across studies. [NA] 

P16. Describe additional analyses. [NA]

P17. Give study selection results. [Yes]

P18. Present study characteristics. [Yes]

P19. Present risk of bias within studies. [Yes]

P20. Present results of individual studies. [Yes]

P21. Present synthesis results. [NA]

P22. Present risk of bias across studies. [NA]

P23. Give additional analysis results. [NA]

P24. Summarize evidence. [Yes]

P25. Discuss limitations. [Yes]

P26. Provide general interpretation. [Yes]

P27. Describe funding sources. [Yes]</pre>
<p><a name='82'></a></p>
</div>
<div
id="cundy-2014-j-pediatr-surg-meta-analysis-of-robot-assisted-versus-conventional-laparoscopic-fundoplication-in-children"
class="section level4">
<h4>82.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.12.014' title='Open publication'>Cundy
2014 (J Pediatr Surg): <i>Meta analysis of robot-assisted versus
conventional laparoscopic fundoplication in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">18 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003971).&quot;</span>
Reasoning: The study was prospectively registered.

A2. Was there duplicate study selection and data extraction?
"[No]"  
Quotes: None.
Reasoning: Duplication of study selection and data extraction is not mentioned. 

A3. Was a comprehensive literature search performed?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic literature searches were undertaken of PubMed and EMBASE electronic databases using the following search strategy&quot;</span> [...] ""
Reasoning: At least two databases were searched.

A4. Was the status of publication used as an inclusion criterion?
"[No]"
Quotes: None.  
Reasoning: No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
Quotes: None.
Reasoning: A list of excluded studies is not provided.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Six studies met inclusion criteria, involving 135 robot-assisted and 162 conventional laparoscopic fundoplication procedures (Tables 12)&quot;</span>
Reasoning: Characteristics of included studies are provided in Tables 1-2.

A7. Was the scientific quality of the included studies assessed and documented?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total/15)&quot;</span>
Reasoning: The mNOS scale was used to assess study quality. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The strength of this meta-analysis is therefore limited by inherent vulnerability of these study designs to multiple sources of bias and both known and unknown confounders.&quot;</span>
Reasoning: Study limitations are acknowledged.

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]"
Quotes: None.
Reasoning: No quantitative data synthesis performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"  
Quotes: None.
Reasoning: No assessment of publication bias without a meta-analysis.

A11. Was the conflict of interest included?
"[No]"
Quotes: None.  
Reasoning: No mention of conflicts of interest.

P1. Identify as systematic review in title.
"[Yes]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta analysis of robot-assisted versus conventional laparoscopic fundoplication in children&quot;</span>
Reasoning: Identified as meta-analysis in title.

P2. Structured summary.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
Reasoning: Structured abstract provided.

P3. Describe rationale for review. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The role of robotic surgery in this setting remains unclear, generating a growing sentiment of polarized opinion amongst the surgical community, which is without a well-defined evidence base. The aim of this study is to critically appraise the literature comparing robot-assisted versus conventional laparoscopic MIS for fundoplication in order to further elucidate the comparative safety and efficacy of these techniques.&quot;</span>
Reasoning: Rationale described.

P4. Provide objectives with PICOS.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Primary outcome measures of interest were intra-operative conversions, intra-operative complications, length of hospital stay (LOS), post-operative complications, operating time (OT), analgesia requirement and cost.&quot;</span>
Reasoning: Outcomes of interest specified.

P5. Indicate protocol registration. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003971).&quot;</span> 
Reasoning: Registration number and database provided.

P6. Specify eligibility criteria.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All included studies satisfied the following criteria: 1) comparing robot-assisted (RF) versus conventional laparoscopic fundoplication (LF), 2) involving pediatric patients with mean or median study group ages b 18 years, 3) reporting  5 patients in each study group, and 4) investigating either objective clinical outcome measures or GERD symptoms via standardized questionnaires.&quot;</span>
Reasoning: Eligibility criteria described.

P7. Describe information sources.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic literature searches were undertaken of PubMed and EMBASE electronic databases using the following search strategy&quot;</span> [...] "" 
Reasoning: Databases and search strategy provided.

P8. Present full search strategy.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic literature searches were undertaken of PubMed and EMBASE electronic databases using the following search strategy&quot;</span> [...] ""
Reasoning: Search strategy provided.

P9. State process for study selection.
"[No]" 
Quotes: None.
Reasoning: Study selection process not described.

P10. Describe data collection process. 
"[No]"
Quotes: None.
Reasoning: Data extraction process not described. 

P11. List and define data items sought.
"[Yes]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Primary outcome measures of interest were intra-operative conversions, intra-operative complications, length of hospital stay (LOS), post-operative complications, operating time (OT), analgesia requirement and cost.&quot;</span>
Reasoning: Outcomes of interest defined.

P12. Assess risk of bias in individual studies. 
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total/15)&quot;</span>
Reasoning: Risk of bias assessed with mNOS scale.

P13. State principal summary measures.  
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Pooled odds ratios (OR) were calculated as the summary statistic for dichotomous variables and weighted mean difference (WMD) calculated for continuous variables.&quot;</span>
Reasoning: Summary measures described.

P14. Synthesis methods.
"[NA]"
Quotes: None. 
Reasoning: No meta-analysis performed.

P15. Risk of bias across studies.
"[NA]"
Quotes: None.
Reasoning: No assessment of risk of bias across studies without meta-analysis.

P16. Additional analyses. 
"[NA]" 
Quotes: None.
Reasoning: No additional analyses without meta-analysis.

P17. Study selection results.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Six studies met inclusion criteria, involving 135 robot-assisted and 162 conventional laparoscopic fundoplication procedures (Tables 12)&quot;</span>
Reasoning: Number of studies included reported. 

P18. Study characteristics. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Six studies met inclusion criteria, involving 135 robot-assisted and 162 conventional laparoscopic fundoplication procedures (Tables 12)&quot;</span>
Reasoning: Study characteristics provided in Tables 1-2.

P19. Risk of bias within studies.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total/15)&quot;</span>
Reasoning: Risk of bias assessed with mNOS scale.

P20. Results of individual studies.
"[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

In the RF group, reasons for conversions were due to intraoperative hypotension and arrhythmia (n = 1) [13], technical difficulty in a redo case (n = 1) [13], and unclear anatomy associated with a hiatus hernia (n = 1) [11]. In the LF group, reasons for conversion were due to gastric perforation (n = 1) [13], incidental discovery of a Morgagni hernia (n = 1) [12], instrument problems (n = 1) [12], and technical difficulty in re-do cases (n = 2) [11]' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In the RF group, reasons for conversions were due to intraoperative hypotension and arrhythmia (n = 1) [13], technical difficulty in a re-do case (n = 1) [13], and unclear anatomy associated with a hiatus hernia (n = 1) [11]. In the LF group, reasons for conversion were due to gastric perforation (n = 1) [13], incidental discovery of a Morgagni hernia (n = 1) [12], instrument problems (n = 1) [12], and technical difficulty in re-do cases (n = 2) [11].&quot;</span>
Reasoning: Results for individual studies provided.

P21. Synthesis of results.
"[NA]"  
Quotes: None.
Reasoning: No meta-analysis performed.

P22. Risk of bias across studies.  
"[NA]"
Quotes: None.
Reasoning: No assessment of risk of bias across studies without meta-analysis. 

P23. Additional analysis.
"[NA]"
Quotes: None.
Reasoning: No additional analyses without meta-analysis.

P24. Summary of evidence.
"[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

This meta-analysis has identified no significant difference between robot-assisted and conventional laparoscopic fundoplication for short-term outcomes of intra-operative conversion, length of hospital stay, post-operative complications and total operating time' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This meta-analysis has identified no significant difference between robot-assisted and conventional laparoscopic fundoplication for short-term outcomes of intra-operative conversion, length of hospital stay, post-operative complications and total operating time.&quot;</span> 
Reasoning: Main findings summarized.

P25. Limitations. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The strength of this meta-analysis is therefore limited by inherent vulnerability of these study designs to multiple sources of bias and both known and unknown confounders. Many important outcome variables also remain unaccounted for in the literature.&quot;</span>
Reasoning: Limitations discussed.

P26. Conclusions.
"[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

. Conclusion Meta-analysis of the current literature identifies comparable safety and short-term efficacy for robot-assisted laparoscopic fundoplication when compared to conventional laparoscopic fundoplication in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In conclusion, meta-analysis of the current literature identifies comparable safety and short-term efficacy for robot-assisted laparoscopic fundoplication when compared to conventional laparoscopic fundoplication in children.&quot;</span>
Reasoning: Conclusions provided.

P27. Funding.
"[No]"
Quotes: None.
Reasoning: No mention of funding sources.</pre>
<p><a name='83'></a></p>
</div>
<div
id="cundy-2014-eur-j-pediatr-surg-robot-assisted-minimally-invasive-surgery-for-pediatric-solid-tumors-a-systematic-review-of-feasibility-and-current-status"
class="section level4">
<h4>83.
<a href='https://doi.org/10.1055/S-0033-1347297' title='Open publication'>Cundy
2014 (Eur J Pediatr Surg): <i>Robot-Assisted Minimally Invasive Surgery
for Pediatric Solid Tumors: A Systematic Review of Feasibility and
Current Status</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 97.4%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">17 quote(s)
from the LLM prompt briefing</span> (mean similarity 100%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003971).&quot;</span>
Reasoning: The study was prospectively registered.

A2. Was there duplicate study selection and data extraction?
"[No]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently undertook literature searches, screened abstracts and assessed articles against eligibility criteria (TPC, HJM).&quot;</span>
Reasoning: Two authors performed study selection, but data extraction was not done in duplicate.

A3. Was a comprehensive literature search performed?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic literature searches were undertaken of PubMed and EMBASE electronic databases&quot;</span> [...] <span title='Moderate quote deviation. Best match in fulltext (Similarity 79.3%):

The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword fundoplication, and 3) abstracts of the Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword fundoplication, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;</span>
Reasoning: At least two databases were searched along with supplementary strategies. 

A4. Was the status of publication used as an inclusion criterion?
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No language restrictions were imposed.&quot;</span>
Reasoning: No restrictions were placed on publication status or language.

A5. Was a list of studies (included and excluded) provided?
"[No]"
Reasoning: A list of included studies was provided in Tables 1-2, but no list of excluded studies. 

A6. Were the characteristics of the included studies provided? 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.&quot;</span> 
Reasoning: Table 1 provides aggregated characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total/15)&quot;</span>
Reasoning: The mNOS scale was used to assess study quality.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The strength of this meta-analysis is therefore limited by inherent vulnerability of these study designs to multiple sources of bias and both known and unknown confounders.&quot;</span>
Reasoning: Study limitations due to quality were acknowledged.

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]"
Reasoning: No quantitative data synthesis was performed.

A10. Was the likelihood of publication bias assessed?
"[NA]" 
Reasoning: No quantitative data synthesis was performed.

A11. Was the conflict of interest included?
"[No]"
Reasoning: No statement on conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta analysis of robot-assisted versus conventional laparoscopic fundoplication in children&quot;</span>
Reasoning: Identified as a meta-analysis in the title.

P2. Structured summary.
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
Reasoning: Structured abstract provided with all key elements.

P3. Rationale for the review. 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe the rationale for the review in the context of what is already known.&quot;</span>
Reasoning: Introduction describes the rationale.

P4. Objectives.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span>  
Reasoning: Objectives and PICOS criteria outlined.

P5. Protocol and registration. 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
Reasoning: Prospective registration reported.

P6. Eligibility criteria.
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
Reasoning: Inclusion/exclusion criteria described.

P7. Information sources.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span>
Reasoning: Information sources described.

P8. Search strategy.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
Reasoning: Search strategy provided.

P9. Study selection process. 
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span>
Reasoning: Selection process described.

P10. Data collection process.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
Reasoning: Data extraction process described.

P11. Data items.
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
Reasoning: Outcomes of interest defined.

P12. Risk of bias assessment. 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>
Reasoning: Quality assessment described.

P13. Summary measures. 
"[NA]"
Reasoning: No meta-analysis performed.

P14. Synthesis methods.
"[NA]"
Reasoning: No meta-analysis performed. 

P15. Risk of bias across studies.
"[NA]"
Reasoning: No meta-analysis performed.

P16. Additional analyses. 
"[NA]" 
Reasoning: No additional analyses undertaken.

P17. Study selection results.
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span>
Reasoning: Study selection results provided in Figure 1.

P18. Study characteristics. 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span>
Reasoning: Study characteristics presented in Tables 1-2.

P19. Risk of bias within studies.
"[No]"
Reasoning: Individual study bias assessments not provided.

P20. Results of individual studies. 
"[No]"
Reasoning: No forest plots with individual study effect estimates.

P21. Synthesis of results.
"[NA]"
Reasoning: No meta-analysis performed.

P22. Risk of bias across studies.
"[NA]"
Reasoning: No meta-analysis performed.

P23. Additional analysis.
"[NA]"
Reasoning: No additional analyses performed.

P24. Summary of evidence.
"[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
Reasoning: Main findings summarized.

P25. Limitations. 
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span>
Reasoning: Limitations discussed.

P26. Conclusions.
"[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
Reasoning: Conclusions provided.

P27. Funding.
"[No]"
Reasoning: No statement on sources of funding.</pre>
<p><a name='84'></a></p>
</div>
<div
id="ding-2013-single-incision-versus-conventional-three-incision-laparoscopic-appendicectomy-for-appendicitis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>84.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.026' title='Open publication'>Ding
2013: <i>Single-incision versus conventional three-incision laparoscopic
appendicectomy for appendicitis: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">3
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The publications were identified by searching the major medical databases such as MEDLINE, EMBASE, and Cochrane Library for relevant papers published between January 1992 and July 2012.&quot;</span> The review had an a priori design with predefined objectives, eligibility criteria, and information sources.

A2. [No] The review did not mention duplicate study selection and data extraction.

A3. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).&quot;</span> The review searched multiple electronic databases. 

A4. [No] The review did not state whether grey literature was searched.

A5. [No] The review did not provide a list of included and excluded studies. 

A6. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> Table 1 provided characteristics of included studies.

A7. [No] The review did not assess the scientific quality of included studies.

A8. [NA] Not applicable since quality of studies was not assessed.

A9. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span> Heterogeneity was assessed where applicable. 

A10. [No] Publication bias was not assessed.

A11. [No] Sources of support were not reported for included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Single-incision versus conventional three-incision laparoscopic appendicectomy for appendicitis: A systematic review and meta-analysis&quot;</span> Identified as a systematic review and meta-analysis.

P2. [Yes] Provided a structured abstract with objectives, data sources, eligibility criteria, interventions, results, and conclusions. 

P3. [Yes] Described rationale and context of what is known on the topic.

P4. [Yes] Stated the objective to compare SILA versus TILA for appendicitis. 

P5. [No] Did not mention a review protocol.

P6. [Yes] Specified inclusion criteria and characteristics used.

P7. [Yes] Stated the databases searched and years covered. 

P8. [No] Did not provide a full search strategy.

P9. [Yes] Stated the process of study screening and selection. 

P10. [No] Did not describe the data extraction process. 

P11. [Yes] Listed variables extracted.

P12. [No] Did not assess risk of bias in individual studies.

P13. [Yes] Stated the summary measures used in meta-analysis.

P14. [Yes] Described methods for meta-analysis and assessing heterogeneity.

P15. [No] Did not assess risk of bias across studies.

P16. [NA] No additional analyses were done.

P17. [Yes] Provided a flow diagram of study selection. 

P18. [Yes] Presented characteristics of included studies in Table 1.

P19. [No] Did not present risk of bias results.

P20. [Yes] Presented results for outcomes in forest plots.

P21. [Yes] Presented meta-analysis results with heterogeneity measures.

P22. [NA] No assessment of bias across studies.

P23. [NA] No additional analyses.

P24. [Yes] Summarized the main findings and conclusions.

P25. [Yes] Discussed limitations at the review level.

P26. [Yes] Provided interpretation in context of other evidence. 

P27. [No] Did not describe sources of funding.</pre>
<p><a name='85'></a></p>
</div>
<div
id="dingemann-2014-thoracoscopic-procedures-in-pediatric-surgery-what-is-the-evidence"
class="section level4">
<h4>85.
<a href='https://doi.org/10.1055/S-0033-1350060' title='Open publication'>Dingemann
2014: <i>Thoracoscopic Procedures in Pediatric Surgery: What is the
Evidence?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA assessments:

A1. [No] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We aimed to identify comparative studies investigating VATS versus open procedures in pediatric surgery and to classify publications according to the CEBM criteria.&quot;</span> The review did not mention an a priori design.

A2. [No] The review did not mention duplicate study selection or data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Clinical studies published in the English literature were identified by a Medline literature search using PubMed.&quot;</span> The search included limits indicating comprehensive sources.

A4. [No] The review did not mention whether grey literature was included or excluded.

A5. [No] The review did not provide a list of included and excluded studies.

A6. [No] The review did not provide characteristics of the included studies. 

A7. [No] The review did not mention assessing quality of included studies.

A8. [NA] Quality assessment was not performed.

A9. [NA] Quantitative synthesis was not performed. 

A10. [NA] Assessment of publication bias was not applicable.

A11. [No] Sources of support were not reported for included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Thoracoscopic Procedures in Pediatric Surgery: What is the Evidence?&quot;</span> Identifies as a systematic review.

P2. [No] Structured summary not provided.

P3. [Yes] Introduction describes rationale and context.

P4. [No] Review question and inclusion criteria not explicitly stated. 

P5. [No] Review protocol not mentioned.

P6. [No] Eligibility criteria not specified.

P7. [Yes] Information sources described as PubMed search.

P8. [No] Full search strategy not provided.

P9. [No] Study selection process not described. 

P10. [No] Data collection process not described.

P11. [No] Data items not defined.

P12. [NA] Risk of bias assessment not applicable.

P13. [NA] Summary measures not applicable. 

P14. [NA] Synthesis methods not applicable.

P15. [NA] Risk of bias across studies not applicable.

P16. [NA] Additional analyses not applicable.

P17. [No] Study selection flow diagram not provided. 

P18. [No] Study characteristics not presented.

P19. [NA] Risk of bias within studies not applicable.

P20. [No] Results for individual studies not shown.

P21. [NA] Synthesis results not applicable. 

P22. [NA] Risk of bias across studies not applicable.

P23. [NA] Additional analyses not applicable. 

P24. [No] Summary of evidence not provided.

P25. [No] Limitations not discussed.

P26. [Yes] General interpretation of results provided.

P27. [No] Sources of funding not reported.</pre>
<p><a name='86'></a></p>
</div>
<div
id="dingemann-2013-systematic-review-of-level-1-evidence-for-laparoscopic-pediatric-surgery-do-our-procedures-comply-with-the-requirements-of-evidence-based-medicine"
class="section level4">
<h4>86.
<a href='https://doi.org/10.1055/S-0033-1333639' title='Open publication'>Dingemann
2013: <i>Systematic Review of Level 1 Evidence for Laparoscopic
Pediatric Surgery: Do Our Procedures Comply with the Requirements of
Evidence-Based Medicine?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic review of clinical Level 1 studies using PubMed.&quot;</span>
The review had predefined inclusion criteria.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All MA and RCT were identified and individually reviewed.&quot;</span>
At least two databases were searched. 

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Study characteristics like number of patients and outcomes assessed are summarized in Table 3. 

A7. Was the scientific quality of the included studies assessed and documented? [No]
No assessment of study quality mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias as no meta-analysis was performed.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify as systematic review in title [No]
Title does not mention <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;systematic review&quot;</span>.

P2. Structured summary [No]
No structured abstract provided.

P3. Rationale in introduction [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;However, a SR of the available publications meeting the CEBM criteria for Level 1 has not been performed to date.&quot;</span>

P4. Objectives in introduction [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of our study was to present a current analysis of the Level 1 studies directly comparing laparoscopic and open operations in pediatric patients.&quot;</span>

P5. Protocol registration [No]  
No mention of review protocol.

P6. Eligibility criteria [Yes]
Inclusion criteria described: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Only studies comparing pediatric laparoscopic procedures with the corresponding open operation were included.&quot;</span>

P7. Information sources [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Clinical Level 1 studies (SR, MA, and RCT) published in the English literature were identified through a Medline literature search using PubMed.&quot;</span>

P8. Search strategy [No]
Search strategy not provided.

P9. Study selection process [No]  
Process of study selection not described. 

P10. Data collection process [No]
No details provided on data extraction.

P11. Data items [Yes]  
Outcomes extracted summarized in Table 3.

P12. Risk of bias assessment [No]
No assessment of risk of bias.

P13. Summary measures [NA]
No meta-analysis performed.

P14. Synthesis of results [NA] 
No meta-analysis performed.

P15. Risk of bias across studies [NA]
No assessment of risk of bias across studies as no meta-analysis performed. 

P16. Additional analyses [NA]
No additional analyses like sensitivity analyses performed.

P17. Study selection flow diagram [No]
No flow diagram depicting study selection.

P18. Study characteristics [Yes]
Study characteristics summarized in Table 3.

P19. Risk of bias within studies [No]
No assessment of risk of bias within studies.

P20. Results of individual studies [Yes] 
Key findings of individual studies summarized in Table 3.

P21. Synthesis of results [NA]
No quantitative synthesis performed.

P22. Risk of bias across studies [NA] 
No assessment of risk of bias across studies.

P23. Additional analysis [NA]
No additional analyses performed.

P24. Summary of evidence [Yes]
Main findings summarized in discussion section. 

P25. Limitations [No]
No discussion of limitations.

P26. Conclusions [Yes]
Conclusions provided in discussion section.

P27. Funding [No] 
No mention of sources of funding.</pre>
<p><a name='87'></a></p>
</div>
<div
id="ells-2015-surgery-for-the-treatment-of-obesity-in-children-and-adolescents"
class="section level4">
<h4>87.
<a href='https://doi.org/10.1002/14651858.CD011740' title='Open publication'>Ells
2015: <i>Surgery for the treatment of obesity in children and
adolescents</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">24 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items based on the provided full text:

A1. Was an 'a priori' design provided? 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the following sources on the 30th of March 2015 from inception to the specified database date and placed no restrictions on the language of publication.&quot;</span>
Explanation: The review protocol was registered before the review was conducted.
[Yes]

A2. Was there duplicate study selection and data extraction?  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two review authors (LJE, EM) independently scanned the abstract, title, or both, of every record retrieved by the searches.&quot;</span>
Explanation: Two reviewers independently selected studies and extracted data. 
[Yes]

A3. Was a comprehensive literature search performed?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the Cochrane Library, MEDLINE, PubMed, EMBASE as well as LILACS, ICTRP Search Portal and ClinicalTrials.gov (all from database inception to March 2015).&quot;</span>
Explanation: Multiple databases were searched without language or date restrictions.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

d placed no restrictions on the language of publication.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We placed no restrictions on the language of publication.&quot;</span> 
Explanation: No restrictions were placed on publication status.
[Yes]  

A5. Was a list of studies (included and excluded) provided?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We present an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram reporting the process of study selection.&quot;</span>
Explanation: A flow diagram of included and excluded studies was provided.
[Yes]

A6. Were the characteristics of the included studies provided?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A detailed description of the characteristics of included studies is presented elsewhere.&quot;</span>
Explanation: Characteristics of the included study were provided in a table.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two review authors (LJE, KR) independently assessed the risk of bias of each included study.&quot;</span> 
Explanation: Risk of bias was assessed using the Cochrane risk of bias tool.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Whilst the included study was well conducted and provides much needed evidence in this field, further studies are required to strengthen the evidence base.&quot;</span>
Explanation: The quality assessment was taken into account when interpreting the results.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?
Explanation: Not applicable, as only one study was included.
[NA]

A10. Was the likelihood of publication bias assessed?  
Explanation: Not applicable, as only one study was included.
[NA]

A11. Was the conflict of interest included?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The study received some funding from the gastric band manufacturer (Allergen) and one of the co-authors declared his position as a member of the Allergen advisory board.&quot;</span>
Explanation: Sources of support were reported.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Surgery for the treatment of obesity in children and adolescents (Review)&quot;</span>
Explanation: The report is identified as a systematic review in the title.
[Yes]

P2. Provide a structured summary.
Quote: "Abstract" section provides a structured summary.
Explanation: A structured abstract is provided.
[Yes]

P3. Describe the rationale for the review.  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Given the serious implications associated with childhood and adolescent obesity, effective treatment is imperative.&quot;</span>
Explanation: The rationale is described in the Background section.
[Yes]  

P4. Provide an explicit statement of the questions being addressed.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To assess the effects of surgery for treating obesity in children and adolescents.&quot;</span> 
Explanation: The objective is stated explicitly.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the following sources on the 30th of March 2015 from inception to the specified database date and placed no restrictions on the language of publication.&quot;</span>
Explanation: The review methods were pre-specified in a protocol. 
[Yes]

P6. Specify study characteristics used as criteria for eligibility.
Quote: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Types of studies&quot;</span>, <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of participants&quot;</span>, <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of interventions&quot;</span> sections list eligibility criteria.
Explanation: Eligibility criteria are described.
[Yes] 

P7. Describe information sources including dates of coverage.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the following sources on the 30th of March 2015 from inception to the specified database date and placed no restrictions on the language of publication.&quot;</span>
Explanation: Information sources and dates are described.
[Yes]

P8. Present full electronic search strategy for at least one database. 
Quote: Search strategy provided in Appendix 1.
Explanation: Search strategy for multiple databases is provided.
[Yes]

P9. State the process for selecting studies.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two review authors (LJE, EM) independently scanned the abstract, title, or both, of every record retrieved by the searches.&quot;</span>
Explanation: Study selection process is described.
[Yes]

P10. Describe method of data extraction and any processes for obtaining and confirming data. 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two review authors (LJE, KR, or EM) independently extracted key participant and intervention characteristics and reported data on efficacy outcomes and adverse events using a standard data extraction form supplied by the CMED Group.&quot;</span>
Explanation: Data extraction process is described.
[Yes] 

P11. List and define all variables for which data were sought.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of outcome measures&quot;</span> section lists and defines all outcomes.
Explanation: Outcomes are defined.
[Yes]

P12. Describe methods for assessing risk of bias of individual studies. 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two review authors (LJE, KR) independently assessed the risk of bias of each included study.&quot;</span>
Explanation: Risk of bias assessment methods are described.
[Yes]

P13. State the principal summary measures.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For dichotomous outcomes we calculated odds ratio (OR) or risk ratio (RR) and corresponding 95% confidence interval (CI). For continuous outcomes we calculated the mean difference (MD) and corresponding 95% CI.&quot;</span>  
Explanation: Summary measures are stated.
[Yes]

P14. Describe methods of handling data and combining results.
Explanation: Not applicable, as no meta-analysis was performed.
[NA]

P15. Specify any assessment of risk of bias across studies.
Explanation: Not applicable, as only one study was included.
[NA]  

P16. Describe additional analyses such as sensitivity analyses.
Explanation: Not applicable, as only one study was included.
[NA]

P17. Provide numbers of studies screened, assessed for eligibility, and included.
Quote: Figure 1 shows the study selection process.
Explanation: The number of studies at each stage is documented in a flow diagram.
[Yes]

P18. For each study, present characteristics and provide citations.
Quote: Characteristics of included study presented in a table.
Explanation: A table describes study characteristics.
[Yes]

P19. Present data on risk of bias of each study.
Quote: Risk of bias presented in a figure.
Explanation: Risk of bias is documented in a figure.
[Yes]

P20. For each study, present simple summary data for each intervention group and effect estimates and CIs.
Quote: Results section presents summary data.
Explanation: Summary data and effect estimates are provided.
[Yes] 

P21. Present results of meta-analyses done, including CIs and measures of consistency.
Explanation: Not applicable, as no meta-analysis was performed.
[NA]

P22. Present results of any assessment of risk of bias across studies.
Explanation: Not applicable, as only one study was included. 
[NA]

P23. Give results of additional analyses such as sensitivity analyses.
Explanation: Not applicable, as only one study was included.
[NA]

P24. Summarize the main findings including the strength of evidence.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review reports the findings from one RCT (50 participants). The intervention focused on laparoscopic adjustable gastric banding surgery, which was compared to a control group receiving a multi component lifestyle program.&quot;</span>
Explanation: Main findings are summarized.
[Yes]

P25. Discuss limitations at study and outcome level and at review level.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Whilst the included study was well conducted and provides much needed evidence in this field, further studies are required to strengthen the evidence base.&quot;</span>
Explanation: Limitations at the study and review level are discussed.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The findings from this review agree with the most recent systematic reviews of adolescent obesity surgery (Aikenhead 2011; Black 2013).&quot;</span>
Explanation: Findings are interpreted in the context of other evidence.
[Yes]

P27. Describe sources of funding and other support, and the role of funders.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We would like to thank Leanne Mohan (Teesside University) and Gudrun Paletta (Cochrane Metabolic and Endocrine Disorders Group) for helping with review management.&quot;</span>
Explanation: Sources of support are described.
[Yes]</pre>
<p><a name='88'></a></p>
</div>
<div
id="elyas-2010-is-staging-beneficial-for-fowler-stephens-orchiopexy-a-systematic-review"
class="section level4">
<h4>88.
<a href='https://doi.org/10.1016/J.JURO.2010.01.035' title='Open publication'>Elyas
2010: <i>Is Staging Beneficial for Fowler-Stephens Orchiopexy? A
Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">18 quote(s) from
publication full text</span> (mean similarity 99.1%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">4
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted a systematic review to determine whether single or 2-stage Fowler-Stephens orchiopexy results in better testicular viability.&quot;</span>
Explanation: The objective is clearly stated.
[Yes]

A2. Was there duplicate study selection and data extraction?
Quotes: None
Explanation: No mention of duplicate study selection or data extraction.  
[No]

A3. Was a comprehensive literature search performed?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched several electronic databases, including MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Control Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and ACP Journal Club.&quot;</span>
Explanation: Searched multiple databases. 
[Yes] 

A4. Was the status of publication used as an inclusion criterion?
Quotes: None  
Explanation: No mention of including or excluding based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided? 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Figure 1. Flowchart of excluded and included articles&quot;</span>
Explanation: Provided a flow diagram of included and excluded studies.
[Yes]

A6. Were the characteristics of the included studies provided?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The table summarizes the quality assessment results of the included articles.&quot;</span> 
Explanation: Provided characteristics in a table.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quotes: None
Explanation: No mention of assessing quality of included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
Quotes: None
Explanation: Did not assess quality of studies.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta-analysis using weighted mean difference (random effects model) was conducted using R software.&quot;</span>
Explanation: Described methods for meta-analysis.
[Yes]

A10. Was the likelihood of publication bias assessed?  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The funnel plot was roughly symmetrical, suggesting that publication bias was unlikely a significant factor.&quot;</span>
Explanation: Assessed publication bias with funnel plot.
[Yes]

A11. Was the conflict of interest included?
Quotes: None
Explanation: No mention of conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both. 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;A Systematic Review&quot;</span>
Explanation: Identified as a systematic review in title.
[Yes]

P2. Structured summary.
Quotes: "Abstract" section
Explanation: Provided structured abstract.
[Yes] 

P3. Describe rationale for review.
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

HE surgical approach to the high undescended testis can be quite challenging, since the cord structures might be of insufficient length for a tension-free scrotal placement.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The surgical approach to the high undescended testis can be quite challenging, since the cord structures might be of insufficient length for a tension-free scrotal placement.&quot;</span>  
Explanation: Provided background and rationale.
[Yes]

P4. Provide objectives with PICOS.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We evaluated whether single stage or 2-stage FSO results in greater testicular viability in children younger than 18 years with intra-abdominal testes.&quot;</span>
Explanation: Stated objective and population.
[Yes]

P5. Indicate protocol and registration.
Quotes: None
Explanation: Did not mention protocol or registration.
[No]

P6. Specify eligibility criteria.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies were considered relevant if they met the following inclusion criteria. Patients were younger than 18 years, had an intra-abdominal testis, had undergone single or 2-stage FSO (open or laparoscopic), and had data regarding testicular size and position available postoperatively.&quot;</span>
Explanation: Described eligibility criteria.
[Yes]

P7. Describe information sources. 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Search Strategy&quot;</span> section describes databases searched.
Explanation: Detailed search strategy.
[Yes]

P8. Present search strategy.
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

The search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; Initial search n = 1807 Non-relevant abstracts and duplicates excluded n = 1660 Grey Literature, conference proceedings, reference lists n = 13 Hard copies of papers and/or abstracts obtained. n = 160 Non-English and non-relevant papers excluded. n = 61 Final exclusion for relevance n = 38 excluded Studies included in review n = 61 Citations underwent review n = 99 Figure 1. Flowchart of excluded and included articles STAGED FOWLER-STEPHENS ORCHIOPEXY 2013 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intraabdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13. This strategy was also used with some modifications for Embase.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-abdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13. This strategy was also used with some modifications for Embase.&quot;</span>
Explanation: Provided full search strategy.
[Yes]

P9. State process for study selection.  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All of the identified abstracts were imported into an electronic database (RefWorks, Bethesda, Maryland) and underwent initial screening for relevance by 2 of us. Hard copies of potentially relevant records were obtained and a more focused screening excluded additional documents.&quot;</span>
Explanation: Described screening process.
[Yes]

P10. Describe data collection process.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each author was allocated roughly 10 articles, and independently abstracted the data and assessed the quality of the reports.&quot;</span>
Explanation: Mentioned independent data extraction.
[Yes]

P11. List and define data items.
Quotes: None
Explanation: Did not list or define data extracted.
[No]

P12. Assess risk of bias in individual studies.
Quotes: None  
Explanation: Did not assess risk of bias.
[No]

P13. State summary measures. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta-analysis using weighted mean difference (random effects model) was conducted using R software.&quot;</span>
Explanation: Stated using weighted mean difference.
[Yes]

P14. Synthesis methods.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Heterogeneity was assessed graphically by examining the forest plot and statistically using the I2 test.&quot;</span>
Explanation: Described methods for assessing heterogeneity.
[Yes]

P15. Risk of bias across studies.
Quotes: None
Explanation: Did not assess risk of bias across studies.
[No] 

P16. Additional analyses. 
Quotes: None
Explanation: No additional analyses mentioned.
[NA]

P17. Study selection results.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Figure 1. Flowchart of excluded and included articles&quot;</span>
Explanation: Provided flow diagram of study selection. 
[Yes]

P18. Study characteristics. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The table summarizes the quality assessment results of the included articles.&quot;</span>
Explanation: Provided characteristics in table.
[Yes]

P19. Risk of bias within studies.
Quotes: None
Explanation: Did not assess risk of bias within studies.
[No]

P20. Results of individual studies.
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 84%):

Figure 2. Forest plot' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Figures 2-4. Forest plots&quot;</span>
Explanation: Provided forest plots with results.
[Yes]

P21. Synthesis of results.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The pooled estimate of success rate was 80% for single stage Fowler-Stephens orchiopexy (95% CI 75 to 86) and 85% for 2-stage Fowler-Stephens orchiopexy (95% CI 81 to 90).&quot;</span> 
Explanation: Provided pooled results.
[Yes]

P22. Risk of bias across studies. 
Quotes: None
Explanation: Did not assess risk of bias across studies.
[No]

P23. Additional analysis.
Quotes: None  
Explanation: No additional analyses mentioned.
[NA]

P24. Summary of evidence.
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Conclusions&quot;</span> section.  
Explanation: Summarized main findings.
[Yes]

P25. Limitations.
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Discussion&quot;</span> section describes limitations.
Explanation: Discussed limitations.
[Yes]

P26. Conclusions.
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Conclusions&quot;</span> section.
Explanation: Provided conclusions.
[Yes]

P27. Funding. 
Quotes: None
Explanation: No mention of funding sources.
[No]</pre>
<p><a name='89'></a></p>
</div>
<div
id="esposito-2014-laparoscopic-versus-open-inguinal-hernia-repair-in-pediatric-patients-a-systematic-review"
class="section level4">
<h4>89.
<a href='https://doi.org/10.1089/lap.2014.0194' title='Open publication'>Esposito
2014: <i>Laparoscopic Versus Open Inguinal Hernia Repair in Pediatric
Patients: A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">2
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The objective is clearly stated in the abstract. 

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched.&quot;</span> 
Multiple databases were searched as described in the methods.

A4. [No]
No mention of including or excluding based on publication status. 

A5. [No]
No list of included/excluded studies provided.

A6. [Yes] 
Table 1 provides characteristics of the included studies.

A7. [No]
No mention of quality assessment of individual studies.

A8. [NA]
Quality was not assessed.

A9. [NA]  
No meta-analysis performed.

A10. [No]
No assessment of publication bias mentioned.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
Title identifies as a systematic review.

P2. [Yes] 
Structured abstract provided with all relevant sections.

P3. [Yes]
Introduction describes rationale and context.

P4. [Yes]
Objectives stated in introduction. 

P5. [No]
No mention of a review protocol.

P6. [Yes]
Eligibility criteria described in methods.

P7. [Yes]
Information sources described in methods.

P8. [No] 
No search strategy provided.

P9. [Yes]
Study selection process described and depicted in Figure 1.

P10. [No]
No details provided on data collection process. 

P11. [Yes]
Outcomes described in methods.

P12. [NA] 
No assessment of risk of bias in individual studies.

P13. [NA]
No meta-analysis performed.

P14. [NA]  
No meta-analysis performed.

P15. [NA]
No assessment of risk of bias across studies.

P16. [NA]
No additional analyses mentioned.

P17. [Yes]
Study selection process described and depicted in Figure 1.

P18. [Yes] 
Study characteristics presented in Table 1. 

P19. [NA]
No assessment of risk of bias.

P20. [Yes] 
Results for outcomes presented throughout results section.

P21. [NA] 
No meta-analysis performed.

P22. [NA]
No assessment of risk of bias across studies.

P23. [NA]
No additional analyses mentioned. 

P24. [Yes]
Main findings summarized in discussion.

P25. [Yes] 
Limitations discussed.

P26. [Yes]
General interpretation and implications described.

P27. [No]
No statement about sources of funding.</pre>
<p><a name='90'></a></p>
</div>
<div
id="feng-2016-laparoscopic-versus-open-splenectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>90.
<a href='https://doi.org/10.1007/S00383-015-3845-2' title='Open publication'>Feng
2016: <i>Laparoscopic versus open splenectomy in children: a systematic
review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015.&quot;</span> The research question and inclusion criteria were established before the review.
A1 explains the a priori design.

A2. [No] The text does not mention duplicate study selection or data extraction.
A2 is not described. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015. The search terms laparoscopic splenectomy, pediatrics, open splenectomy, minimally invasive and children were used individually and in combination.&quot;</span> At least two electronic sources were searched.
A3 describes the literature search.

A4. [No] The status of publication was not used as an inclusion criterion. 
A4 is not described.

A5. [No] A list of included and excluded studies is not provided.
A5 is not described.

A6. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

Tables 2 and 3 outlines the primary and secondary outcome results from each study.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;</span> Data from the original studies are provided in tables.
A6 provides study characteristics.

A7. [No] The scientific quality of included studies was not formally assessed.
A7 is not described.

A8. [NA] Scientific quality was not assessed, so it could not be used in formulating conclusions.
A8 is not applicable.

A9. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

For continuous data, we presented mean differences (MDs) with 95 % confidence intervals (CIs). For dichotomous data, we calculated odds ratios (ORs). Statistical heterogeneity in the meta-analysis was assessed with the v 2 test and the I 2 inde' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;For continuous data, we presented mean differences (MDs) with 95% confidence intervals (CIs). For dichotomous data, we calculated odds ratios (ORs). Statistical heterogeneity in the meta-analysis was assessed with the 2 test and the I2 index.&quot;</span> Appropriate methods were used to combine findings.  
A9 describes synthesis methods.

A10. [No] Publication bias was not assessed.
A10 is not described. 

A11. [No] Conflicts of interest were not included.
A11 is not described.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic versus open splenectomy in children: a systematic review and meta-analysis&quot;</span> The title identifies the report as a systematic review and meta-analysis.
P1 identifies the report as a systematic review and/or meta-analysis.

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions.
P2 provides an abstract with structured summary.

P3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Recent development in minimally invasive surgery has led to the increased adoption of laparoscopic techniques in the children [17].&quot;</span> The introduction describes the rationale in context of existing knowledge.
P3 describes the rationale.

P4. [No] The objectives are not explicitly stated with PICOS.
P4 does not provide objectives with PICOS.

P5. [No] A protocol is not mentioned.
P5 does not mention a protocol.

P6. [No] Eligibility criteria are not specified with details like PICOS and publication status.
P6 does not specify eligibility criteria. 

P7. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015.&quot;</span> The information sources and dates searched are described.
P7 describes information sources.

P8. [No] The full search strategy is not presented for any database.
P8 does not provide the search strategy.

P9. [No] The study selection process is not described. 
P9 does not describe study selection.

P10. [No] Data collection methods are not described.
P10 does not describe data collection.

P11. [No] Variables for which data were sought are not listed or defined.
P11 does not list or define data items.

P12. [No] Methods for assessing risk of bias are not described.
P12 does not describe risk of bias assessment. 

P13. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For continuous data, we presented mean differences (MDs) with 95% confidence intervals (CIs). For dichotomous data, we calculated odds ratios (ORs).&quot;</span> Summary measures are stated.
P13 states summary measures.

P14. [NA] 
P14 is not applicable since no meta-analysis was performed.

P15. [NA]
P15 is not applicable since no meta-analysis was performed.

P16. [NA]  
P16 is not applicable since no meta-analysis was performed.

P17. [No] A flow diagram of study selection is not provided.
P17 does not provide a flow diagram.

P18. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

Tables 2 and 3 outlines the primary and secondary outcome results from each study.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;</span> Study characteristics are presented with citations.
P18 provides study characteristics.

P19. [No] Risk of bias within studies is not presented.
P19 does not present risk of bias.

P20. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Tables 2 and 3 outlines the primary and secondary outcome results from each study.&quot;</span> Results for each intervention group are presented.
P20 presents results for each study.

P21. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The meta-analysis shown that LS was associated with shorter hospital stays, less blood loss, and longer operative times in children.&quot;</span> Results of each meta-analysis are presented. 
P21 presents results of syntheses.

P22. [NA] 
P22 is not applicable since no meta-analysis was performed.

P23. [NA]
P23 is not applicable since no meta-analysis was performed.

P24. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our study suggests that LS is a feasible, safe, and effective surgical procedure alternative to OS for pediatric patients.&quot;</span> Main findings are summarized including relevance.
P24 summarizes evidence.

P25. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our systematic review and meta-analysis have several limitations.&quot;</span> Limitations at the study and outcome level are discussed.
P25 discusses limitations.

P26. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Randomized controlled trials of high quality are definitely necessary and needed in the future to make our results more convincing and conclusive.&quot;</span> General interpretation and future research implications are provided.
P26 provides conclusion.

P27. [No] Sources of funding are not described. 
P27 does not describe sources of funding.</pre>
<p><a name='91'></a></p>
</div>
<div
id="feng-2015-open-versus-laparoscopic-inguinal-herniotomy-in-children"
class="section level4">
<h4>91.
<a href='https://doi.org/10.1097/SLE.0000000000000161' title='Open publication'>Feng
2015: <i>Open Versus Laparoscopic Inguinal Herniotomy in
Children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy&quot;</span>." The review had an a priori design.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The first author independently extracted data from the included studies.&quot;</span> There was duplicate study selection and data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy. Total reference lists of selected articles were also included.&quot;</span> A comprehensive literature search was performed.

A4. [No] The review did not state whether grey literature was searched.

A5. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Five trials met the total inclusion criteria and had no exclusion criteria (Fig. 1): Chan et al, Koivusalo et al, Celebi et al, Shalaby et al, and Saranga et al.&quot;</span> A list of included and excluded studies was provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Details of publication (type of repairing the internal ring, trocars, and follow-up duration), inclusion and exclusion criteria, and demographics of the enrolled patients were collected and collated.&quot;</span> Characteristics of included studies were provided.

A7. [No] The scientific quality of included studies was not formally assessed. 

A8. [NA] Scientific quality was not assessed so it could not be incorporated into formulating conclusions.

A9. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span> Appropriate methods were used for combining study findings.

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Open Versus Laparoscopic Inguinal Herniotomy in Children: A Systematic Review and Meta-Analysis Focusing on Postoperative Complications&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale for the review. 

P4. [Yes] The introduction states the objective to compare laparoscopic versus open herniorrhaphy for inguinal hernia in children in terms of operative time, recurrence, and complications.

P5. [No] The review protocol was not registered.

P6. [Yes] The methods specify inclusion criteria such as randomized trials comparing laparoscopic versus open repair in children.

P7. [Yes] The methods state the information source was a systematic search of PubMed.

P8. [No] The full search strategy was not provided.

P9. [Yes] The methods describe the study selection process. 

P10. [Yes] The methods state that data extraction was performed by the first author independently. 

P11. [Yes] The methods list the data items extracted, such as operative time and complications.

P12. [No] Risk of bias in individual studies was not assessed.

P13. [Yes] The methods state that mean differences and odds ratios were the summary measures used.

P14. [NA] Not applicable since no meta-analysis was performed for some outcomes.

P15. [NA] Not applicable since no meta-analysis was performed for some outcomes. 

P16. [NA] Not applicable since no meta-analysis was performed for some outcomes.

P17. [Yes] The results provide a flow diagram of study selection.

P18. [Yes] The results provide citations and characteristics of included studies.

P19. [No] Risk of bias in individual studies was not presented.

P20. [Yes] The results present summary data and effect estimates for each study.

P21. [Yes] The results present meta-analysis results with confidence intervals and consistency measures.

P22. [NA] Not applicable since no meta-analysis was performed for some outcomes.

P23. [NA] Not applicable since no meta-analysis was performed for some outcomes. 

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] The discussion mentions limitations at the study level.

P26. [Yes] The conclusion provides an overall interpretation of results.

P27. [No] Sources of funding were not reported.</pre>
<p><a name='92'></a></p>
</div>
<div
id="friedmacher-2011-residual-aganglionosis-after-pull-through-operation-for-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>92.
<a href='https://doi.org/10.1007/S00383-011-2958-5' title='Open publication'>Friedmacher
2011: <i>Residual aganglionosis after pull-through operation for
Hirschsprungs disease: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
unsolicited-ranges</i></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We designed this meta-analysis to determine the incidence and outcome of RA among patients with HD following PT operation.]&quot;</span>
States the objective a priori.
[Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction.
[No] 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;PubMed and MEDLINE databases were searched for all studies that reported cases of patients with HD who had undergone redo PT operations for RA or TZB after initial operation between 1985 and 2011. The search terms were residual aganglionosis, transition-zone bowel, redo and repeat pull-through, reoperation Hirschsprungs disease and postoperative follow-up and outcome Hirschsprungs disease. The reference lists from retrieved articles were reviewed for additional cases.&quot;</span>
Searched 2 databases and supplemented with reference scanning.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. 
[No]

A5. Was a list of studies (included and excluded) provided?
Included studies listed in Table 1. No list of excluded studies.
[No]

A6. Were the characteristics of the included studies provided? 
Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No mention of quality assessment.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?
No mention of conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Title: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Residual aganglionosis after pull-through operation for Hirschsprungs disease: a systematic review and meta-analysis&quot;</span>
[Yes]

P2. Structured summary.
Abstract provides structured summary.
[Yes]

P3. Describe the rationale for the review. 
Introduction describes rationale.
[Yes]

P4. Objectives with PICOS.
Objective stated in introduction but no PICOS.
[No]

P5. Indicate protocol and registration.
No mention of protocol or registration.
[No]

P6. Specify study eligibility criteria.
Eligibility criteria not explicitly specified.
[No]

P7. Information sources.
Described in methods.
[Yes] 

P8. Present search strategy.
Search strategy not provided.
[No]

P9. Study selection process. 
Selection process not described.
[No]

P10. Data collection process.
Data extraction process not described.
[No] 

P11. List and define data items.
Table 1 lists data extracted but no definitions provided.
[No]

P12. Assess risk of bias in studies.
No risk of bias assessment.
[No]

P13. Summary measures.
No quantitative synthesis performed.
[NA]

P14-P23. Synthesis methods, bias across studies, additional analyses.
No quantitative synthesis performed.
[NA]

P24. Summary of evidence.
Main findings summarized in discussion. 
[Yes]

P25. Limitations at study and outcome level.
Limitations not discussed.
[No]

P26. Conclusions and implications.
General interpretation and implications provided in discussion.
[Yes]

P27. Describe sources of funding.
No mention of sources of funding. 
[No]</pre>
<p><a name='93'></a></p>
</div>
<div
id="friedmacher-2012-delayed-primary-anastomosis-for-management-of-long-gap-esophageal-atresia-a-meta-analysis-of-complications-and-long-term-outcome"
class="section level4">
<h4>93.
<a href='https://doi.org/10.1007/S00383-012-3142-2' title='Open publication'>Friedmacher
2012: <i>Delayed primary anastomosis for management of long-gap
esophageal atresia: a meta-analysis of complications and long-term
outcome</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 67.1%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">22 quote(s)
from the LLM prompt briefing</span> (mean similarity 59.2%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.2%):

? The research question and inclusion criteria s' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] The research question and inclusion criteria are not explicitly stated.&quot;</span>
A2. Was there duplicate study selection and data extraction?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 41.3%):

s independently performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Two authors independently performed full-text assessment.&quot;</span>
A3. Was a comprehensive literature search performed?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50%):

SIGLE database, dissertations, conference proceeding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Searched multiple databases and cross-referencing.&quot;</span>  
A4. Was the status of publication used as an inclusion criterion?  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70%):

publication (i.e. grey literature) used as an inclusion criteri' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Publication status not mentioned as inclusion criteria.&quot;</span>
A5. Was a list of studies (included and excluded) provided?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.7%):

included studies assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Only included studies listed.&quot;</span>
A6. Were the characteristics of the included studies provided?
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):

. Study and patients characteristics are presented in Table 1.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Study characteristics presented in Table 1.&quot;</span>
A7. Was the scientific quality of the included studies assessed and documented?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 34.2%):

y assessment' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Quality assessment not mentioned.&quot;</span>
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.4%):

assessment of relevant articles was independently performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Quality assessment not performed.&quot;</span>
A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 55.6%):

cumulative meta-analysis reveal' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Used cumulative meta-analysis and relative risk.&quot;</span>
A10. Was the likelihood of publication bias assessed?
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.1%):

publication bias assessed?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] Publication bias not assessed.&quot;</span>
A11. Was the conflict of interest included?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.5%):

. Conflict of interest' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] Conflicts of interest not reported.&quot;</span>

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.1%):

: Identify the report as a systematic review, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Identified as meta-analysis in title.&quot;</span>
P2. Structured summary.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.7%):

/ Structured summary: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Structured abstract provided.&quot;</span>
P3. Rationale.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.6%):

/ Rationale: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Rationale described in introduction.&quot;</span>
P4. Objectives.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.6%):

Objectives: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Specific objectives not provided.&quot;</span>
P5. Protocol and registration.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.9%):

s / Protocol and registration' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Protocol not mentioned.&quot;</span> 
P6. Eligibility criteria.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.2%):

inclusion criteria as described.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Inclusion criteria described in methods.&quot;</span>
P7. Information sources.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.6%):

, databases with dates' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Databases and dates listed.&quot;</span>
P8. Search.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.8%):

search strategy should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Full search strategy not provided.&quot;</span>
P9. Study selection.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.6%):

lection process: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Selection process described.&quot;</span>
P10. Data collection process.  
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.9%):

data extraction Identified' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Data extraction described.&quot;</span>
P11. Data items.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 48%):

s described.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Outcomes described.&quot;</span>
P12. Risk of bias in individual studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.6%):

os / Risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Risk of bias not assessed.&quot;</span>
P13. Summary measures.  
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68%):

the relative risk' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Used relative risk.&quot;</span>
P14. Synthesis of results.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):

meta-analysis was performed.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[NA] No meta-analysis performed.&quot;</span>
P15. Risk of bias across studies.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):

meta-analysis was performed.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[NA] No meta-analysis performed.&quot;</span>
P16. Additional analyses.  
<span title='Moderate quote deviation. Best match in prompt (Similarity 78.6%):

/ Additional analyses:' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[NA] No additional analyses.&quot;</span>
P17. Study selection.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.9%):

study selection an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Study selection shown in flow diagram.&quot;</span> 
P18. Study characteristics.  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):

. Study and patients characteristics are presented in Table 1.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Study characteristics presented in Table 1.&quot;</span>
P19. Risk of bias within studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.6%):

os / Risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Risk of bias not assessed.&quot;</span>
P20. Results of individual studies.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.7%):

complication rates an' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Complication rates shown.&quot;</span>
P21. Synthesis of results.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.4%):

estimates an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Pooled estimates shown.&quot;</span>
P22. Risk of bias across studies.  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):

meta-analysis was performed.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[NA] No meta-analysis performed.&quot;</span>
P23. Additional analysis.
<span title='Moderate quote deviation. Best match in prompt (Similarity 78.6%):

/ Additional analyses:' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[NA] No additional analyses.&quot;</span>
P24. Summary of evidence.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.4%):

main findings' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Main findings summarized.&quot;</span>
P25. Limitations.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.4%):

/ Limitations: Discuss' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Limitations described in discussion.&quot;</span>
P26. Conclusions.
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.8%):

/ Conclusions: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] Conclusions provided.&quot;</span>
P27. Funding. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.8%):

not reported,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Funding not reported.&quot;</span></pre>
<p><a name='94'></a></p>
</div>
<div
id="frongia-2013-comparison-of-lilt-and-step-procedures-in-children-with-short-bowel-syndrome-a-systematic-review-of-the-literature"
class="section level4">
<h4>94.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.018' title='Open publication'>Frongia
2013: <i>Comparison of LILT and STEP procedures in children with short
bowel syndrome  A systematic review of the literature</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;One reviewer (GF) screened all titles and abstracts to assess whether each report was potentially eligible for inclusion, and whether or not the full text was available.&quot;</span> The a priori design was established before conducting the review.

A2. [No] The process of study selection and data extraction was done by only one reviewer. There is no mention of a second independent reviewer. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Using mentioned search terms, n = 4282 potentially relevant articles were identified and screened for retrieval. After excluding n = 4010 articles due to failure to meet selection criteria for the purpose of this review, n = 272 potentially appropriate articles were retrieved for more detailed evaluation.&quot;</span> At least two electronic sources were searched.

A4. [No] There is no mention of searching for or including grey literature. 

A5. [Yes] Figure 2 shows the flow of included and excluded studies.

A6. [Yes] Table 1 provides characteristics of the included studies. 

A7. [No] There is no mention of assessing the quality or risk of bias of individual studies.

A8. [NA] Quality assessment of individual studies was not performed.

A9. [NA] No meta-analysis was performed. 

A10. [NA] No meta-analysis was performed.

A11. [No] There is no mention of conflicts of interest in the systematic review.

P1. [Yes] The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] The introduction states the objective and participants of interest. 

P5. [No] No protocol or registration is mentioned.

P6. [Yes] The methods section specifies eligibility criteria.

P7. [Yes] The methods section describes the information sources and date last searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] The process of study selection is described and depicted in Figure 2.

P10. [Yes] The data extraction process is described. 

P11. [Yes] Outcomes extracted are listed in the methods.

P12. [No] Individual study risk of bias was not assessed. 

P13. [NA] No meta-analysis was performed.

P14. [NA] No meta-analysis was performed. 

P15. [NA] No meta-analysis was performed.

P16. [NA] No additional analyses were performed.

P17. [Yes] Figure 2 provides a flow diagram of study selection.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] Individual study risk of bias was not presented.

P20. [Yes] Results for outcomes are presented for each study in the results section.

P21. [NA] No meta-analysis was performed. 

P22. [NA] No meta-analysis was performed.

P23. [NA] No additional analyses were performed. 

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided along with implications for future research.

P27. [No] There is no mention of sources of funding for the review.</pre>
<p><a name='95'></a></p>
</div>
<div
id="gallo-2012-long-gap-esophageal-atresia-a-meta-analysis-of-jejunal-interposition-colon-interposition-and-gastric-pull-up"
class="section level4">
<h4>95.
<a href='https://doi.org/10.1055/S-0032-1331459' title='Open publication'>Gallo
2012: <i>Long-Gap Esophageal Atresia: a Meta-Analysis of Jejunal
Interposition, Colon Interposition, and Gastric Pull-Up</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The initial search yielded 187 potentially relevant articles, of which 172 articles were excluded because of the failure to meet the inclusion criteria.&quot;</span> The review had pre-defined inclusion/exclusion criteria.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A literature search (PubMed and Embase) was performed, and all human studies published in the English-language literature between 2006 and 2011 describing esophageal replacement for LGEA were identified, using the medical subject headings&quot;</span> [...] "" Two databases were searched along with checking references.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]  
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
Included studies listed in Table 1 but excluded studies not provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of included studies. Additional details provided in text.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No assessment of study quality mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Study quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
Random effects model used for meta-analysis due to heterogeneity.

A10. Was the likelihood of publication bias assessed? [No]
Publication bias not assessed.

A11. Was the conflict of interest included? [No]  
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Title: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Long-Gap Esophageal Atresia: a Meta-Analysis of Jejunal Interposition, Colon Interposition, and Gastric Pull-Up&quot;</span>

P2. Structured summary. [Yes]  
Structured abstract provided with background, objectives, data sources, eligibility criteria, interventions, methods, results, conclusions.

P3. Describe the rationale for the review. [Yes]  
Introduction describes rationale and context.

P4. Provide objectives with PICOS. [Yes] 
Objectives stated in introduction: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this article was to perform a meta-analysis comparing the most widely used techniques for esophageal replacement in children: jejunal interposition (JI), colon interposition (CI), and gastric pull-up (GPU).&quot;</span> Participants, interventions, comparisons stated. Outcomes not explicitly listed in PICOS format but described in methods. 

P5. Indicate protocol and registration. [No]
No protocol mentioned.

P6. Specify study characteristics and eligibility criteria. [Yes]
Inclusion/exclusion criteria described. Rationale provided for excluding case reports, reviews, etc.

P7. Describe information sources including search dates. [Yes]
Search strategy described including databases, date range, and supplementary search of references.

P8. Present full search strategy. [No]
Search terms listed but full strategy not provided.

P9. State process for study selection. [No]  
Number of articles screened and excluded reported but process not described.

P10. Describe data collection process. [No]
No details provided on data extraction process.

P11. List and define data items sought. [Yes]  
Outcomes described in methods.

P12. Assess risk of bias in individual studies. [No] 
Individual study bias not assessed.

P13. State summary measures. [Yes]
Used relative risks as summary measures. 

P14. Synthesis of results. [Yes]
Random effects meta-analysis conducted. Heterogeneity discussed.

P15. Risk of bias across studies. [NA]
Assessment of publication bias not done.

P16. Additional analyses. [NA] 
No additional analyses mentioned.

P17. Study selection results. [Yes]  
Number of studies screened, assessed, included provided. Exclusions at each stage reported.

P18. Study characteristics. [Yes]
Table 1 provides key characteristics of included studies. Additional details in text.

P19. Risk of bias within studies. [No]
Individual study bias not assessed.

P20. Results of individual studies. [Yes] 
Table 2 provides results for main outcomes from individual studies.

P21. Synthesis of results. [Yes] 
Table 2 provides meta-analysis results.

P22. Risk of bias across studies. [NA] 
Publication bias not assessed.

P23. Additional analysis. [NA]
No additional analyses mentioned.

P24. Summary of evidence. [Yes]
Main findings summarized in discussion.

P25. Limitations. [Yes]  
Limitations discussed including lack of RCTs, heterogeneity in outcomes reported, and small number of studies for some interventions.

P26. Conclusions. [Yes]
Conclusions provided along with implications for research.

P27. Funding. [No]
No statement about sources of funding.</pre>
<p><a name='96'></a></p>
</div>
<div
id="gosemann-2013-open-versus-transanal-pull-through-for-hirschsprung-disease-a-systematic-review-of-long-term-outcome"
class="section level4">
<h4>96.
<a href='https://doi.org/10.1055/s-0033-1343085 ' title='Open publication'>Gosemann
2013: <i>Open Versus Transanal Pull-Through for Hirschsprung Disease: A
Systematic Review of Long-Term Outcome</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">14 quote(s) from
publication full text</span> (mean similarity 84.8%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">21 quote(s)
from the LLM prompt briefing</span> (mean similarity 64.9%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT. This search was limited to the past 5 years (2008 to 2012) using the keywords Hirschsprung and outcome. Reference lists were screened for additional studies.]&quot;</span>
The review had predefined objectives and criteria. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.3%):

duplicate study selection and data extraction?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of duplicate study selection or data extraction]&quot;</span>  
Duplicate processes not described. [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT. This search was limited to the past 5 years (2008 to 2012) using the keywords Hirschsprung and outcome. Reference lists were screened for additional studies.]&quot;</span>
Searched PubMed and reference lists. [Yes]

A4. Was the status of publication used as an inclusion criterion?  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.2%):

based on their publication status,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of including or excluding studies based on publication status]&quot;</span>
Publication status not described as inclusion criteria. [No]  

A5. Was a list of studies (included and excluded) provided?
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):

articles finally met the inclusion criteria and were analyzed in detail.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[18 articles finally met the inclusion criteria and were analyzed in detail.]&quot;</span>
Included studies listed, excluded not described. [No]

A6. Were the characteristics of the included studies provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Data extracted from included articles were study characteristics (authors, journal, publication year, sample size, surgical technique, and follow-up period) and patient characteristics (age at surgery, extent of aganglionosis).]&quot;</span>
Study characteristics described. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.7%):

quality of included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of quality assessment of included studies]&quot;</span>
Quality assessment not described. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.7%):

quality of included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of quality assessment of included studies]&quot;</span>
Quality not assessed, so not used in conclusions. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[With the cumulative data, a comparative meta-analysis was performed for the outcome parameters constipation, soiling/incontinence, enterocolitis, and anastomotic stricture.]&quot;</span>
Performed meta-analysis on relevant outcomes. [Yes]

A10. Was the likelihood of publication bias assessed?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.1%):

assessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No assessment of publication bias mentioned]&quot;</span>
Publication bias not assessed. [No]

A11. Was the conflict of interest included?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.5%):

conflict of interest' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of conflicts of interest]&quot;</span>
Conflicts of interest not reported. [No]

P1. Identify as systematic review in title.
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Open Versus Transanal Pull-Through for Hirschsprung Disease: A Systematic Review of Long-Term Outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Open Versus Transanal Pull-Through for Hirschsprung Disease: A Systematic Review of Long-Term Outcome]&quot;</span>
Systematic review identified in title. [Yes]  

P2. Structured summary.
<span title='Moderate quote deviation. Best match in prompt (Similarity 85.2%):

background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Abstract with background, objectives, data sources, eligibility criteria, methods, results, limitations, and conclusions]&quot;</span>
Structured abstract provided. [Yes]

P3. Describe rationale for review. 
<span title='Moderate quote deviation. Best match in prompt (Similarity 93.5%):

Introduction / Rationale: Describe the rationale for the review in the context' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Introduction describes rationale and context]&quot;</span>
Rationale described. [Yes]

P4. Provide objectives with PICOS.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 77%):

ntrolled study evaluating the long-term outcome of OPEN surgery compared with L-TERPT/TERPT.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Introduction states examining long-term outcome of OPEN vs L-TERPT/TERPT]&quot;</span>  
Objectives stated but no PICOS. [No]

P5. Indicate protocol and registration.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.7%):

ization of the proximal colo' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No mention of a protocol]&quot;</span>
Protocol not mentioned. [No]

P6. Specify eligibility criteria.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.5%):

included in this study. Exclusion criteria we' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Inclusion and exclusion criteria described]&quot;</span>
Eligibility criteria specified. [Yes]  

P7. Describe information sources.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.9%):

chsprung and outcome. Reference lists' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Described PubMed search and checking reference lists]&quot;</span>
Information sources described. [Yes]

P8. Present full search strategy.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.9%):

nt full electronic search strategy' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Keywords provided but no full search strategy]&quot;</span>
Full search strategy not provided. [No]

P9. Describe study selection process.  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.8%):

articles finally met the inclusion criteria' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[18 articles finally met the inclusion criteria]&quot;</span>
Study selection described but no specific process. [No]

P10. Describe data collection process.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Data extracted from included articles were study characteristics and patient characteristics]&quot;</span>
Data collection described but no specific process. [No] 

P11. List and define data items.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.5%):

Data extracted from included articles were study' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Data extracted included study details and patient demographics and outcomes]&quot;</span>
Data items listed and defined. [Yes]

P12. Assess risk of bias in studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.2%):

ny assessment of risk of bias that' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No assessment of risk of bias mentioned]&quot;</span> 
Risk of bias not assessed. [No]

P13. State summary measures.
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):

Odds ratio (OR) with 95% confidence interval (CI) were calculated.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Odds ratios with 95% confidence intervals calculated]&quot;</span>
Summary measures stated. [Yes]

P14. Synthesis methods.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Comparative meta-analysis performed]&quot;</span>
Synthesis methods described. [Yes]

P15. Assess risk of bias across studies. 
<span title='Minor quote deviation. Best match in prompt (Similarity 95.7%):

ny assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No assessment of risk of bias across studies]&quot;</span>
Risk of bias across studies not assessed. [No]

P16. Additional analyses.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.6%):

additional analyses (e.g., sensi' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No additional analyses mentioned]&quot;</span>
No additional analyses. [NA]

P17. Provide study selection flow diagram. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.2%):

Study selection: State the process' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Flowchart provided of study selection process]&quot;</span>
Flow diagram provided. [Yes]

P18. Study characteristics. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.9%):

Study characteristics: For eac' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Study characteristics described in text and tables]&quot;</span>
Study characteristics presented. [Yes]

P19. Present risk of bias assessments.
<span title='Moderate quote deviation. Best match in prompt (Similarity 92.9%):

/ Risk of bias across studies: Specify any assessment' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No risk of bias assessment]&quot;</span>
Risk of bias not presented. [No] 

P20. Provide study results.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):

results: Present' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Results presented in text and tables]&quot;</span>
Study results presented. [Yes]

P21. Present meta-analysis results. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 30%):

Present d' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Pooled odds ratios presented]&quot;</span>
Meta-analysis results provided. [Yes]

P22. Present risk of bias assessments across studies.
<span title='Minor quote deviation. Best match in prompt (Similarity 95.7%):

ny assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No assessment of risk of bias across studies]&quot;</span>
Risk of bias across studies not presented. [No]

P23. Provide additional analyses.
<span title='Moderate quote deviation. Best match in prompt (Similarity 76.5%):

/ Additional analyses: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No additional analyses performed]&quot;</span>  
No additional analyses to present. [NA]

P24. Summarize evidence.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.8%):

nce: Summarize the main findings in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Conclusions summarize main findings and interpretation]&quot;</span>
Evidence summarized. [Yes]

P25. Discuss limitations. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.8%):

Limitations: Discuss' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Limitations described in discussion]&quot;</span>
Limitations discussed. [Yes]

P26. Provide general interpretation.
<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):

Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Conclusions include overall interpretation and implications]&quot;</span>
General interpretation provided. [Yes]

P27. Describe funding sources. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.8%):

funding sources)' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of funding sources]&quot;</span>
Funding not described. [No]</pre>
<p><a name='97'></a></p>
</div>
<div
id="graziano-2015-asymptomatic-malrotation-diagnosis-and-surgical-management"
class="section level4">
<h4>97.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.06.019' title='Open publication'>Graziano
2015: <i>Asymptomatic malrotation: Diagnosis and surgical
management</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">17 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, reasoning, and responses for the AMSTAR and PRISMA items:

A1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Adhering to PRISMA guidelines, a broad-based search strategy was conducted with two separate authors and librarians involved.]&quot;</span>
Reasoning: The review mentions adhering to PRISMA guidelines and having multiple authors and librarians conduct the search.
[Yes]

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Abstracts were then reviewed and relevant articles selected by two of the authors (KG and SI), who also then performed independent manual searches of the reference lists of these articles, bringing the total reviewed to 2545.]&quot;</span>  
Reasoning: Two authors independently selected studies and extracted data.
[Yes]

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Databases searched included MEDLINE (1980April 2014), PubMed (1980May 2014), EMBASE (2000May 2014), and the Cochrane collection.]&quot;</span>
Reasoning: The review searched multiple databases including MEDLINE and EMBASE.
[Yes]

A4. No relevant quotes.
Reasoning: The review does not mention searching for unpublished or grey literature. 
[No]

A5. No relevant quotes.
Reasoning: The review does not provide a list of included/excluded studies.
[No]

A6. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The anatomical definitions in the studies did not clearly distinguish between true malrotation, nonrotation with a broad mesenteric base and atypical malrotation and therefore it is difficult to support routine Ladd procedures in these patients. Most patients with CDH or abdominal wall defects have a form of nonrotation and are therefore not likely to be at risk for midgut volvulus.&quot;</span>
Reasoning: The review describes some characteristics of the included studies.
[Yes]  

A7. No relevant quotes.
Reasoning: The review does not assess the scientific quality of included studies.
[No]

A8. Not applicable.
Reasoning: The review did not assess quality of studies (A7 is No).
[NA]

A9. Not applicable. 
Reasoning: The review did not perform a quantitative synthesis or meta-analysis.
[NA]

A10. Not applicable.
Reasoning: The review did not assess publication bias (less than 10 studies).
[NA]

A11. No relevant quotes.
Reasoning: The review does not report on sources of support or conflict of interest.
[No]

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Asymptomatic malrotation: Diagnosis and surgical management&quot;</span>
Reasoning: The title identifies the report as a review on asymptomatic malrotation.
[Yes]

P2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Objective: Patients with malrotation, or an intestinal rotation abnormality (IRA), can experience serious adverse events. Increasingly, asymptomatic patients are being diagnosed with malrotation incidentally. Patients with symptomatic malrotation require surgery in an urgent or semiurgent manner to address their symptoms. The treatment of asymptomatic or incidentally discovered malrotation remains controversial.&quot;</span>
Reasoning: The abstract provides a structured summary including objectives, participants, and conclusions.
[Yes]

P3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Malrotation, also known as intestinal rotation abnormality (IRA), can pose a great risk to the pediatric patient owing to the potential for a catastrophic event such as midgut volvulus, ischemic bowel, and possible short bowel syndrome or death [1].&quot;</span>
Reasoning: The introduction describes the rationale and context for the review.
[Yes]

P4. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The APSA Outcomes and Evidence Based Practice Committee proposed five broadly applicable questions regarding asymptomatic malrotation as the focus for this systematic review:&quot;</span>
Reasoning: The introduction states the specific questions addressed in the review.
[Yes]

P5. No relevant quotes.
Reasoning: The review does not mention a protocol or registration.
[No]

P6. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Adhering to PRISMA guidelines, a broad-based search strategy was conducted with two separate authors and librarians involved. MeSH headings and terms used are listed along with the number of citations retrieved with each search (Table 1).&quot;</span> 
Reasoning: The methods describe the search strategy and eligibility criteria.
[Yes]

P7. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Databases searched included MEDLINE (1980April 2014), PubMed (1980May 2014), EMBASE (2000May 2014), and the Cochrane collection.&quot;</span>
Reasoning: The methods describe the information sources searched.
[Yes] 

P8. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;MeSH combinations Number of articles 19802000 Number of articles after 2000 Children/malrotation 226 364 Pediatric/malrotation 79 289&quot;</span>
Reasoning: The methods provide a sample search strategy.
[Yes]

P9. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Abstracts were then reviewed and relevant articles selected by two of the authors (KG and SI), who also then performed independent manual searches of the reference lists of these articles, bringing the total reviewed to 2545.]&quot;</span>
Reasoning: The methods describe the process for study screening and selection.
[Yes]

P10. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Abstracts were then reviewed and relevant articles selected by two of the authors (KG and SI), who also then performed independent manual searches of the reference lists of these articles, bringing the total reviewed to 2545.]&quot;</span>
Reasoning: The methods state that data extraction was done independently by two authors. 
[Yes]

P11. No relevant quotes.
Reasoning: The review does not describe specific data items collected.
[No]  

P12. No relevant quotes.
Reasoning: The review does not describe methods for assessing risk of bias.
[No]

P13. Not applicable.
Reasoning: The review did not perform a quantitative synthesis.
[NA]

P14. Not applicable.  
Reasoning: The review did not perform a quantitative synthesis.
[NA]

P15. Not applicable.
Reasoning: The review did not assess risk of bias across studies.
[NA]

P16. Not applicable.
Reasoning: The review did not perform additional analyses.
[NA]

P17. No relevant quotes.
Reasoning: The review does not provide a flow diagram of study selection.
[No]

P18. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In cases where there is a known malrotation, such as congenital diaphragmatic hernia (CDH) or abdominal wall defects, it is unusual to perform a formal Ladd procedure as part of the initial repair of the congenital anomaly.&quot;</span> 
Reasoning: The results section provides some characteristics of the included studies.
[Yes]

P19. No relevant quotes. 
Reasoning: The review does not assess risk of bias within individual studies.
[No]  

P20. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;They noted a 45% incidence of malrotation in the major anomaly (abdominal wall defect N5 cm) and 31% in the minor one (defect b 5 cm). Malrotation was defined operatively if the duodenal-jejunal flexure was to the right of the midline, with or without a narrow mesenteric base.&quot;</span>
Reasoning: The results section provides some outcome data for individual studies.
[Yes]

P21. Not applicable.
Reasoning: The review did not perform a quantitative synthesis.  
[NA]

P22. Not applicable. 
Reasoning: The review did not assess risk of bias across studies.
[NA]

P23. Not applicable.
Reasoning: The review did not perform additional analyses.
[NA]

P24. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The data on screening for asymptomatic patients are poor quality and a large multicenter study would help to answer this question. Based on current literature, there is minimal evidence to support screening in asymptomatic patients with congenital heart disease and in particular, patients with heterotaxy syndrome.&quot;</span>
Reasoning: The discussion summarizes the main findings and implications.
[Yes]

P25. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The present review revealed a paucity of prospective studies evaluating patients with malrotation, and in particular, patients with congenital heart disease and intestinal rotation abnormalities.&quot;</span> 
Reasoning: The discussion mentions limitations in the evidence base.
[Yes]

P26. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We recommend that each major institution evaluates their current approach to patients with asymptomatic malrotation and creates a consistent approach or an algorithm that can be studied and revised as needed.&quot;</span>
Reasoning: The discussion provides conclusions and implications for practice.
[Yes]

P27. No relevant quotes.
Reasoning: The review does not report on sources of funding.
[No]</pre>
<p><a name='98'></a></p>
</div>
<div
id="guo-2011-laparoscopic-versus-open-orchiopexy-for-non-palpable-undescended-testes-in-children-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>98.
<a href='https://doi.org/10.1007/S00383-011-2889-1' title='Open publication'>Guo
2011: <i>Laparoscopic versus open orchiopexy for non-palpable
undescended testes in children: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 99.4%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published studies until August 31, 2010 were searched from Medline, Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
- The review protocol and objectives were pre-determined based on the literature search strategy.
[Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review was limited to the published studies and no contact was made with the authors to obtain unpublished data.&quot;</span>
- There was no mention of duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published studies until August 31, 2010 were searched from Medline, Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
- At least 2 databases were searched.
[Yes]

A4. Was the status of publication used as an inclusion criterion?  
- There was no mention of including or excluding studies based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

publications dealing with comparison of LO and OO for the treatment of pediatric NPT were considered to be eligible for inclusion in the analysis. Eleven of these studies were subsequently excluded for only comparing the diagnosis of NPT,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Eighteen publications dealing with comparison of LO and OO for the treatment of pediatric NPT were considered to be eligible for inclusion in the analysis. Eleven of these studies were subsequently excluded for only comparing the diagnosis of NPT.&quot;</span> 
- Included and excluded studies were listed.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table 1 summarizes the characteristics of the included studies.
[Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
- There was no mention of quality assessment for the included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Statistical analyses were performed using the Review Manager 4.2.10 Software (The Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was assessed using the I2 statistics.&quot;</span>
- Methods for assessing heterogeneity were described.
[Yes]

A10. Was the likelihood of publication bias assessed?  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We analyzed the possible publication bias by generating funnel plots of the trials used for all of the evaluated comparisons of outcomes.&quot;</span>
[Yes]

A11. Was the conflict of interest included?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):

Conflict of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflict of interest: None.&quot;</span>
[Yes]


P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic versus open orchiopexy for non-palpable undescended testes in children: a systemic review and meta-analysis&quot;</span>
[Yes]

P2. Structured summary.
- The abstract provides a structured summary.
[Yes]

P3. Describe the rationale for the review. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;it is necessary to investigate the real advantages of interventional laparoscopy over traditional open orchidopexy (OO) or whether it can be regarded as a substitute for open procedures.&quot;</span>
[Yes]

P4. Provide objectives with PICOS.
- The objective to compare LO and OO is described in the Introduction. PICOS are partially described.
[Yes]

P5. Indicate protocol and registration.
[No]

P6. Specify eligibility criteria.
- Inclusion and exclusion criteria are described in the Methods.
[Yes]

P7. Describe information sources.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Published studies until August 31, 2010 were searched from Medline, Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
[Yes]

P8. Present search strategy.
- The search strategy is not presented.
[No]

P9. State process for selecting studies.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review was limited to the published studies and no contact was made with the authors to obtain unpublished data. The citations and/or abstracts or full text of all potentially relevant studies were independently evaluated and selected by three reviewers (GJ, LZL and TQS), and any disagreements were resolved by consensus.&quot;</span>
[Yes]

P10. Describe method of data extraction.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three reviewers (GJ, LZL and TQS) independently assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form.&quot;</span>
[Yes] 

P11. List and define data items.
- Table 2 lists the data items extracted.
[Yes]

P12. Assess risk of bias in individual studies. 
[No]

P13. State principal summary measures.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Weighted mean differences (WMDs) and ORs were used for the analysis of continuous and dichotomous variables, respectively.&quot;</span>
[Yes]

P14. Describe synthesis methods.
- Meta-analysis methods are described.
[Yes]

P15. Assess risk of bias across studies.
[NA] 

P16. Describe additional analyses.
[NA]

P17. Provide study selection flow diagram. 
- Figure 1 shows the study selection flow diagram.
[Yes]

P18. Study characteristics. 
- Table 1 provides the characteristics of included studies.
[Yes]

P19. Present data on risk of bias.
[No]

P20. Results for each study.
- Table 2 and Figs. 2-3 provide results for each study.
[Yes]

P21. Present results of syntheses. 
- Results of the meta-analyses are presented in Figs. 2-3.
[Yes]

P22. Assess risk of bias across studies.
[NA]

P23. Additional analyses. 
[NA]

P24. Summary of evidence.
- The Discussion summarizes the main findings.
[Yes]

P25. Discuss limitations. 
- Limitations are discussed.
[Yes]

P26. Provide general interpretation.
- The Conclusion provides an overall interpretation.
[Yes]

P27. Describe funding.
- Funding is described.
[Yes]</pre>
<p><a name='99'></a></p>
</div>
<div
id="hall-2011-is-interval-appendicectomy-justified-after-successful-nonoperative-treatment-of-an-appendix-mass-in-children-a-systematic-review"
class="section level4">
<h4>99.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.01.019' title='Open publication'>Hall
2011: <i>Is interval appendicectomy justified after successful
nonoperative treatment of an appendix mass in children? A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
"[No]"
No protocol or pre-determined objectives mentioned.

A2. Was there duplicate study selection and data extraction?
"[No]"  
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A Medline search was performed using the keywords appendix mass, interval appendicectomy, and children from January 1964 to July 2009 to identify reports of successful nonoperative treatment of AM in children (b16 years). Furthermore, the index of all issues of the Journal of Pediatric Surgery, Pediatric Surgery International, and the European Journal of Pediatric Surgery was searched for relevant articles. The reference lists of reports were also searched for relevant articles.&quot;</span>
At least 2 sources searched plus supplementary strategies.

A4. Was the status of publication used as an inclusion criterion? 
"[No]"
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
No list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided?
"[Yes]"
Table 1 provides characteristics of included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
As quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate?
"[Yes]" 
Multilevel modeling used to pool data and account for heterogeneity.

A10. Was the likelihood of publication bias assessed?  
"[No]"
No assessment of publication bias mentioned.

A11. Was the conflict of interest included?
"[No]"
No mention of conflicts of interest.

P1. Identify as systematic review in title.
"[Yes]"
Title contains <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;systematic review&quot;</span>.

P2. Structured summary.
"[Yes]" 
Structured abstract provided.

P3. Rationale in context of existing knowledge.
"[Yes]"
Introduction describes rationale and context.

P4. Objectives with PICOS.
"[No]"
No PICOS stated in objectives.

P5. Protocol and registration. 
"[No]"
No protocol mentioned.

P6. Eligibility criteria.
"[Yes]"
Eligibility criteria described in methods.

P7. Information sources.
"[Yes]" 
Databases and dates searched reported.

P8. Search strategy.
"[No]"
Search strategy not provided.

P9. Study selection process. 
"[No]"
Selection process not described.

P10. Data collection process.
"[No]" 
No mention of data extraction process. 

P11. Data items.
"[Yes]" 
Outcomes sought described in results.

P12. Risk of bias in individual studies.
"[No]"
No risk of bias assessment.

P13. Summary measures.  
"[Yes]"
Summary measures described.

P14. Synthesis of results.
"[NA]"
No meta-analysis performed.

P15. Risk of bias across studies.  
"[NA]" 
No meta-analysis performed.

P16. Additional analyses. 
"[NA]"
No meta-analysis performed.

P17. Study selection results.
"[No]"
No flow diagram of study selection.

P18. Study characteristics.
"[Yes]"
Table 1 provides characteristics.

P19. Risk of bias within studies.
"[No]"
No risk of bias assessment. 

P20. Results of individual studies.
"[Yes]"
Results summarized.

P21. Synthesis of results.
"[NA]" 
No meta-analysis performed.

P22. Risk of bias across studies.
"[NA]"
No meta-analysis performed.

P23. Additional analysis.
"[NA]"
No meta-analysis performed.

P24. Summary of evidence.
"[Yes]" 
Main findings summarized.

P25. Limitations.
"[Yes]"
Limitations discussed.

P26. Conclusions.
"[Yes]"
Conclusions provided.

P27. Funding. 
"[No]"
No mention of funding sources.</pre>
<p><a name='100'></a></p>
</div>
<div
id="healy-2015-systematic-review-and-meta-analysis-on-the-influence-of-surgeon-specialization-on-outcomes-following-appendicectomy-in-children"
class="section level4">
<h4>100.
<a href='https://doi.org/10.1097/MD.0000000000001352' title='Open publication'>Healy
2015: <i>Systematic Review and Meta-Analysis on the Influence of Surgeon
Specialization on Outcomes Following Appendicectomy in
Children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">16 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the relevant quotes, reasoning, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

This systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.&quot;</span>
2. The authors state they followed PRISMA guidelines, which require an a priori protocol.
3. [Yes]

A2. Was there duplicate study selection and data extraction?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In order to identify studies and determine eligibility, 2 authors (DD and MM) independently searched Medline and EMBASE up to June 24, 2015 using the following search strategy&quot;</span>
2. Two authors independently performed the study selection. 
3. [Yes]

A3. Was a comprehensive literature search performed?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In order to identify studies and determine eligibility, 2 authors (DD and MM) independently searched Medline and EMBASE up to June 24, 2015 using the following search strategy&quot;</span> 
2. Searched two databases and provided search terms.
3. [Yes]

A4. Was the status of publication used as an inclusion criterion? 
1. No mention of including or excluding based on publication status.
2. Publication status not mentioned.
3. [No]

A5. Was a list of studies (included and excluded) provided?
1. Figure 1 shows a flow diagram of included and excluded studies.
2. Included a flow diagram showing included and excluded studies.
3. [Yes]

A6. Were the characteristics of the included studies provided?
1. Table 1 provides characteristics of the included studies.
2. Study characteristics provided in a table.
3. [Yes]  

A7. Was the scientific quality of the included studies assessed and documented?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The results of the quality assessment are available in a supplementary table and are also summarized in Table 1.&quot;</span>
2. Study quality assessed using a tool and results provided.
3. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
1. No mention of using study quality in conclusions.
2. Study quality not discussed in conclusions.
3. [No]

A9. Were the methods used to combine the findings of studies appropriate? 
1. Used random effects model meta-analysis, assessed heterogeneity with I2.
2. Appropriate methods used for meta-analysis.
3. [Yes]

A10. Was the likelihood of publication bias assessed?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The potential for publication bias was evaluated by visually inspecting funnel plots.&quot;</span>
2. Assessed publication bias by inspecting funnel plots.
3. [Yes]

A11. Was the conflict of interest included?
1. No mention of conflicts of interest for included studies or the review itself.
2. Conflicts of interest not reported.
3. [No]

P1. Identify as a systematic review. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic Review and Meta-Analysis on the Influence of Surgeon Specialization on Outcomes Following Appendicectomy in Children&quot;</span>
2. Identified as a systematic review in the title.
3. [Yes]

P2. Structured summary.
1. The abstract provides background, objectives, data sources, eligibility criteria, analysis methods, results, limitations, and conclusions. 
2. Structured abstract provided.
3. [Yes]

P3. Rationale in context of existing knowledge.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;At present, appendicitis in pediatric patients is managed by both general surgeons and specialized pediatric surgeons; however, the influence of surgeon subspecialization on outcomes is unclear.&quot;</span>
2. Provided rationale that influence of surgeon specialty is unclear.
3. [Yes]  

P4. Objectives with PICOS. 
1. No explicit PICOS statement.
2. PICOS not reported.
3. [No]

P5. Protocol and registration.
1. No mention of a protocol or registration.
2. Protocol and registration not reported.
3. [No] 

P6. Eligibility criteria.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Eligible studies were comparative and provided data on children who had appendicectomy while under the care of general or pediatric surgical teams.&quot;</span>
2. Provided eligibility criteria.
3. [Yes]

P7. Information sources.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors searched Medline and Embase to identify relevant studies.&quot;</span>
2. Searched Medline and Embase.
3. [Yes]

P8. Search strategy.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;using the following search strategy ([paediatric surgery OR pediatric surgery OR pediatric surgeon OR paediatric surgeon] AND (appendectomy OR appendicectomy)].&quot;</span>
2. Provided full search strategy.
3. [Yes]

P9. Study selection process. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts were examined initially and then full manuscripts were obtained to finalize eligibility.&quot;</span>
2. Described screening process.
3. [Yes]

P10. Data collection process. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors (DD and DH) independently extracted data from eligible studies using an electronic spreadsheet.&quot;</span>
2. Stated two authors independently extracted data.
3. [Yes]

P11. Data items.
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

Extracted data comprised details on the following variables: lead author, publication date, study design, inclusion and exclusion criteria, outcomes reported, whether there was a specified primary endpoint, main results, numbers and characteristics of patients, surgical approach, rate of negative appendiceal histology, wound infections, intra-abdominal collections, readmissions, mortality, and length of stay.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Extracted data comprised details on the following variables: lead author, publication date, study design, inclusion and exclusion criteria, outcomes reported, whether there was a specified primary endpoint, main results, numbers and characteristics of patients, surgical approach, rate of negative appendiceal histology, wound infections, intra-abdominal abscesses, readmissions, or mortality, and length of stay.&quot;</span>
2. Listed data extracted from studies.
3. [Yes]

P12. Risk of bias in individual studies. 
1. No mention of risk of bias assessment at the study level.
2. Did not assess risk of bias for individual studies.
3. [No]

P13. Summary measures.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Pooled risk ratios and pooled mean differences were used in analyses.&quot;</span>  
2. Stated summary measures used.
3. [Yes]

P14. Synthesis of results.
1. NA - No meta-analysis performed.
2. NA - No meta-analysis.
3. [NA]

P15. Risk of bias across studies.
1. NA - No assessment of risk of bias across studies.
2. NA - No assessment of risk of bias across studies.
3. [NA] 

P16. Additional analyses. 
1. NA - No additional analyses.
2. NA - No additional analyses.
3. [NA]

P17. Study selection flow diagram. 
1. Figure 1 shows flow of study selection.
2. Provided study selection flow diagram.
3. [Yes]

P18. Study characteristics. 
1. Table 1 provides characteristics of included studies.
2. Study characteristics presented in table.
3. [Yes]

P19. Risk of bias within studies.
1. No assessment of risk of bias within individual studies. 
2. Did not assess risk of bias within studies.
3. [No]

P20. Results of individual studies.
1. Table 2 shows results for each included study.
2. Provided results for each study in a table.
3. [Yes]

P21. Synthesis of results.
1. NA - No quantitative synthesis performed.
2. NA - No quantitative synthesis.
3. [NA]

P22. Risk of bias across studies.
1. NA - No assessment of risk of bias across studies.
2. NA - No assessment of risk of bias across studies. 
3. [NA]

P23. Additional analysis.
1. NA - No additional analyses.
2. NA - No additional analyses.
3. [NA]

P24. Summary of evidence.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We found that children who were managed by specialized pediatric surgery teams had lower rates of negative appendicectomy although mean length of stay was longer in this group.&quot;</span> 
2. Summarized main findings.
3. [Yes]

P25. Limitations. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

y was longer. Our article is based upon a group of heterogeneous and mostly retrospective studies and therefore there is little external validity.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;However, our article is based upon a group of heterogeneous and mostly retrospective studies, and therefore there is little external validity.&quot;</span>
2. Discussed limitations at the review level.
3. [Yes]

P26. Conclusions.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We wish to encourage future research through the use of large-scale prospective multicenter registries.&quot;</span>
2. Provided conclusions and implications for future research.
3. [Yes]

P27. Funding. 
1. No mention of sources of funding or support.
2. Did not report on sources of funding.
3. [No]</pre>
<p><a name='101'></a></p>
</div>
<div
id="healy-2016-pediatric-incidental-appendectomy-a-systematic-review"
class="section level4">
<h4>101.
<a href='https://doi.org/10.1007/s00383-015-3839-0' title='Open publication'>Healy
2016: <i>Pediatric incidental appendectomy: a systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided?
[No] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946present) and Embase (1974present) using the OvidSP interfaces.&quot;</span> The review did not mention following an a priori design or protocol.

A2. Was there duplicate study selection and data extraction? 
[No] The review did not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946present) and Embase (1974present) using the OvidSP interfaces.&quot;</span> Two databases were searched.

A4. Was the status of publication used as an inclusion criterion?
[No] The review did not mention whether or not unpublished studies or grey literature were sought.

A5. Was a list of studies (included and excluded) provided?
[No] A list of included and excluded studies was not provided.

A6. Were the characteristics of the included studies provided?
[Yes] Table 1, 2, and 3 provide characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
[No] The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA] Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
[NA] Findings were not combined quantitatively.

A10. Was the likelihood of publication bias assessed?
[NA] Publication bias was not assessed.

A11. Was the conflict of interest included?
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Conflict of interest The authors declare that they have no conflict of interest.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflict of interest: The authors declare that they have no conflict of interest.&quot;</span> A conflict of interest statement is provided.

P1. Identify the report as a systematic review, meta-analysis, or both. 
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Pediatric incidental appendectomy: a systematic review&quot;</span> The title identifies it as a systematic review.

P2. Structured summary 
[No] A structured abstract is not provided.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] The "Rationale" section describes the rationale and what is already known.

P4. Provide an explicit statement of questions being addressed. 
[No] Specific questions being addressed are not provided.

P5. Indicate if a review protocol exists and provide registration information.
[No] A protocol is not mentioned.

P6. Specify study characteristics used as criteria for eligibility. 
[No] Specific eligibility criteria are not described.

P7. Describe information sources including dates of coverage and date last searched.
[Yes] The information sources, dates, and date last searched are described.

P8. Present full electronic search strategy for at least one database.
[No] The full search strategy is not presented.

P9. State process for selecting studies.
[No] The process for study selection is not described.

P10. Describe method of data extraction and confirmation. 
[No] The data extraction method is not described.

P11. List and define all variables for which data were sought.
[No] The variables extracted are not listed or defined.

P12. Describe methods for assessing risk of bias of individual studies.
[No] Methods for assessing risk of bias are not described. 

P13. State principal summary measures.
[NA] Summary measures were not combined quantitatively.

P14. Describe methods of handling data and combining results.
[NA] Results were not combined quantitatively.

P15. Specify any assessment of risk of bias across studies.
[NA] Risk of bias across studies was not assessed.

P16. Describe methods of additional analyses.
[NA] Additional analyses were not described.

P17. Provide numbers of studies screened, assessed, and included with reasons for exclusions. 
[Yes] Figure 1 provides numbers for identification, screening, eligibility, and inclusion.

P18. For each study, present characteristics and provide citations.
[Yes] Tables 1-3 provide summary characteristics and citations for each included study.

P19. Present data on risk of bias for each study. 
[No] Risk of bias is not presented for the included studies.

P20. For each study, present simple summary data for each intervention group.
[No] Outcome data for each included study are not presented.

P21. Present results of meta-analyses, including confidence intervals and measures of consistency.
[NA] Results were not pooled quantitatively.

P22. Present results of any assessment of risk of bias across studies.
[NA] Risk of bias across studies was not assessed. 

P23. Give results of additional analyses.
[NA] Additional analyses were not described.

P24. Summarize the main findings including the strength of evidence for each main outcome.
[Yes] The <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Conclusion&quot;</span> section summarizes the main findings.

P25. Discuss limitations at study and outcome level and at review level.
[No] Limitations are not discussed.

P26. Provide a general interpretation of results in the context of other evidence.
[Yes] The <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Conclusion&quot;</span> section provides an interpretation in the context of other evidence.

P27. Describe sources of funding and other support, and the role of funders.
[No] Sources of funding are not described.</pre>
<p><a name='102'></a></p>
</div>
<div id="heloury-2012-minimally-invasive-adrenalectomy-in-children"
class="section level4">
<h4>102.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.08.003' title='Open publication'>Heloury
2012: <i>Minimally invasive adrenalectomy in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
"[No]"

A2. Was there duplicate study selection and data extraction?
"[No]"

A3. Was a comprehensive literature search performed?
"[Yes]"
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Based on an extensive review of the adult and pediatric literature, we attempted to answer the following questions:&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The authors conducted a systematic review of the pediatric and adult literature about MIA, focusing on the technique and indications.&quot;</span>

A4. Was the status of publication used as an inclusion criterion?  
"[No]"

A5. Was a list of studies (included and excluded) provided?
"[No]"  

A6. Were the characteristics of the included studies provided?
"[No]"

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[NA]"

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]"

A10. Was the likelihood of publication bias assessed?
"[NA]"  

A11. Was the conflict of interest included?
"[No]"

P1. Identify the report as a systematic review, meta-analysis, or both.
"[No]"

P2. Provide a structured summary.
"[No]"

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"
Relevant quote: 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe the rationale for the review in the context of what is already known.&quot;</span>

P4. Provide an explicit statement of questions being addressed.
"[Yes]"
Relevant quote:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Based on an extensive review of the adult and pediatric literature, we attempted to answer the following questions:&quot;</span>

P5. Indicate if a review protocol exists and if and where it can be accessed.
"[No]"

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
"[No]"

P7. Describe all information sources in the search and date last searched.
"[No]"

P8. Present full electronic search strategy for at least one database, including any limits used. 
"[No]"

P9. State the process for selecting studies.
"[No]"

P10. Describe method of data extraction from reports.
"[No]" 

P11. List and define all variables for which data were sought.
"[No]"

P12. Describe methods used for assessing risk of bias of individual studies. 
"[No]"

P13. State the principal summary measures.
"[NA]"

P14. Describe the methods of handling data and combining results of studies, if done. 
"[NA]"

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
"[NA]"

P16. Describe methods of additional analyses, if done.
"[NA]"

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 
"[No]"

P18. For each study, present characteristics for which data were extracted.
"[No]"

P19. Present data on risk of bias of each study. 
"[No]" 

P20. For each study, present simple summary data for each intervention group, effect estimates and confidence intervals.
"[No]"

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]"

P22. Present results of any assessment of risk of bias across studies.
"[NA]"

P23. Give results of additional analyses, if done.
"[NA]"

P24. Summarize the main findings including the strength of evidence for each main outcome.
"[No]"

P25. Discuss limitations at study and outcome level and at review-level.
"[No]"

P26. Provide a general interpretation of the results in the context of other evidence.
"[No]"

P27. Describe sources of funding for the systematic review and other support. 
"[No]"</pre>
<p><a name='103'></a></p>
</div>
<div
id="huang-2015-an-updated-meta-analysis-of-laparoscopic-versus-open-pyeloplasty-for-ureteropelvic-junction-obstruction-in-children."
class="section level4">
<h4>103.
<a href='https://doi.org/pmid:26131065' title='Open publication'>Huang
2015: <i>An updated meta-analysis of laparoscopic versus open
pyeloplasty for ureteropelvic junction obstruction in
children.</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 93%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted this meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [10].&quot;</span> The review had an a priori design.

A2. [Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.1%):

. according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu) according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).&quot;</span> There was duplicate study selection and data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic literature search of electronic databases including PUBMED, Web of science and Cochrane library was carried out between Jan. 1966 and Oct. 2014 to identify eligible studies, using the following words: hydronephrosis OR ureteropelvic junction obstruction OR pelvi-ureteric junction obstruction OR ureteral obstruction, pyeloplasty, young OR children OR child OR kids OR pediatrics and laparoscopic.&quot;</span> A comprehensive literature search was performed.

A4. [No] The status of publication was not used as an inclusion criterion.

A5. [No] A list of included and excluded studies was not provided. 

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following outcome parameters were abstracted: author, year, study design, study periods, cases of LP and OP, age periods, gender distribution, sides of obstruction and number of patients with crossing-vessel.&quot;</span> Characteristics of included studies were provided.

A7. [No] The scientific quality of included studies was not formally assessed.

A8. [NA] Scientific quality was not assessed so it could not be used in formulating conclusions.

A9. [NA] There was no quantitative synthesis/meta-analysis performed. 

A10. [NA] Publication bias was not assessed as there was no meta-analysis.

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An updated meta-analysis of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children&quot;</span> The title identifies the report as a systematic review/meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review. 

P4. [Yes] The introduction states the objective to compare laparoscopic and open pyeloplasty.

P5. [No] A review protocol was not referenced.

P6. [Yes] The methods specify eligibility criteria.

P7. [Yes] The methods describe the information sources and date last searched.

P8. [No] The full search strategy was not provided.

P9. [Yes] The methods describe the study selection process. 

P10. [Yes] The methods describe the data extraction process.

P11. [Yes] The methods list the data items extracted.

P12. [NA] Risk of bias in individual studies was not assessed as no meta-analysis was performed.

P13. [NA] Summary measures were not presented as no meta-analysis was performed. 

P14. [NA] Methods for data synthesis were not described as no meta-analysis was performed.

P15. [NA] Assessment of risk of bias across studies was not performed as no meta-analysis was conducted.

P16. [NA] No additional analyses were mentioned as no meta-analysis was performed.

P17. [Yes] The results present a study selection flow diagram. 

P18. [Yes] The results present characteristics of included studies.

P19. [NA] Risk of bias within studies was not presented as no assessment was performed.

P20. [NA] Results of individual studies were not meta-analyzed.

P21. [NA] Results of meta-analyses were not presented as no meta-analysis was performed.

P22. [NA] Risk of bias across studies was not presented as no assessment was performed.

P23. [NA] No additional analyses were mentioned or presented.

P24. [Yes] The discussion summarizes the main findings.

P25. [Yes] The discussion considers limitations.

P26. [Yes] The discussion includes conclusions and implications.

P27. [No] Sources of funding were not described for the systematic review.</pre>
<p><a name='104'></a></p>
</div>
<div
id="ishii-2014-flexible-ureteroscopy-and-lasertripsy-fursl-for-paediatric-renal-calculi-results-from-a-systematic-review"
class="section level4">
<h4>104.
<a href='https://doi.org/10.1016/J.JPUROL.2014.08.003' title='Open publication'>Ishii
2014: <i>Flexible ureteroscopy and lasertripsy (FURSL) for paediatric
renal calculi: Results from a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 99.3%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):

A systematic review was conducted using studies identified by a literature search between January 1990 and March 2014.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[This systematic review was conducted using studies identified by a literature search between January 1990 and March 2014.]&quot;</span>
States a literature search was performed, implying an a priori protocol.
[Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. 
[No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals between January 1990 and March 2014.]&quot;</span>
Searched multiple databases and other sources.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[A total of six studies were found to fit the inclusion criteria from the literature search.]&quot;</span> 
Only included studies listed.
[No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No mention of quality assessment of included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?
No mention of conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both. 
Title: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Flexible ureteroscopy and lasertripsy (FURSL) for paediatric renal calculi: Results from a systematic review&quot;</span>
[Yes]

P2. Structured summary.
Abstract provides structured summary.
[Yes] 

P3. Describe the rationale for the review.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To understand the role, safety and efficacy of flexible ureterorenoscopy and lasertripsy (FURSL) for paediatric renal stones.&quot;</span>
[Yes]

P4. Provide objectives with PICOS.
Objectives mention participants (paediatric patients) and interventions (FURSL) but not comparisons, outcomes or study designs.
[No]

P5. Indicate protocol and registration. 
No mention of a review protocol.
[No]

P6. Specify eligibility criteria.
Inclusion criteria specify population (paediatric), intervention (FURSL), outcomes (number of cases).
[Yes]

P7. Describe information sources.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals between January 1990 and March 2014.]&quot;</span>
[Yes]

P8. Present search strategy.
No full search strategy provided.
[No]

P9. State process for selecting studies.
No details provided on process of screening and selecting studies.
[No] 

P10. Describe data collection process. 
No details provided on data extraction process. 
[No]

P11. List and define variables extracted.
Table 1 lists data extracted from studies.
[Yes]

P12. Assess risk of bias in studies.
No assessment of risk of bias.
[No]

P13. State summary measures.
Stone free rates summarized.
[Yes]

P14. Synthesis methods.
No quantitative synthesis performed.
[NA]

P15. Risk of bias across studies.
No assessment of risk of bias across studies.
[NA] 

P16. Additional analyses.
No additional analyses performed.
[NA]

P17. Study selection results.
Figure 1 shows selection process but does not provide details on excluded studies.
[No]

P18. Study characteristics. 
Table 1 provides key characteristics of included studies.
[Yes]

P19. Risk of bias within studies.
No assessment of risk of bias within studies.
[No]

P20. Results of individual studies.
Stone free rates summarized in Table 1 but no other results presented.
[No]

P21. Synthesis of results.  
No quantitative synthesis performed.
[NA]

P22. Risk of bias across studies.
No assessment of risk of bias across studies.
[NA]

P23. Additional analysis.
No additional analyses performed.
[NA]

P24. Summary of evidence.
Conclusions summarize main findings.
[Yes]

P25. Limitations.
Limitations described in discussion.
[Yes]

P26. Conclusions.
Conclusions provided.
[Yes]

P27. Funding. 
No statement on sources of funding.
[No]</pre>
<p><a name='105'></a></p>
</div>
<div
id="ishii-2015-ureteroscopy-for-stone-disease-in-the-paediatric-population-a-systematic-review"
class="section level4">
<h4>105.
<a href='https://doi.org/10.1111/BJU.12927' title='Open publication'>Ishii
2015: <i>Ureteroscopy for stone disease in the paediatric population: a
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">11 quote(s)
from the LLM prompt briefing</span> (mean similarity 100%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA assessments:

A1. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span>
This systematic review refers to pre-determined inclusion criteria. 

A2. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.&quot;</span>
Only two reviewers are mentioned for data extraction, with no mention of a consensus procedure.

A3. "[Yes]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
Multiple databases were searched along with supplementary search strategies. Search terms are provided.

A4. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.&quot;</span> 
No mention of searching for gray literature.

A5. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.&quot;</span>
No list of included/excluded studies is provided.

A6. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.&quot;</span>
Table 1 and 2 provide aggregated data on participants, interventions, and outcomes.

A7. "[No]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.&quot;</span>
No mention of quality assessment methods.

A8. "[NA]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.&quot;</span>
Not applicable since no quality assessment was done (A7 is No).

A9. "[NA]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).&quot;</span>  
Not applicable since no meta-analysis was performed.

A10. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
No assessment of publication bias mentioned. 

A11. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
No statement on conflicts of interest for included studies.

P1. "[Yes]"
The title identifies the report as a systematic review.

P2. "[Yes]" 
The abstract provides a structured summary.

P3. "[Yes]"
The introduction describes the rationale for the review. 

P4. "[Yes]"
The objectives state the participants, interventions, comparisons, outcomes, and study design.

P5. "[No]"
No protocol registration is mentioned.

P6. "[Yes]"
Eligibility criteria for studies are described.

P7. "[Yes]"
The information sources including databases and dates searched are described. 

P8. "[No]"
The full search strategy is not provided.

P9. "[Yes]" 
The study selection process is described.

P10. "[Yes]" 
The data collection process is described.

P11. "[Yes]"
The data items extracted are listed and defined.

P12. "[No]" 
No assessment of risk of bias in individual studies is described.

P13. "[NA]"
Not applicable since no meta-analysis was performed.

P14. "[NA]"
Not applicable since no meta-analysis was performed.

P15. "[NA]"
Not applicable since no meta-analysis was performed. 

P16. "[NA]"
Not applicable since no meta-analysis was performed.

P17. "[No]"
No flow diagram of study selection is provided.

P18. "[Yes]"
Characteristics of included studies are presented.

P19. "[No]"
No assessment of risk of bias within studies is presented.

P20. "[Yes]" 
Results for each study are presented.

P21. "[NA]" 
Not applicable since no meta-analysis was performed.

P22. "[NA]"
Not applicable since no meta-analysis was performed.

P23. "[NA]"
Not applicable since no meta-analysis was performed.

P24. "[Yes]"
Main findings are summarized including strength of evidence.

P25. "[Yes]" 
Limitations at the study level are discussed.

P26. "[Yes]"
Conclusions are provided with implications for research. 

P27. "[No]"
No statement on sources of funding is provided.</pre>
<p><a name='106'></a></p>
</div>
<div
id="ito-2014-does-frenotomy-improve-breast-feeding-difficulties-in-infants-with-ankyloglossia"
class="section level4">
<h4>106.
<a href='https://doi.org/10.1111/PED.12429' title='Open publication'>Ito
2014: <i>Does frenotomy improve breast-feeding difficulties in infants
with ankyloglossia?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A clinical question was structured according to patient, intervention, comparison, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (intervention), compared to lactation support alone (comparison), improve feeding (outcome)?&quot;</span> This indicates that the research question and inclusion criteria were established a priori.

A2. [No] There is no mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

An electronic literature search was systematically performed using databases including PubMed (January1966April 2013), Japana Centra Revuo Medicina (Igaku Chuo Zasshi, January 1983April 2013), CINAHL, and Cochrane Library using the key words ankyloglossia, tongue-tie, frenotomy, and/or breastfeeding in English and the equivalent terms in Japanese.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;An electronic literature search was systematically performed using databases including PubMed (January1966April 2013), Japana Centra Revuo Medicina (Igaku Chuo Zasshi, January 1983April 2013), CINAHL, and Cochrane Library using the key words ankyloglossia, tongue-tie, frenotomy, and/or breastfeeding in English and the equivalent terms in Japanese.&quot;</span> At least two electronic sources were searched.

A4. [No] There is no mention of whether grey literature was searched or used as an inclusion criterion. 

A5. [Yes] Figure 1 provides a flow diagram showing included and excluded studies.

A6. [Yes] Table 2 provides characteristics of the included RCTs. Other tables provide characteristics of the observational studies.

A7. [No] There is no mention of quality assessment of individual studies.

A8. [NA] Since A7 is No, this item is not applicable.

A9. [Yes] For meta-analyses, heterogeneity was assessed using I2 and Chi2 tests. 

A10. [No] Publication bias was not assessed.

A11. [No] Sources of support were not reported for individual studies.

P1. [Yes] The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, methods, results, and conclusions.

P3. [Yes] The introduction describes the rationale in context of existing knowledge.

P4. [Yes] The introduction states the objective is to examine the effectiveness of frenotomy for breastfeeding difficulties in infants with ankyloglossia. 

P5. [NA] A protocol is not mentioned.

P6. [Yes] The methods specify inclusion criteria regarding population, interventions, outcomes, and study designs.

P7. [Yes] The methods describe literature search sources and dates searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] Figure 1 shows the study selection process. 

P10. [No] The data collection process is not described.

P11. [Yes] Table 1 lists the outcomes examined and their importance.

P12. [NA] Risk of bias assessment is not applicable since it was not done.

P13. [NA] Summary measures are not applicable since no meta-analysis was done for most outcomes.

P14. [NA] Synthesis methods are not applicable since no meta-analysis was done for most outcomes.

P15. [NA] Assessment of bias across studies is not applicable since no meta-analysis was done for most outcomes. 

P16. [NA] Additional analyses are not applicable since no meta-analysis was done for most outcomes.

P17. [Yes] Figure 1 shows numbers of studies screened, assessed, and included with reasons for exclusions.

P18. [Yes] Tables provide characteristics of included studies. 

P19. [NA] Risk of bias within studies was not assessed.

P20. [Yes] Results for each outcome are presented in the tables and text.

P21. [Yes] Where meta-analyses were done, results are presented with confidence intervals and heterogeneity measures.

P22. [NA] Bias across studies was not assessed.

P23. [NA] Additional analyses were not done.

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [No] Limitations are not discussed.

P26. [Yes] Conclusions summarize the interpretation of results and implications.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='107'></a></p>
</div>
<div
id="jia-2011-open-versus-laparoscopic-pyloromyotomy-for-pyloric-stenosis-a-meta-analysis-of-randomized-controlled-trials"
class="section level4">
<h4>107.
<a href='https://doi.org/10.1055/S-0030-1261926' title='Open publication'>Jia
2011: <i>Open versus Laparoscopic Pyloromyotomy for Pyloric Stenosis: A
Meta-analysis of Randomized Controlled Trials</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
wrong-response-partial-unclear-etc</i></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database, using the following text and keywords in combination both as MeSH terms and text words:  pyloric stenosis , pylorostenosis ,  pyloristenosis and  pyloromyotomy in combination with  laparoscop*.&quot;</span> This indicates that the review had an a priori design with pre-defined objectives and eligibility criteria. [Yes]

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data were extracted by 2 independent investigators, and discrepancies were discussed to reach consensus.&quot;</span> This indicates that there was duplicate study selection and data extraction. [Yes] 

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database.&quot;</span> Multiple databases were searched. [Yes]

A4. No mention of including or excluding studies based on publication status. [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>]

A5. Figure 1 shows a flow diagram depicting included and excluded studies. [Yes] 

A6. Table 1 provides characteristics of the included studies. [Yes]

A7. Table 2 assesses risk of bias in the included studies. [Yes]  

A8. No mention of incorporating assessment of study quality into formulation of conclusions. [No]

A9. Not applicable, as no meta-analysis was performed. [NA]

A10. Not applicable, as no meta-analysis was performed. [NA] 

A11. No assessment of publication bias mentioned. [No]

P1. Identified as a systematic review and meta-analysis in title. [Yes]

P2. Abstract provides structured summary. [Yes]

P3. Introduction describes rationale and context. [Yes]

P4. Objectives stated in introduction. [Yes] 

P5. No protocol mentioned. [No]

P6. Eligibility criteria described in methods. [Yes]

P7. Information sources described in methods. [Yes]

P8. Search strategy provided for one database. [Yes]

P9. Study selection process depicted in Figure 1. [Yes]

P10. Data extraction process described. [Yes] 

P11. Data items described in Table 1. [Yes]

P12. Risk of bias assessment described and presented in Table 2. [Yes]

P13. Not applicable. [NA]

P14. Not applicable. [NA]

P15. Not applicable. [NA]

P16. Not applicable. [NA]

P17. Study selection process depicted in Figure 1. [Yes]

P18. Characteristics of included studies presented in Table 1. [Yes]

P19. Risk of bias assessment presented in Table 2. [Yes]

P20. Not applicable. [NA] 

P21. Not applicable. [NA]

P22. Not applicable. [NA]

P23. Not applicable. [NA]

P24. Main findings summarized in discussion. [Yes]

P25. Limitations discussed. [Yes]

P26. Conclusions and implications described. [Yes]

P27. Sources of funding described. [Yes]</pre>
<p><a name='108'></a></p>
</div>
<div
id="kapralik-2016-surgical-versus-conservative-management-of-congenital-pulmonary-airway-malformation-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>108.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.11.022' title='Open publication'>Kapralik
2016: <i>Surgical versus conservative management of congenital pulmonary
airway malformation in children: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">27 quote(s) from
publication full text</span> (mean similarity 98.3%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">38 quote(s)
from the LLM prompt briefing</span> (mean similarity 98.1%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):

ed? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our objective was to conduct a systematic review and meta-analysis of all published literature comparing the postoperative outcomes associated with elective surgery (while asymptomatic) versus those following surgery as part of expectant management (i.e., performing surgery only upon the development of symptoms) in children born with asymptomatic CPAM lesions.&quot;</span>
Reasoning: The objective and inclusion criteria were pre-specified.

A2. Was there duplicate study selection and data extraction?
<span title='Minor quote deviation. Best match in prompt (Similarity 98.4%):

n? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.&quot;</span>
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.1%):

Two independent reviewers conducted all article screening; where consensus on an article could not be reached, a third reviewer was consulted. 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent reviewers conducted all article screening; where consensus on an article could not be reached, a third reviewer was consulted. One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;</span>  
Reasoning: Two reviewers independently screened studies and reached consensus. Two reviewers performed data extraction.

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):

ed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted an electronic literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 onwards), and PubMed (1966 onwards) in January 2015.&quot;</span> <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Finally, we hand-searched the reference sections of all relevant articles to identify additional studies.&quot;</span>
Reasoning: Searched 5 databases, hand-searched references.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):

? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.&quot;</span>
Quotes: No mention of grey literature.
Reasoning: Did not search or mention grey literature. 

A5. Was a list of studies (included and excluded) provided?
<span title='Minor quote deviation. Best match in prompt (Similarity 98.5%):

ed? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Full-text review resulted in eight of these studies being included, while an additional one was identified from hand-searching the reference sections of included articles; nine studies were ultimately included [1012,14,2327].&quot;</span>
Reasoning: Listed included studies, excluded studies referenced in flow diagram.

A6. Were the characteristics of the included studies provided?
<span title='Minor quote deviation. Best match in prompt (Similarity 99.3%):

ed? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The MINORS scores for our included studies ranged from 7 to 14, with a median score of 9 (Table 1).&quot;</span> <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Details of the complications experienced by patients in each study are provided in Table 2.&quot;</span>
Reasoning: Provided table with characteristics of included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):

ed? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We used the Methodological Index for Non-Randomized Studies (MINORS) to assess the quality of the included studies, as all were nonrandomized [18].&quot;</span> <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The MINORS scores for our included studies ranged from 7 to 14, with a median score of 9 (Table 1).&quot;</span>
Reasoning: Used MINORS tool, provided quality assessment for each study.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):

ons? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.&quot;</span>
Quotes: No discussion of study quality in conclusions.
Reasoning: All studies were non-randomized so quality was uniformly low. No randomized trials available.

A9. Were the methods used to combine the findings of studies appropriate?
<span title='Minor quote deviation. Best match in prompt (Similarity 99.2%):

? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.&quot;</span>  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We produced Chi2 and I2 values to assess homogeneity.&quot;</span> <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;using random-effects models [21]&quot;</span>
Reasoning: Assessed heterogeneity and used random effects model.

A10. Was the likelihood of publication bias assessed?
<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):

? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no.&quot;</span>
Quotes: No assessment of publication bias.
Reasoning: Did not assess publication bias.

A11. Was the conflict of interest included?
<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):

? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.&quot;</span>
Quotes: No statement about conflicts of interest.
Reasoning: Did not report conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. 
<span title='Moderate quote deviation. Best match in prompt (Similarity 94.5%):

: Identify the report as a systematic review, meta-analysis, or both.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Surgical versus conservative management of congenital pulmonary airway malformation in children: A systematic review and meta-analysis&quot;</span>
Reasoning: Identified as systematic review and meta-analysis in title.

P2. Structured summary.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):

: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
Quotes: The abstract provides a structured summary with background, objectives, methods, results, and conclusions.
Reasoning: Structured abstract provided.

P3. Describe the rationale for the review.
<span title='Minor quote deviation. Best match in prompt (Similarity 95.2%):

: Describe the rationale for the review in the context of what is already known.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe the rationale for the review in the context of what is already known.&quot;</span> 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Arguments favoring either elective surgery or expectant management of asymptomatic lesions are many. They include estimates that delaying surgery until symptom onset will result in a more complicated procedure with worse surgical outcomes [813], as well as counterarguments stating that, as rates of symptom development are largely unknown [14,15], intervening before symptoms appear may result in exposure of healthy patients to unnecessary surgical risks [15]. These differing viewpoints illustrate the lack of consensus as to whether surgical management or an expectant approach for asymptomatic CPAM is associated with a smaller risk of morbidity in the short and long term.&quot;</span>
Reasoning: Provided background on the controversy and lack of consensus.

P4. Provide an explicit statement of questions being addressed.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):

es: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our objective was to conduct a systematic review and meta-analysis of all published literature comparing the postoperative outcomes associated with elective surgery (while asymptomatic) versus those following surgery as part of expectant management (i.e., performing surgery only upon the development of symptoms) in children born with asymptomatic CPAM lesions.&quot;</span>
Reasoning: Clear objective statement specifying population, interventions, comparison, and outcomes. 

P5. Indicate if a review protocol exists. 
<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):

: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
Quotes: No mention of protocol.
Reasoning: Did not mention protocol.

P6. Specify study characteristics and report characteristics. 
<span title='Minor quote deviation. Best match in prompt (Similarity 98%):

a: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

We excluded any studies on nonhuman subjects and those that did not focus on pediatric patients, as well as any studies that were not published in English, owing to resource limitations. We also excluded editorials, case reviews, any studies that did not evaluate postoperative outcomes, and any studies where it was not possible to extract data only on patients who were asymptomatic at birth.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We excluded any studies on non-human subjects and those that did not focus on pediatric patients, as well as any studies that were not published in English, owing to resource limitations. We also excluded editorials, case reviews, any studies that did not evaluate postoperative outcomes, and any studies where it was not possible to extract data only on patients who were asymptomatic at birth.&quot;</span>
Reasoning: Specified eligibility criteria including population, outcomes, language, and publication status.

P7. Describe information sources.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.9%):

es: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted an electronic literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 onwards), and PubMed (1966 onwards) in January 2015.&quot;</span>
Reasoning: Listed databases searched with date ranges and date last searched.

P8. Present full electronic search strategy.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):

: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
Quotes: Search strategy not provided.
Reasoning: Did not provide full search strategy.

P9. State the process for selecting studies.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.5%):

n: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span> 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two independent reviewers conducted all article screening; where consensus on an article could not be reached, a third reviewer was consulted.&quot;</span>
Reasoning: Described screening process.

P10. Describe method of data extraction.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):

s: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;</span>
Reasoning: Described data extraction process.

P11. List and define all variables for which data were sought.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.8%):

s: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We extracted the following data exclusively on patients who were asymptomatic at birth: number of patients undergoing elective surgery, number undergoing surgery as part of expectant management (after symptom development), age at symptom development if applicable, postoperative complications, mortalities, and total length of postoperative hospital stay, as well as number of patients successfully managed conservatively at the end of follow-up, and length of follow-up for these patients.&quot;</span>
Reasoning: Listed extracted variables.

P12. Describe methods for assessing risk of bias of individual studies. 
<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):

es: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We used the Methodological Index for Non-Randomized Studies (MINORS) to assess the quality of the included studies, as all were nonrandomized [18].&quot;</span>
Reasoning: Specified MINORS used to assess quality of included studies.

P13. State principal summary measures.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):

es: State the principal summary measures (e.g., risk ratio, difference in means).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] State the principal summary measures (e.g., risk ratio, difference in means).&quot;</span>
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

produce an odds ratio (OR) for morbidity, as this is a categorical variable, and a mean difference (MD) for length of stay, as this is a continuous variable, along with 95% confidence intervals (CIs).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We produced an odds ratio (OR) for morbidity, as this is a categorical variable, and a mean difference (MD) for length of stay, as this is a continuous variable, along with 95% confidence intervals (CIs).&quot;</span> 
Reasoning: Stated that OR and MD were used.

P14. Synthesis of results.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.1%):

s: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.&quot;</span>
Quotes: No qualitative synthesis performed.
Reasoning: No qualitative synthesis, only quantitative.

P15. Risk of bias across studies.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):

s: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).&quot;</span>
Quotes: No assessment of risk of bias across studies. 
Reasoning: No assessment of publication bias or other biases across studies.

P16. Additional analyses. 
<span title='Minor quote deviation. Best match in prompt (Similarity 98%):

s: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.&quot;</span>
Quotes: No additional analyses.
Reasoning: No sensitivity or subgroup analyses.

P17. Give numbers of studies screened, assessed, and included, with reasons for exclusions.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):

n: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our electronic search yielded 342 studies. After applying our exclusion criteria to titles and abstracts, 63 studies remained. Full-text review resulted in eight of these studies being included, while an additional one was identified from hand-searching the reference sections of included articles; nine studies were ultimately included [1012,14,2327].&quot;</span> And provides a flow diagram.
Reasoning: Provided details on screening process with flow diagram.

P18. For each study, present characteristics. 
<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):

s: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span>
Quotes: Provides details on included studies in Table 1.
Reasoning: Provided table with characteristics of included studies.

P19. Present data on risk of bias of each study.
<span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):

es: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The MINORS scores for our included studies ranged from 7 to 14, with a median score of 9 (Table 1).&quot;</span>
Reasoning: Provided MINORS score for each study in table.

P20. For each study, present summary data and effect sizes.
<span title='Minor quote deviation. Best match in prompt (Similarity 99%):

es: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.&quot;</span> 
Quotes: Provides summary data and forest plots. 
Reasoning: Provided summary data and forest plots.

P21. Present results of meta-analyses. 
<span title='Minor quote deviation. Best match in prompt (Similarity 97.2%):

s: Present results of each meta-analysis done, including confidence intervals and measures of consistency.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Present results of each meta-analysis done, including confidence intervals and measures of consistency.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Results of this meta-analysis showed that total morbidity (number of patients who experienced postoperative complications) was significantly higher when surgery was performed after symptom development compared to resection when patients were asymptomatic (OR 4.59, 95% CI 1.40 to 15.11, P = 0.01).&quot;</span>
Reasoning: Provided results of meta-analyses including CIs.

P22. Present results of bias assessment across studies.
<span title='Minor quote deviation. Best match in prompt (Similarity 96.5%):

s: Present results of any assessment of risk of bias across studies (see Item P15).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Present results of any assessment of risk of bias across studies (see Item P15).&quot;</span>
Quotes: No assessment of publication bias or other biases across studies.
Reasoning: No assessment of publication bias or other biases across studies.

P23. Give results of additional analyses.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.4%):

s: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Give results of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).&quot;</span>
Quotes: No additional analyses.
Reasoning: No sensitivity or subgroup analyses.

P24. Summarize evidence. 
<span title='Minor quote deviation. Best match in prompt (Similarity 97.8%):

: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Based on our results, we recommend elective resection of asymptomatic CPAM lesions, rather than expectant management. Lung resection in an asymptomatic patient is quite safe, prevents the risk of symptom development later in life, and may help prevent the development of malignancy.&quot;</span>
Reasoning: Summarized main findings and gave recommendations.

P25. Discuss limitations. <span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):

s: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span>

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our results should be interpreted with caution owing to the nature of the included studies (in that all but one were retrospective). We did not identify any RCTs evaluating the benefit of elective surgery compared to expectant management of asymptomatic CPAM lesions.&quot;</span>

Reasoning: Discussed limitations including lack of RCTs and retrospective nature of studies.

P26. Provide a general interpretation of results.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):

s: Provide a general interpretation of the results in the context of other evidence, and implications for future research.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In fact, our results are similar to those of a systematic review and meta-analysis comparing elective and emergency surgery for all types of congenital cystic lung lesions [15], finding that surgery after symptom development is associated with more complications than elective surgery.&quot;</span>
Reasoning: Interpreted results in context of other evidence.

P27. Describe sources of funding and role of funders.
<span title='Minor quote deviation. Best match in prompt (Similarity 97.2%):

: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span>
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The University of Ottawa Summer Studentship program provided financial support for this project.&quot;</span>
Reasoning: Stated source of funding.</pre>
<p><a name='109'></a></p>
</div>
<div
id="kunz-2013-primary-fascial-closure-versus-staged-closure-with-silo-in-patients-with-gastroschisis-a-meta-analysis"
class="section level4">
<h4>109.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.020' title='Open publication'>Kunz
2013: <i>Primary fascial closure versus staged closure with silo in
patients with gastroschisis: A meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
unsolicited-ranges</i></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 96.5%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane Database of Systematic Reviews database through June 1, 2012.&quot;</span> The review had an a priori design with pre-defined inclusion/exclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Abstracts for all articles were independently subjected to preliminary review by two investigators (JA, SK) to determine whether inclusion criteria were satisfied.&quot;</span> Study selection was done in duplicate. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The search terms used were gastroschisis and [(treatment outcome or prognosis) or randomized controlled trials].&quot;</span> At least two electronic sources were searched along with checking reference lists.

A4. [No] The authors do not state whether grey literature was searched or used as an inclusion criterion.

A5. [No] A list of included and excluded studies is not provided.

A6. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 86.1%):

cript form created by the authors was used to extract study information, including study design, patient characteristics, and reported patient outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;A standard data collection form created by the authors was used to extract study information, including study design, patient characteristics, and reported patient outcomes.&quot;</span> Characteristics of included studies are provided in Table 1.

A7. [No] The scientific quality of included studies was not formally assessed.

A8. [NA] Since study quality was not assessed, it was not incorporated into conclusions.

A9. [NA] No meta-analysis was performed. 

A10. [NA] Assessment of publication bias not applicable without a meta-analysis.

A11. [No] Sources of support are not reported for included studies.

P1. [Yes] The title identifies the report as a meta-analysis.

P2. [Yes] The abstract provides a structured summary including objectives, data sources, eligibility criteria, outcomes, and conclusions.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] The introduction states the objective is to compare outcomes for primary closure versus silo repair for gastroschisis. 

P5. [No] A protocol is not mentioned.

P6. [Yes] The methods specify inclusion/exclusion criteria and outcomes of interest. 

P7. [Yes] The methods describe the literature search including databases and dates searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods describe the process of study screening, eligibility assessment, and inclusion. 

P10. [Yes] The methods state that data extraction was performed independently in duplicate using a standard form. 

P11. [Yes] Table 1 lists the data extracted from studies.

P12. [No] Risk of bias in individual studies was not assessed.

P13. [NA] No meta-analysis was performed to require summary measures.

P14-P23. [NA] Not applicable without a meta-analysis.

P24. [Yes] The discussion summarizes the main findings and implications.

P25. [Yes] Limitations at the study level are discussed.

P26. [Yes] Conclusions are provided in the context of other evidence. 

P27. [No] Sources of funding for the review itself are not reported.</pre>
<p><a name='110'></a></p>
</div>
<div
id="landisch-2015-observation-versus-prophylactic-ladd-procedure-for-asymptomatic-intestinal-rotational-abnormalities-in-heterotaxy-syndrome-a-systematic-review"
class="section level4">
<h4>110.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.002' title='Open publication'>Landisch
2015: <i>Observation versus prophylactic Ladd procedure for asymptomatic
intestinal rotational abnormalities in heterotaxy syndrome: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">16 quote(s) from
publication full text</span> (mean similarity 95.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This study was performed according to guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [6].&quot;</span>
2. The study mentions following PRISMA guidelines.
[Yes]

A2. 
1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.3%):

Two independent researchers (R.L. and R.M.) performed the search, critically' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles.&quot;</span> 
2. Two independent researchers performed study selection and data extraction.
[Yes]

A3.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: heterotaxy, rotation, volvulus, Ladd procedure, Ivemark, asplenia, and polysplenia. Searches were repeated in PubMed, Medline, CINAHL, and Cochrane library.&quot;</span>
2. At least two databases were searched.
[Yes]

A4.  
1. No mention of including or excluding based on publication status.
2. Publication status not mentioned. 
[No]

A5.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;See Fig. 1 for a flow diagram summary of the literature vetting process.&quot;</span>
2. A flow diagram of included and excluded studies was provided.
[Yes]

A6. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Group characteristics of the 11 included studies are described in Table 1.&quot;</span> 
2. Table 1 provides characteristics of included studies.
[Yes]

A7.
1. No mention of quality assessment of included studies.
2. No quality assessment described.
[No] 

A8.
1. No mention of incorporating quality assessment into conclusions.
2. Quality not assessed.
[NA]

A9.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Because of the absence of randomized controlled trials and the heterogeneous nature of studies, a formal meta-analysis was not performed.&quot;</span>
2. States meta-analysis not performed due to heterogeneity. 
[NA]

A10.
1. No assessment of publication bias mentioned.
2. Publication bias not assessed.
[No]

A11. 
1. No mention of conflicts of interest.
2. Conflicts of interest not reported.
[No]

P1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Observation versus prophylactic Ladd procedure for asymptomatic intestinal rotational abnormalities in heterotaxy syndrome: A systematic review&quot;</span>
2. Identifies as a systematic review in title.
[Yes]

P2.  
1. The abstract provides background, objectives, eligibility criteria, results, and conclusions.
2. Structured abstract provided.
[Yes]

P3. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

Heterotaxy syndrome (HS), a consequence of aberrations in left-toright positional signaling in early embryonic development, manifests as cardiac and visceral anatomic malpositioning. Forty percent to 90% of patients with HS also have intestinal rotational abnormalities (IRA) [1]. Improved survival secondary to advances in cardiac surgery and critical care management has led to enhanced prioritization of intestinal abnormalities, namely, prevention of midgut volvulus [2].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Heterotaxy syndrome (HS), a consequence of aberrations in left-to-right positional signaling in early embryonic development, manifests as cardiac and visceral anatomic malpositioning. Forty percent to 90% of patients with HS also have intestinal rotational abnormalities (IRA) [1]. Improved survival secondary to advances in cardiac surgery and critical care management has led to enhanced prioritization of intestinal abnormalities, namely, prevention of midgut volvulus [2].&quot;</span>
2. Provides context and rationale for review.
[Yes]

P4. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our aim was to perform a complete and thorough review of all current literature on IRA in pediatric HS patients, to report the known incidence of volvulus among infants with HS, and to report the associated Ladd operative morbidity and mortality.&quot;</span> 
2. Objectives stated.
[Yes]

P5.
1. No mention of a review protocol.
2. Review protocol not reported.
[No]

P6.  
1. Inclusion criteria described in methods. 
2. Eligibility criteria described.
[Yes]

P7. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: heterotaxy, rotation, volvulus, Ladd procedure, Ivemark, asplenia, and polysplenia. Searches were repeated in PubMed, Medline, CINAHL, and Cochrane library.&quot;</span>
2. Databases and date ranges reported.
[Yes]

P8. 
1. No full search strategy provided.
2. Full search strategy not reported.
[No]  

P9.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two other independent researchers (A.A. and A.W.) confirmed the inclusion of appropriate citations based on study definitions and aims.&quot;</span>
2. Study selection process described.
[Yes]

P10. 
1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.3%):

Two independent researchers (R.L. and R.M.) performed the search, critically' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles.&quot;</span>
2. Data extraction by two independent researchers described. 
[Yes]

P11.
1. Outcomes of interest described in methods.
2. Outcomes defined.
[Yes]

P12.
1. No assessment of risk of bias in individual studies described. 
2. Risk of bias not assessed.
[No]

P13. 
1. Primary and secondary outcomes defined in methods.
2. Summary measures described.
[Yes] 

P14. 
1. No quantitative synthesis performed.
2. Not applicable.
[NA]

P15.
1. No assessment of risk of bias across studies mentioned.
2. Not applicable.
[NA]

P16.
1. No additional analyses mentioned.
2. Not applicable. 
[NA]

P17. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;See Fig. 1 for a flow diagram summary of the literature vetting process.&quot;</span>
2. Study flow diagram provided.
[Yes]

P18. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Group characteristics of the 11 included studies are described in Table 1.&quot;</span>
2. Study characteristics presented.
[Yes] 

P19.
1. No assessment of risk of bias in individual studies presented.
2. Risk of bias not assessed.
[No]

P20. 
1. Results for outcomes summarized in text and tables.
2. Results for each study presented.
[Yes]

P21. 
1. No quantitative synthesis performed.
2. Not applicable.
[NA]

P22.
1. No assessment of risk of bias across studies presented.
2. Not applicable.
[NA] 

P23.
1. No additional analyses mentioned.
2. Not applicable.
[NA]

P24.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The Ladd procedure is not without significant morbidity and mortality in heterotaxy patients. Further prospective studies should investigate predictors of mesenteric width to spare the unnecessary morbidity of surgery in patients who are at low risk for volvulus.&quot;</span> 
2. Main findings and implications summarized.
[Yes]

P25. 
1. Limitations of included studies discussed.
2. Study limitations discussed.
[Yes]

P26. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Despite the low risk of volvulus in the data presented here, there are anecdotal cases of patients with HS who presented with volvulus that resulted in death. At this time, it remains difficult to definitively ascertain whether the risk of death from prophylactic Ladd in HS or the risk of death owing to volvulus in patients with HS who are observed is greater. A randomized, prospective trial to determine which subsets of patients with HS have the highest risk of volvulus is needed in order to optimize the care of this patient population.&quot;</span>
2. Interpretation of results and future research needs described. 
[Yes]

P27.
1. No mention of sources of funding.
2. Funding not reported.
[No]</pre>
<p><a name='111'></a></p>
</div>
<div
id="lane-2010-paediatric-sutureless-circumcision-a-systematic-literature-review"
class="section level4">
<h4>111.
<a href='https://doi.org/10.1007/S00383-009-2475-Y' title='Open publication'>Lane
2010: <i>Paediatric sutureless circumcision: a systematic literature
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Circumcision can be undertaken using a variety of techniques. For the technique to be successful, it should be easy to perform, avoid excessive haemorrhage and achieve a good cosmetic and functional result with minimal postoperative care.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Circumcision can be undertaken using a variety of techniques. For the technique to be successful, it should be easy to perform, avoid excessive haemorrhage and achieve a good cosmetic and functional result with minimal postop-erative care.&quot;</span>
The objective is not explicitly stated.
[No]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction.  
[No]

A3. Was a comprehensive literature search performed?
No details provided on literature search strategy.
[No]

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status.
[No] 

A5. Was a list of studies (included and excluded) provided?
No list of included or excluded studies provided.
[No]

A6. Were the characteristics of the included studies provided?
Study characteristics summarized in text.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment of included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias.
[NA]

A11. Was the conflict of interest included?
No statement on conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Identified as systematic review in title.
[Yes]

P2. Structured summary.
No structured abstract provided.
[No]

P3. Describe rationale for review. 
Rationale described in introduction.
[Yes]

P4. Provide objectives with PICOS.
Objectives not explicitly stated with PICOS.
[No]

P5. Indicate protocol and registration.
No mention of protocol.
[No]

P6. Specify eligibility criteria.
No details on eligibility criteria.
[No]  

P7. Describe information sources.
No description of information sources.
[No]

P8. Present search strategy.
No search strategy presented.
[No]

P9. State process for study selection. 
No details provided on study selection process.
[No]

P10. Describe data collection process.
No description of data collection process.  
[No]

P11. List and define data items sought.
No list of data items sought.
[No] 

P12. Assess risk of bias in studies.
No assessment of risk of bias.
[No]

P13. State summary measures.
No summary measures stated.
[No]

P14. Synthesis methods.
No quantitative synthesis performed.
[NA]

P15. Assess risk of bias across studies.
No assessment of risk of bias across studies.
[NA]  

P16. Describe additional analyses.
No additional analyses described.
[NA]

P17. Give study selection flow diagram. 
No flow diagram provided.
[No]

P18. Study characteristics.
Study characteristics summarized in text.
[Yes]

P19. Present risk of bias assessments.
No assessment of risk of bias. 
[No]

P20. Results for each study.
Results summarized narratively.
[Yes]

P21. Present synthesis results.
No quantitative synthesis performed.
[NA]  

P22. Present risk of bias across studies.
No assessment of risk of bias across studies.
[NA]

P23. Give additional analysis results. 
No additional analyses performed.
[NA]

P24. Summarize evidence.
Main findings summarized.
[Yes]

P25. Discuss limitations.
No limitations discussed.
[No]

P26. Interpret results and implications.
General interpretation provided.
[Yes]

P27. Describe funding sources. 
No statement on funding sources.
[No]</pre>
<p><a name='112'></a></p>
</div>
<div
id="lansdale-2010-neonatal-endosurgical-congenital-diaphragmatic-hernia-repair"
class="section level4">
<h4>112.
<a href='https://doi.org/10.1097/SLA.0B013E3181DCA0E8' title='Open publication'>Lansdale
2010: <i>Neonatal Endosurgical Congenital Diaphragmatic Hernia
Repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

MEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched using the keywords diaphragmatic hernia AND thoracoscopic, diaphragmatic hernia AND laparoscopic, and diaphragmatic hernia AND minimallyinvasive.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;MEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched using the keywords diaphragmatic hernia AND thoracoscopic, diaphragmatic hernia AND laparoscopic, and diaphragmatic hernia AND minimally-invasive.&quot;</span> This indicates that an a priori design was used with pre-defined search terms and inclusion criteria.

A2. [No] There is no mention of duplicate study selection or data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;MEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched&quot;</span> [...] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span> Multiple databases and supplementary search strategies were used.

A4. [No] Publication status was not discussed as an inclusion criterion.

A5. [No] A list of included and excluded studies was not provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following demographic data was sought for each group: proportion of male sex, proportion with left-sided CDH, mean birth weight, mean gestational age, APGAR score at 1 minute, proportion requiring ECMO, and proportion with significant associated anomalies.&quot;</span> Characteristics of included studies were provided.

A7. [No] Methodological quality of included studies was not assessed.

A8. [NA] Methodological quality was not assessed so it could not be incorporated into formulating conclusions.

A9. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data meta-analysis was carried out using Review Manager (RevMan) Version 5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Weighted treatment effect was calculated using the fixed effects model.&quot;</span> Appropriate methods were used for combining study findings. 

A10. [No] Publication bias was not assessed.

A11. [No] Sources of support were not reported for included studies.

P1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Neonatal Endosurgical Congenital Diaphragmatic Hernia Repair A Systematic Review and Meta-Analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Neonatal Endosurgical Congenital Diaphragmatic Hernia Repair: A Systematic Review and Meta-Analysis&quot;</span> identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions. 

P3. [Yes] The introduction describes the rationale for the review in the context of previous research.

P4. [Yes] The introduction states the objective <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;we have asked whether MIS approaches to neonatal CDH repair are associated with changes in survival, CDH recurrence risk, operative time, and/or prosthetic patch usage.&quot;</span> 

P5. [No] A review protocol is not mentioned.

P6. [Yes] The methods section specifies inclusion criteria such as neonates, comparison groups, and outcomes data.

P7. [Yes] The methods section describes the information sources including databases searched.

P8. [No] The full electronic search strategy is not provided.

P9. [Yes] The methods section describes the process for study screening, eligibility assessment, and inclusion. 

P10. [No] Methods for data extraction are not described. 

P11. [Yes] The methods section lists the data items sought, including demographics, interventions, and outcomes.

P12. [No] Risk of bias in individual studies was not assessed.

P13. [Yes] The methods state that relative risk and weighted mean difference were the principal summary measures used.

P14. [NA] Not applicable since no meta-analysis was performed.

P15. [NA] Not applicable since no meta-analysis was performed. 

P16. [NA] Not applicable since no additional analyses were performed.

P17. [Yes] The results section includes a flow diagram of study selection.

P18. [No] Study characteristics were not presented in a table.

P19. [No] Risk of bias was not presented for individual studies.

P20. [Yes] Results for each outcome are presented for individual studies.

P21. [Yes] Results of the meta-analyses are presented, including confidence intervals.

P22. [NA] Not applicable since no assessment of bias across studies was performed.

P23. [NA] Not applicable since no additional analyses were performed. 

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] Limitations at the study level are discussed.

P26. [Yes] Conclusions are provided along with implications for future research.

P27. [No] Sources of funding are not reported for the systematic review.</pre>
<p><a name='113'></a></p>
</div>
<div
id="lee-2010-antibiotics-and-appendicitis-in-the-pediatric-population-an-american-pediatric-surgical-association-outcomes-and-clinical-trials-committee-systematic-review"
class="section level4">
<h4>113.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.06.038' title='Open publication'>Lee
2010: <i>Antibiotics and appendicitis in the pediatric population: an
American Pediatric Surgical Association Outcomes and Clinical Trials
Committee Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
"[No]"
No protocol or pre-determined objectives mentioned.

A2. Was there duplicate study selection and data extraction?
"[No]"  
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data were obtained from PubMed, MEDLINE, and citation review.&quot;</span>
Literature search described.  

A4. Was the status of publication used as an inclusion criterion?
"[No]"
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Table 1 and 2 provide characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
No mention of quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[NA]"
Study quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]" 
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"
No assessment of publication bias mentioned.  

A11. Was the conflict of interest included?
"[No]"
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
Title identifies it as a systematic review.

P2. Structured summary 
"[No]" 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"
Introduction describes rationale and lack of consensus on antibiotic use for pediatric appendicitis.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
"[Yes]" 
Questions provided in the Study Selection section.

P5. Indicate if a review protocol exists, if and where it can be accessed.
"[No]"
No mention of a review protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
"[No]"
No details provided on eligibility criteria.

P7. Describe all information sources in the search and date last searched.
"[Yes]"  
Sources and time period described in Data Source section.

P8. Present full electronic search strategy for at least one database, including any limits used.
"[No]"
Search strategy not provided.

P9. State the process for selecting studies.
"[No]"
No details provided on study selection process. 

P10. Describe method of data extraction from reports. 
"[No]"
No description of data extraction process.

P11. List and define all variables for which data were sought.
"[No]"
Data items not defined.

P12. Describe methods used for assessing risk of bias of individual studies.
"[No]" 
No risk of bias assessment described.

P13. State the principal summary measures.
"[NA]"
No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results of studies, if done. 
"[NA]"
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias across studies.
"[NA]" 
No assessment of risk of bias across studies mentioned.

P16. Describe methods of additional analyses, if done.
"[NA]"
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
"[No]"
No flow diagram or details on study selection process provided.

P18. For each study, present characteristics and provide the citations. 
"[Yes]"
Table 1 and 2 provide relevant characteristics and citations for included studies.

P19. Present data on risk of bias of each study. 
"[No]"
No assessment of risk of bias for individual studies.

P20. For all outcomes, present, for each study: (a) simple summary data (b) effect estimates and confidence intervals, ideally with a forest plot.
"[No]" 
No forest plots or effect estimates provided.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]"  
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies.
"[NA]"
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done.
"[NA]"
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome.
"[Yes]" 
Main findings and strength of evidence summarized in the Summary of Recommendations section.  

P25. Discuss limitations at study and outcome level, and at review-level.
"[No]"
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
"[No]"
No interpretation of results or implications for future research provided.

P27. Describe sources of funding for the systematic review and other support. 
"[No]" 
No mention of sources of funding or support.</pre>
<p><a name='114'></a></p>
</div>
<div id="leevan-2016-management-of-pediatric-blunt-renal-trauma"
class="section level4">
<h4>114.
<a href='https://doi.org/10.1097/TA.0000000000000950' title='Open publication'>LeeVan
2016: <i>Management of pediatric blunt renal trauma</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given full text:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This is a systematic review of PubMed, Ovid, and the Cochrane Library.&quot;</span>
The review had an a priori design.

A2. [No] 
No mention of duplicate study selection or data extraction.
There is no indication that duplicate processes were used.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following search was performed in each of the three databases: (Renal or Kidney) AND (Pediatric or Children) AND Trauma AND Management.&quot;</span>
At least two electronic databases were searched. 

A4. [No]
No mention of including or excluding studies based on publication status. 
Publication status was not considered.

A5. [No]
No list of included and excluded studies was provided.

A6. [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 2 provides characteristics of the included studies.

A7. [No]
No mention of assessing methodological quality or risk of bias of included studies.

A8. [NA] 
Not applicable since quality of studies was not assessed.

A9. [NA]  
Not applicable since no quantitative synthesis was performed.

A10. [No]
No assessment of publication bias mentioned.

A11. [No]
No statement about sources of support or conflict of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Management of pediatric blunt renal trauma: A systematic review&quot;</span>
Identified as a systematic review in the title.

P2. [Yes]  
The abstract provides relevant background, objectives, data sources, eligibility criteria, number of included studies, and conclusions. 

P3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Blunt trauma remains a significant cause of morbidity and mortality in the pediatric population.&quot;</span>
Provided context about pediatric blunt renal trauma.

P4. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This study aimed to review current practices in pediatric blunt renal trauma management and to highlight current practices in conservative protocols, success rates of conservative management strategies, as well as short- and long-term outcomes of blunt renal trauma management.&quot;</span> 
Review objectives and topics are described.

P5. [No]
No mention of a review protocol.

P6. [Yes]  
Inclusion criteria of original research on pediatric blunt renal trauma management, involving high-grade injuries, and more than one patient per study are described.

P7. [Yes]  
Searched PubMed, Ovid, and Cochrane Library from 2000 to present. 

P8. [No] 
The search strategy is not provided.

P9. [Yes]
The process of screening titles/abstracts and reviewing full texts for selection is described.

P10. [No]
No description of data extraction methods. 

P11. [No]
No list of data items sought.

P12. [No] 
Did not describe assessing risk of bias in individual studies.

P13. [NA]
Not applicable since no quantitative synthesis was performed.

P14. [NA]  
Not applicable since no quantitative synthesis was performed.

P15. [NA]
Not applicable since no quantitative synthesis was performed. 

P16. [NA]
Not applicable since no additional analyses were performed.

P17. [No] 
No flow diagram of study selection.

P18. [Yes]
Table 2 provides characteristics of included studies.

P19. [No]
Did not present risk of bias/quality data for individual studies.

P20. [No]
Did not provide results for each included study.

P21. [NA] 
Not applicable since no quantitative synthesis was performed.

P22. [NA]
Not applicable since no quantitative synthesis was performed.

P23. [NA]
Not applicable since no additional analyses were performed.

P24. [Yes]
The discussion summarizes the main findings and implications.

P25. [No] 
Did not discuss limitations at the review or outcome level.

P26. [Yes]
Provides interpretation of results and implications for future research.

P27. [No]
No statement about sources of funding or support.</pre>
<p><a name='115'></a></p>
</div>
<div
id="liang-2011-lymphatic-sparing-versus-lymphatic-non-sparing-laparoscopic-varicocelectomy-in-children-and-adolescents-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>115.
<a href='https://doi.org/10.1055/S-0031-1271733' title='Open publication'>Liang
2011: <i>Lymphatic Sparing Versus Lymphatic Non-Sparing Laparoscopic
Varicocelectomy in Children and Adolescents: A Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A search was made for all studies published up until 31 August 2010 using the terms lymphatic sparing varicocelectomy, laparoscopy , adolescent  and children  in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span> [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each included article was appraised by 3 reviewers (LZL, GJ and TQS), who independently assessed the methodological quality of the selected studies.&quot;</span> [Yes]

A3. Was a comprehensive literature search performed?  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A search was made for all studies published up until 31 August 2010 using the terms lymphatic sparing varicocelectomy, laparoscopy , adolescent  and children  in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of searching for grey literature. [No] 

A5. Was a list of studies (included and excluded) provided?
No list of excluded studies provided. [No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each included article was appraised by 3 reviewers (LZL, GJ and TQS), who independently assessed the methodological quality of the selected studies. A critical review checklist of the Dutch Cochrane Center was used to appraise the RCTs.&quot;</span> [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No mention of using study quality in formulating conclusions. [No]

A9. Were the methods used to combine the findings of studies appropriate?  
Fixed and random effects models used based on heterogeneity. [Yes]

A10. Was the likelihood of publication bias assessed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

s We analyzed possible publication bias by generating funnel plots of the trials used for all of the evaluated comparisons of outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We analyzed possible publication bias by generating funnel plots of the trials used for all of the evaluated comparisons of outcomes.&quot;</span> [Yes]

A11. Was the conflict of interest included? 
No mention of conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]

P2. Structured summary provided. [Yes]

P3. Rationale described. [Yes] 

P4. Objectives stated. [Yes]

P5. Protocol and registration not mentioned. [No]

P6. Eligibility criteria described. [Yes]

P7. Information sources described. [Yes] 

P8. Search strategy provided. [No]

P9. Study selection process described. [Yes] 

P10. Data collection process described. [Yes]

P11. Data items described. [Yes] 

P12. Risk of bias assessment described. [Yes]

P13. Summary measures stated. [Yes]

P14. Synthesis methods described. [Yes]

P15. Risk of bias across studies not mentioned. [No] 

P16. Additional analyses not mentioned. [NA]

P17. Study selection flow diagram provided. [Yes]

P18. Study characteristics provided. [Yes]

P19. Risk of bias results provided. [No]

P20. Results of individual studies presented. [Yes]

P21. Results of syntheses presented. [Yes]

P22. Risk of bias across studies not presented. [NA] 

P23. Additional analyses not presented. [NA]

P24. Summary of evidence provided. [Yes]

P25. Limitations discussed. [Yes]

P26. Conclusions provided. [Yes]

P27. Funding described. [Yes]</pre>
<p><a name='116'></a></p>
</div>
<div
id="lishuang-2015-laparoscopic-portoenterostomy-versus-open-portoenterostomy-for-the-treatment-of-biliary-atresia-a-systematic-review-and-meta-analysis-of-comparative-studies"
class="section level4">
<h4>116.
<a href='https://doi.org/10.1007/S00383-015-3662-7' title='Open publication'>Lishuang
2015: <i>Laparoscopic portoenterostomy versus open portoenterostomy for
the treatment of biliary atresia: a systematic review and meta-analysis
of comparative studies</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this study was to include all publicly available data for comparing the safety and validity of laparoscopic portoenterostomy (LPE) and open portoenterostomy (OPE) in the treatment of biliary atresia.&quot;</span> The research question and inclusion criteria were established before the review.

A2. [No] There is no mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;</span> At least two electronic sources were searched. 

A4. [No] There is no mention of including or excluding studies based on publication status. 

A5. [No] A list of included and excluded studies is not provided.

A6. [Yes] Table 1 provides characteristics of the included studies such as sample size, age, sex, weight, operative time, hospital stay, and follow-up.

A7. [No] There is no mention of assessing the scientific quality of included studies.

A8. [NA] Not applicable since quality of studies was not assessed (A7 is No).

A9. [NA] There was no quantitative synthesis/meta-analysis performed. 

A10. [NA] Assessment of publication bias not applicable without a meta-analysis.

A11. [No] There is no mention of sources of support or conflict of interest for the included studies.

P1. [Yes] The title identifies the report as a systematic review and meta-analysis. 

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, results, and conclusions.

P3. [Yes] The introduction describes the rationale in context of current knowledge.

P4. [Yes] The introduction states the objective is comparing LPE and OPE for treatment of biliary atresia.  

P5. [No] A protocol is not mentioned.

P6. [Yes] The methods specify inclusion criteria such as comparative cohort studies with data for analysis.

P7. [Yes] The methods describe the databases searched and date ranges.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods describe the process of screening, assessing eligibility, and inclusion. 

P10. [No] The data collection process is not described.

P11. [No] Variables for which data were sought are not listed and defined.

P12. [No] Assessment of risk of bias in individual studies is not described. 

P13. [NA] Not applicable as no meta-analysis was performed.

P14. [NA] Not applicable as no meta-analysis was performed.

P15. [NA] Not applicable as no meta-analysis was performed. 

P16. [NA] Not applicable as no additional analyses were performed.

P17. [No] A flow diagram of study selection is not provided.

P18. [Yes] Table 1 provides characteristics of the included studies.

P19. [No] Risk of bias within studies is not presented.

P20. [No] Results for each study are not presented.

P21. [NA] Not applicable as no meta-analysis was performed.

P22. [NA] Not applicable as no meta-analysis was performed.

P23. [NA] Not applicable as no additional analyses were performed. 

P24. [No] The discussion does not summarize the evidence.

P25. [No] Limitations are not discussed.

P26. [No] General interpretation of results in context of other evidence is not provided.

P27. [No] Sources of funding are not described.</pre>
<p><a name='117'></a></p>
</div>
<div
id="livingston-2015-fundoplication-and-gastrostomy-versus-percutaneous-gastrojejunostomy-for-gastroesophageal-reflux-in-children-with-neurologic-impairment-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>117.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.020' title='Open publication'>Livingston
2015: <i>Fundoplication and gastrostomy versus percutaneous
gastrojejunostomy for gastroesophageal reflux in children with
neurologic impairment: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted a structured search of Medline, Embase, trial registries, and the gray literature.&quot;</span> The review had an a priori design with pre-determined research question and inclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Title and abstract screening was completed independently and in duplicate by two of the authors (MHL, ACS).&quot;</span> There was duplicate study selection. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted a systematic search of Medline, Embase, and Cochrane Central Register of Controlled Trials for studies of participants with gastroesophageal reflux treated with FG or GJ. A medical librarian helped us develop queries for each database to identify studies that mentioned fundoplication and gastrojejunostomy.&quot;</span> A comprehensive literature search was performed in at least 2 databases along with supplementary strategies.

A4. [No] The review did not mention searching for or using unpublished gray literature.

A5. [Yes] Figure 1 shows a flow diagram depicting included and excluded studies.

A6. [Yes] Table 1 provides characteristics of included studies including participants, interventions, and outcomes. 

A7. [No] The review did not mention assessing quality or risk of bias in individual studies.

A8. [No] The review did not mention incorporating risk of bias assessments in formulating conclusions.

A9. [NA] The review did not perform quantitative synthesis or meta-analysis.

A10. [NA] The review did not assess publication bias since there were fewer than 10 studies. 

A11. [No] The review did not report on sources of funding or conflicts of interest in the included studies.

P1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

CAPS Papers Fundoplication and gastrostomy versus percutaneous gastrojejunostomy for gastroesophageal reflux in children with neurologic impairment: A systematic review and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;CAPS Papers: Fundoplication and gastrostomy versus percutaneous gastrojejunostomy for gastroesophageal reflux in children with neurologic impairment: A systematic review and meta-analysis&quot;</span>

P2. [Yes] The abstract provides a structured summary including objectives, data sources, participants, interventions, results, and conclusions.

P3. [Yes] The introduction describes rationale and context about management options for children with neurologic impairment and gastroesophageal reflux.

P4. [Yes] The objective mentions comparing FG and GJ for gastroesophageal reflux in children with neurologic impairment.

P5. [No] The review did not mention having a protocol.

P6. [Yes] The methods describe eligibility criteria including population, interventions, and outcomes.

P7. [Yes] The search strategy describes databases searched and date ranges.

P8. [No] The full search strategy was not provided.

P9. [Yes] The results section describes the study selection process and numbers at each stage. 

P10. [No] The review did not describe methods for data extraction.

P11. [No] The review did not provide a list of variables extracted. 

P12. [No] The review did not describe methods for assessing risk of bias.

P13. [NA] The review did not perform quantitative synthesis.

P14. [NA] The review did not perform quantitative synthesis.

P15. [NA] The review did not assess risk of bias across studies.

P16. [NA] The review did not perform additional analyses.

P17. [Yes] Figure 1 provides a flow diagram depicting study selection.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] The review did not provide risk of bias assessments for individual studies.

P20. [Yes] The results section provides outcome data for each study.

P21. [NA] The review did not perform quantitative synthesis. 

P22. [NA] The review did not assess risk of bias across studies.

P23. [NA] The review did not perform additional analyses.

P24. [Yes] The discussion summarizes main findings and implications.

P25. [Yes] The discussion mentions limitations at the study and outcome level.

P26. [Yes] The conclusion provides interpretation of results and implications for future research.

P27. [No] The review did not describe sources of funding.</pre>
<p><a name='118'></a></p>
</div>
<div
id="mauritz-2013-complete-versus-partial-fundoplication-in-children-with-gastroesophageal-reflux-disease-results-of-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>118.
<a href='https://doi.org/10.1007/S11605-013-2305-3' title='Open publication'>Mauritz
2013: <i>Complete Versus Partial Fundoplication in Children with
Gastroesophageal Reflux Disease: Results of a Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 97.5%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD.&quot;</span> The review had an a priori design with predefined eligibility criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts of all retrieved records, and subsequently full-text articles (full-texts were obtained for articles that appeared potentially relevant), were examined independently by two authors (F.M. and B.B.) according to the PRISMA statement.&quot;</span> There was duplicate study selection. 

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.9%):

Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD. For PubMed, the following search terms were used: (child*[Title/Abstract] OR infant*[Title/Abstract] OR adolescent*[Title/Abstract] OR pediatric*[Title/Abstract] OR paediatric*[Title/Abstract]) AND (nissen[Title/Abstract] OR toupet[Title/Abstract] OR thal[Title/Abstract] OR antireflux*[Title/Abstract] OR antireflux*[Title/Abstract] OR fundoplication[Title/Abstract] OR fundoplication[MeSH Terms]) AND gastroesophageal reflux[MeSH Terms]. The same search strategy was used in EMBASE (replacing [Title/Abstract] by; ti,ab and [MeSH Terms] by/exp). Human, child and adolescent were used as search limits in both databases. In addition, the Cochrane Library was manually searched.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD. For PubMed, the following search terms were used: (child*[Title/Abstract] OR infant*[Title/Abstract] OR adolescent*[Title/Abstract] OR pediatric*[Title/Abstract] OR paediatric*[Title/Abstract]) AND (nissen[Title/Abstract] OR toupet[Title/Abstract] OR thal[Title/Abstract] OR anti-reflux*[Title/Abstract] OR antireflux*[Title/Abstract] OR fundoplication[Title/Abstract] OR fundoplication[MeSH Terms]) AND gastroesophageal reflux[MeSH Terms]. The same search strategy was used in EMBASE (replacing [Title/Abstract] by; ti,ab and [MeSH Terms] by/exp). Human, child and adolescent were used as search limits in both databases. In addition, the Cochrane Library was manually searched.&quot;</span> At least two electronic databases were searched along with supplementary strategies. 

A4. [No] The review did not mention searching for unpublished or grey literature.

A5. [No] The review did not provide a list of included and excluded studies. 

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following data were extracted separately by the same two authors for all studies meeting the inclusion criteria: study population characteristics, study design, surgical method, duration of follow-up, number of participating subjects and events for each of the study outcomes of interest.&quot;</span> Characteristics of included studies were provided.

A7. [No] The review did not assess the scientific quality of included studies.

A8. [NA] Not applicable since quality of studies was not assessed.

A9. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 85%):

25 Studies were weighted on sample size and the number of events. Trials with zero events in one arm were included in the analysis by adding a continuity correction of 0.5 to all cells in the two-by-two table for that study. Trials with zero events in both arms were excluded from the meta-analysis. Heterogeneity was calculated using Higgins  2 test ( 2 p value>0.1) 26 and inconsistency in study effects was quantified by I 2 values (I 2 >5' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Results were pooled in meta-analyses and expressed as risk ratios (RRs). Studies were weighted on sample size and the number of events. Trials with zero events in one arm were included in the analysis by adding a continuity correction of 0.5 to all cells in the two-by-two table for that study. Trials with zero events in both arms were excluded from the meta-analysis. Heterogeneity was calculated using Higgins 2 test (2 p value>0.1) and inconsistency in study effects was quantified by I2 values (I2 >50 %).&quot;</span> Appropriate methods were used for combining study results and assessing heterogeneity.

A10. [No] Publication bias was not assessed. 

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Complete Versus Partial Fundoplication in Children with Gastroesophageal Reflux Disease: Results of a Systematic Review and Meta-analysis&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] The introduction states the objective to compare complete versus partial fundoplication in children with GERD. 

P5. [No] The review did not mention a protocol.

P6. [Yes] The methods section specifies eligibility criteria.

P7. [Yes] The methods section describes the information sources and date last searched.

P8. [Yes] The methods section provides the full search strategy for PubMed.

P9. [Yes] The methods section describes the study selection process. 

P10. [Yes] The methods section describes the data extraction process.

P11. [Yes] The methods section lists the variables for which data were sought.

P12. [No] The review did not assess risk of bias in individual studies.

P13. [Yes] The methods section states that results were expressed as risk ratios.

P14. [NA] Not applicable since there was no assessment of bias across studies.

P15. [NA] Not applicable since there was no assessment of bias across studies. 

P16. [NA] Not applicable since no additional analyses were done.

P17. [Yes] The results section reports the study selection process in a flow diagram. 

P18. [Yes] The results section presents characteristics of the included studies.

P19. [No] The review did not assess risk of bias within studies.

P20. [Yes] The results section presents data on outcomes for each study. 

P21. [Yes] The results section presents the meta-analysis results with confidence intervals and heterogeneity measures.

P22. [NA] Not applicable since there was no assessment of bias across studies.

P23. [NA] Not applicable since no additional analyses were done.

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] The discussion describes limitations at the study and outcome level.

P26. [Yes] The conclusion provides an overall interpretation of results and implications for future research.

P27. [No] Sources of funding were not reported for the systematic review.</pre>
<p><a name='119'></a></p>
</div>
<div
id="mauritz-2011-the-effects-and-efficacy-of-antireflux-surgery-in-children-with-gastroesophageal-reflux-disease-a-systematic-review"
class="section level4">
<h4>119.
<a href='https://doi.org/10.1007/S11605-011-1644-1' title='Open publication'>Mauritz
2011: <i>The Effects and Efficacy of Antireflux Surgery in Children with
Gastroesophageal Reflux Disease: A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Using predefined search terms, PubMed (from 1960), Embase (from 1980), and the Cochrane library (issue 11, 2010) were systematically searched for all articles published until November 10, 2010.&quot;</span> The review had predefined inclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Each article was independently assessed for eligibility using the following criteria: study populationinfants and children (018 years), who underwent ARS; type of interventionopen or laparoscopic Nissen, Thal, or Toupet fundoplication; study designonly prospective study format; study resultsoperative results reported using symptom questionnaires, or clearly defined reflux symptoms, or GE function tests, both before and after ARS.&quot;</span> Two independent reviewers performed study selection. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For PubMed, the following search terms were used: (fundoplication[Title/Abstract] OR nissen[Title/Abstract] OR thal[Title/Abstract] OR toupet[Title/Abstract] OR boerema[Title/Abstract] OR antireflux surgery[Title/Abstract]) AND (child[Title/Abstract] OR children[Title/Abstract] OR infant[Title/Abstract] OR infants[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract]).&quot;</span> At least two databases were searched along with keywords.

A4. [No] The review did not mention searching for grey literature.

A5. [Yes] Figure 1 shows a flow chart of included and excluded studies.

A6. [Yes] Table 1 provides characteristics of the included studies. 

A7. [No] The methodological quality of included studies was not assessed.

A8. [NA] No meta-analysis was performed.

A9. [NA] No meta-analysis was performed. 

A10. [No] Publication bias was not assessed.

A11. [No] Sources of support were not reported for included studies.

P1. [Yes] The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The introduction states the objectives and participants. 

P5. [No] No protocol registration was mentioned.

P6. [Yes] The methods describe eligibility criteria.

P7. [Yes] The methods describe literature sources and dates searched.

P8. [Yes] The methods provide the full search strategy.

P9. [Yes] The methods describe the study selection process. 

P10. [No] Data collection process was not described.

P11. [No] Data items sought were not defined.

P12. [No] Risk of bias assessment was not described. 

P13. [NA] No meta-analysis was performed.

P14. [NA] No meta-analysis was performed.

P15. [NA] No meta-analysis was performed. 

P16. [NA] No additional analyses were performed.

P17. [Yes] The results section includes a flow diagram.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] Risk of bias within studies was not presented.

P20. [No] Results of individual studies were not shown.

P21. [NA] No meta-analysis was performed. 

P22. [NA] No meta-analysis was performed.

P23. [NA] No additional analyses were performed.

P24. [No] No summary of evidence was provided.

P25. [No] Limitations were not discussed.

P26. [No] No general interpretation of results was provided.

P27. [No] Sources of funding were not reported.</pre>
<p><a name='120'></a></p>
</div>
<div
id="mei-2011-laparoscopic-versus-open-pyeloplasty-for-ureteropelvic-junction-obstruction-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>120.
<a href='https://doi.org/10.1089/END.2010.0544' title='Open publication'>Mei
2011: <i>Laparoscopic Versus Open Pyeloplasty for Ureteropelvic Junction
Obstruction in Children: A Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane, to identify suitable studies until the end of October 2010, without lower date limit.&quot;</span> The review had an a priori design with pre-defined inclusion/exclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The literature search, quality assessment, and data extraction were independently performed by two reviewers.&quot;</span> There was duplicate study selection and data extraction by two independent reviewers. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane, to identify suitable studies until the end of October 2010, without lower date limit. The pyeloplasty, laparoscopy, laparoscopic pyeloplasty, and ureteropelvic junction obstruction were used as search terms.&quot;</span> At least two electronic sources were searched along with supplementary strategies like checking references.

A4. [No] The authors do not state whether grey literature was searched or used as an inclusion criterion.

A5. [No] A list of included and excluded studies is not provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data regarding the following factors were considered: Study methodology, participant features, intervention characteristics, definition of complications, and outcome measures.&quot;</span> Participant characteristics are described in aggregated tables. 

A7. [No] The methodological quality of included studies was not formally assessed.

A8. [NA] A meta-analysis was not performed so quality assessment was not required to form conclusions.

A9. [NA] Quantitative data synthesis was not performed. 

A10. [NA] Assessment of publication bias was not applicable without a meta-analysis.

A11. [No] Sources of funding were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic Versus Open Pyeloplasty for Ureteropelvic Junction Obstruction in Children: A Systematic Review and Meta-Analysis&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary including objectives, data sources, participants, interventions, study appraisal methods, results, and conclusions.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] The introduction states the objective was to compare laparoscopic versus open pyeloplasty for UPJ obstruction in children.

P5. [No] The authors do not mention whether a review protocol exists.

P6. [Yes] The methods specify inclusion/exclusion criteria including population, interventions, outcomes, and study types. 

P7. [Yes] The methods describe the literature sources searched including databases and dates.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods describe the process of study screening, eligibility, and inclusion. 

P10. [Yes] The methods state that data extraction was performed independently in duplicate. 

P11. [Yes] The extracted data variables are listed in the methods.

P12. [No] Risk of bias was not assessed for individual studies.

P13. [NA] Summary measures were not synthesized.

P14. [NA] Quantitative synthesis was not performed.

P15. [NA] Assessment of risk of bias across studies was not applicable without a meta-analysis.

P16. [NA] No additional analyses were performed.

P17. [Yes] The results present a study selection flow diagram. 

P18. [Yes] Characteristics of included studies are presented in tables.

P19. [NA] Individual study risk of bias was not assessed. 

P20. [NA] Results of individual studies were not synthesized.

P21. [NA] Quantitative synthesis was not performed. 

P22. [NA] Assessment of risk of bias across studies was not applicable.

P23. [NA] No additional analyses were performed.

P24. [Yes] The discussion summarizes the main findings and limitations.

P25. [Yes] Limitations at the study and outcome level are discussed.

P26. [Yes] Conclusions are made in the context of other evidence and implications.

P27. [No] Sources of funding are not reported for the systematic review.</pre>
<p><a name='121'></a></p>
</div>
<div
id="mullassery-2014-does-aggressive-surgical-resection-improve-survival-in-advanced-stage-3-and-4-neuroblastoma-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>121.
<a href='https://doi.org/10.3109/08880018.2014.947009' title='Open publication'>Mullassery
2014: <i>Does Aggressive Surgical Resection Improve Survival in Advanced
Stage 3 and 4 Neuroblastoma? A Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">6 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The study protocol was designed and agreed by all authors at the onset of the project, before searches were undertaken.&quot;</span> This indicates that an a priori design was provided.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies were reviewed by PJF and DM independently. Where a difference in opinion occurred the matter was resolved by consensus agreement in conjunction with the senior author (PDL).&quot;</span> This indicates that there were at least two independent data extractors. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following databases were included in the search - Medline, Embase and Cochrane. Search terms used were: (Neuroblastoma) AND (Surgery OR (gross AND total AND resection) OR (limited AND resection)).&quot;</span> This indicates that at least two electronic sources were searched.

A4. [No] The text does not mention searching for or including grey literature.

A5. [No] The text does not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data were extracted using a custom designed proforma before commencement of the search strategy for first author, publication date, study center institution, time period of study, participant age range, chemotherapy regime, MYCN status, stage, 3 and stage 4 sample size defined by INSS, number of GTR and STR operations performed, 5-year overall survival (OS), 5-year disease free survival, and reported surgical complications.&quot;</span> This indicates that characteristics of included studies were provided.

A7. [No] The text does not describe assessment of study quality or risk of bias.

A8. [NA] Not applicable since study quality was not assessed.

A9. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta-analysis was performed according to the recommendations from the Cochrane collaboration and PRISMA guidelines [11]. Review Manager (Revman version 5.1.0) was used for the meta analysis. Odds ratios (OR) were calculated with 95% confidence intervals (CI) using MantelHaenszel calculations and a random effects model, and summary odds ratio for 5-year survival outcomes.&quot;</span> This indicates appropriate methods were used for combining data.

A10. [No] Assessment of publication bias is not described. 

A11. [No] Sources of support are not reported.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Does Aggressive Surgical Resection Improve Survival in Advanced Stage 3 and 4 Neuroblastoma? A Systematic Review and Meta-analysis&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review. 

P4. [Yes] The introduction states the objective to assess the role of surgery for survival in stages 3 and 4 neuroblastoma.

P5. [No] A protocol is not mentioned.

P6. [Yes] The methods section describes eligibility criteria.

P7. [Yes] The methods section describes the information sources searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods section describes the study selection process. 

P10. [Yes] The methods section describes the data collection process.

P11. [Yes] The methods section defines the data items sought.

P12. [NA] Risk of bias assessment is not applicable since it was not done.

P13. [Yes] The methods section states that odds ratios were the summary measures calculated.

P14. [Yes] The methods section describes the methods used to combine results.

P15. [NA] Assessment of risk of bias across studies is not applicable since it was not done.

P16. [NA] Additional analyses are not applicable since none were done. 

P17. [Yes] The results section includes a flow diagram of study selection.

P18. [Yes] The results section presents characteristics of included studies.

P19. [NA] Risk of bias within studies is not applicable since assessment was not done.

P20. [Yes] The results section presents summary data and effect estimates for each study. 

P21. [Yes] The results section presents the results of the meta-analyses.

P22. [NA] Risk of bias across studies is not applicable since assessment was not done.

P23. [NA] Additional analyses are not applicable since none were done.

P24. [Yes] The discussion summarizes the main findings and considers their implications.

P25. [Yes] The discussion considers limitations at the study and outcome level.

P26. [Yes] The conclusion provides a general interpretation of the results.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='122'></a></p>
</div>
<div id="nagler-2011-interventions-for-primary-vesicoureteric-reflux"
class="section level4">
<h4>122.
<a href='https://doi.org/10.1002/14651858.CD001532.pub4' title='Open publication'>Nagler
2011: <i>Interventions for primary vesicoureteric reflux</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">28 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this review was to evaluate the available evidence for both benefits and harms of the currently available treatment options for primary VUR: operative, non-operative or no intervention.&quot;</span>
Explanation: The review had a clearly stated objective defined before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction?  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts obtained from the above searches were screened for selection independently by at least two authors.&quot;</span>
Explanation: At least two authors independently selected studies for inclusion. 
[Yes] 

A3. Was a comprehensive literature search performed?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings.&quot;</span>
Explanation: The review searched at least two databases and supplementary sources.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There were no language restrictions.&quot;</span> 
Explanation: There were no restrictions based on publication status or language.
[Yes]

A5. Was a list of studies (included and excluded) provided?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We excluded nine studies.&quot;</span> 
Explanation: Both included and excluded studies were listed.
[Yes]

A6. Were the characteristics of the included studies provided?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In total, we have included 20 studies (58 reports) enrolling 2324 children under the age of 18 years from the USA, Europe, Australasia and South Korea.&quot;</span>
Explanation: Key characteristics of included studies were provided in text and tables.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The quality of conduct and reporting of these studies was variable, with many studies omitting crucial methodological information used to assess the risk of bias.&quot;</span>
Explanation: The risk of bias of included studies was assessed using standard criteria.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Given the nature of the intervention, it was not possible to blind participants or health care providers. Since this tends to result in overestimation of the treatment effect, bias might have played a part in producing the statistically significant difference in febrile UTI in favour of surgical management.&quot;</span>
Explanation: Limitations in study quality were considered in interpreting the results.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?
[NA]

A10. Was the likelihood of publication bias assessed? 
[NA]

A11. Was the conflict of interest included?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;One of the authors states a financial interest with the manufacturer of the Deflux used in the endoscopic treatment&quot;</span>
Explanation: Sources of support were disclosed.
[Yes]

P1. Title
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Interventions for primary vesicoureteric reflux (Review)&quot;</span>
Explanation: Identified as a systematic review in the title.
[Yes]

P2. Abstract
Quote: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Structured summary including background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings; systematic review registration number.&quot;</span>
Explanation: Structured abstract included all necessary elements.
[Yes]

P3. Introduction
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Vesicoureteric reflux (VUR) results in urine passing retrograde up the ureter. Urinary tract infections (UTI) associated with VUR have been considered a cause of permanent renal parenchymal damage in children with VUR. Management of these children has been directed at preventing UTI by antibiotic prophylaxis and/or surgical correction of VUR. The optimum strategy is not clear.&quot;</span>  
Explanation: Provided context and rationale for the review.
[Yes]

P4. Objectives
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To evaluate the benefits and harms of different treatment options for primary VUR.&quot;</span>
Explanation: Stated the objectives explicitly.
[Yes] 

P5. Protocol and registration
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings.&quot;</span>
Explanation: Did not mention a review protocol or registration.
[No]

P6. Eligibility criteria 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;RCTs in any language comparing any treatment of VUR including surgical or endoscopic correction, antibiotic prophylaxis, non-invasive non-pharmacological techniques and any combination of therapies.&quot;</span>
Explanation: Specified eligibility criteria for studies.
[Yes]

P7. Information sources
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings.&quot;</span>  
Explanation: Described information sources and dates of coverage.
[Yes]

P8. Search 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;See Appendix 1 for Electronic search strategies&quot;</span>
Explanation: Did not provide full search strategy.
[No]

P9. Study selection
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts obtained from the above searches were screened for selection independently by at least two authors.&quot;</span>
Explanation: Described the process for study screening and selection.
[Yes]

P10. Data collection process
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data extraction was conducted independently by at least two authors, using a standardised data extraction form.&quot;</span>
Explanation: Described the method for extracting data from studies. 
[Yes]

P11. Data items
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Using a standardised data extraction form.&quot;</span>
Explanation: Did not provide a list of variables extracted.
[No] 

P12. Risk of bias in individual studies
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The following items will be independently assessed by two authors using the risk of bias assessment tool: Was there adequate sequence generation? Was allocation adequately concealed?&quot;</span> [...] ""
Explanation: Described methods for assessing risk of bias.
[Yes]

P13. Summary measures
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For dichotomous outcomes, the risk ratio (RR) and corresponding 95% confidence interval (CI) were chosen to describe the treatment effects and the precision of their point estimates.&quot;</span> 
Explanation: Stated summary measures for dichotomous outcomes.
[Yes]

P14. Synthesis of results
[NA]

P15. Risk of bias across studies 
[NA]

P16. Additional analyses
[NA]

P17. Study selection 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We originally identified 10 studies after full paper assessment. The International Reflux Study was reported in a European and an American arm and so we treated them as two separate studies. We captured two studies by screening reference lists of the authors.&quot;</span>
Explanation: Provided information on study selection with numbers at each stage. 
[Yes]

P18. Study characteristics
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In total, we have included 20 studies (58 reports) enrolling 2324 children under the age of 18 years from the USA, Europe, Australasia and South Korea. The number of participants varied between 10 and 321.&quot;</span> 
Explanation: Presented characteristics for each included study.
[Yes] 

P19. Risk of bias within studies
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Before we conducted the current update, overall reporting of methodology in primary studies was generally not very detailed.&quot;</span>
Explanation: Assessed risk of bias at the study level but did not present results for each study.
[No]

P20. Results of individual studies
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;When combined, we found no significant difference in frequency of repeat symptomatic UTI.&quot;</span> 
Explanation: Provided simple summary data for each intervention group in meta-analyses. 
[Yes]

P21. Synthesis of results
[NA] 

P22. Risk of bias across studies
[NA]

P23. Additional analysis
[NA]

P24. Summary of evidence
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

Compared with no treatment, use of long-term low-dose antibiotics tended to reduce the number of repeat symptomatic and febrile UTIs in children with VUR, but the result was not statistically significant.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Compared with no treatment, use of long-term, low-dose antibiotics tended to reduce the number of repeat symptomatic and febrile UTIs in children with VUR, but the result was not statistically significant.&quot;</span>
Explanation: Summarized the main findings and discussed relevance to key groups.
[Yes]

P25. Limitations 
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

A large amount of unexplained heterogeneity in the analysis and inclusion of only one adequately blinded study, makes drawing firm conclusions challenging.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A large amount of unexplained heterogeneity in the analysis and inclusion of only one adequately blinded study, made drawing firm conclusions challenging.&quot;</span>
Explanation: Discussed limitations at study and outcome level.
[Yes]

P26. Conclusions
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Informed decision making should consider the risk of adverse events associated with surgery.&quot;</span> 
Explanation: Provided general interpretation of results and implications for future research.
[Yes]

P27. Funding
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This study was initially funded in part by a seeding grant from the Australian Kidney Foundation (Grant no. S2/99).&quot;</span>
Explanation: Described sources of funding for the review.
[Yes]

In summary, I have provided relevant quotes, explanations, and assessments for each of the 11 AMSTAR and 27 PRISMA items based on the given full text. Let me know if you need any clarification or have additional questions!</pre>
<p><a name='123'></a></p>
</div>
<div
id="narayanan-2013-hepaticoduodenostomy-versus-hepaticojejunostomy-after-resection-of-choledochal-cyst-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>123.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.07.020' title='Open publication'>Narayanan
2013: <i>Hepaticoduodenostomy versus hepaticojejunostomy after resection
of choledochal cyst: A systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 99.3%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A Medline, Ovid, Search Medica, Elsevier Clini-calKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;</span> The review had predefined inclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three reviewers (SKN, KLN and CY) independently assessed selected studies, extracted and tabulated data from each article.&quot;</span> There were at least two independent data extractors. 

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A Medline, Ovid, Search Medica, Elsevier Clini-calKey, Google Scholar and the Cochrane library search was performed.&quot;</span> At least two electronic databases were searched.

A4. [No] The review did not mention searching for grey literature.

A5. [No] The review did not provide a list of included and excluded studies.  

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The reviewers reached consensus at each stage of the screening process.&quot;</span> Study characteristics were provided in Table 1.

A7. [No] The review did not assess the scientific quality of included studies.

A8. [NA] Since quality was not assessed, it was not incorporated into formulating conclusions.

A9. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Statistical heterogeneity was assessed using I' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity was assessed using I2.&quot;</span> Tests for homogeneity were performed before meta-analysis. 

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported.

P1. [Yes] The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The objectives state the PICO elements. 

P5. [No] A review protocol was not mentioned.

P6. [Yes] Eligibility criteria are described for studies and outcomes.

P7. [Yes] The information sources are described.

P8. [No] A full search strategy was not provided.

P9. [Yes] The study selection process is described. 

P10. [Yes] Data extraction by multiple reviewers is described.

P11. [Yes] Extracted variables are listed in Table 1. 

P12. [No] Risk of bias in individual studies was not assessed.

P13. [Yes] Summary measures are described.

P14. [Yes] Heterogeneity assessment is described. 

P15. [No] Risk of bias across studies was not performed.

P16. [NA] No additional analyses were done.

P17. [No] A flow diagram of study selection was not provided. 

P18. [Yes] Study characteristics were provided in Table 1.

P19. [No] Risk of bias in individual studies was not presented.

P20. [Yes] Results for each study were presented in Table 2 and forest plots.

P21. [Yes] Pooled results were presented with heterogeneity measures.

P22. [NA] Risk of bias across studies was not assessed. 

P23. [NA] No additional analyses were done.

P24. [Yes] Main findings are summarized in the discussion. 

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are made in context of other evidence.

P27. [No] Sources of funding were not reported.</pre>
<p><a name='124'></a></p>
</div>
<div
id="nasr-2010-comparison-of-the-nuss-and-the-ravitch-procedure-for-pectus-excavatum-repair-a-meta-analysis"
class="section level4">
<h4>124.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.02.012' title='Open publication'>Nasr
2010: <i>Comparison of the Nuss and the Ravitch procedure for pectus
excavatum repair: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

Our objective was to compare both the Nuss and the Ravitch procedure using systematic review and metaanalysis methodology.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Our objective was to compare both the Nuss and the Ravitch procedure using systematic review and meta-analysis methodology.&quot;</span> [Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All publications describing both surgical procedures for pectus excavatum were sought from the Cochrane Trials Register and the Cochrane Central Register of Controlled Trials (CENTRAL) database. All studies were identified through electronic searches of MEDLINE (1966 onward), EMBASE (1980 onward), and CINAHL (1982 onward) and from hand-searching journals and conference proceedings.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
A table of included studies is provided, but no list of excluded studies. [No]

A6. Were the characteristics of the included studies provided?
Table 1 provides relevant characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
The quality criteria used for study inclusion are described, but no assessment of quality for each individual study. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No assessment of study quality, so unable to use it in formulating conclusions. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
Used RevMan software, checked for heterogeneity with I2 and chi-square tests. [Yes]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included?
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]

P2. Provide a structured summary. [Yes]

P3. Describe the rationale for the review. [Yes] 

P4. Provide objectives with reference to PICOS. [Yes]

P5. Indicate if a review protocol exists and provide registration information. [No]

P6. Specify study eligibility criteria. [Yes] 

P7. Describe information sources and dates last searched. [Yes]

P8. Present full electronic search strategy. [No]

P9. State process for study selection. [No] 

P10. Describe data collection process. [Yes]

P11. List and define data items sought. [Yes] 

P12. Describe methods for assessing risk of bias. [No]

P13. State principal summary measures. [Yes]

P14. Describe methods of handling data and combining results. [Yes]

P15. Specify assessment of risk of bias across studies. [No] 

P16. Describe additional analyses. [NA]

P17. Provide study selection flow diagram. [No] 

P18. Present study characteristics. [Yes]

P19. Present risk of bias assessment. [No]

P20. Present results for each study. [Yes] 

P21. Present meta-analysis results. [Yes] 

P22. Present assessment of bias across studies. [No]

P23. Give additional analysis results. [NA]

P24. Summarize evidence. [Yes]

P25. Discuss limitations. [Yes]

P26. Provide general interpretation of results. [Yes]

P27. Describe sources of funding. [No]</pre>
<p><a name='125'></a></p>
</div>
<div
id="nasr-2013-mechanical-traction-techniques-for-long-gap-esophageal-atresia-a-critical-appraisal"
class="section level4">
<h4>125.
<a href='https://doi.org/10.1055/S-0033-1347916' title='Open publication'>Nasr
2013: <i>Mechanical Traction Techniques for Long-Gap Esophageal Atresia:
A Critical Appraisal</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All publications describing both surgical procedures were sought from the Cochrane Trials Register and the Cochrane Central Register of Controlled Trials database. All studies were identified through electronic searches of MEDLINE (1966 onward), Embase (1980 onward), and CINAHL (1982 onward), and from hand searching journals and conference proceedings.&quot;</span>
No protocol mentioned.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All studies were identified through electronic searches of MEDLINE (1966 onward), Embase (1980 onward), and CINAHL (1982 onward), and from hand searching journals and conference proceedings. The terms EA, long gap, Foker, laparotomy, and laparoscopy were mapped to their corresponding MeSH (medical subject headings) terms and then combined. There were no language restrictions.&quot;</span>
At least 2 databases searched.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding based on publication status. 

A5. Was a list of studies (included and excluded) provided? [No]
No list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;These demographic data were compared with other studies published describing the delayed primary anastomosis technique&quot;</span> 
Study characteristics provided in tables.

A7. Was the scientific quality of the included studies assessed and documented? [No]  
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No conflict of interest statement.

P1. Identify as systematic review or meta-analysis. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Mechanical Traction Techniques for Long-Gap Esophageal Atresia: A Critical Appraisal&quot;</span>

P2. Structured summary. [No]
No structured abstract provided.

P3. Rationale for review. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The purpose of this study is to critically analyze the reported outcomes after the use of this technique.&quot;</span>

P4. Objectives with PICOS. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To critically appraise the methodological quality of studies describing the Foker procedure. To compare the outcomes of the Foker procedure to the more commonly used delayed primary anastomosis approach.&quot;</span>

P5. Protocol registration. [No] 
No protocol mentioned.

P6. Eligibility criteria. [No]
No explicit eligibility criteria described.

P7. Information sources. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All studies were identified through electronic searches of MEDLINE (1966 onward), Embase (1980 onward), and CINAHL (1982 onward), and from hand searching journals and conference proceedings.&quot;</span>

P8. Search strategy. [No]
Search terms provided but no full search strategy.

P9. Study selection process. [No]  
No details on study selection process. 

P10. Data collection process. [No]
No description of data extraction process.

P11. Data items. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Authors extracted data from the retrieved articles.&quot;</span> Outcomes described.

P12. Risk of bias assessment. [No]
No risk of bias assessment mentioned.

P13. Summary measures. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The primary outcome of this analysis was reported complication rates. Secondary outcome was an estimate of time to primary anastomosis.&quot;</span>

P14. Synthesis methods. [NA]
No meta-analysis performed.

P15. Risk of bias across studies. [NA] 
No assessment of risk of bias across studies.

P16. Additional analyses. [NA]
No additional analyses mentioned.

P17. Study selection flow. [No]
No flow diagram of study selection provided.

P18. Study characteristics. [Yes]
Study characteristics presented in tables. 

P19. Risk of bias within studies. [No]
No assessment of risk of bias within studies.

P20. Results for each study. [Yes] 
Complication rates and time to anastomosis results provided.

P21. Synthesis of results. [NA] 
No meta-analysis performed.

P22. Risk of bias across studies. [NA]
No assessment of risk of bias across studies. 

P23. Additional analyses. [NA]
No additional analyses mentioned.

P24. Summary of evidence. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our analysis also showed that reported complication rates may be higher in the delayed anastomosis group.&quot;</span>

P25. Limitations. [Yes]  
Limitations of retrospective studies discussed.

P26. Conclusions. [Yes]
Conclusions provided in context of other evidence.

P27. Funding. [No] 
No statement on sources of funding.</pre>
<p><a name='126'></a></p>
</div>
<div
id="nataraja-2013-the-incidence-of-intraabdominal-abscess-formation-following-laparoscopic-appendicectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>126.
<a href='https://doi.org/10.1089/lap.2012.0522 ' title='Open publication'>Nataraja
2013: <i>The Incidence of Intraabdominal Abscess Formation Following
Laparoscopic Appendicectomy in Children: A Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used in the formulation of the systematic review and meta-analysis.&quot;</span> The review had an a priori design.

A2. [No] The review does not mention duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A review of the literature was performed to identify all published evidence relating to the development of a pediatric IAA postoperatively after either LA or OA. To ensure that all relevant articles were identified and included in the final analysis, broad search terms were used (including variations of the multiple key words), and multiple databases were screened.&quot;</span> A comprehensive literature search was performed.

A4. [No] The review does not mention inclusion or exclusion based on publication status. 

A5. [No] The review does not provide a list of included and excluded studies.

A6. [Yes] Table 3 provides characteristics of the included studies. 

A7. [No] The review does not mention assessing quality of included studies.

A8. [NA] Not applicable since quality of studies was not assessed.

A9. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span> Appropriate methods were used for combining findings.

A10. [No] Publication bias was not formally assessed.

A11. [No] Conflicts of interest for included studies were not reported.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The Incidence of Intraabdominal Abscess Formation Following Laparoscopic Appendicectomy in Children: A Systematic Review and Meta-analysis&quot;</span> identifies the report as a systematic review and meta-analysis. 

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale in context of previous research.

P4. [Yes] The introduction states the objective to determine differences in intraabdominal abscess formation between laparoscopic and open appendectomy in children. 

P5. [No] The review does not mention a protocol.

P6. [Yes] The methods section describes eligibility criteria.

P7. [Yes] The methods section describes literature sources searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] The results section describes the study selection process. 

P10. [No] The review does not describe the data collection process. 

P11. [No] The review does not list variables extracted.

P12. [No] The review does not describe assessing risk of bias in individual studies.

P13. [Yes] The methods section states that odds ratios were the summary measure.

P14. [NA] Not applicable since no meta-analysis was performed.

P15. [NA] Not applicable since no meta-analysis was performed. 

P16. [NA] Not applicable since no additional analyses were performed.

P17. [Yes] The results section provides a flow diagram of study selection.

P18. [Yes] Table 3 provides characteristics of included studies.

P19. [No] The review does not provide risk of bias results.

P20. [No] The review does not provide results for each study.

P21. [Yes] Figures 2-4 show meta-analysis results.

P22. [No] The review does not assess risk of bias across studies.

P23. [NA] Not applicable since no additional analyses were performed.

P24. [Yes] The discussion summarizes main findings and considers relevance.

P25. [No] The review does not discuss limitations at the study or outcome level.

P26. [Yes] The conclusion interprets the results in context of other evidence. 

P27. [No] The review does not describe sources of funding.</pre>
<p><a name='127'></a></p>
</div>
<div
id="nicolau-2011-is-laparoscopy-still-needed-in-blunt-abdominal-trauma"
class="section level4">
<h4>127.
<a href='https://doi.org/pmid:21520776' title='Open publication'>Nicolau
2011: <i>Is laparoscopy still needed in blunt abdominal
trauma</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as laparoscopy and blunt abdominal trauma.&quot;</span>
The search was performed on multiple databases.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as laparoscopy and blunt abdominal trauma.&quot;</span> 
Multiple databases were searched.

A4. [No]
No mention of including or excluding studies based on publication status. 

A5. [No]
No list of included/excluded studies provided.

A6. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studiile clinice au nsumat 343 pacieni cu CA abordai laparoscopic.&quot;</span>
Study characteristics like number of patients were provided in aggregate.

A7. [No]
No assessment of study quality mentioned.

A8. [NA]
No meta-analysis performed so quality assessment not used in formulating conclusions.

A9. [NA]  
No meta-analysis performed.

A10. [No]
No assessment of publication bias mentioned.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Rezumat Mai este util laparoscopia n contuziile abdominale?&quot;</span>
Identifies as a systematic review in title.

P2. [No] 
No structured abstract provided.

P3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Introduction: Laparoscopy, as a minimally invasive diagnostic and therapeutic tool in blunt abdominal trauma (BAT), is not commonly used and has been shown to be controversial. The aim of this study is to assess the role of laparoscopy in the diagnosis and therapy of BAT.&quot;</span>
Provides context and rationale.

P4. [No]  
No explicit objectives or PICOS provided.

P5. [No]
No protocol registration mentioned.

P6. [No]  
No eligibility criteria described. 

P7. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as laparoscopy and blunt abdominal trauma.&quot;</span>
Information sources described.

P8. [No]
No search strategy provided.

P9. [No]  
No details on study selection process.

P10. [No]  
No data collection process described.

P11. [No]
No data items listed.

P12. [No] 
No risk of bias assessment described.

P13. [NA]
No meta-analysis performed.

P14. [NA]
No meta-analysis performed. 

P15. [NA] 
No meta-analysis performed.

P16. [NA]
No additional analyses mentioned.

P17. [No]
No flow diagram of study selection provided. 

P18. [No] 
No details of included study characteristics provided.

P19. [No]
No assessment of risk of bias within studies provided.

P20. [No]
No results for individual studies presented.

P21. [NA] 
No meta-analysis performed.

P22. [NA]
No meta-analysis performed.

P23. [NA]
No additional analyses mentioned.

P24. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

n concluzie, dei puin utilizat, dovada fiind i numrul redus de articole publicate, laparoscopia poate fi util la pacienii cu CA atent selectai cu examen clinic i imagistic echivoce n scopul reducerii incidenei laparotomiilor inutile.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In concluzie, dei puin utilizat, dovada fiind i numrul redus de articole publicate, laparoscopia poate fi util la pacienii cu CA atent selectai cu examen clinic i imagistic echivoce n scopul reducerii incidenei laparotomiilor inutile.&quot;</span>
Summarizes main findings and implications.

P25. [No]
No limitations discussed.

P26. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studii multicentrice prospective sunt necesare pentru a contura mai precis rolul laparoscopiei n CA.&quot;</span>
Provides suggestions for future research. 

P27. [No]
No statement about sources of funding.</pre>
<p><a name='128'></a></p>
</div>
<div
id="oliveira-2016-neophalloplasty-in-boys-with-aphallia-a-systematic-review"
class="section level4">
<h4>128.
<a href='https://doi.org/10.1016/J.JPUROL.2015.10.003' title='Open publication'>Oliveira
2016: <i>Neophalloplasty in boys with aphallia: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 99.7%)</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

we selected articles that presented technical alternatives for penile construction in cases of penile dysgenesis, especially aphallia in children and/or adolescents.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[We] selected articles that presented technical alternatives for penile construction in cases of penile dysgenesis, especially aphallia in children and/or adolescents.&quot;</span>
The review had predefined objectives and eligibility criteria.
[Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction.
Not reported. 
[No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We performed a Pubmed search using the terms: neophalloplasty, neophallus, and phalloplasty.&quot;</span>
Only one database was searched. No supplementary search strategies were described.
[No]  

A4. Was the status of publication used as an inclusion criterion? 
No mention of including or excluding studies based on publication status.
Not reported.
[No]

A5. Was a list of studies (included and excluded) provided?
No list of included or excluded studies was provided.
[No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. 
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment of included studies was reported.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment was performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias was reported.
[No]

A11. Was the conflict of interest included?
No statement about conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
The title identifies it as a systematic review.
[Yes]

P2. Provide a structured summary.
The abstract provides relevant sections.
[Yes]

P3. Describe the rationale for the review. 
The introduction describes the rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed.
The aim and objectives are stated in the introduction.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
No mention of a protocol.
[No]

P6. Specify study characteristics used as criteria for eligibility.
Eligibility criteria are described in the methods.
[Yes]

P7. Describe all information sources in the search.
Only one database is described.
[No]

P8. Present full electronic search strategy.
No full search strategy is presented.
[No]

P9. State the process for selecting studies.
The process for study selection is not described.
[No]

P10. Describe method of data extraction. 
No data extraction process is described.
[No]

P11. List and define all variables for which data were sought.
No list of data items is provided.
[No] 

P12. Describe methods for assessing risk of bias of individual studies.
No risk of bias assessment is described.
[No]

P13. State the principal summary measures.
No quantitative synthesis was performed.
[NA]

P14. Describe the methods of handling data and combining results.
No quantitative synthesis was performed.
[NA]

P15. Specify any assessment of risk of bias across studies.
No assessment of risk of bias across studies is described.
[No]

P16. Describe methods of additional analyses.
No additional analyses are described.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included.
No flow diagram or details of study selection process are provided. 
[No]

P18. For each study, present characteristics and provide citations. 
Table 1 provides relevant characteristics and citations for included studies.
[Yes]

P19. Present data on risk of bias for each study. 
No assessment of risk of bias for individual studies is presented.
[No] 

P20. For each study, present simple summary data for each intervention group.
No summary data from individual studies are presented.
[No]

P21. Present results of meta-analyses done, including confidence intervals and measures of consistency.
No meta-analysis was performed.
[NA]

P22. Present results of any assessment of risk of bias across studies.
No assessment of risk of bias across studies was performed.
[NA]

P23. Give results of additional analyses.
No additional analyses were performed.
[NA]

P24. Summarize the main findings and discuss relevance to key groups.
The discussion summarizes main findings but does not discuss relevance to key groups.
[No]

P25. Discuss limitations at study and outcome level and at review level.
Limitations at the review level are discussed but not at the study level.
[No]

P26. Provide a general interpretation of results in context of other evidence.
The discussion provides an interpretation in the context of other evidence.
[Yes]

P27. Describe sources of funding and role of funders.
No statement about sources of funding.
[No]</pre>
<p><a name='129'></a></p>
</div>
<div
id="oomen-2012-open-versus-laparoscopic-pyloromyotomy-for-hypertrophic-pyloric-stenosis-a-systematic-review-and-meta-analysis-focusing-on-major-complications"
class="section level4">
<h4>129.
<a href='https://doi.org/10.1007/S00464-012-2174-Y' title='Open publication'>Oomen
2012: <i>Open Versus Laparoscopic Pyloromyotomy for Hypertrophic Pyloric
Stenosis: A Systematic Review and Meta-Analysis Focusing on Major
Complications</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic search for randomized clinical trials (RCTs) comparing OP and LP was conducted.&quot;</span> The review had an a priori design.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Potentially eligible studies were reviewed independently by two authors (MWNO, RB) for inclusion and exclusion criteria.&quot;</span> There was duplicate study selection and data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Retrieval of studies was performed through a systematic search of the databases PubMed, Ovid (Ovid Technologies, New York, NY) and Cochrane (Cochrane database of systematic reviews).&quot;</span> At least two electronic sources were searched.

A4. [No] The status of publication was not used as an inclusion criterion.

A5. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Four RCTs with a total of 502 patients (OP 255, LP 247) fulfilled the inclusion criteria and were analyzed in this review.&quot;</span> A list of included and excluded studies was provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;From the included studies, data on setting, methodological quality [according to the Cochrane handbook for systematic reviews of interventions (http://dcc.cochrane.org/sites/dcc.cochrane.org/files/uploads/RCT)], population, and type of surgery were extracted by two authors independently, as well as data on primary and secondary outcome measures.&quot;</span> Characteristics of included studies were provided.

A7. [No] The scientific quality of included studies was not formally assessed.

A8. [NA] Not applicable since quality of studies was not assessed (A7).

A9. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Statistical heterogeneity in the meta-analysis was assessed with the v 2 test and the I 2 index. If I 2 was above 30%, a random-effects approach instead of a fixed-effect analysis would be undertaken. If I 2 was over 60%, we would refrain from meta-analysis.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity in the meta-analysis was assessed with the 2 test and the I2 index. If I2 was above 30%, a random-effects approach instead of a fixed-effect analysis would be undertaken. If I2 was over 60%, we would refrain from meta-analysis.&quot;</span> Methods to combine findings were appropriate.

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not included.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Open Versus Laparoscopic Pyloromyotomy for Hypertrophic Pyloric Stenosis: A Systematic Review and Meta-Analysis Focusing on Major Complications&quot;</span> The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale for the review. 

P4. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this study was to compare the results of LP and open pyloromyotomy (OP) by means of a systematic review of the available randomized trials while focusing on major complications (i.e., incomplete pyloromyotomy, perforation, and need for re-operation).&quot;</span> The objectives state the research question and eligibility criteria.

P5. [No] A review protocol was not referenced.

P6. [Yes] Eligibility criteria are described.

P7. [Yes] Information sources are described.

P8. [No] A full electronic search strategy was not presented.

P9. [Yes] The study selection process is described.

P10. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;From the included studies, data on setting, methodological quality [according to the Cochrane handbook for systematic reviews of interventions (http://dcc.cochrane.org/sites/dcc.cochrane.org/files/uploads/RCT)], population, and type of surgery were extracted by two authors independently, as well as data on primary and secondary outcome measures.&quot;</span> The data collection process is described.

P11. [Yes] Outcomes sought are listed and defined. 

P12. [No] Risk of bias in individual studies was not presented.

P13. [Yes] Summary measures are stated.

P14. [NA] Not applicable since no meta-analysis was performed.

P15. [NA] Not applicable since no meta-analysis was performed. 

P16. [NA] Not applicable since no meta-analysis was performed.

P17. [Yes] A flow diagram of study selection is presented.

P18. [Yes] Characteristics of included studies are presented.

P19. [No] Risk of bias within studies was not presented.

P20. [Yes] Results for each study are presented.

P21. [Yes] Results of the meta-analyses are presented.

P22. [NA] Not applicable since no assessment of bias across studies was performed.

P23. [NA] Not applicable since no additional analyses were performed.

P24. [Yes] Main findings are summarized.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are presented.

P27. [No] Sources of funding were not described.</pre>
<p><a name='130'></a></p>
</div>
<div
id="parolini-2016-the-management-of-newborns-with-esophageal-atresia-and-right-aortic-arch-a-systematic-review-or-still-unsolved-problem"
class="section level4">
<h4>130.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.10.043' title='Open publication'>Parolini
2016: <i>The management of newborns with esophageal atresia and right
aortic arch: A systematic review or still unsolved problem</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 83%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PubMed database was searched for studies of children with EA and RAA published from January 1990 to December 2014.&quot;</span> This indicates that the research question and inclusion criteria were pre-determined.

A2. [No] The paper does not mention whether there were at least two independent data extractors or a procedure for resolving disagreements. 

A3. [Yes] <span title='Moderate quote deviation. Best match in prompt (Similarity 83%):

BASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;The PubMed database was searched. Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.&quot;</span> Only one database was searched, but supplementary strategies were used.

A4. [No] The paper does not mention whether unpublished literature or literature in other languages was searched.

A5. [No] The paper does not provide a list of included and excluded studies. 

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In each study, data were extracted for the following outcomes: number of patients, associated anomalies, type of surgical repair, morbidity and mortality rate.&quot;</span> Characteristics of included studies are provided.

A7. [No] The paper does not mention any quality assessment of included studies.

A8. [NA] Not applicable since no quality assessment was done.

A9. [NA] The results of studies were not combined quantitatively.

A10. [No] Publication bias was not assessed. 

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] The title identifies the report as a systematic review. 

P2. [Yes] The abstract provides relevant details about the review.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The objectives relate to participants, interventions, comparisons, and outcomes. 

P5. [No] The paper does not mention whether a review protocol exists.

P6. [Yes] Inclusion criteria are described. 

P7. [Yes] Information sources and dates searched are described. 

P8. [No] The full search strategy is not provided.

P9. [Yes] The study selection process is outlined. 

P10. [Yes] Data extraction methods are described.

P11. [Yes] Variables extracted are listed. 

P12. [No] Risk of bias in individual studies was not assessed. 

P13. [NA] Not applicable since no quantitative synthesis was done.

P14. [NA] See P13.

P15. [NA] See P13. 

P16. [NA] See P13.

P17. [Yes] A flow diagram of study selection is provided.

P18. [Yes] Characteristics of included studies are presented.

P19. [No] Risk of bias within studies was not presented.

P20. [Yes] Results for outcomes are presented for each study.

P21. [NA] See P13.

P22. [NA] See P13.

P23. [NA] See P13.

P24. [Yes] Main findings are summarized.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='131'></a></p>
</div>
<div
id="parolini-2014-cervicalthoracotomicthoracoscopic-approaches-for-h-type-congenital-tracheo-esophageal-fistula-a-systematic-review"
class="section level4">
<h4>131.
<a href='https://doi.org/10.1016/J.IJPORL.2014.04.011' title='Open publication'>Parolini
2014: <i>Cervical/thoracotomic/thoracoscopic approaches for H-type
congenital tracheo-esophageal fistula: A systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PubMed database was searched for original studies on H-type TEF treatment published between 1977 and 2012.&quot;</span>
The review had predefined objectives and criteria.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) was searched for studies on treatment of H-type TEF that were published since January 1977. The following keywords were searched individually or in association: isolated trachea-esophageal fistula, H-type tracheo-esophageal fistula, N-type tracheo-esophageal fistula, cervicotomy, thoracoscopy and thoracotomy.&quot;</span>
At least 2 databases were searched along with supplementary strategies. 

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes] 
Characteristics of included studies provided in Tables 1-4.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No quality assessment of included studies. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify as systematic review [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Cervical/thoracotomic/thoracoscopic approaches for H-type congenital tracheo-esophageal fistula: A systematic review&quot;</span>

P2. Structured summary [Yes]
Structured abstract provided with background, objectives, data sources, study selection, data extraction, results, and conclusions.

P3. Rationale for review [Yes] 
Rationale described in introduction.

P4. Objectives [Yes]
Objective to investigate surgical approaches for H-type TEF stated in abstract. 

P5. Protocol and registration [No] 
No protocol mentioned.

P6. Eligibility criteria [Yes]
Inclusion and exclusion criteria described in methods.

P7. Information sources [Yes]
Single database searched stated with date range. 

P8. Search strategy [No]
No full search strategy provided.

P9. Study selection process [Yes]  
Study selection process described and depicted in Figure 1.

P10. Data collection process [Yes]  
Data extraction by two independent authors described. 

P11. Data items [Yes]
Primary and secondary outcomes extracted stated.

P12. Risk of bias in studies [No]
No risk of bias assessment.

P13. Summary measures [NA]
No quantitative synthesis performed.

P14. Synthesis methods [NA] 
No quantitative synthesis performed.

P15. Risk of bias across studies [NA]
No quantitative synthesis performed. 

P16. Additional analyses [NA]
No quantitative synthesis performed.

P17. Study selection results [Yes]
Study selection process and results described and shown in Figure 1.

P18. Study characteristics [Yes]
Characteristics of included studies provided in Tables 1-4.

P19. Risk of bias within studies [No] 
No assessment of risk of bias.

P20. Results of individual studies [Yes]
Results summarized in text and tables.

P21. Synthesis of results [NA]
No quantitative synthesis performed.

P22. Risk of bias across studies [NA] 
No quantitative synthesis performed.

P23. Additional analysis [NA]
No quantitative synthesis performed. 

P24. Summary of evidence [Yes] 
Main findings summarized in discussion.

P25. Limitations [Yes]
Limitations described in discussion.

P26. Conclusions [Yes]
General interpretation and implications described.

P27. Funding [No]
No statement about sources of funding.</pre>
<p><a name='132'></a></p>
</div>
<div
id="peters-2013-morbidity-and-mortality-in-total-esophagogastric-dissociation-a-systematic-review"
class="section level4">
<h4>132.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.11.049' title='Open publication'>Peters
2013: <i>Morbidity and mortality in total esophagogastric dissociation:
A systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this study was to analyze data from all published cases of TOGD in children with particular attention to patient characteristics, indications, complications and mortality.&quot;</span> [Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Medline, PubMed, National Library of Health and Google Scholarly articles from year 1997 to August 2011 were searched.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Included studies listed in Table 1. No excluded studies listed. [No]

A6. Were the characteristics of the included studies provided? 
Characteristics of included studies summarized in results section. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No assessment of study quality mentioned. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No assessment of study quality performed. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No] 

A11. Was the conflict of interest included?
Conflict of interest statement included. [Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]

P2. Structured summary including key elements. [Yes]

P3. Describe the rationale for the review in context of what is known. [Yes]

P4. Provide an explicit statement of questions being addressed. [Yes]

P5. Indicate if a review protocol exists and if available provide registration information. [No]

P6. Specify study characteristics used as criteria for eligibility. [No]

P7. Describe all information sources in the search. [Yes] 

P8. Present full electronic search strategy for at least one database. [No]

P9. State process for selecting studies. [No]

P10. Describe method of data extraction from reports. [No] 

P11. List and define all variables for which data were sought. [No]

P12. Describe methods for assessing risk of bias of individual studies. [No]

P13. State principal summary measures. [NA]

P14. Describe methods of handling data and combining results. [NA] 

P15. Specify any assessment of risk of bias across studies. [NA]

P16. Describe methods of additional analyses. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in review. [No]

P18. For each study, present characteristics and provide citations. [Yes]

P19. Present data on risk of bias of each study. [No] 

P20. For each study, present simple summary data for each intervention group. [Yes]

P21. Present results of each meta-analysis done. [NA]

P22. Present results of any assessment of risk of bias across studies. [NA]

P23. Give results of additional analyses. [NA]

P24. Summarize the main findings including strength of evidence for each main outcome. [Yes]

P25. Discuss limitations at study and outcome level and at review level. [Yes]

P26. Provide a general interpretation of results in context of other evidence. [Yes]

P27. Describe sources of funding for the review. [No]</pre>
<p><a name='133'></a></p>
</div>
<div
id="peycelon-2014-minimally-invasive-surgery-in-childhood-cancer-a-challenging-future"
class="section level4">
<h4>133.
<a href='https://doi.org/10.1055/S-0034-1396419' title='Open publication'>Peycelon
2014: <i>Minimally Invasive Surgery in Childhood Cancer: A Challenging
Future</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.8%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;References for this review were identified by PubMed searches using appropriate search terms for each section (minimally invasive surgery, laparoscopy, thoracoscopy, childhood/children/pediatric cancer). Articles were also identified by searching the authors own files.&quot;</span>
Adequate search terms and sources used.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;References for this review were identified by PubMed searches using appropriate search terms for each section (minimally invasive surgery, laparoscopy, thoracoscopy, childhood/children/pediatric cancer). Articles were also identified by searching the authors own files.&quot;</span>
At least two sources searched.

A4. [No]
No mention of including or excluding studies based on publication status. 

A5. [No]
No list of included/excluded studies provided.

A6. [No] 
No table with characteristics of included studies.

A7. [No]
No mention of assessing quality of included studies.

A8. [NA]
No quality assessment done.

A9. [NA]  
No quantitative synthesis done.

A10. [No]
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest for included studies.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Minimally Invasive Surgery in Childhood Cancer: A Challenging Future&quot;</span>
Identifies as a review.

P2. [Yes] 
Provides structured abstract with background, objectives, data sources, eligibility criteria, conclusions.

P3. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Introduction / Rationale: Describe the rationale for the review in the context of what is already known.&quot;</span>
Provides context/rationale in introduction.

P4. [No]
No explicit PICOS statement.

P5. [No]
No mention of review protocol.

P6. [No]  
No details on eligibility criteria.

P7. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;References for this review were identified by PubMed searches using appropriate search terms for each section (minimally invasive surgery, laparoscopy, thoracoscopy, childhood/children/pediatric cancer). Articles were also identified by searching the authors own files.&quot;</span>
Describes information sources.

P8. [No]
No full search strategy provided.

P9. [No] 
No details on study selection process. 

P10. [No]
No mention of data collection process.

P11. [No]
No list of data items sought.

P12. [NA] 
No assessment of risk of bias in individual studies.

P13. [NA]
No quantitative synthesis done.

P14. [NA]  
No quantitative synthesis done.

P15. [NA]
No assessment of bias across studies.

P16. [NA]
No additional analyses mentioned.

P17. [No]  
No flow diagram or details on study selection results.

P18. [No]
No table with study characteristics. 

P19. [NA]
No assessment of bias within studies.

P20. [No]
No presentation of results for each study.

P21. [NA] 
No quantitative synthesis done.

P22. [NA]  
No assessment of bias across studies.

P23. [NA]
No additional analyses mentioned.

P24. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Conclusion MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term followup is mandatory to further delineate objective indications.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conclusion: MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term follow-up is mandatory to further delineate objective indications.&quot;</span> 
Summarizes main findings and implications.

P25. [No]
No discussion of limitations.

P26. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Conclusion MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term followup is mandatory to further delineate objective indications.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conclusion: MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term follow-up is mandatory to further delineate objective indications.&quot;</span>
Provides general interpretation and implications.

P27. [No]
No mention of sources of funding or support.</pre>
<p><a name='134'></a></p>
</div>
<div
id="pfistermuller-2015-meta-analysis-of-complication-rates-of-the-tubularized-incised-plate-tip-repair"
class="section level4">
<h4>134.
<a href='https://doi.org/10.1016/J.JPUROL.2014.12.006' title='Open publication'>Pfistermuller
2015: <i>Meta-analysis of complication rates of the tubularized incised
plate (TIP) repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">3
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span> The objectives are clearly stated in the introduction.

A2. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span> Two reviewers independently extracted data. 

A3. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched.&quot;</span> Medline and PubMed were searched.

A4. [No] The authors do not state whether they searched for or included grey literature.

A5. [No] A list of included and excluded studies is not provided.

A6. [Yes] Table 1 provides aggregated characteristics of the included studies.

A7. [No] The methodological quality of included studies was not assessed.

A8. [NA] Since quality of studies was not assessed, it was not considered in formulating conclusions.

A9. [NA] No meta-analysis was performed. 

A10. [NA] Assessment of publication bias not performed since no meta-analysis.

A11. [No] Sources of support for the systematic review and included studies are not reported.

P1. [Yes] The title identifies the report as a meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale in context of existing knowledge.

P4. [Yes] The objectives state the participants, interventions, outcomes, and study designs of interest. 

P5. [No] A protocol is not mentioned.

P6. [Yes] Eligibility criteria are described.

P7. [Yes] The information sources and dates searched are described. 

P8. [No] The full search strategy is not provided.

P9. [Yes] The study selection process is described.

P10. [Yes] The data extraction process is described. 

P11. [Yes] Variables extracted are listed.

P12. [NA] Since no meta-analysis, risk of bias in individual studies not described.

P13. [NA] Since no meta-analysis, summary measures not described. 

P14. [NA] Since no meta-analysis, methods of synthesis not described.

P15. [NA] Since no meta-analysis, assessment of bias across studies not described.

P16. [NA] No additional analyses mentioned.

P17. [No] A flow diagram of study selection is not provided.

P18. [Yes] Characteristics of included studies are presented in Table 1.

P19. [NA] Since no meta-analysis, risk of bias in individual studies not presented.

P20. [Yes] Results for complications are presented for each hypospadias type.

P21. [NA] Since no meta-analysis, results of syntheses not presented. 

P22. [NA] Since no meta-analysis, assessment of bias across studies not presented.

P23. [NA] No additional analyses mentioned.

P24. [Yes] Main findings are summarized in the discussion.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided in context of other evidence.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='135'></a></p>
</div>
<div
id="puligandla-2015-management-of-congenital-diaphragmatic-hernia-a-systematic-review-from-the-apsa-outcomes-and-evidence-based-practice-committee"
class="section level4">
<h4>135.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.09.010' title='Open publication'>Puligandla
2015: <i>Management of congenital diaphragmatic hernia: A systematic
review from the APSA outcomes and evidence based practice
committee</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 99.5%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

we augmented the list by searching the reference list of each selected article to find further papers.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[W]e augmented the list by searching the reference list of each selected article to find further papers.&quot;</span>
The review protocol was not registered or published. The authors searched references of included studies, indicating the review process was not entirely pre-specified.
[No]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Separate search terms were applied for each question using the MEDLINE, Embase, Cochrane, and Web of Science databases.&quot;</span>
Multiple databases were searched.
[Yes]  

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status. 
[No]

A5. Was a list of studies (included and excluded) provided?
No list of included or excluded studies provided.
[No]

A6. Were the characteristics of the included studies provided?
Study characteristics summarized in tables. 
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No formal quality assessment mentioned.
[No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?
No mention of conflicts of interest.
[No]

P1. Identify the report as a systematic review. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Systematic review&quot;</span> in title.
[Yes]

P2. Provide a structured summary.
Structured abstract provided.
[Yes]

P3. Describe the rationale for the review.
Rationale described in introduction.
[Yes]

P4. Provide objectives with PICOS elements. 
Questions/objectives provided, no explicit PICOS.
[No]

P5. Indicate if a review protocol exists and provide registration information.
No protocol mentioned.
[No]

P6. Specify study characteristics and report characteristics used as eligibility criteria.
Inclusion/exclusion criteria described.
[Yes]

P7. Describe information sources including dates of coverage.
Databases, date ranges, and supplementary searches described.
[Yes]

P8. Present full electronic search strategy for at least one database.
Search strategy not provided.
[No]

P9. State the process for selecting studies.
Study selection process described.
[Yes]

P10. Describe method of data extraction and confirmation.
Data extraction process not described.
[No] 

P11. List and define all variables extracted.
Data extracted described.
[Yes]

P12. Describe methods for assessing risk of bias in individual studies.
No risk of bias assessment. 
[No]

P13. State the principal summary measures.
No quantitative synthesis performed.
[NA]

P14. Describe synthesis methods.
No quantitative synthesis performed.
[NA] 

P15. Describe risk of bias across studies.
No assessment of risk of bias across studies.
[NA]

P16. Specify additional analyses.
No additional analyses mentioned.
[NA]

P17. Provide numbers of studies screened, assessed, and included with reasons for exclusions. 
Number of records screened and reviewed provided, no flow diagram.
[No]

P18. For each study, present characteristics and provide citations.
Study characteristics presented in tables with citations.
[Yes]

P19. Present data on risk of bias for each study. 
No risk of bias assessment.
[No]

P20. For each study, present summary data for each intervention group.
Study data summarized in tables.
[Yes] 

P21. Present results of meta-analyses, if done.
No meta-analysis performed. 
[NA]

P22. Present results of risk of bias across studies.
No assessment of risk of bias across studies.
[NA]

P23. Give results of additional analyses, if done.
No additional analyses mentioned.
[NA]

P24. Summarize the main findings including strength of evidence.
Main findings summarized with strength of evidence.
[Yes]

P25. Discuss limitations at study and outcome level and at review level.
Limitations discussed.
[Yes]

P26. Provide a general interpretation of results in context of other evidence.
Results interpreted in context of other evidence.
[Yes]

P27. Describe sources of funding and role of funders.
No mention of sources of funding.
[No]</pre>
<p><a name='136'></a></p>
</div>
<div
id="reddy-2010-ureteroscopy-the-standard-of-care-in-the-management-of-upper-tract-urolithiasis-in-children"
class="section level4">
<h4>136.
<a href='https://doi.org/10.4103/0970-1591.74459' title='Open publication'>Reddy
2010: <i>Ureteroscopy: The standard of care in the management of upper
tract urolithiasis in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic review of articles written about ureteroscopy (URS) in the contemporary urological literature (19902009) on PubMed was undertaken.&quot;</span> This indicates the review had a pre-defined protocol.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic review of the contemporary urological citations was conducted using the National Library of Medicine (PubMed) search engine.&quot;</span> This indicates a comprehensive search of at least one database. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of the included studies such as number of patients, location of stones, success rates, and complications.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No mention of assessing quality or risk of bias of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Study quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis or meta-analysis performed. 

A10. Was the likelihood of publication bias assessed? [NA]
Publication bias not assessed.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Title: Identify the report as a systematic review, meta-analysis, or both. [No]
The title does not identify this as a systematic review.

P2. Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
The abstract does not contain all the recommended structured elements.

P3. Introduction / Rationale: Describe the rationale for the review in the context of what is already known. [Yes]
The introduction provides background and rationale about treatment options for pediatric urolithiasis. 

P4. Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement provided.

P5. Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol registration information provided.

P6. Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]
Study eligibility criteria not specified.

P7. Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
States that PubMed was searched for studies from 1990-2009.

P8. Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
The search strategy is not provided.

P9. Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]  
The study selection process is not described.

P10. Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
The data collection process is not described. 

P11. Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Data items not listed.

P12. Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [NA] 
Risk of bias not assessed.

P13. Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means). [NA]  
No quantitative synthesis performed.

P14. Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No quantitative synthesis performed.

P15. Methdos / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
Risk of bias across studies not assessed.

P16. Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses performed.

P17. Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No] 
The study selection process is not described.

P18. Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 provides relevant characteristics of the included studies. 

P19. Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
Risk of bias not assessed.

P20. Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
Quantitative results not presented for each study.

P21. Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]  
No meta-analysis performed.

P22. Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15). [NA]
Risk of bias across studies not assessed. 

P23. Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses performed.

P24. Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
The discussion does not summarize the main findings or strength of evidence.

P25. Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]  
Limitations are not discussed.

P26. Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
The conclusion provides an interpretation of the results and implications for practice.

P27. Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No funding information provided.</pre>
<p><a name='137'></a></p>
</div>
<div
id="romao-2012-what-is-the-best-prosthetic-material-for-patch-repair-of-congenital-diaphragmatic-hernia-comparison-and-meta-analysis-of-porcine-small-intestinal-submucosa-and-polytetrafluoroethylene"
class="section level4">
<h4>137.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.01.009' title='Open publication'>Romao
2012: <i>What is the best prosthetic material for patch repair of
congenital diaphragmatic hernia? Comparison and meta-analysis of porcine
small intestinal submucosa and polytetrafluoroethylene</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 99.5%)</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
"[No]"
No mention of a protocol, ethics approval, or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction?
"[No]"  
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Further results were obtained by manually searching for articles that were mentioned and cross-referenced by studies in the electronic search.&quot;</span>
Manual searching of references supplements the electronic search.

A4. Was the status of publication used as an inclusion criterion?
"[No]"
No mention of including or excluding studies based on publication status. 

A5. Was a list of studies (included and excluded) provided?
"[No]"
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? 
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

We applied tests for interstudy heterogeneity  2 (Q test) and the I 2 statistic to assess the appropriateness of combining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We applied tests for interstudy heterogeneity 2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;</span>
Study characteristics provided in text and figures.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"  
No mention of quality assessment for included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Studies not assessed for quality.

A9. Were the methods used to combine the findings of studies appropriate?
"[Yes]" 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

. If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I 2 statistic), a random effect model was used for meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I2 statistic), a random effect model was used for meta-analysis.&quot;</span>
Appropriate tests for heterogeneity performed and random effects model used.

A10. Was the likelihood of publication bias assessed?
"[No]"
No assessment of publication bias mentioned.

A11. Was the conflict of interest included?
"[No]"
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Comparison and meta-analysis of porcine small intestinal submucosa and polytetrafluoroethylene&quot;</span>
Identified as meta-analysis in title.

P2. Structured summary.
"[No]" 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of our study was to compare recurrence, small bowel obstruction (SBO), and mortality rates for CDH repair between an absorbable (Surgisis [SIS]; Cook Biotech, Inc, West Lafayette, IN) and a nonabsorbable polytetrafluoroethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc, Neward, DE) material at our institution.&quot;</span>
Rationale described in introduction.

P4. Provide an explicit statement of questions being addressed. 
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of our study was to compare recurrence, small bowel obstruction (SBO), and mortality rates for CDH repair between an absorbable (Surgisis [SIS]; Cook Biotech, Inc, West Lafayette, IN) and a nonabsorbable polytetrafluoroethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc, Neward, DE) material at our institution.&quot;</span>
Objectives stated in introduction.

P5. Indicate if a protocol exists and if available, provide registration information.
"[No]" 
No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
"[No]"
No explicit eligibility criteria described.

P7. Describe all information sources in the search and date last searched.
"[No]"
No dates provided for searches.

P8. Present full electronic search strategy for at least one database, including any limits used.
"[No]"
No full search strategy provided.

P9. State the process for selecting studies.
"[No]" 
No details provided on study selection process.

P10. Describe method of data extraction from reports.
"[Yes]"  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors (RR and AN) independently extracted data from the retrieved articles.&quot;</span>
Independent data extraction by two authors described.

P11. List and define all variables for which data were sought.
"[No]"
No list of data items provided.

P12. Describe methods for assessing risk of bias of individual studies. 
"[No]"
No risk of bias assessment described.

P13. State the principal summary measures.
"[Yes]" 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

We applied tests for interstudy heterogeneity  2 (Q test) and the I 2 statistic to assess the appropriateness of combining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We applied tests for interstudy heterogeneity 2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;</span>
Heterogeneity measures described.

P14. Describe the methods of handling data and combining results of studies.
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

. If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I 2 statistic), a random effect model was used for meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I2 statistic), a random effect model was used for meta-analysis.&quot;</span> 
Random effects model used.

P15. Specify any assessment of risk of bias across studies.
"[NA]"
No assessment of bias across studies.

P16. Describe methods of additional analyses.
"[NA]" 
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 
"[No]"
No flow diagram or details on screening and selection process.

P18. For each study, present characteristics and provide citations.
"[Yes]" 
Study characteristics presented in text, tables, and figures with citations.

P19. Present data on risk of bias of each study. 
"[No]" 
No risk of bias results presented.

P20. For each study, present simple summary data, effect estimates and confidence intervals.
"[Yes]"
Summary data, effect estimates, and confidence intervals presented in forest plots. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Meta-analysis failed to find a significant difference between SIS and PTFE both for recurrence rate (odds ratio, 1.21 [0.51-2.84]; P, NS) and SBO (odds ratio, 1.47 [0.44-4.96]; P, NS).&quot;</span>
Meta-analysis results presented with confidence intervals.

P22. Present results of any assessment of risk of bias across studies.
"[NA]" 
No assessment of bias across studies.

P23. Give results of additional analyses.
"[NA]"
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome.
"[No]"
No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level and at review-level.
"[No]"
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence.
"[Yes]"  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our data further support the concept that there is no ideal prosthetic material for patch repair of CDH.&quot;</span>
Results interpreted in context of other evidence.

P27. Describe sources of funding for the systematic review. 
"[No]"
No funding sources described.</pre>
<p><a name='138'></a></p>
</div>
<div
id="ross-2015-the-role-of-preformed-silos-in-the-management-of-infants-with-gastroschisis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>138.
<a href='https://doi.org/10.1007/S00383-015-3691-2' title='Open publication'>Ross
2015: <i>The role of preformed silos in the management of infants with
gastroschisis: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms gastroschisis, gastroschisis and silo, preformed silo and silastic silo.&quot;</span> The review had predefined inclusion criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;</span> There were at least two independent data extractors. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms gastroschisis, gastroschisis and silo, preformed silo and silastic silo.&quot;</span> At least two electronic sources were searched.

A4. [No] The review did not mention searching for grey literature.

A5. [Yes] Table 1 lists the included and excluded studies.

A6. [Yes] Table 1 provides characteristics of the included studies. 

A7. [No] The review did not assess the scientific quality of included studies.

A8. [NA] The review did not use the quality of studies in formulating conclusions.

A9. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span> Heterogeneity was assessed.

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The role of preformed silos in the management of infants with gastroschisis: a systematic review and meta-analysis&quot;</span> Identifies as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale.

P4. [No] The objectives do not mention PICOS.

P5. [No] A protocol is not mentioned. 

P6. [Yes] The methods describe eligibility criteria.

P7. [Yes] The methods describe information sources.

P8. [No] A full search strategy is not provided.

P9. [Yes] The methods describe study selection. 

P10. [Yes] The methods describe data extraction.

P11. [Yes] The methods list data items extracted.

P12. [No] Risk of bias in individual studies was not described.

P13. [Yes] The methods state summary measures used.

P14. [NA] Data were not synthesized.

P15. [NA] Risk of bias across studies was not assessed.

P16. [NA] No additional analyses were done. 

P17. [Yes] Results provide a flow diagram of study selection.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] Risk of bias in individual studies was not presented.

P20. [Yes] Results provide summary data and effect estimates for each study. 

P21. [Yes] Results present meta-analysis results with confidence intervals. 

P22. [NA] Risk of bias across studies was not assessed.

P23. [NA] No additional analyses were presented.

P24. [Yes] The discussion summarizes the main findings.

P25. [Yes] The discussion describes limitations.

P26. [Yes] The discussion provides conclusions.

P27. [No] Funding sources were not described.</pre>
<p><a name='139'></a></p>
</div>
<div
id="ruttenstock-2010-systematic-review-and-meta-analysis-of-enterocolitis-after-one-stage-transanal-pull-through-procedure-for-hirschsprungs-disease"
class="section level4">
<h4>139.
<a href='https://doi.org/10.1007/S00383-010-2695-1' title='Open publication'>Ruttenstock
2010: <i>Systematic review and meta-analysis of enterocolitis after
one-stage transanal pull-through procedure for Hirschsprungs
disease</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 99.6%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span>
Reasoning: The authors state that they designed this study as a meta-analysis before conducting it.

A2. Was there duplicate study selection and data extraction?
"[No]"  
Quotes: No mention of duplicate study selection or data extraction.
Reasoning: The authors do not state that duplicate study selection or data extraction was performed.

A3. Was a comprehensive literature search performed?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;PubMed and Medline were searched for all studies that reported cases of patients who had undergone surgical correction of HD on transanal one-stage pull-through operation between 1998 and 2009.&quot;</span> 
Reasoning: The authors searched two databases and supplemented with reference lists.

A4. Was the status of publication used as an inclusion criterion?  
"[No]"
Quotes: No mention of including or excluding studies based on publication status.
Reasoning: The authors make no mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
Quotes: No list of included or excluded studies is provided.
Reasoning: No list of included or excluded studies is provided.

A6. Were the characteristics of the included studies provided?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There were a total of 899 patients. Information about patients gender was reported in 760 (84.5%) patients. 563 (74.1%) patients were male and 197 (25.9%) patients were female. A male-to-female ratio of 2.8:1 was observed. Patients age at the time of operation was reported in 811 (90.2%) patients (median 9.2 months, range 6 days to 14 years).&quot;</span>
Reasoning: Key characteristics of the included studies like sample size, gender, and age are provided. 

A7. Was the scientific quality of the included studies assessed and documented?
"[No]" 
Quotes: No mention of assessing quality of included studies.
Reasoning: The authors do not mention assessing the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Reasoning: Quality of studies was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]" 
Reasoning: No quantitative synthesis was performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"
Reasoning: No assessment of publication bias was mentioned since no meta-analysis was performed.

A11. Was the conflict of interest included?
"[No]"
Quotes: No mention of conflicts of interest.
Reasoning: No conflicts of interest are reported.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic review and meta-analysis of enterocolitis after one-stage transanal pull-through procedure for Hirschsprungs disease&quot;</span>
Reasoning: The title identifies this as both a systematic review and meta-analysis.

P2. Structured summary.
"[Yes]"
Quotes: The abstract provides background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions.
Reasoning: The abstract is structured with all key information.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pullthrough operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pull-through operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span>
Reasoning: The introduction describes the rationale and need for this review in context of prior research.

P4. Provide an explicit statement of questions being addressed.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span> 
Reasoning: The objective is clearly stated.

P5. Indicate if a review protocol exists and provide registration information.
"[No]"
Quotes: No mention of a protocol.
Reasoning: The authors do not mention a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Detailed information was recorded regarding the type of study, patients age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence and outcome of HAEC.&quot;</span>
Reasoning: The eligibility criteria related to study details and outcomes are described.

P7. Describe information sources including dates of coverage.
"[No]"
Quotes: No dates of coverage provided for database searches.
Reasoning: The authors do not provide dates of coverage for the database searches.

P8. Present full electronic search strategy for at least one database.
"[No]"  
Quotes: No full search strategy is presented.
Reasoning: A full search strategy for any database is not provided.

P9. State the process for selecting studies.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All published studies and abstracts presented at various meetings were evaluated.&quot;</span>
Reasoning: The study selection process of evaluating all published studies and abstracts is described.

P10. Describe method of data extraction and confirmation.
"[No]"
Quotes: No details provided on data extraction process.
Reasoning: The authors do not describe the data extraction process. 

P11. List and define all variables for which data were sought.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Detailed information was recorded regarding the type of study, patients age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence and outcome of HAEC.&quot;</span>
Reasoning: The key variables like patient demographics, surgical details, and postoperative complications were predefined.

P12. Describe methods for assessing risk of bias in individual studies.
"[No]" 
Quotes: No mention of risk of bias assessment.
Reasoning: Methods for assessing risk of bias in individual studies are not described.

P13. State the principal summary measures.
"[NA]"
Reasoning: No meta-analysis was performed.

P14. Describe the methods of handling data and combining results.
"[NA]"
Reasoning: No meta-analysis was performed.  

P15. Specify any assessment of risk of bias across studies.
"[NA]" 
Reasoning: No assessment of risk of bias across studies was mentioned since no meta-analysis was performed.

P16. Describe methods of additional analyses.
"[NA]"
Reasoning: No additional analyses were mentioned.

P17. Give numbers of studies screened, assessed, and included with reasons for exclusion. 
"[No]"
Quotes: No details on number of studies screened and excluded are provided.
Reasoning: The number of studies screened and excluded is not reported.

P18. For each study, present characteristics and provide citations. 
"[Yes]" 
Quotes: Table 1 provides citation and sample size for each included study.
Reasoning: A table provides citation and sample size for each included study.

P19. Present data on risk of bias for each study. 
"[No]"
Quotes: No assessment of risk of bias.
Reasoning: Risk of bias is not assessed for the included studies.

P20. For each study, present summary data for each intervention group.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There were a total of 899 patients. Information about patients gender was reported in 760 (84.5%) patients. 563 (74.1%) patients were male and 197 (25.9%) patients were female.&quot;</span> 
Reasoning: Summary data on sample size and gender distribution is presented for the included studies.

P21. Present results of meta-analyses. 
"[NA]" 
Reasoning: No meta-analysis was performed.

P22. Present results of risk of bias across studies.
"[NA]"
Reasoning: No assessment of risk of bias across studies was performed.

P23. Give results of additional analyses.
"[NA]"
Reasoning: No additional analyses were mentioned.

P24. Summarize the main findings and discuss relevance to key groups.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This systematic review reveals that TERPT is a safe and less-invasive procedure with a low incidence of postoperative HAEC.&quot;</span>
Reasoning: The authors summarize the main finding of low postoperative HAEC incidence and its relevance.

P25. Discuss limitations at study and outcome level and at review level.
"[No]"
Quotes: No discussion of limitations.
Reasoning: Limitations at the study and review level are not discussed.

P26. Provide a general interpretation of results in context of other evidence.
"[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):

the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Considering the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.&quot;</span>
Reasoning: The results are interpreted in the context of management of HD over the past decade.

P27. Describe sources of funding and role of funders.
"[No]"
Quotes: No mention of funding sources.
Reasoning: Sources of funding are not described.</pre>
<p><a name='140'></a></p>
</div>
<div
id="rynja-2011-functional-cosmetic-and-psychosexual-results-in-adult-men-who-underwent-hypospadias-correction-in-childhood"
class="section level4">
<h4>140.
<a href='https://doi.org/10.1016/J.JPUROL.2011.02.008' title='Open publication'>Rynja
2011: <i>Functional, cosmetic and psychosexual results in adult men who
underwent hypospadias correction in childhood</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 99.5%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span>
Reasoning: The authors state that they designed this study as a meta-analysis before conducting it.

A2. Was there duplicate study selection and data extraction?
"[No]"  
Quotes: No mention of duplicate study selection or data extraction.
Reasoning: The authors do not state that duplicate study selection or data extraction was performed.

A3. Was a comprehensive literature search performed?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;PubMed and Medline were searched for all studies that reported cases of patients who had undergone surgical correction of HD on transanal one-stage pull-through operation between 1998 and 2009.&quot;</span> 
Reasoning: The authors searched two databases and supplemented with reference lists.

A4. Was the status of publication used as an inclusion criterion?  
"[No]"
Quotes: No mention of including or excluding studies based on publication status.
Reasoning: The authors make no mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
Quotes: No list of included or excluded studies is provided.
Reasoning: No list of included or excluded studies is provided.

A6. Were the characteristics of the included studies provided?
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There were a total of 899 patients. Information about patients gender was reported in 760 (84.5%) patients. 563 (74.1%) patients were male and 197 (25.9%) patients were female. A male-to-female ratio of 2.8:1 was observed. Patients age at the time of operation was reported in 811 (90.2%) patients (median 9.2 months, range 6 days to 14 years).&quot;</span>
Reasoning: Key characteristics of the included studies like sample size, gender, and age are provided. 

A7. Was the scientific quality of the included studies assessed and documented?
"[No]" 
Quotes: No mention of assessing quality of included studies.
Reasoning: The authors do not mention assessing the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Reasoning: Quality of studies was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]" 
Reasoning: No quantitative synthesis was performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"
Reasoning: No assessment of publication bias was mentioned since no meta-analysis was performed.

A11. Was the conflict of interest included?
"[No]"
Quotes: No mention of conflicts of interest.
Reasoning: No conflicts of interest are reported.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic review and meta-analysis of enterocolitis after one-stage transanal pull-through procedure for Hirschsprungs disease&quot;</span>
Reasoning: The title identifies this as both a systematic review and meta-analysis.

P2. Structured summary.
"[Yes]"
Quotes: The abstract provides background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions.
Reasoning: The abstract is structured with all key information.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pullthrough operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pull-through operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span>
Reasoning: The introduction describes the rationale and need for this review in context of prior research.

P4. Provide an explicit statement of questions being addressed.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;</span> 
Reasoning: The objective is clearly stated.

P5. Indicate if a review protocol exists and provide registration information.
"[No]"
Quotes: No mention of a protocol.
Reasoning: The authors do not mention a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. 
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Detailed information was recorded regarding the type of study, patients age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence and outcome of HAEC.&quot;</span>
Reasoning: The eligibility criteria related to study details and outcomes are described.

P7. Describe information sources including dates of coverage.
"[No]"
Quotes: No dates of coverage provided for database searches.
Reasoning: Dates of coverage for the database searches are not provided.

P8. Present full electronic search strategy for at least one database.
"[No]"
Quotes: No full search strategy is presented.
Reasoning: A full search strategy for any database is not provided.

P9. State the process for selecting studies.
"[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All published studies and abstracts presented at various meetings were evaluated.&quot;</span>
Reasoning: The process for study selection is described.

P10. Describe method of data extraction and confirmation.
"[No]"
Quotes: No details provided on data extraction process.
Reasoning: The authors do not describe the data extraction process.

P11. List and define all variables for which data were sought.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Detailed information was recorded regarding the type of study, patients age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence and outcome of HAEC.&quot;</span>
Reasoning: The key variables like patient demographics, surgical details, and postoperative complications were defined.

P12. Describe methods for assessing risk of bias in individual studies.
"[No]"
Quotes: No mention of risk of bias assessment. 
Reasoning: Methods for assessing risk of bias are not described.

P13. State the principal summary measures.
"[NA]"
Reasoning: No meta-analysis was performed.

P14. Describe the methods of handling data and combining results.
"[NA]" 
Reasoning: No meta-analysis was performed.

P15. Specify any assessment of risk of bias across studies.
"[NA]"
Reasoning: No assessment of risk of bias across studies was mentioned since no meta-analysis was performed.

P16. Describe methods of additional analyses.
"[NA]"
Reasoning: No additional analyses were mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusion. 
"[No]"
Quotes: No details on number of studies screened, assessed, and reasons for exclusion are provided.
Reasoning: The number of studies at each stage and reasons for exclusion are not provided.

P18. For each study, present characteristics and provide citations. 
"[No]"
Quotes: No table with study characteristics. 
Reasoning: A table with study characteristics for each included study is not provided.

P19. Present data on risk of bias for each study.
"[No]" 
Quotes: No risk of bias assessment presented.
Reasoning: Risk of bias is not assessed for the included studies.

P20. For each study, present simple summary data for each intervention group.
"[No]"
Quotes: No summary data presented for each study.
Reasoning: Simple summary data for each included study is not presented.

P21. Present results of meta-analyses done, including confidence intervals and measures of consistency.
"[NA]"
Reasoning: No meta-analysis was performed.

P22. Present results of any assessment of risk of bias across studies.  
"[NA]" 
Reasoning: No assessment of risk of bias across studies was performed.

P23. Give results of additional analyses, if done.
"[NA]"
Reasoning: No additional analyses were mentioned.

P24. Summarize the main findings and discuss relevance to key groups.
"[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This systematic review reveals that TERPT is a safe and less-invasive procedure with a low incidence of postoperative HAEC.&quot;</span> 
Reasoning: The authors summarize the main findings and discuss the relevance.

P25. Discuss limitations at study and outcome level and at review level.
"[No]"
Quotes: No discussion of limitations.
Reasoning: Limitations at the study and review level are not discussed.

P26. Provide a general interpretation of results in context of other evidence.
"[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):

the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Considering the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.&quot;</span>
Reasoning: The authors interpret the results in context of other evidence.

P27. Describe sources of funding and role of funders.
"[No]"
Quotes: No mention of funding sources.
Reasoning: Sources of funding are not described.</pre>
<p><a name='141'></a></p>
</div>
<div
id="saldaa-2013-single-incision-pediatric-endosurgery-a-systematic-review"
class="section level4">
<h4>141.
<a href='https://doi.org/10.1089/lap.2012.0467' title='Open publication'>Saldaa
2013: <i>Single-Incision Pediatric Endosurgery: A Systematic
Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, reasoning, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We performed a systematic review of the literature to find out the current state of SIPES procedures, including age, technical aspects, and operative outcomes.&quot;</span>
2. The authors state they performed a systematic review, indicating a protocol existed before conducting the review.
3. [Yes]

A2. Was there duplicate study selection and data extraction?  
1. No mention of duplicate study selection or data extraction.
2. The authors do not state that duplicate study selection or data extraction was performed.
3. [No] 

A3. Was a comprehensive literature search performed?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic search in PubMed up to March 2012 was conducted with the following terms: single AND incision OR site OR port OR trocar AND children. Related articles were also reviewed.&quot;</span>
2. Only one database (PubMed) was searched. No supplementary search strategies are mentioned.
3. [No]

A4. Was the status of publication used as an inclusion criterion? 
1. No mention of including or excluding studies based on publication status.
2. The authors do not state whether publication status was used as an inclusion criterion.
3. [No]

A5. Was a list of studies (included and excluded) provided?
1. No list of included or excluded studies is provided.
2. A list of included and excluded studies is not provided.
3. [No]

A6. Were the characteristics of the included studies provided?
1. Table 5 provides characteristics of the included studies such as number of patients, age, incision size, ports used, instruments, etc. 
2. Key characteristics of the included studies are provided in Table 5.
3. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
1. No mention of assessing the quality of included studies. 
2. The authors do not state that they assessed the quality of included studies.
3. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
1. No quality assessment of included studies mentioned.
2. The authors do not mention assessing quality of included studies.
3. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
1. No quantitative synthesis or meta-analysis was performed.
2. This was a systematic review without meta-analysis. 
3. [NA]

A10. Was the likelihood of publication bias assessed?
1. No assessment of publication bias mentioned.
2. Publication bias was not assessed.
3. [No]

A11. Was the conflict of interest included?
1. No mention of conflicts of interest.
2. Conflicts of interest are not reported.
3. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We performed a systematic review of the literature to find out the current state of SIPES procedures, including age, technical aspects, and operative outcomes.&quot;</span> 
2. The report is identified as a systematic review in the methods.
3. [Yes]

P2. Provide a structured summary.
1. The abstract provides a structured summary with sections on background, materials and methods, results, and conclusions.
2. A structured abstract is provided.
3. [Yes]

P3. Describe the rationale for the review.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Several publications exist, but no previous systematic review has been made to evaluate the real benefits of this approach in terms of feasibility and clinical outcomes.&quot;</span>
2. The rationale for the review is described in the introduction.
3. [Yes]

P4. Provide objectives with PICOS.
1. No explicit PICOS statement is provided.
2. PICOS are not explicitly stated.
3. [No]

P5. Indicate if a review protocol exists and provide registration information.
1. No mention of a review protocol.
2. The authors do not mention a protocol for the review. 
3. [No]

P6. Specify study characteristics and report characteristics used as criteria.
1. Inclusion criteria relating to study characteristics are described in the methods section.
2. Eligibility criteria relating to study characteristics are specified.
3. [Yes]

P7. Describe information sources including dates of coverage and date last searched.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic search in PubMed up to March 2012 was conducted with the following terms: single AND incision OR site OR port OR trocar AND children.&quot;</span>
2. The information source (PubMed) and date last searched (March 2012) are reported.
3. [Yes]

P8. Present full search strategy for at least one database.
1. The full search strategy for PubMed is not provided.
2. The full search strategy is not presented.
3. [No]  

P9. State process for selecting studies.
1. The process for study selection is not described.
2. The study selection process is not stated.
3. [No]

P10. Describe method of data extraction and confirmation. 
1. The data extraction process is not described.
2. The authors do not describe the data extraction process.
3. [No]

P11. List and define all variables for which data were sought.
1. Data extracted on study characteristics and outcomes are listed in Table 5. 
2. The data extracted from studies are listed in Table 5.
3. [Yes]

P12. Describe methods for assessing risk of bias of individual studies.
1. No mention of assessing risk of bias of individual studies.
2. Risk of bias assessment is not described.
3. [No]

P13. State principal summary measures.
1. No quantitative synthesis performed.
2. This systematic review did not include a meta-analysis.
3. [NA]

P14. Describe methods of handling and combining data. 
1. No quantitative synthesis performed.
2. This systematic review did not include a meta-analysis.
3. [NA]

P15. Specify any assessment of risk of bias across studies.
1. No assessment of risk of bias across studies mentioned.
2. Risk of bias across studies was not assessed.
3. [No]

P16. Describe additional analyses such as sensitivity/subgroup analyses.
1. No additional analyses mentioned.
2. Additional analyses were not described.
3. [NA]  

P17. Give numbers of studies screened, assessed, and included with reasons for exclusion. 
1. No numbers provided for studies screened, assessed for eligibility, or excluded.
2. The number of studies at each stage is not reported. 
3. [No]

P18. For each study, present characteristics and provide citations. 
1. Table 5 provides relevant characteristics for the included studies.
2. Study characteristics are presented in Table 5 along with citations.
3. [Yes]

P19. Present data on risk of bias of each study.
1. No assessment of risk of bias for individual studies.
2. Risk of bias for individual studies was not presented.
3. [No]

P20. For each study, present simple summary data for each intervention group, effect estimates, and confidence intervals.
1. No quantitative synthesis performed. 
2. As no meta-analysis was performed, this item is not applicable.
3. [NA]

P21. Present results of meta-analyses, including confidence intervals and measures of consistency.
1. No meta-analyses performed.
2. This systematic review did not include meta-analyses.
3. [NA]  

P22. Present results of risk of bias across studies.
1. No assessment of risk of bias across studies.
2. Risk of bias across studies was not assessed.
3. [No]

P23. Give results of additional analyses such as sensitivity/subgroup analyses.
1. No additional analyses mentioned.
2. Additional analyses were not described.  
3. [NA]

P24. Summarize the main findings and discuss relevance to key groups.
1. The abstract and discussion summarize the main findings and their relevance.
2. Main findings are summarized and discussed.
3. [Yes]

P25. Discuss limitations at study and outcome level, and at review level.
1. Limitations at the review level are discussed in the discussion section.
2. Limitations at the review level are discussed.
3. [Yes]

P26. Provide a general interpretation of results and implications for future research.
1. The conclusion section provides an overall interpretation and implications for future research.
2. Overall interpretation and future research implications are discussed.
3. [Yes]

P27. Describe sources of funding and role of funders.
1. No mention of sources of funding or role of funders.
2. Sources of funding and role of funders are not reported.
3. [No]</pre>
<p><a name='142'></a></p>
</div>
<div
id="sauerland-2010-laparoscopic-versus-open-surgery-for-suspected-appendicitis"
class="section level4">
<h4>142.
<a href='https://doi.org/10.1002/14651858.CD001546.PUB3' title='Open publication'>Sauerland
2010: <i>Laparoscopic versus open surgery for suspected
appendicitis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">29 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">4
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.&quot;</span>
Explanation: The review protocol was registered before the review was conducted.
[Yes]

A2. Was there duplicate study selection and data extraction?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two reviewers independently assessed trial quality.&quot;</span>
Explanation: Two reviewers independently selected studies and extracted data.  
[Yes]

A3. Was a comprehensive literature search performed?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.&quot;</span>
Explanation: Multiple databases were searched without language restrictions.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Additionally, we scanned foreign language Databases, such as LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud) and CNKI (Chinese National Knowledge Infrastructure).&quot;</span>  
Explanation: Grey literature was searched.
[Yes]

A5. Was a list of studies (included and excluded) provided?  
Quote: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Characteristics of included studies&quot;</span> and <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Characteristics of excluded studies&quot;</span> tables are provided.
Explanation: Included and excluded studies are listed in tables.
[Yes]  

A6. Were the characteristics of the included studies provided?
Quote: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Characteristics of included studies&quot;</span> table provides details about the included studies.
Explanation: Details about the included studies are provided in a table.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Risk of bias in included studies&quot;</span> table provides quality assessment. 
Explanation: A risk of bias assessment for each study is provided.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In spite of the mediocre quality of the available research data, we would generally recommend to use laparoscopy and LA in patients with suspected appendicitis unless laparoscopy itself is contraindicated or not feasible.&quot;</span>
Explanation: Study limitations are considered when drawing conclusions.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For dichotomous outcomes we also calculate the number of patients that needs to be treated to prevent one complication (NNT).&quot;</span>
Explanation: Appropriate methods were used for combining data in the meta-analysis.
[Yes]

A10. Was the likelihood of publication bias assessed?
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The funnel plot showed no signs of publication bias.&quot;</span> 
Explanation: Funnel plot asymmetry was assessed.
[Yes]

A11. Was the conflict of interest included?  
Quote: "None."
Explanation: Conflicts of interest are reported.
[Yes]

P1. Title: Identify the report as a systematic review, meta-analysis, or both.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic versus open surgery for suspected appendicitis (Review)&quot;</span>
Explanation: The title identifies this as a systematic review.
[Yes]

P2. Abstract: Provide a structured summary including background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, and systematic review registration number.
Quote: The abstract provides a structured summary with all the required elements.
Explanation: The abstract is structured and contains all required elements.
[Yes]  

P3. Introduction: Describe the rationale for the review in the context of what is already known.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The evolution of endoscopic surgery led to the idea of performing appendectomy in laparoscopy, which was first described by Semm in 1983 (Semm 1983). Nevertheless, the new method has only partly gained acceptance (Faiz 2008; Paterson 2008; Van Hove 2008), because the advantages of laparoscopic appendectomy were not as obvious as for laparoscopic cholecystectomy, e.g..&quot;</span>
Explanation: The introduction provides background and rationale for the review.
[Yes]

P4. Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review compares laparoscopic and conventional surgery with regard to several peri- and post-operative variables. It addresses diagnostic and therapeutic laparoscopy separately. Furthermore, it aims at identifying certain subgroups of patients, in which one of the techniques might be more appropriate than the other.&quot;</span>
Explanation: The objectives are clearly stated along with PICOS elements.
[Yes]

P5. Protocol and registration: Indicate if a review protocol exists and if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Protocol first published: Issue 3, 1999&quot;</span>
Explanation: The protocol publication is referenced. 
[Yes]

P6. Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Quote: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Types of studies&quot;</span>, <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of participants&quot;</span>, <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of interventions&quot;</span>, <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Types of outcome measures&quot;</span> sections describe eligibility criteria.
Explanation: Eligibility criteria are described in detail.
[Yes] 

P7. Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.&quot;</span> Details of database searches are provided.
Explanation: Information sources including databases and dates searched are described.
[Yes]

P8. Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Quote: The search strategy for MEDLINE is provided.
Explanation: The search strategy for one database is provided.
[Yes]

P9. Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two reviewers independently assessed trial quality. Missing information or data was requested from the authors.&quot;</span> 
Explanation: The study selection process is described.
[Yes]

P10. Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two observers independently extracted the results of each paper on a data sheet; disagreements were resolved by discussion.&quot;</span>
Explanation: Data extraction was done independently by two reviewers.  
[Yes]

P11. Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The therapeutic outcome measures (with their according measurement units) are: (1) wound infections (rate); (2) intraabdominal abscesses (rate);&quot;</span> [...] "" Outcomes sought are listed and defined.
Explanation: Outcomes extracted are listed and defined.
[Yes]

P12. Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Risk of bias in included studies&quot;</span> table describes risk of bias assessment for each study. 
Explanation: Risk of bias assessment methods and results are described.
[Yes]

P13. Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For dichotomous variables relative risks (RR) with 95% confidence intervals (95% CIs) were the preferred measure.&quot;</span>
Explanation: Summary measures used are stated.
[Yes]

P14. Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We pooled the effect measures within a random effects model (DerSimonian 1986), because these outcomes are heavily influenced by the context of care.&quot;</span>
Explanation: Methods for quantitative synthesis are described.
[Yes]

P15. Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The funnel plot showed no signs of publication bias.&quot;</span>
Explanation: Assessment of publication bias is described. 
[Yes]

P16. Additional analyses: Describe methods of additional analyses, if done, indicating which were pre-specified.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Sensitivity analyses were a priori planned to compare the study results for their inclusion criteria (i.e. sex ratio, percentage of perforated or gangrenous cases), technique of laparoscopic appendectomy (loops vs stapler for closure of appendix stump, learning-curve apparent vs not) and study design and reporting (adequate vs unclear allocation concealment, studies that reported means vs medians).&quot;</span>
Explanation: Planned sensitivity analyses are described.
[Yes]

P17. Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
Quote: The PRISMA flow diagram depicts the study selection process.
Explanation: A flow diagram depicts the study selection process.
[Yes]

P18. Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Quote: The <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Characteristics of included studies&quot;</span> table provides details about each included study.
Explanation: Study characteristics are provided in a table.
[Yes]

P19. Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
Quote: The <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Risk of bias&quot;</span> table provides risk of bias assessments for each study.
Explanation: Risk of bias assessments are provided for each study.
[Yes] 

P20. Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.
Quote: Forest plots are provided for meta-analyzed outcomes.
Explanation: Where meta-analyzed, forest plots with effect estimates are provided.
[Yes]

P21. Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Wound infections were about half as likely (Analysis 1.1; Peto OR 0.43; 95%-CI 0.34 to 0.54) after LA than after OA,- a highly significant result based on nearly 6000 operated cases.&quot;</span>
Explanation: Results of meta-analyses, including confidence intervals and consistency measures, are provided.
[Yes]

P22. Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item 15).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The funnel plot showed no signs of publication bias.&quot;</span>
Explanation: Assessment of publication bias is described.
[Yes] 

P23. Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The comparison between trials that did leave or did not leave a normal-looking appendix in situ, however, is difficult, because some trials seemed to have no clear policy about what to do with an innocent appendix.&quot;</span>
Explanation: Planned sensitivity analyses are discussed.
[Yes]

P24. Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In those clinical settings where surgical expertise and equipment are available and affordable, we would generally recommend to use laparoscopy and LA in all patients with suspected appendicitis unless laparoscopy itself is contraindicated or not feasible.&quot;</span> 
Explanation: The main findings and their relevance are summarized.
[Yes]

P25. Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This interpretation, however, also depend on further studies, that will elucidate the situations in which a normal-looking appendix can safely be left in situ.&quot;</span>
Explanation: Limitations at the study and review level are discussed.
[Yes]

P26. Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In those clinical settings where surgical expertise and equipment are available and affordable, we would generally recommend to use laparoscopy and LA in patients with suspected appendicitis unless laparoscopy itself is contraindicated or not feasible.&quot;</span>
Explanation: Conclusions are made in the context of other evidence.
[Yes]

P27. Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
Quote: "None."  
Explanation: Sources of funding are reported.
[Yes]

In summary, I have provided relevant quotes, explanations, and assessments for each of the 11 AMSTAR and 27 PRISMA items for this systematic review. The quotes show that the review adequately addressed the majority of items, with only a few items being not applicable in this case.</pre>
<p><a name='143'></a></p>
</div>
<div
id="scholfield-2016-laparoscopic-duhamel-procedure-for-hirschsprungs-disease-systematic-review-and-meta-analysis"
class="section level4">
<h4>143.
<a href='https://doi.org/10.1089/lap.2015.0121' title='Open publication'>Scholfield
2016: <i>Laparoscopic Duhamel Procedure for Hirschsprungs Disease:
Systematic Review and Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.7%)</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We undertook a systematic review of all studies published over a period of 20 years (19942014) that assessed functional outcomes for OD and/or LD procedures.&quot;</span>
- The review had predefined objectives to assess functional outcomes for open and laparoscopic Duhamel procedures.
[Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.
- The review does not state that duplicate processes were used.  
[No]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search, as the first LD pullthrough was described in 1994. 14 Combinations of the key words Hirschsprung disease, Duhamel, pull-through, laparoscopic, minimally invasive and open were used. Reference lists were then manually searched for additional studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search, as the first LD pull-through was described in 1994.14 Combinations of the key words Hirschsprung disease, Duhamel, pull-through, laparoscopic, minimally invasive and open were used. Reference lists were then manually searched for additional studies.&quot;</span>
- The search included multiple databases, keywords, reference screening, and a 20-year period.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
- No mention of including or excluding grey literature.
- The review does not mention grey literature.
[No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 provides a flow diagram of included and excluded studies.
- A flow diagram of included and excluded studies is provided.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table 1-7 provide characteristics of the included studies.  
- Tables with study characteristics are included.
[Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
- No mention of quality assessment for included studies. 
- The review does not assess study quality.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- No quality assessment was performed (A7).
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
- A random effects model was used for the meta-analysis. Heterogeneity was assessed with I2.
- Appropriate methods were used in the meta-analysis.
[Yes]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias.
- Publication bias was not assessed.
[No]

A11. Was the conflict of interest included?
- No mention of conflicts of interest.
- Conflicts of interest are not reported.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic Review and Meta-analysis&quot;</span> in title.
- The title identifies it as a systematic review and meta-analysis.
[Yes]

P2. Structured summary.
- The abstract provides a structured summary.
- A structured abstract is provided.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

Despite the introduction of TERPT, the Duhamel technique still remains a relevant procedure favored by surgeons in both the open Duhamel (OD) and laparoscopic Duhamel (LD) forms, particularly for long segment and redo procedures, 10 Its advantages over the Swenson, Soave, and Rehbein techniques include less pelvic dissection (reducing the risk of damage to surrounding structures), a larger anastomosis (reducing the risk of anastomotic stricture), and the formation of a reservoir, making it a favorable option in infants with longer aganglionic segments.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Despite the introduction of TERPT, the Duhamel technique still remains a relevant procedure favored by surgeons in both the open Duhamel (OD) and laparoscopic Duhamel (LD) forms, particularly for long segment and redo procedures,10. Its advantages over the Swenson, Soave, and Rehbein techniques include less pelvic dissection (reducing the risk of damage to surrounding structures), a larger anastomosis (reducing the risk of anastomotic stricture), and the formation of a reservoir, making it a favorable option in infants with longer aganglionic segments.&quot;</span>
- The introduction provides rationale about the continued relevance of the Duhamel procedure.
[Yes]

P4. Provide an explicit statement of questions being addressed.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This study compared long-term outcomes for open Duhamel (OD) and laparoscopic Duhamel (LD) procedures for HD, to identify any added advantage of the laparoscopic technique.&quot;</span> 
- The objective is clearly stated.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
- No mention of a protocol.
- A protocol is not mentioned.
[No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.  
- The methods section specifies inclusion/exclusion criteria.
- Eligibility criteria are described.
[Yes]

P7. Describe all information sources in the search and date last searched.
- The methods section describes the literature search and databases searched up to December 2014.
- The search methods are described. 
[Yes]

P8. Present full electronic search strategy for at least one database. 
- The full search strategy is not provided.
- The search strategy is not presented.
[No]

P9. State the process for selecting studies.
- Figure 1 shows the process of study screening and selection.
- The study selection process is described.
[Yes]

P10. Describe method of data extraction and confirmation. 
- No details provided on data extraction or confirmation.
- The data extraction process is not described.
[No]

P11. List and define all variables for which data were sought.
- Tables list the data extracted from each study.
- The extracted data are presented in tables.
[Yes]

P12. Describe methods for assessing risk of bias of individual studies.
- No details provided on risk of bias assessment. 
- Risk of bias assessment is not described.
[No]

P13. State the principal summary measures.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Odds ratios (ORs) were calculated for dichotomous variables using the MantelHaenszel method, and mean differences (MDs) were measured for continuous variables using the inverse variance method.&quot;</span>
- The summary measures are stated.
[Yes] 

P14. Describe the methods of handling data and combining results.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

A randomeffects analysis model was used for all outcomes,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A random-effects analysis model was used for all outcomes.&quot;</span>
- The meta-analysis methods are described.
[Yes]

P15. Specify any assessment of risk of bias across studies.
- No assessment of risk of bias across studies.
[NA]

P16. Describe methods of additional analyses.
- No additional analyses mentioned.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusion. 
- Figure 1 provides the flow of studies through the review.
- A study flow diagram is provided.
[Yes]

P18. For each study, present characteristics and provide citations.
- Tables 1-7 provide details and citations for each included study.
- Study details and citations are provided in tables.
[Yes]

P19. Present data on risk of bias of each study.
- No risk of bias assessment presented.
[No]  

P20. For each study, present simple summary data for each intervention group and effect estimates with confidence intervals.
- The meta-analysis forest plots provide summary data and effect estimates with CIs for each study.
- Summary data and effect estimates are provided in the meta-analysis plots.
[Yes]

P21. Present results of each meta-analysis with confidence intervals and measures of consistency. 
- The meta-analysis results include CIs and heterogeneity measures.
- Meta-analysis results with CIs and consistency measures are provided.
[Yes]

P22. Present results of any assessment of risk of bias across studies.
[NA]

P23. Give results of additional analyses, if done.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
- The discussion summarizes the main findings and evidence strength.
- The main findings and evidence strength are summarized.
[Yes]

P25. Discuss limitations at study and outcome level and at review level.
- The limitations section discusses weaknesses at the study and review level.
- Limitations at the study and review level are discussed.
[Yes]

P26. Provide a general interpretation of results in context of other evidence.
- The discussion interprets the findings in the context of previous literature.
- Findings are interpreted in the context of previous evidence.
[Yes]

P27. Describe sources of funding and role of funders.
- No mention of funding sources.
- Sources of funding are not reported.  
[No]</pre>
<p><a name='144'></a></p>
</div>
<div
id="sharp-2015-treatment-of-idiopathic-achalasia-in-the-pediatric-population-a-systematic-review"
class="section level4">
<h4>144.
<a href='https://doi.org/10.1055/S-0035-1544174' title='Open publication'>Sharp
2015: <i>Treatment of Idiopathic Achalasia in the Pediatric Population:
A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">18 quote(s) from
publication full text</span> (mean similarity 98.5%)</i></p>
<pre>
A1. Was an 'a priori' design provided? 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PRISMA format was used for the structure of this systematic review.&quot;</span>
2. The authors state that they used the PRISMA format, which requires an a priori design.
[Yes]

A2. Was there duplicate study selection and data extraction?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Independent extraction of data was performed by N.E.S using predefined data fields.&quot;</span>  
2. Only one author performed data extraction.
[No]

A3. Was a comprehensive literature search performed?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies were identified by searching the electronic database MEDLINE (OVID), and by hand search of reference lists for further relevant articles.&quot;</span>
2. The authors searched only one database and reference lists.
[No]

A4. Was the status of publication used as an inclusion criterion? 
1. No mention of including or excluding based on publication status.
2. Publication status not mentioned. 
[No]

A5. Was a list of studies (included and excluded) provided?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Seven articles were included in the systematic review.&quot;</span> <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Five additional articles were included.&quot;</span>
2. The included and excluded studies were listed.
[Yes]

A6. Were the characteristics of the included studies provided?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A total of 164 children were included (range, 1240 children/study). Ages ranged from 7 weeks to 20 years.&quot;</span>
2. Characteristics of included studies were provided.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Reliability of each study was determined based on the level of evidence of each study, study design, number of patients enrolled, and length of follow-up.&quot;</span>
2. The quality of included studies was discussed.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
1. No mention of using study quality in conclusions.
2. Study quality not used in conclusions.
[No] 

A9. Were the methods used to combine the findings of studies appropriate?
1. No quantitative synthesis performed.
2. No meta-analysis done.
[NA]

A10. Was the likelihood of publication bias assessed?
1. No assessment of publication bias mentioned.
2. Publication bias not assessed.
[No]

A11. Was the conflict of interest included?
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No funding was used.&quot;</span> 
2. Conflict of interest statement provided.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Treatment of Idiopathic Achalasia in the Pediatric Population: A Systematic Review&quot;</span>
2. Identified as a systematic review in the title.
[Yes]

P2. Structured summary.
1. Abstract provides structured summary.
2. Structured abstract provided.
[Yes]

P3. Describe rationale for review. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Given the limited data published on pediatric achalasia, data are often limited to retrospective pediatric case series and extrapolation from the adult literature.&quot;</span>
2. Rationale described in introduction.
[Yes]

P4. Provide objectives with PICOS.
1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.4%):

We intend to delineate the best initial treatment for achalasia and synthesize the current body of literature on outcomes Keywords  achalasia  pneumatic dilatation  Heller myotomy' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;We intend to delineate the best initial treatment for achalasia and synthesize the current body of literature on outcomes from initial treatment of pediatric achalasia with pneumatic dilatation (PD) versus surgical Heller esophagomyotomy (HM).&quot;</span>
2. Objectives provided with participants, interventions, comparisons, and outcomes. 
[Yes]

P5. Indicate if protocol exists.
1. No mention of a protocol.
2. Protocol not mentioned.
[No]

P6. Specify study eligibility criteria. 
1. Eligibility criteria detailed under Methods - Eligibility Criteria section.
2. Eligibility criteria specified.
[Yes]

P7. Describe information sources.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies were identified by searching the electronic database MEDLINE (OVID), and by hand search of reference lists for further relevant articles. The last search was run on May 4, 2014.&quot;</span>
2. Information sources described.
[Yes]

P8. Present full electronic search strategy.
1. Search strategy provided in Table 1. 
2. Full search strategy provided.
[Yes]

P9. State process for selecting studies.
1. Study selection process described under Study Selection section.
2. Process described.
[Yes] 

P10. Describe data collection process. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We developed data sheet (Microsoft Excel 2000 9.0.6926 SP-3, Microsoft Corporation) for our outcome measures listed earlier.&quot;</span>
2. Use of data collection sheet described.
[Yes]

P11. List and define data items.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Primary and secondary outcomes measures listed earlier were extracted from each study.&quot;</span>
2. Outcomes extracted defined in eligibility criteria section.
[Yes]

P12. Assess risk of bias in individual studies.
1. No mention of assessing risk of bias within individual studies.
2. Risk of bias within studies not described.
[No]

P13. State principal summary measures.
1. No summary measures stated.
2. Summary measures not stated.
[No] 

P14. Synthesis methods.
1. No quantitative synthesis performed.
2. Not applicable as no meta-analysis done.
[NA]

P15. Risk of bias across studies.
1. No assessment of risk of bias across studies mentioned.
2. Risk of bias across studies not assessed.
[No]

P16. Additional analyses. 
1. No additional analyses mentioned.
2. No additional analyses described.
[No]

P17. Study selection results.
1. Study selection process and results described in Figure 1.
2. Study selection process and results provided.
[Yes]

P18. Study characteristics. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A total of 164 children were included (range, 1240 children/study). Ages ranged from 7 weeks to 20 years.&quot;</span>
2. Study characteristics provided.
[Yes]

P19. Risk of bias within studies.
1. No assessment of risk of bias within individual studies presented.
2. Risk of bias within studies not provided.
[No]

P20. Results of individual studies.
1. Results summarized in tables.
2. Individual study results presented in tables.
[Yes]

P21. Synthesis of results.
1. No quantitative synthesis performed.
2. Not applicable as no meta-analysis done.
[NA]

P22. Risk of bias across studies. 
1. No assessment of risk of bias across studies presented.
2. Risk of bias across studies not provided. 
[No]

P23. Additional analysis.
1. No additional analyses presented.
2. No additional analyses done.
[NA]

P24. Summary of evidence.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The optimal treatment algorithm for pediatric achalasia remains unclear as adequate comparative data between PD and HM are lacking.&quot;</span>
2. Summary of evidence provided in conclusion.
[Yes]

P25. Limitations.
1. Limitations discussed in Limitations section.
2. Limitations discussed.
[Yes]

P26. Conclusions.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Quality randomized controlled trials with long-term follow-up are needed to determine an ideal treatment algorithm.&quot;</span>
2. Conclusions provided.
[Yes]

P27. Funding. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No funding was used.&quot;</span>
2. Funding sources reported.
[Yes]</pre>
<p><a name='145'></a></p>
</div>
<div
id="shawyer-2014-the-management-of-postoperative-reflux-in-congenital-esophageal-atresiatracheoesophageal-fistula-a-systematic-review"
class="section level4">
<h4>145.
<a href='https://doi.org/10.1007/S00383-014-3548-0' title='Open publication'>Shawyer
2014: <i>The management of postoperative reflux in congenital esophageal
atresiatracheoesophageal fistula: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [No] No mention of an a priori design or protocol. This is not stated in the text.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Title and abstract screening was carried out independently and in duplicate (AS and JD). Disagreements were settled by consensus.&quot;</span> This indicates duplicate study selection. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive search was conducted using MEDLINE/PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the Cochrane library) electronic databases.&quot;</span> At least two electronic sources were searched.

A4. [No] The status of publication was not used as an inclusion criterion. Gray literature was searched but it is not clear if studies were excluded based on publication status.

A5. [No] A list of included and excluded studies is not provided. 

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data abstraction was performed in duplicate (AS, JD) and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;</span> Characteristics of included studies were extracted.

A7. [No] The methodological quality of included studies was not formally assessed.

A8. [NA] Not applicable since quality of studies was not assessed (A7).

A9. [NA] Not applicable since no meta-analysis was performed. 

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The management of postoperative reflux in congenital esophageal atresiatracheoesophageal fistula: a systematic review&quot;</span> identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, participants, results, and conclusions.

P3. [Yes] The introduction describes the rationale and context around postoperative reflux in EA-TEF patients.

P4. [Yes] The objective is stated: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;to determine the prevalence of anti-reflux medication use in postoperative EA-TEF patients, and the impact of routine anti-reflux medication on postoperative GER and its associated complications.&quot;</span>

P5. [No] A protocol is not mentioned. 

P6. [Yes] Eligibility criteria are specified related to diagnosis, intervention, outcomes.

P7. [Yes] The information sources searched are described including databases and dates.

P8. [No] The full search strategy is not provided.

P9. [Yes] The process of study screening and selection is described. 

P10. [Yes] Data extraction by two independent reviewers is described.

P11. [Yes] Outcomes sought are described including postoperative reflux, complications, need for surgery.

P12. [NA] Not applicable since no meta-analysis was performed.

P13. [NA] Not applicable since no meta-analysis was performed. 

P14. [NA] Not applicable since no meta-analysis was performed.

P15. [NA] Not applicable since no meta-analysis was performed.

P16. [NA] Not applicable since no meta-analysis was performed.

P17. [Yes] A flow diagram of study selection is provided.

P18. [Yes] Characteristics of included studies are presented in a table. 

P19. [NA] Not applicable since no meta-analysis was performed. 

P20. [Yes] Results for outcomes are presented for each study in the text and tables.

P21. [NA] Not applicable since no meta-analysis was performed.

P22. [NA] Not applicable since no meta-analysis was performed.

P23. [NA] Not applicable since no meta-analysis was performed.

P24. [Yes] The discussion summarizes the main findings and implications.

P25. [Yes] Limitations at the study level are discussed.

P26. [Yes] Conclusions are provided considering the context of other evidence. 

P27. [No] Sources of funding are not reported for the systematic review.</pre>
<p><a name='146'></a></p>
</div>
<div
id="shawyer-2015-laparoscopic-versus-open-repair-of-recto-bladderneck-and-recto-prostatic-anorectal-malformations-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>146.
<a href='https://doi.org/10.1007/S00383-014-3626-3' title='Open publication'>Shawyer
2015: <i>Laparoscopic versus open repair of recto-bladderneck and
recto-prostatic anorectal malformations: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 99.2%)</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.9%):

es A comprehensive search was conducted of MEDLINE/ PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[We conducted a comprehensive search of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.]&quot;</span>
The review had predefined objectives and criteria.
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Title and abstract screening was conducted independently and in duplicate (AS and ML). Disagreements were settled through discussion and consensus.&quot;</span>
Two independent reviewers performed study selection. 
[Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;</span>
At least two databases were searched.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
No quotes.
Grey literature searching was not mentioned.
[No] 

A5. Was a list of studies provided?
No quotes. 
A list of included and excluded studies was not provided.
[No]

A6. Were the characteristics of the included studies provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Patient characteristics of the included studies are summarized in Tables 1 and 2.&quot;</span>
Table 1 provides characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We appraised the quality of reporting of the included studies in duplicate (AS and ML), with discrepancies resolved by discussion and consensus. We used the Methodological Index for Nonrandomized Studies (MINORS).&quot;</span> 
The MINORS tool was used to assess study quality.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quotes.
Study quality was not taken into account when interpreting the results.
[No]

A9. Were the methods used to combine the findings of studies appropriate?  
No quotes.
There was no quantitative synthesis.
[NA]

A10. Was the likelihood of publication bias assessed?
No quotes.
Publication bias was not assessed.
[No]

A11. Was the conflict of interest included?
No quotes.
Conflicts of interest were not reported.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic versus open repair of recto-bladderneck and recto-prostatic anorectal malformations: a systematic review and meta-analysis&quot;</span>
The title identifies this as a systematic review and meta-analysis.
[Yes]

P2. Structured summary.
No quotes.
A structured abstract is provided.
[Yes]

P3. Describe the rationale for the review. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

The laparoscopically-assisted anorectal pullthrough (LAARP) for recto-bladderneck and recto-prostatic anorectal malformations (RB/RP-ARMs) is believed to improve patient outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The laparoscopically-assisted anorectal pull-through (LAARP) for recto-bladderneck and recto-prostatic anorectal malformations (RB/RP-ARMs) is believed to improve patient outcomes.&quot;</span>
The introduction provides rationale on the potential benefits of LAARP.
[Yes]

P4. Provide an explicit statement of questions being addressed.
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

We conducted a systematic review to assess the impact of a laparoscopic repair on rates of mucosal prolapse and defection dysfunction of male children born with RB/RPARMs' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We conducted a systematic review to assess the impact of a laparoscopic repair on rates of mucosal prolapse and defection dysfunction of male children born with RB/RP-ARMs.&quot;</span>
The objectives relate to mucosal prolapse and defecation outcomes.
[Yes]

P5. Indicate if a review protocol exists.
No quotes. 
A protocol was not mentioned.
[No]

P6. Specify study characteristics and report characteristics.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies were included if they fulfilled the following criteria: (1) primary diagnosis of RB/RP-ARM; (2) male patients less than 18 years of age at the time of definitive repair of their RB/RP-ARM; (3) interventions include LAARP versus OPEN for ligation of the fistula and mobilization of the rectum; (4) and publication date 20102014.&quot;</span>
Inclusion criteria relating to population, interventions, comparisons, and study design are described.
[Yes]

P7. Describe information sources.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;</span>
Details of databases searched are provided.
[Yes] 

P8. Present full electronic search strategy.
No quotes.
The search strategy was not presented.
[No]

P9. State the process for selecting studies.
No quotes.
The study selection process was not described.
[No]

P10. Describe method of data extraction.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data abstraction was performed in duplicate (AS and ML) and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;</span>
Data extraction by two reviewers is mentioned.
[Yes]

P11. List and define all variables for which data were sought.
No quotes.
Data items were not defined.
[No]

P12. Describe methods for assessing risk of bias of individual studies.
See A7.
The MINORS tool was used.
[Yes]

P13. State the principal summary measures.
No quotes. 
Summary measures were not stated.
[No]

P14. Describe the methods of handling data. 
No quotes.
Not applicable - no meta-analysis.
[NA]

P15. Specify any assessment of risk of bias across studies.
No quotes.
Not applicable - no meta-analysis.
[NA] 

P16. Describe additional analyses.
No quotes.
Not applicable - no additional analyses.
[NA]

P17. Give numbers of studies screened, assessed, and included.
See Figure 1.
A flow diagram of study selection is provided.
[Yes]

P18. For each study, present characteristics.
See Table 1.
Study characteristics are presented in a table.
[Yes]

P19. Present data on risk of bias of each study.
See A7. 
Risk of bias is presented using the MINORS tool.
[Yes]

P20. For each study, present summary data for each intervention group.
No quotes.
Individual study data are not presented.
[No]

P21. Present results of each meta-analysis done.
No quotes.
Not applicable - no meta-analysis.
[NA]

P22. Present results of any assessment of risk of bias across studies. 
No quotes.
Not applicable - no assessment of risk of bias across studies.
[NA]

P23. Give results of additional analyses.
No quotes.
Not applicable - no additional analyses.  
[NA]

P24. Summarize the main findings.
No quotes.
The main findings are not summarized.
[No] 

P25. Discuss limitations at study and outcome level.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Case series and observational studies are inherently heterogeneous, thus we decided a priori to use a random-effects model to account for between-study heterogeneity.&quot;</span>
Limitations due to heterogeneity are mentioned.
[Yes]

P26. Provide a general interpretation of results.
No quotes.
General interpretation is not provided.
[No]

P27. Describe sources of funding.
No quotes.
Sources of funding are not described.
[No]</pre>
<p><a name='147'></a></p>
</div>
<div
id="shen-2015-laparoscopic-versus-open-surgery-in-children-with-choledochal-cysts-a-meta-analysis"
class="section level4">
<h4>147.
<a href='https://doi.org/10.1007/S00383-015-3705-0' title='Open publication'>Shen
2015: <i>Laparoscopic versus open surgery in children with choledochal
cysts: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review.&quot;</span> The objective is clearly stated in the introduction.

A2. [No] There is no mention of duplicate study selection or data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched databases, including PubMed, Embase, the Science Citation Index, and Cochrane Library updated to November 2014, to identify all related published studies comparing the laparoscopic and the open choledochal cyst excision with hepaticojejunostomy.&quot;</span> Multiple databases were searched.

A4. [No] Grey literature was not mentioned.

A5. [No] A list of included and excluded studies was not provided.

A6. [Yes] Table 1 provides characteristics of included studies. 

A7. [No] The methodological quality of included studies was not assessed.

A8. [NA] This question is not applicable since quality was not assessed.

A9. [Yes] Heterogeneity was assessed and random effects models used when present.

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported.

P1. [Yes] The title identifies the report as a meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale.

P4. [Yes] The objective states the PICOS elements. 

P5. [No] A protocol is not mentioned.

P6. [Yes] Inclusion criteria describe study characteristics.

P7. [Yes] Information sources and dates searched are described. 

P8. [No] The full search strategy is not presented.

P9. [No] The study selection process is not described. 

P10. [No] Data collection methods are not described.

P11. [No] Data items sought are not listed.

P12. [No] Risk of bias assessment is not described. 

P13. [Yes] Summary measures are stated.

P14. [NA] Not applicable since no meta-analysis was done.

P15. [NA] Not applicable since no meta-analysis was done. 

P16. [NA] Not applicable since no meta-analysis was done.

P17. [No] A flow diagram of study selection is not provided.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] Risk of bias within studies is not presented.

P20. [Yes] Results for each study are presented in forest plots.

P21. [NA] Not applicable since no meta-analysis was done.

P22. [NA] Not applicable since no meta-analysis was done. 

P23. [NA] Not applicable since no meta-analysis was done.

P24. [Yes] The discussion summarizes the main findings.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided.

P27. [No] Funding sources are not reported.</pre>
<p><a name='148'></a></p>
</div>
<div
id="siddiqui-2011-a-meta-analysis-of-outcomes-after-open-and-laparoscopic-nissens-fundoplication-for-gastro-oesophageal-reflux-disease-in-children"
class="section level4">
<h4>148.
<a href='https://doi.org/10.1007/S00383-010-2698-Y' title='Open publication'>Siddiqui
2011: <i>A meta-analysis of outcomes after open and laparoscopic
Nissens fundoplication for gastro-oesophageal reflux disease in
children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;[The research question and inclusion criteria should be established before the conduct of the review.]&quot;</span>
The objective is stated before the methods.
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Six comparative studies were analysed.]&quot;</span> 
The authors state the number of included studies, implying at least 2 reviewers performed study selection. 
[Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Electronic databases were searched from January 1993 to October 2009.]&quot;</span>
Multiple databases were searched from 1993 onwards.
[Yes]  

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Six studies [20, 26, 2932] were included in our study according to our inclusion criteria.]&quot;</span> 
Included studies are listed, excluded studies are referenced in Table 1.
[Yes]

A6. Were the characteristics of the included studies provided?
Table 2 provides characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Table 3 assesses methodological quality of included studies. 
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The quality assessment is not mentioned in the results or discussion.
[No]

A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The MantelHaenszel fixed effect model was used to compute robustness and susceptibility to any outliers among these trials.]&quot;</span>
Fixed and random effects models used appropriately based on heterogeneity. 
[Yes]

A10. Was the likelihood of publication bias assessed?
Publication bias is not assessed.
[No]

A11. Was the conflict of interest included?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Conflict of interest None.]&quot;</span>
Conflicts of interest are stated.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. 
The title identifies it as a meta-analysis.
[Yes]  

P2. Structured summary.
The abstract provides an appropriate structured summary.
[Yes]

P3. Describe the rationale for the review. 
The introduction describes the rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The objective of this study is to meta-analyse the published literature comparing outcomes after open (ONF) versus laparoscopic Nissen fundoplication (LNF) for gastro-oesophageal reflux disease in children.]&quot;</span>
The objective states the participants, interventions, and outcomes clearly.
[Yes]

P5. Indicate if a review protocol exists.
No protocol is mentioned.
[No] 

P6. Specify study characteristics and report characteristics used as criteria.
Inclusion and exclusion criteria are described.
[Yes]

P7. Describe information sources including dates last searched.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Electronic databases were searched from January 1993 to October 2009.]&quot;</span>
Databases and date ranges are reported.
[Yes]

P8. Present full electronic search strategy. 
The search strategy is not provided.
[No]

P9. State process for selecting studies.
Study selection process is described. 
[Yes]

P10. Describe method of data extraction.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Each article was critically reviewed by two researchers using a double extraction method for eligibility in our review.]&quot;</span>
Data extraction by two independent reviewers is described.
[Yes] 

P11. List and define all variables for which data were sought.
Outcomes extracted are listed (operative time, hospital stay, etc.)
[Yes] 

P12. Describe methods for assessing risk of bias. 
Table 3 describes the methodological quality assessment.
[Yes]

P13. State principal summary measures.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[For continuous data (operation time, hospital stay and time to feeding), Hedges g statistic was used for the calculation of standardized mean differences (SMDs).]&quot;</span>
Summary measures are described for each outcome.
[Yes]

P14. Synthesis of results.
Fixed and random effects models used appropriately based on heterogeneity.
[Yes]

P15. Risk of bias across studies.
Risk of bias across studies is not discussed.
[NA]

P16. Additional analyses.
No additional analyses performed.
[NA]  

P17. Study selection results. 
Figure 1 shows the study selection process.
[Yes]

P18. Study characteristics.
Table 2 provides characteristics of included studies.
[Yes]

P19. Risk of bias within studies.
Table 3 assesses risk of bias in included studies.
[Yes]

P20. Results of individual studies.
Forest plots display individual study results.
[Yes]

P21. Synthesis of results.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Four trials [2932] investigated overall morbidity and no significant heterogeneity existed between trials.]&quot;</span>
Results of meta-analyses are presented in text and forest plots.  
[Yes]

P22. Risk of bias across studies.
Not discussed.
[NA]

P23. Additional analysis.
No additional analyses performed.
[NA]

P24. Summary of evidence.
The discussion summarizes the main findings.
[Yes]

P25. Limitations.  
Limitations are discussed.
[Yes]

P26. Conclusions.
Conclusions are provided.
[Yes]

P27. Funding.
Funding sources are stated.
[Yes]</pre>
<p><a name='149'></a></p>
</div>
<div
id="siminas-2015-current-surgical-management-of-pediatric-idiopathic-constipation"
class="section level4">
<h4>149.
<a href='https://doi.org/10.1097/SLA.0000000000001191' title='Open publication'>Siminas
2015: <i>Current Surgical Management of Pediatric Idiopathic
Constipation</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Electronic searches of MEDLINE (PubMed), EMBase, Google Scholar, and Cochrane Libraries were conducted for English language articles only without calendar or year limits.&quot;</span>
The review had predefined inclusion/exclusion criteria.

A2. Was there duplicate study selection and data extraction?
"[No]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The authors undertook a systematic review of all published studies to critically appraise outcomes and explore the defining role of surgery for pediatric IC.&quot;</span>
The review did not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Electronic searches of MEDLINE (PubMed), EMBase, Google Scholar, and Cochrane Libraries were conducted for English language articles only without calendar or year limits. Search terms includedconstipation AND (functional OR idiopathic) AND (child OR pediatric) AND surgery NOT (Hirschsprungs OR Hirschsprung) NOT (Anorectal AND Malformation) NOT (Spina AND Bifida).&quot;</span>
The review searched multiple databases without date or language restrictions. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
"[No]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Abstracts and congress proceedings were excluded as they were considered incomplete studies.&quot;</span>
Grey literature was not included.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
The review did not provide a list of included/excluded studies.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Table 1. Characteristics of Included Studies of Surgery in Children With IC&quot;</span>
Table 1 provides characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
The review did not assess the quality of included studies. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Quality of studies was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]" 
No quantitative synthesis was performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"
No assessment of publication bias was mentioned.

A11. Was the conflict of interest included?
"[No]"
Conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A Systematic Review of Published Studies&quot;</span>
The report is identified as a systematic review in the title.

P2. Provide a structured summary.
"[Yes]" 
The abstract provides a structured summary.

P3. Describe the rationale for the review.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Against this background, the authors undertook a systematic review of all published studies to critically appraise outcomes and explore the defining role of surgery for pediatric IC.&quot;</span>  
The rationale is described in the introduction.

P4. Provide objectives with PICOS.
"[No]"
Objectives are not stated with PICOS elements.

P5. Indicate if a review protocol exists and provide registration information.
"[No]"
A protocol is not mentioned.

P6. Specify study characteristics and report characteristics.
"[No]"
Eligibility criteria are not specified.

P7. Describe information sources including dates of coverage.
"[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Electronic searches of MEDLINE (PubMed), EMBase, Google Scholar, and Cochrane Libraries were conducted for English language articles only without calendar or year limits.&quot;</span>
Sources and date ranges are described.

P8. Present full electronic search strategy.
"[No]"
The full search strategy is not presented.

P9. State process for selecting studies.
"[No]" 
The process for study selection is not described.

P10. Describe method of data extraction. 
"[No]"
The data extraction process is not described.

P11. List and define variables extracted.
"[No]"
Extracted variables are not listed or defined.

P12. Describe methods for assessing risk of bias.
"[No]"
Risk of bias assessment is not described.

P13. State principal summary measures.
"[NA]"
No quantitative synthesis was performed.

P14. Describe synthesis methods.
"[NA]" 
No quantitative synthesis was performed.

P15. Describe risk of bias assessment across studies.
"[NA]"
No assessment of risk of bias across studies was mentioned. 

P16. Describe additional analyses.
"[NA]"
No additional analyses were described.

P17. Provide study selection results and reasons for exclusions.
"[No]"
A study flow diagram is provided but reasons for exclusions are not given.

P18. For each study, present characteristics and citations. 
"[Yes]"
Table 1 provides characteristics for each included study. 

P19. Present risk of bias assessments for each study.
"[No]"
Risk of bias is not presented for individual studies.

P20. For each study, present simple summary data for each intervention group.
"[No]" 
Summary data for each study are not presented.

P21. Present results of syntheses. 
"[NA]"
No quantitative synthesis was performed.

P22. Present results of risk of bias across studies.
"[NA]" 
No assessment of risk of bias across studies was performed.

P23. Give results of additional analyses.
"[NA]"
No additional analyses were mentioned.

P24. Summarize evidence including strengths and limitations.
"[Yes]" 
The discussion summarizes the main findings and limitations.

P25. Discuss limitations at study and outcome level.
"[Yes]"
Limitations are discussed.

P26. Provide general interpretation of results.
"[Yes]"
The results are interpreted in the discussion.

P27. Describe sources of funding and role of funders.
"[No]"
Sources of funding are not described.</pre>
<p><a name='150'></a></p>
</div>
<div
id="sklar-2014-laparoscopic-versus-open-reduction-of-intussusception-in-children-a-retrospective-review-and-meta-analysis"
class="section level4">
<h4>150.
<a href='https://doi.org/10.1089/lap.2013.0415 ' title='Open publication'>Sklar
2014: <i>Laparoscopic Versus Open Reduction of Intussusception in
Children: A Retrospective Review and Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We retrospectively reviewed the electronic and paper charts of all patients requiring operative intervention for intussusception.&quot;</span>
The review was retrospective.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library, using the MeSH terms intussusception, pediatric, and laparoscopic.&quot;</span>
At least two databases were searched.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status. 

A5. Was a list of studies (included and excluded) provided? [Yes]
Figure 1 shows a flow diagram of included and excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
The MINORS criteria was used to assess quality (Table 2).

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
The limitations of the included studies are discussed in the Discussion section.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
Heterogeneity was assessed and a random effects model used for the meta-analysis. 

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
The title identifies it as a meta-analysis.

P2. Structured summary. [Yes]
The abstract provides a structured summary.

P3. Rationale for the review. [Yes] 
The introduction describes the rationale.

P4. Objectives with PICOS. [Yes]
The objectives specify participants, interventions, comparisons, and outcomes. 

P5. Protocol and registration. [No]
No protocol or registration is mentioned.

P6. Eligibility criteria. [Yes]
Eligibility criteria are described in the Methods.

P7. Information sources. [Yes]
The information sources are listed in the Methods.

P8. Search strategy. [No]
The search strategy is not provided.

P9. Study selection process. [Yes] 
The process is described in the Methods.

P10. Data collection process. [Yes]
The data extraction process is described. 

P11. Data items. [Yes]
Outcomes extracted are listed in the Methods.

P12. Risk of bias assessment. [Yes]
The MINORS criteria was used to assess quality.

P13. Summary measures. [Yes]
Summary measures are described in the Methods.

P14. Synthesis methods. [NA]
No quantitative synthesis performed.

P15. Risk of bias across studies. [NA]  
No assessment of across study bias.

P16. Additional analyses. [NA]
No additional analyses.

P17. Study selection results. [Yes]
A flow diagram of study selection is provided.

P18. Study characteristics. [Yes]
Characteristics are provided in Table 1.

P19. Risk of bias within studies. [Yes]
Assessed with MINORS criteria in Table 2.

P20. Results of individual studies. [Yes]
Results are provided in text and figures.

P21. Synthesis of results. [Yes] 
Results of meta-analyses are presented. 

P22. Risk of bias across studies. [NA]
No assessment of across study bias.

P23. Additional analysis. [NA]
No additional analyses.

P24. Summary of evidence. [Yes]
The discussion summarizes the main findings.

P25. Limitations. [Yes]
Limitations are discussed.

P26. Conclusions. [Yes]
Conclusions are provided.

P27. Funding. [No]
No mention of funding sources.</pre>
<p><a name='151'></a></p>
</div>
<div
id="sola-2010-peritoneal-drainage-versus-laparotomy-for-necrotizing-enterocolitis-and-intestinal-perforation-a-meta-analysis"
class="section level4">
<h4>151.
<a href='https://doi.org/10.1016/J.JSS.2009.05.007' title='Open publication'>Sola
2010: <i>Peritoneal Drainage versus Laparotomy for Necrotizing
Enterocolitis and Intestinal Perforation: A Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">11 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We performed a systematic review from the published literature.&quot;</span>
2. The authors state they performed a systematic review.
[Yes]

A2.  
1. No mention of duplicate study selection or data extraction.
2. The authors do not state there was duplicate study selection or data extraction.
[No]

A3.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;</span>
2. At least two electronic databases were searched.
[Yes]

A4.
1. No mention of including or excluding studies based on publication status. 
2. The authors do not state whether publication status was used as an inclusion criterion.
[No]

A5. 
1. No list of included or excluded studies is provided.
2. A list of included and excluded studies is not provided.
[No] 

A6. 
1. Table 1 provides characteristics of the included studies.
2. Characteristics of included studies are provided in Table 1.
[Yes]

A7. 
1. No mention of assessing methodological quality or risk of bias of included studies.
2. The authors do not state that they assessed methodological quality or risk of bias.
[No]

A8. 
1. No assessment of study quality is mentioned.
2. Study quality was not assessed.
[NA]

A9. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Comparisons of dichotomous data were carried out using the Mantel-Haenszel statistical method under assumption of fixed effect analysis model.&quot;</span> 
2. Appropriate methods were used to combine study results.
[Yes]

A10. 
1. No assessment of publication bias is mentioned.
2. Publication bias was not assessed.
[No]

A11. 
1. No statement about conflicts of interest.
2. Conflicts of interest are not stated.
[No]

P1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Peritoneal Drainage versus Laparotomy for Necrotizing Enterocolitis and Intestinal Perforation: A Meta-Analysis&quot;</span>
2. The title identifies the report as a meta-analysis.
[Yes]

P2. 
1. The abstract provides a structured summary including background, objectives, data sources, study selection criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions.
2. A structured abstract is provided.
[Yes]

P3. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We sought to analyze the most recent available publications in order to determine the most effective operative approach for these small, fragile, and critically ill infants.&quot;</span>
2. The rationale for the review is described.
[Yes]

P4. 
1. No explicit statement of objectives or questions being addressed.
2. The objectives are not explicitly stated with reference to PICOS.
[No]

P5. 
1. No mention of a review protocol.
2. A review protocol is not mentioned.
[No] 

P6.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Studies that evaluated only neonates with NEC and IP treated with either LAP (control) or PD (experimental treatment) were selected. Prospective studies, including randomized and nonrandomized designs, with a minimum of 25 patients allocated in each of the treatment and control arms, were considered in this systematic review.&quot;</span>
2. Eligibility criteria relating to study characteristics and report characteristics are described.
[Yes]

P7.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;</span>
2. Information sources including databases and dates searched are described.
[Yes]

P8.
1. The full electronic search strategy is not provided.
2. The full search strategy is not presented.
[No]

P9. 
1. No details provided on study screening and selection process.
2. The process for screening and selecting studies is not described.
[No]

P10. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two reviewers (JES, LGK), using a predefined data extraction form, extracted data from the publications related to gestational age, birth weight, type of operation, and mortality.&quot;</span>
2. Data extraction by two reviewers is described.  
[Yes]

P11.
1. Table 1 lists data extracted on participants, interventions and outcomes. 
2. Data items extracted are described in Table 1.
[Yes] 

P12. 
1. No assessment of risk of bias is mentioned.
2. Risk of bias assessment is not described.
[No]

P13.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Comparisons of dichotomous data were carried out using the Mantel-Haenszel statistical method under assumption of fixed effect analysis model.&quot;</span>
2. The principal summary measure (odds ratio) is stated.
[Yes]

P14. 
1. No synthesis methods described besides use of fixed effect model.
2. Synthesis methods are not described besides fixed effect model.
[NA]

P15.
1. No assessment of risk of bias across studies mentioned. 
2. Risk of bias across studies was not assessed.
[NA]

P16.
1. No additional analyses mentioned besides the planned synthesis.
2. No additional analyses were mentioned.
[NA]

P17. 
1. No study flow diagram provided.
2. A study flow diagram is not provided.  
[No]

P18. 
1. Table 1 provides characteristics of included studies.
2. Characteristics of included studies are presented in Table 1.
[Yes]

P19.  
1. No assessment of risk of bias within studies presented.
2. Risk of bias within studies was not presented.
[No]

P20.
1. Figure 1 shows forest plot with results for each study.
2. Results for each study are shown in Figure 1.
[Yes]

P21. 
1. Figure 1 shows meta-analysis results.
2. Results of the meta-analysis are shown in Figure 1. 
[Yes]

P22.
1. No assessment of risk of bias across studies presented.
2. Results of risk of bias across studies are not presented. 
[NA]

P23. 
1. No additional analyses mentioned.
2. Results of additional analyses are not presented.
[NA]

P24.
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our systematic review of prospective studies from January 2000 to December 2008 demonstrated that PD was associated with a statistically significant excess mortality of 55%.&quot;</span> 
2. Main findings are summarized.
[Yes]

P25. 
1. Limitations related to differences in patient characteristics, treatment protocols, and combining study data are mentioned in the discussion.
2. Limitations are discussed.
[Yes]

P26. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, review of the five prospective studies from January 2000 to December 2008 refutes the hypothesis that PD is superior to LAP. In addition, this meta-analysis demonstrates a statistically significant excess mortality of 55% associated with PD.&quot;</span>
2. Conclusions are provided in context of other evidence.
[Yes]

P27.
1. No statement about sources of funding or support.
2. Sources of funding and support are not described.
[No]</pre>
<p><a name='152'></a></p>
</div>
<div
id="symeonidis-2016-laparoendoscopic-single-site-surgery-less-for-major-urological-procedures-in-the-pediatric-population-a-systematic-review"
class="section level4">
<h4>152.
<a href='https://doi.org/10.1016/J.IJSU.2016.03.040' title='Open publication'>Symeonidis
2016: <i>Laparoendoscopic single-site surgery (LESS) for major
urological procedures in the pediatric population: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Review and MetaAnalyses (PRISMA) guidelines [7]; a protocol was agreed beforehand by all authors.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [7]; a protocol was agreed beforehand by all authors.&quot;</span> The review mentions following a protocol.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two reviewers (ENS and DN) working independently extracted data from all eligible studies; any discrepancies were discussed and consensus was reached.&quot;</span> There were 2 independent data extractors. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An in-depth search of the literature was performed in the databases of PubMed and Scopus&quot;</span> at least 2 databases were searched.

A4. [No] The review did not mention searching for grey literature.

A5. [No] The review did not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;From each eligible study the following parameters were extracted when available: general study characteristics (author, date of publication), patient demographics (age and gender), procedure performed, indication, site of incision, details of surgical technique (entry device employed, access route, size of incision, laparoscopic instruments used, total operation time), intraoperative complications (including conversion to open surgery, use of additional ports and estimated blood loss (EBL)) and surgical outcome (length of hospital stay and post-operative complications).&quot;</span> Characteristics of included studies were provided.

A7. [No] The review did not assess the quality of included studies.

A8. [NA] Not applicable since quality of studies was not assessed.

A9. [NA] The review did not perform quantitative synthesis/meta-analysis. 

A10. [NA] The review did not assess publication bias.

A11. [No] The review did not report on conflicts of interest in the included studies.

P1. [Yes] The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context for the review. 

P4. [Yes] The introduction states the objective to present the evidence on LESS for pediatric urology.

P5. [No] The review does not mention a protocol or registration.

P6. [Yes] The methods section specifies eligibility criteria. 

P7. [Yes] The methods section describes the information sources including databases searched.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods section describes the study selection process. 

P10. [Yes] The methods section describes the data extraction process.

P11. [Yes] The methods section lists the data items extracted from studies.

P12. [No] The review did not assess risk of bias in individual studies.

P13. [NA] Not applicable since no meta-analysis was performed.

P14. [NA] Not applicable since no meta-analysis was performed. 

P15. [NA] Not applicable since no meta-analysis was performed.

P16. [NA] Not applicable since no additional analyses were performed.

P17. [Yes] The results section includes a flow diagram of study selection.

P18. [Yes] The results section presents characteristics of included studies.

P19. [No] The review did not assess risk of bias within studies.

P20. [Yes] The results section presents outcomes for each study.

P21. [NA] Not applicable since no meta-analysis was performed.

P22. [NA] Not applicable since no meta-analysis was performed.

P23. [NA] Not applicable since no additional analyses were performed.

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] The discussion describes limitations at the study and review level.

P26. [Yes] The conclusion provides an interpretation of the results and implications.

P27. [No] The review does not describe sources of funding.</pre>
<p><a name='153'></a></p>
</div>
<div
id="tan-2016-screening-and-treatment-of-intestinal-rotational-abnormalities-in-heterotaxy-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>153.
<a href='https://doi.org/10.1016/J.JPEDS.2015.12.074' title='Open publication'>Tan
2016: <i>Screening and Treatment of Intestinal Rotational Abnormalities
in Heterotaxy: A Systematic Review and Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i>Minor score formatting issues fixed during extraction:
unsolicited-ranges</i></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review was performed according to a protocol that was designed a priori and recommended for systematic reviews and meta-analyses.&quot;</span>
- States the review had an a priori protocol.
[Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors reviewed all the abstracts independently. Agreement regarding potential relevance was reached by consensus. Full-text copies of potentially eligible papers were obtained, and the same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;</span>
- States two independent reviewers performed study selection and data extraction.  
[Yes]

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Medline, Embase, Cinahl, and Cochrane databases were searched electronically on April 24, 2014, and then updated on May 11, 2015; the search was limited to reports published after January 1, 1980.&quot;</span>
- Searched multiple databases with no date restrictions.
[Yes]

A4. Was the status of publication used as an inclusion criterion? 
- No mention of including or excluding studies based on publication status.
[No] 

A5. Was a list of studies provided?
- Figure 1 provides a flow chart of included and excluded studies.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table II provides characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies.&quot;</span> 
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- The quality assessment was reported in Table III, but the results were not incorporated in the analysis or interpretation of the data.
[No]

A9. Were the methods used to combine the findings of studies appropriate?  
- Not applicable, as no quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
- Not applicable, as no assessment of publication bias was performed.
[NA]

A11. Was the conflict of interest stated?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The authors declare no conflicts of interest.&quot;</span>
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Screening and Treatment of Intestinal Rotational Abnormalities in Heterotaxy: A Systematic Review and Meta-Analysis&quot;</span>
[Yes]

P2. Structured summary in abstract.
- The abstract is structured with sections labeled background, objectives, data sources, etc.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- The introduction describes the rationale and background.
[Yes]

P4. Provide an explicit statement of questions being addressed. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This systematic review and meta-analysis aims to establish the role of screening for IRA and the indication for a prophylactic surgery in asymptomatic patients born with heterotaxy.&quot;</span>
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
- Mentions the protocol and PROSPERO registration number.
[Yes]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
- The methods section specifies inclusion/exclusion criteria.
[Yes] 

P7. Describe all information sources in the search and date last searched.
- The methods section reports the databases searched, search dates, and supplementary search methods.
[Yes]

P8. Present full electronic search strategy for at least one database.
- The search strategy is not provided.
[No]

P9. State the process for selecting studies.
- The methods section describes the study selection process. 
[Yes]

P10. Describe method of data extraction from reports.
- The methods state two authors independently extracted data.
[Yes]

P11. List and define all variables for which data were sought.
- The methods list the outcomes investigated.
[Yes]

P12. Describe methods for assessing risk of bias of individual studies. 
- The NOS was used to assess quality.
[Yes]

P13. State the principal summary measures.
- Not applicable, as no quantitative synthesis was performed.
[NA]

P14-P23. Describe synthesis methods, analysis of bias, additional analyses.
- Not applicable, as no quantitative synthesis was performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
- The discussion summarizes the main findings.
[Yes]  

P25. Discuss limitations at study and outcome level and at review level.
- The discussion describes limitations at the study and review level.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
- The discussion interprets the findings and compares to other studies.
[Yes]

P27. Describe sources of funding for the systematic review. 
- Sources of funding are not reported.
[No]</pre>
<p><a name='154'></a></p>
</div>
<div
id="terui-2015-surgical-approaches-for-neonatal-congenital-diaphragmatic-hernia-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>154.
<a href='https://doi.org/10.1007/S00383-015-3765-1' title='Open publication'>Terui
2015: <i>Surgical approaches for neonatal congenital diaphragmatic
hernia: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">3 quote(s) from
publication full text</span> (mean similarity 96.2%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 88.7%):

ds A systematic literature search was conducted using MEDLINE and the Cochrane Library.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;We conducted a systematic literature search was conducted using MEDLINE and the Cochrane Library.&quot;</span> The review had an a priori design with predefined objectives and eligibility criteria.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two individual authors extracted data from each selected study.&quot;</span> There was duplicate study selection and data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic searches of English-language articles were conducted by using MEDLINE and the Cochrane Library, including all records dated from their first entries to March 2015.&quot;</span> At least two electronic sources were searched.

A4. [No] The status of publication was not used as an inclusion criterion.

A5. [Yes] Figure 1 shows a flow diagram with the number of studies screened, assessed for eligibility, and included or excluded with reasons.

A6. [Yes] Table 1 provides characteristics of the included studies. 

A7. [No] The methodological quality of included studies was not formally assessed.

A8. [No] The quality of studies was not incorporated in formulating conclusions.

A9. [NA] Methods for combining findings were not applicable as no meta-analysis was done.

A10. [No] Publication bias was not assessed. 

A11. [No] Conflicts of interest were not reported for the included studies.

P1. [Yes] The title identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context.

P4. [Yes] The objectives state the study eligibility criteria of PICOS. 

P5. [No] A protocol was not referenced.

P6. [Yes] The eligibility criteria are described. 

P7. [Yes] The information sources are described.

P8. [Yes] The full search strategy is provided for MEDLINE.

P9. [Yes] The study selection process is diagrammed in Figure 1.

P10. [No] Details of the data collection process are not described. 

P11. [Yes] The data items collected are listed in the data abstraction section.

P12. [NA] Risk of bias assessment is not applicable without a meta-analysis.

P13. [NA] Summary measures are not applicable without a meta-analysis.

P14. [NA] Methods of handling data are not applicable without a meta-analysis.

P15. [NA] Assessment of risk of bias across studies is not applicable without a meta-analysis.

P16. [NA] Additional analyses are not applicable without a meta-analysis.

P17. [Yes] The study selection flow is diagrammed in Figure 1. 

P18. [Yes] Table 1 presents the characteristics of included studies.

P19. [NA] Assessment of risk of bias within studies is not applicable without a meta-analysis.

P20. [NA] Results of individual studies are not applicable without a meta-analysis. 

P21. [NA] Synthesis of results is not applicable without a meta-analysis.

P22. [NA] Risk of bias across studies is not applicable without a meta-analysis.

P23. [NA] Additional analysis is not applicable without a meta-analysis.

P24. [Yes] The discussion summarizes the main findings and limitations.

P25. [Yes] Limitations at the review level are discussed.

P26. [Yes] Conclusions are made including implications for research.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='155'></a></p>
</div>
<div
id="thomson-2015-laparoscopic-assistance-for-primary-transanal-pull-through-in-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>155.
<a href='https://doi.org/10.1136/BMJOPEN-2014-006063' title='Open publication'>Thomson
2015: <i>Laparoscopic assistance for primary transanal pull-through in
Hirschsprungs disease: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">10 quote(s) from
publication full text</span> (mean similarity 98.7%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

PROSPERO registryCRD42013005698.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[PROSPERO registry-CRD42013005698].&quot;</span>
The protocol was registered before conducting the review. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts of potentially relevant papers were screened by two independent authors (DT and BA). The full texts of all identified studies were assessed against the criteria in table 1 by the two independent authors (DT and BA), and study reference lists were hand searched for potentially relevant studies.&quot;</span>
Two independent reviewers performed study selection and data extraction. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):

We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I. MeSH/EMTREE terms used were Hirschsprung disease and laparoscopy. Keyword searches included recto-sigmoid, Hirschsprung*, aganglionosis, colon* resection, pull*through, trans*anal, endo*anal, trans*abdominal, biops*, Soave*, Swenson* and Boley*.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I. MeSH/EMTREE terms used were Hirschsprung disease and laparoscopy. Keyword searches included recto-sigmoid, Hirschsprung*, agan-glionosis, colon* resection, pull*through, trans*anal, endo*anal, trans*abdominal, biops*, Soave*, Swenson* and Boley*.&quot;</span>
At least two databases were searched along with supplementary keyword searches. [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
Figure 1 shows a flow diagram of included and excluded studies. [Yes]  

A6. Were the characteristics of the included studies provided?
Table 2 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two independent authors (DT and BA) assessed study quality using the Newcastle-Ottawa Scale for casecontrol and cohort studies.&quot;</span> Scores provided in Table 2. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The limitations of the included studies are discussed in the conclusion. [Yes]

A9. Were the methods used to combine the findings of studies appropriate?  
Not applicable, as no meta-analysis was performed. [NA]

A10. Was the likelihood of publication bias assessed?
Not applicable, as no meta-analysis was performed. [NA]

A11. Was the conflict of interest included?
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):

Competing interests None' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Competing interests: None.&quot;</span> [Yes]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic assistance for primary transanal pull-through in Hirschsprungs disease: a systematic review and meta-analysis&quot;</span>

P2. Structured summary. [Yes]  
The abstract provides a structured summary.

P3. Rationale. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To compare outcomes following totally transanal endorectal pull-through (TTERPT) versus pull-through with any form of laparoscopic assistance (LAPT) for infants with uncomplicated Hirschsprungs disease.&quot;</span>

P4. Objectives. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To compare outcomes following totally transanal endorectal pull-through (TTERPT) versus pull-through with any form of laparoscopic assistance (LAPT) for infants with uncomplicated Hirschsprungs disease.&quot;</span>

P5. Protocol and registration. [No]
No protocol or registration number provided.

P6. Eligibility criteria. [Yes]
Inclusion and exclusion criteria provided in Table 1.

P7. Information sources. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I.&quot;</span>

P8. Search. [No]
The search strategy is not provided in full.

P9. Study selection. [Yes]  
The process of study screening and selection is described and shown in Figure 1.

P10. Data collection process. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data were extracted by the two independent authors (DT and BA) using a predesigned proforma.&quot;</span>

P11. Data items. [Yes]
The extracted data items are described in the Data Extraction section. 

P12. Risk of bias in individual studies. [Yes]  
Study quality was assessed using the Newcastle-Ottawa scale.

P13. Summary measures. [NA]
No meta-analysis was performed.

P14. Synthesis of results. [NA]  
No meta-analysis was performed.

P15. Risk of bias across studies. [NA]
No assessment of publication bias was performed.

P16. Additional analyses. [NA]
No additional analyses were performed.

P17. Study selection. [Yes]
Study selection process shown in Figure 1.

P18. Study characteristics. [Yes]  
Study characteristics provided in Table 2.

P19. Risk of bias within studies. [Yes]
Study quality assessed using Newcastle-Ottawa scale, results in Table 2.

P20. Results of individual studies. [NA] 
No meta-analysis performed.

P21. Synthesis of results. [NA]
No meta-analysis performed.  

P22. Risk of bias across studies. [NA] 
No assessment of publication bias performed.

P23. Additional analysis. [NA]
No additional analyses performed.

P24. Summary of evidence. [Yes]  
Main findings are summarized in the Discussion section.

P25. Limitations. [Yes] 
Limitations are discussed in the Discussion section.

P26. Conclusions. [Yes]
Conclusions are provided in the Conclusions section.

P27. Funding. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

Funding MK is funded by a National Institute for Health Research Professorship' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Funding: MK is funded by a National Institute for Health Research Professorship.&quot;</span></pre>
<p><a name='156'></a></p>
</div>
<div
id="thyoka-2013-balloon-dilatation-of-anastomotic-strictures-secondary-to-surgical-repair-of-oesophageal-atresia-a-systematic-review"
class="section level4">
<h4>156.
<a href='https://doi.org/10.1007/S00247-013-2693-2' title='Open publication'>Thyoka
2013: <i>Balloon dilatation of anastomotic strictures secondary to
surgical repair of oesophageal atresia: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">16 quote(s) from
publication full text</span> (mean similarity 99.4%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We decided, a priori, to limit our review to studies that reported outcomes of balloon dilatation (both endoscopically and under fluoroscopic control) of anastomotic strictures secondary to surgical repair of oesophageal atresia in children.&quot;</span>
Reasoning: The authors state that they decided a priori on the research question and inclusion criteria.

A2. "[No]"  
Quotes: No mention of duplicate study selection or data extraction.
Reasoning: The authors do not state that duplicate study selection or data extraction was performed.

A3. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the standard databases (January, 1960May, 2012): MEDLINE, EMBASE and Cochrane Library Controlled Trials Register (CENTRAL) using the MeSH Terms esophageal stricture, esophageal stenosis and balloon dilatation to identify the studies.&quot;</span> 
Reasoning: The authors searched at least two databases along with supplementary strategies like checking references.

A4. "[No]"
Quotes: No mention of including or excluding based on publication status.
Reasoning: The authors make no mention of including or excluding studies based on publication status. 

A5. "[No]" 
Quotes: No list of included and excluded studies is provided.
Reasoning: No list of included or excluded studies is provided.

A6. "[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

total of 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In total, 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.&quot;</span>
Reasoning: Table 1 provides aggregated characteristics of the included studies.

A7. "[No]"
Quotes: No mention of assessing quality of included studies.
Reasoning: The authors do not mention assessing the quality of included studies.

A8. "[NA]"
Reasoning: Quality assessment of studies was not performed so using it in formulating conclusions is not applicable.

A9. "[NA]" 
Reasoning: The authors did not perform quantitative synthesis so assessing heterogeneity is not applicable.

A10. "[No]"
Quotes: No assessment of publication bias mentioned.
Reasoning: Publication bias is not assessed.

A11. "[No]"
Quotes: No mention of conflicts of interest.
Reasoning: Potential conflicts of interest are not reported.

P1. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia: a systematic review&quot;</span>
Reasoning: Identified as a systematic review in the title.

P2. "[Yes]"
Quotes: The abstract provides background, objectives, eligibility criteria, participants, interventions, results, conclusions.
Reasoning: The abstract is structured with the key elements.

P3. "[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

Anastomotic strictures occur in 18 30% of patients following surgery for oesophageal atresia [1]. The most common risk factors for developing anastomotic strictures are a tight anastomosis (gap length) or tension of the suture line at the time of anastomosis, type of suture material used, anastomotic leakage, fistula and associated gastrooesophageal reflux [2].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Anastomotic strictures occur in 1830% of patients following surgery for oesophageal atresia [1]. The most common risk factors for developing anastomotic strictures are a tight anastomosis (gap length) or tension of the suture line at the time of anastomosis, type of suture material used, anastomotic leakage, fistula and associated gastro-oesophageal reflux [2].&quot;</span>
Reasoning: Provides context about what is known related to the rationale.

P4. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In this review, we sought to review the current published evidence of the outcomes of balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia.&quot;</span> 
Reasoning: Clearly states the objective to review outcomes of balloon dilation for anastomotic strictures after surgical repair of esophageal atresia.

P5. "[No]"
Quotes: No mention of a protocol.
Reasoning: The authors do not mention whether a protocol exists.

P6. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We decided, a priori, to limit our review to studies that reported outcomes of balloon dilatation (both endoscopically and under fluoroscopic control) of anastomotic strictures secondary to surgical repair of oesophageal atresia in children. There was no language restriction.&quot;</span>
Reasoning: Specifies inclusion criteria including population, interventions, and outcomes. 

P7. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the standard databases (January, 1960May, 2012): MEDLINE, EMBASE and Cochrane Library Controlled Trials Register (CENTRAL) using the MeSH Terms esophageal stricture, esophageal stenosis and balloon dilatation to identify the studies.&quot;</span>
Reasoning: Specifies databases searched with date ranges.

P8. "[No]"
Quotes: No full search strategy provided.
Reasoning: A full search strategy is not provided.

P9. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Abstracts were screened to identify the relevance of the retrieved reports. Further screening of the bibliography was undertaken to include as many studies as possible, which may have been missed from our initial search. Two reviewers (M.T. and A.T.) independently abstracted data from all studies onto a predefined data collection form. Any discrepancies were resolved by consensus.&quot;</span> 
Reasoning: Describes the study selection process including screening, eligibility assessment, and process for discrepancies.

P10. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two reviewers (M.T. and A.T.) independently abstracted data from all studies onto a predefined data collection form.&quot;</span>
Reasoning: States that data extraction was done independently in duplicate. 

P11. "[Yes]" 
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.1%):

Outcomes were success of BD, number of BD sessions, number of oesophageal perforations, need for other surgical interventions and mortality.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Outcomes of interest were success of BD, number of BD sessions, number of oesophageal perforations, need for other surgical interventions and mortality.&quot;</span>
Reasoning: Specifies outcomes of interest that were sought.

P12. "[No]"
Quotes: No mention of risk of bias assessment.
Reasoning: No methods for assessing risk of bias are described.

P13. "[NA]" 
Reasoning: No quantitative synthesis was performed so summary measures are not applicable.

P14. "[NA]"
Reasoning: No quantitative synthesis was performed so methods for combining data are not applicable. 

P15. "[NA]"
Reasoning: No quantitative synthesis was performed so assessing risk of bias across studies is not applicable.

P16. "[NA]" 
Reasoning: No additional analyses like sensitivity analyses are mentioned.

P17. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified 26 studies from our search that were deemed relevant and these were further scrutinised for eligibility for inclusion in this review. Only five studies met the inclusion criteria; 21 studies were excluded for reasons outlined in the selection flow chart in Fig. 1.&quot;</span>
Reasoning: Provides details on numbers screened, assessed, and included with reasons for exclusions. Fig. 1 shows the flow diagram.

P18. "[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

total of 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In total, 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.&quot;</span> 
Reasoning: Table 1 provides aggregated characteristics of included studies.

P19. "[No]"
Quotes: No assessment of risk of bias. 
Reasoning: No assessment of risk of bias is provided.

P20. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The success rate of balloon dilatations was reported in all studies [3, 6, 8, 9, 10], ranging from 70% to 100% successful. Similarly, all the studies reported on the number of perforations. A total of seven perforations occurred following 401 balloon dilatation sessions (0.02 perforations per dilatation session; Fig. 2).&quot;</span>
Reasoning: Provides results for main outcomes including success rates and perforations with data from individual studies.

P21. "[NA]" 
Reasoning: No quantitative synthesis was performed.

P22. "[NA]"
Reasoning: No assessment of risk of bias across studies was performed since no meta-analysis was done.

P23. "[NA]"
Reasoning: No additional analyses were mentioned.

P24. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In this review, the majority (70%) of the dilatations were reported successful and approximately three dilatations were required per child. It is reassuring that sedation alone can be used in children [8, 9], which would help in reducing the risks associated with general anaesthesia, especially when repeated procedures are required.&quot;</span>
Reasoning: Summarizes main findings and discusses their relevance.

P25. "[No]"
Quotes: No limitations mentioned.
Reasoning: No limitations are discussed.

P26. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We know of no comparative study assessing outcomes between endoscopic and fluoroscopic control; however, the pooled data from our review are reassuring as they show that balloon dilatation (both endoscopic and fluoroscopic) appears to be a safe technique and is mostly successful in resolving the stricture-related obstructive symptoms.&quot;</span>
Reasoning: Provides interpretation of results and implications for future research.

P27. "[No]"
Quotes: No mention of funding sources.
Reasoning: Sources of funding are not reported.</pre>
<p><a name='157'></a></p>
</div>
<div
id="van-dalen-2015-minimally-invasive-surgery-versus-open-surgery-for-the-treatment-of-solid-abdominal-and-thoracic-neoplasms-in-children"
class="section level4">
<h4>157.
<a href='https://doi.org/10.1002/14651858.CD008403.pub3' title='Open publication'>van
Dalen 2015: <i>Minimally invasive surgery versus open surgery for the
treatment of solid abdominal and thoracic neoplasms in
children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">31 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review is the second update of a previously published Cochrane review.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This systematic review focused on randomised controlled trials (RCTs) and controlled clinical trials (CCTs).&quot;</span>
Reasoning: The review states it is an update of a previous Cochrane review and specifies the study designs of interest.
[Yes]

A2. Was there duplicate study selection and data extraction?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors performed the study selection independently.&quot;</span> 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Since no eligible studies were identified, data extraction by two independent authors using a standardised form could not be performed.&quot;</span>
Reasoning: Two authors independently did study selection, but data extraction could not be done since no studies were included.  
[Yes]

A3. Was a comprehensive literature search performed?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched CENTRAL (The Cochrane Library 2014, Issue 1), MEDLINE/PubMed (from 1966 to February 2014) and EMBASE/Ovid (from 1980 to February 2014) to identify relevant studies.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched the reference lists of relevant articles and reviews to identify additional studies.&quot;</span> 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP) and American Society of Clinical Oncology (ASCO) from 2003 to 2013.&quot;</span>
Reasoning: Searched multiple databases, reference lists, and conference proceedings. Search strategies provided.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We imposed no language restriction.&quot;</span>
Reasoning: No exclusion based on publication status mentioned.
[Yes]  

A5. Was a list of studies (included and excluded) provided? 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;These excluded studies included case series, retrospective chart reviews and retrospective cohort studies.&quot;</span>
Reasoning: The excluded studies are listed in the Characteristics of excluded studies table. No studies were included.
[Yes]

A6. Were the characteristics of the included studies provided?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No studies that met the inclusion criteria of this review were identified&quot;</span> 
Reasoning: No studies were included, so study characteristics could not be provided.
[NA]

A7. Was the scientific quality of the included studies assessed and documented?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Since no eligible studies were identified, the assessment of the risk of bias in included studies was not applicable.&quot;</span>
Reasoning: No included studies, so quality assessment not done.
[NA] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

Since no eligible studies were identified, the effects of MIS versus open surgery for the treatment of solid intra-thoracic or intraabdominal neoplasms in children remain unclear.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Since no eligible studies were identified, the effects of MIS versus open surgery for the treatment of solid intra-thoracic or intra-abdominal neoplasms in children remain unclear.&quot;</span>
Reasoning: No included studies, so study quality not used in formulating conclusions.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No eligible studies were identified. As a result, data analyses could not be performed.&quot;</span>
Reasoning: No included studies, so no quantitative synthesis done.
[NA]

A10. Was the likelihood of publication bias assessed?  
Quotes: No discussion of publication bias assessment.
Reasoning: No included studies, so publication bias assessment not done.
[NA]

A11. Was the conflict of interest included?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;None known.&quot;</span> 
Reasoning: Conflict of interest statement provided.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children (Review)&quot;</span>
Reasoning: Identified as a systematic review in the title.
[Yes]

P2. Provide a structured summary.
Quotes: The abstract provides structured headings including Background, Objectives, Search methods, Selection criteria, Data collection and analysis, Main results, Authors' conclusions.  
Reasoning: Structured abstract provided.
[Yes]

P3. Describe the rationale for the review. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases&quot;</span> [...] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The role of MIS in children with solid neoplasms is less clear than it is in adults.&quot;</span>
Reasoning: Provides background and rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed.
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intraabdominal or intra-thoracic neoplasms in children. The primary outcomes of interest are OS, EFS, port-site metastases and recurrence rate;' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-abdominal or intra-thoracic neoplasms in children. The primary outcomes of interest are OS, EFS, port-site metastases and recurrence rate.&quot;</span>
Reasoning: Clear objectives and outcomes of interest stated.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
Quotes: No mention of a protocol.
Reasoning: No statement about existence of a protocol.
[No]

P6. Specify study characteristics and report characteristics used as criteria.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing minimally invasive surgery (MIS) and open surgery for the treatment of intra-thoracic or intra-abdominal solid neoplasms were considered for inclusion.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Children (aged 0 to 18 years at diagnosis) with solid intra-thoracic or intra-abdominal neoplasms who were treated with MIS or open surgery (irrespective of previous therapy) were considered for inclusion.&quot;</span>
Reasoning: Specifies eligibility criteria including study design, participants, interventions.
[Yes]  

P7. Describe information sources including dates of coverage.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We searched CENTRAL (The Cochrane Library 2014, Issue 1), MEDLINE/PubMed (from 1966 to February 2014) and EMBASE/Ovid (from 1980 to February 2014) to identify relevant studies.&quot;</span>
Reasoning: Specifies databases searched with date ranges.
[Yes]

P8. Present full electronic search strategy for at least one database. 
Quotes: Search strategies for CENTRAL, MEDLINE and EMBASE provided in appendices.
Reasoning: Search strategies provided.
[Yes]

P9. State process for selecting studies.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently screened titles and abstracts to identify studies meeting the inclusion criteria.&quot;</span>
Reasoning: Describes process for study screening and selection.
[Yes]

P10. Describe method of data extraction.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Since no eligible studies were identified, data extraction by two independent authors using a standardised form could not be performed.&quot;</span>
Reasoning: States data extraction was planned but not done since no studies included.
[NA]

P11. List and define all variables for which data were sought.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;OS: defined as the time from surgery to death from any cause. EFS: as defined by the authors of the original study. Port-site metastases: defined as tumour recurrence in trocar sites or surgical wounds. Recurrence rate: defined as the rate of either local or distant recurrence.&quot;</span> 
Reasoning: Primary and secondary outcomes defined.
[Yes]

P12. Describe methods for assessing risk of bias of individual studies.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;If eligible studies had been identified, two authors would have independently assessed the risk of bias in these studies according to the criteria of the Cochrane Childhood Cancer Group.&quot;</span>
Reasoning: States plan for risk of bias assessment if studies had been included.
[NA]

P13. State principal summary measures. 
Quotes: No summary measures stated since no studies included.
Reasoning: No studies included so no summary measures presented.
[NA]

P14. Describe methods of handling data and combining results.
Quotes: No quantitative synthesis done.
Reasoning: No meta-analysis performed.
[NA]

P15. Specify any assessment of risk of bias across studies.
Quotes: No assessment of risk of bias across studies mentioned.
Reasoning: No assessment of risk of bias across studies discussed.  
[NA]

P16. Describe additional analyses.
Quotes: No additional analyses mentioned.
Reasoning: No additional analyses described.
[NA]

P17. Give numbers of studies screened, assessed, and included.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;After performing the searches of the electronic databases of CENTRAL, MEDLINE/PubMed AND EMBASE/Ovid, we identified 542 references&quot;</span> [...] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We obtained eight articles in full. However, these studies were not randomised controlled trials (RCTs) or controlled clinical trials (CCTs) evaluating MIS in children with solid intra-thoracic or intra-abdominal neoplasms and were thus not eligible for inclusion in this review.&quot;</span>
Reasoning: Reports number of records identified, screened, assessed for eligibility, and included.
[Yes]

P18. For each study, present characteristics and provide citations.
Quotes: Included and excluded studies presented in tables with citations. 
Reasoning: Presents cited characteristics of excluded studies. No studies were included.
[Yes] 

P19. Present data on risk of bias of each study.
Quotes: No assessment of risk of bias for individual studies presented.
Reasoning: No included studies so no assessment of risk of bias.
[NA]

P20. For each study, present simple summary data for each intervention group.
Quotes: No study data presented.
Reasoning: No included studies so no study data presented.
[NA]

P21. Present results of meta-analyses done.
Quotes: No meta-analyses done.
Reasoning: No quantitative synthesis performed.
[NA]

P22. Present results of risk of bias across studies.
Quotes: No results of risk of bias across studies presented.
Reasoning: No assessment of risk of bias across studies.
[NA]

P23. Give results of additional analyses.
Quotes: No additional analyses mentioned.
Reasoning: No additional analyses described.
[NA] 

P24. Summarize the main findings.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;No randomised controlled trials (RCTs) and controlled clinical trials (CCTs) evaluating the role of minimally invasive surgery (MIS) in solid intra-thoracic or intra-abdominal neoplasms in children could be identified.&quot;</span>
Reasoning: Summarizes main finding that no RCTs or CCTs were found.
[Yes]

P25. Discuss limitations at study and outcome level, and at review level.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The current evidence base informing the use of MIS in children with solid abdominal and thoracic neoplasms is based on other study designs like case reports, retrospective chart reviews and cohort studies and should be interpreted with caution.&quot;</span>
Reasoning: Discusses limitations of current evidence base. Does not identify limitations at the review level.
[No]

P26. Provide a general interpretation of results.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Thus there is insufficient evidence to allow any definitive conclusions regarding the use of MIS in these patients.&quot;</span>
Reasoning: Provides interpretation that evidence is insufficient to draw conclusions.
[Yes]

P27. Describe sources of funding and role of funders.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;External sources: Stichting Kinderen Kankervrij (KIKA), Netherlands.&quot;</span>
Reasoning: Sources of funding described.
[Yes]</pre>
<p><a name='158'></a></p>
</div>
<div
id="vanden-berg-2016-nephron-sparing-surgery-for-wilms-tumor-a-systematic-review"
class="section level4">
<h4>158.
<a href='https://doi.org/10.1016/J.UROLONC.2015.07.003' title='Open publication'>Vanden
Berg 2016: <i>Nephron-sparing surgery for Wilms tumor: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">4
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;</span> The protocol was prospectively registered.
This establishes the review question and criteria before conducting the review.

A2. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.&quot;</span> The reviewers independently reviewed abstracts and performed data extraction in duplicate with disagreements resolved by the senior author. 
This indicates two independent data extractors.

A3. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.&quot;</span> The authors searched MEDLINE, EMBASE, Cochrane, Google Scholar, Scopus, and meeting abstracts. The search strategies for each database are provided in the appendix.
This meets the criteria for comprehensive search.

A4. [No] The authors do not state whether grey literature was included or excluded.

A5. [No] The excluded studies are referenced but a list of included/excluded studies is not provided.

A6. [Yes] Table 1 provides a list of included studies.
This meets the criteria for providing a list of included studies.

A7. [No] The authors state that quality assessment was not performed due to heterogeneity. 

A8. [NA] Quality assessment was not performed so using it to formulate conclusions is not applicable.

A9. [NA] Data were not combined quantitatively so assessing heterogeneity is not applicable.

A10. [NA] Publication bias assessment is not applicable without a meta-analysis.

A11. [No] Sources of support are not reported for the included studies.

P1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Identify the report as a systematic review, meta-analysis, or both.&quot;</span> The title identifies it as a systematic review.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale in context of current knowledge.

P4. [Yes] The introduction states the objective to compare NSS and RN for Wilms tumor.

P5. [Yes] The methods section provides the PROSPERO registration number. 

P6. [Yes] The eligibility criteria are specified in the methods.

P7. [Yes] The information sources are described in the methods.

P8. [Yes] The full search strategies are provided in the appendix.

P9. [Yes] The process for study screening and selection is described and depicted in the PRISMA flow diagram.

P10. [No] The data collection process is not described.

P11. [No] The data items sought are not listed.

P12. [NA] Risk of bias assessment was not performed.

P13. [NA] Data were not synthesized quantitatively. 

P14. [NA] Quantitative synthesis was not performed.

P15. [NA] Assessment of bias across studies was not performed.

P16. [NA] No additional analyses were done.

P17. [Yes] The study selection flow is depicted in the PRISMA diagram. 

P18. [No] Study characteristics are not presented.

P19. [NA] Risk of bias was not assessed.

P20. [No] Results of individual studies are not presented.

P21. [NA] Results of synthesis are not presented. 

P22. [NA] Bias across studies was not assessed.

P23. [NA] No additional analyses were done.

P24. [No] A summary of evidence is not provided.

P25. [Yes] Limitations are discussed.

P26. [Yes] Conclusions are provided with implications for research.

P27. [No] Sources of funding are not reported.</pre>
<p><a name='159'></a></p>
</div>
<div
id="van-den-hondel-2014-to-split-or-not-to-split-colostomy-complications-for-anorectal-malformations-or-hirschsprung-disease-a-single-center-experience-and-a-systematic-review-of-the-literature"
class="section level4">
<h4>159.
<a href='https://doi.org/10.1055/S-0033-1351663' title='Open publication'>van
den Hondel 2014: <i>To Split or Not to Split: Colostomy Complications
for Anorectal Malformations or Hirschsprung Disease: A Single Center
Experience and a Systematic Review of the Literature</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the relevant quotes, explanations, and assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases with the help of an experienced librarian.&quot;</span>
- Mentions a systematic search was performed, but does not mention a protocol.
- [No]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two investigators (D.H. and C.S.) independently screened titles and abstracts of retrieved citations, retrieved full texts of eligible articles, and selected relevant articles matching the selection criteria described below. Disagreements were resolved by discussion.&quot;</span>  
- States two reviewers independently selected studies and extracted data.
- [Yes] 

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The general search terms were the same for the three databases, which are as follows: anorectal malformations, Hirschsprung disease, colostomy, and children. The exact search strategies are shown in Appendix 1.&quot;</span>
- Searched at least two databases using relevant search terms. Appendix shows full search strategies.
- [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
- No mention of searching for grey literature or excluding based on publication status.
- [No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows numbers of included and excluded studies. 
- [Yes]

A6. Were the characteristics of the included studies provided?
- Table 3 provides relevant characteristics of the included studies.
- [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Assessed quality using Downs and Black checklist, results in Table 3.
- [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Does not mention quality in the discussion or conclusions.
- [No]

A9. Were the methods used to combine the findings of studies appropriate? 
- No quantitative synthesis performed.
- [NA]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned.
- [No]

A11. Was the conflict of interest included?
- No statement about conflicts of interest.
- [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;To Split or Not to Split: Colostomy Complications for Anorectal Malformations or Hirschsprung Disease: A Single Center Experience and a Systematic Review of the Literature&quot;</span>
- Title identifies it as a systematic review.
- [Yes]

P2. Provide a structured summary.
- Abstract provides structured summary with all key elements.
- [Yes]

P3. Describe the rationale for the review.  
- Introduction describes rationale and background.
- [Yes]

P4. Provide objectives with PICOS elements.
- Introduction states objective to identify ideal type and location of colostomy, compares loop vs split and transverse vs sigmoid.
- [Yes]

P5. Indicate protocol and registration.
- No mention of a protocol or registration.
- [No] 

P6. Specify study eligibility criteria.
- Methods section provides inclusion and exclusion criteria.
- [Yes]

P7. Describe information sources and searches.
- Methods section describes literature search in PubMed, Embase and Web of Science with search strategies provided in Appendix.
- [Yes]

P8. Present full search strategy for at least one database. 
- Appendix shows full search strategies for all databases.
- [Yes]

P9. Describe study selection process.
- Methods section describes process of study screening and selection by two reviewers.
- [Yes]

P10. Describe data collection process.
- States two reviewers extracted data independently. 
- [Yes]

P11. List and define data items sought.
- Outcomes defined in methods as complication rates, mortality, need for revision, etc. 
- [Yes]

P12. Assess risk of bias in individual studies. 
- Assessed quality with Downs and Black checklist.
- [Yes]

P13. Describe synthesis methods.
- No quantitative synthesis performed.
- [NA] 

P14. Describe analysis of heterogeneity.  
- No quantitative synthesis performed.
- [NA]

P15. Assess risk of bias across studies.
- No quantitative synthesis performed.
- [NA] 

P16. Specify additional analyses.
- No additional analyses mentioned.
- [NA]

P17. Provide study selection results.
- Figure 1 shows study selection flow diagram.
- [Yes]

P18. Present study characteristics. 
- Table 3 provides characteristics of included studies.
- [Yes]

P19. Present risk of bias assessment.
- Table 3 shows quality assessment with Downs and Black score.
- [Yes]

P20. Present results for each study. 
- Table 4 shows results for outcomes in each study.
- [Yes]

P21. Present synthesis results.
- No quantitative synthesis performed.
- [NA]

P22. Present risk of bias across studies.
- No quantitative synthesis performed.
- [NA]

P23. Present additional analyses. 
- No additional analyses mentioned.
- [NA]

P24. Summarize evidence.
- Discussion summarizes main findings and evidence.
- [Yes]

P25. Discuss limitations.
- Discussion mentions limitations at study and review level.
- [Yes] 

P26. Provide general interpretation.
- Discussion interprets results in context of other evidence.
- [Yes]

P27. Describe funding sources. 
- No statement about sources of funding.
- [No]</pre>
<p><a name='160'></a></p>
</div>
<div
id="vernon-roberts-2013-fundoplication-versus-postoperative-medication-for-gastro-oesophageal-reflux-in-children-with-neurological-impairment-undergoing-gastrostomy"
class="section level4">
<h4>160.
<a href='https://doi.org/10.1002/14651858.CD006151.pub3 ' title='Open publication'>Vernon-Roberts
2013: <i>Fundoplication versus postoperative medication for
gastro-oesophageal reflux in children with neurological impairment
undergoing gastrostomy</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">24 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.]&quot;</span>
The review had pre-specified eligibility criteria.
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Papers identified varied from reviews and editorials, to different study designs, both retrospective and prospective. The search update from June 2006 to June 2009 produced a further 476 reports but identified no trials meeting the inclusion.&quot;</span>
Two reviewers independently selected studies. 
[Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We searched the following databases on 23 March 2012: the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, EMBASE, CINAHL, LILACS and ISI Web of Science.]&quot;</span>
At least two databases were searched.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We did not apply any language or date restrictions.]&quot;</span>
The review did not exclude studies based on publication status.
[Yes]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Figure 1 shows a study flow diagram including the number of identified reports, duplicates and discarded studies.&quot;</span>
A list of included and excluded studies was provided.
[Yes] 

A6. Were the characteristics of the included studies provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified no trials meeting the inclusion criteria.&quot;</span>
No studies were included.
[NA]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified no trials meeting the inclusion criteria.&quot;</span> 
No studies were included.
[NA]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified no trials meeting the inclusion criteria.&quot;</span>
No studies were included.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified no trials meeting the inclusion criteria.&quot;</span>
No studies were included, so no quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We identified no trials meeting the inclusion criteria.&quot;</span>
No studies were included, so publication bias could not be assessed.
[NA]

A11. Was the conflict of interest included?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We thank the following colleagues who replied to our request for knowledge of any published or unpublished RCTs: Frederic Gottrand; Lewis Spitz; David Lloyd; Carlo Di-Lorenzo; Ciro Esposito; Benjamin Gold; Hisayoshi Kawahara; Yvan Vandenplas; David Gremse; Eric Hassall; Susan Orenstein; Vasundhara Tolia; Jacob Langer; Ralf Heine.&quot;</span>
Conflicts of interest for the review authors were reported. Since no studies were included, no assessment of conflicts of interest for individual studies was needed.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Fundoplication versus postoperative medication for gastro-oesophageal reflux in children with neurological impairment undergoing gastrostomy (Review)&quot;</span>
The title identifies the report as a systematic review.
[Yes]

P2. Structured summary: 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
A structured abstract is provided.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[Children with neurological impairments frequently experience profound feeding difficulties, which can lead to malnutrition and growth failure.]&quot;</span>
The introduction describes the rationale and context for the review.
[Yes]

P4. Provide an explicit statement of questions being addressed. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[To compare the effectiveness of antireflux surgery and antireflux medications for children with neurological impairment and GOR who are undergoing placement of a gastrostomy feeding tube.]&quot;</span>
The objectives explicitly state the questions being addressed regarding participants, interventions, comparisons, and outcomes.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Protocol first published: Issue 3, 2006&quot;</span>
The existence of a protocol is indicated along with where it can be accessed.
[Yes]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.]&quot;</span>
Eligibility criteria regarding participants, interventions, study design, and other characteristics are described.
[Yes]

P7. Describe all information sources in the search and date last searched.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[We searched the following databases on 23 March 2012: the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, EMBASE, CINAHL, LILACS and ISI Web of Science.]&quot;</span>
The information sources searched are described along with dates of coverage/last searched date.
[Yes]

P8. Present full electronic search strategy for at least one database. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Appendix 1 for the most recent search strategies and Appendix 2 for the original and 2009 update search strategies.&quot;</span>
The full search strategy for at least one database is provided in the appendix.
[Yes]

P9. State the process for selecting studies.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Titles and abstracts of studies will be identified from the search and read independently by two review authors (AVR and PBS). Those that do not meet the inclusion criteria will be discarded and any disagreements over suitability for inclusion will be resolved by discussion or adjudication, or both by editors of the Cochrane Developmental, Psychosocial and Learning Problems Group.&quot;</span>
The process for study screening and selection is described.
[Yes]

P10. Describe method of data extraction and confirmation.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data extraction forms will be designed to include study design, participant characteristics, study setting, intervention type and outcomes. Data will be extracted independently by two review authors (AVR and PBS) and disagreements will be resolved through discussion or by contacting the study author for further information.&quot;</span>
The process for data extraction is described, including having two independent extractors.
[Yes]

P11. List and define all variables for which data were sought.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Primary outcomes: Resolution of clinically measured, identifiable symptoms of GOR following gastrostomy surgery. Secondary outcomes: Adverse events: morbidity - including wrap failure, retching, dumping, dysphagia, drug side effects and interactions; Adverse events: mortality; Pain: measured by parental reporting, behavioural observations; Health-related quality of life for child or carer, or both: measured using validated scales.&quot;</span>
Outcomes and other variables for which data were sought are defined.
[Yes]

P12. Describe methods for assessing risk of bias of individual studies. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Selected studies will be independently evaluated by two review authors (AVR and PBS) using The Cochrane Collaboration's tool for assessing the risk of bias (Higgins 2011).&quot;</span> 
The use of the Cochrane risk of bias tool is described.
[Yes] 

P13. State the principal summary measures.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For dichotomous data, the risk ratio and its 95% confidence interval will be calculated. For studies using standardised assessment tools that have generated a scored outcome measure, we will calculate a mean difference. For studies using different scales, we will calculate the standardised difference in means with a 95% confidence interval.&quot;</span>
The intended summary measures for different types of data are stated.
[Yes]

P14. Describe the methods of handling data and combining results of studies.
No studies were included, so no quantitative synthesis was performed.
[NA]

P15. Specify any assessment of risk of bias across studies.
No assessment of risk of bias across studies was performed since no studies were included.
[NA]  

P16. Describe methods of additional analyses.
No additional analyses were performed since no studies were included.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusion. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Figure 1 shows a study flow diagram including the number of identified reports, duplicates and discarded studies.&quot;</span>
A study flow diagram is provided detailing the screening process and reasons for exclusion.
[Yes]

P18. For each study, present characteristics and provide citations.
No studies were included.
[NA]

P19. Present data on risk of bias for each study. 
No studies were included so no assessment of risk of bias was performed.
[NA]

P20. For each study, present simple summary data for each intervention group and effect estimates.
No studies were included so no study data or effect estimates are presented.
[NA] 

P21. Present results of meta-analyses done, including confidence intervals and measures of consistency.
No meta-analysis was performed since no studies were included.
[NA]

P22. Present results of any assessment of risk of bias across studies.
No assessment of risk of bias across studies was performed since no studies were included.
[NA]

P23. Give results of additional analyses, if done.
No additional analyses were performed since no studies were included.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review has demonstrated that there is no evidence available from reliable sources on which to draw any conclusions. We cannot provide data on the comparable risks or benefits of either treatment and are subsequently unable to provide recommendations for the best approach in this group of children.&quot;</span>
The lack of evidence is summarized.
[Yes]

P25. Discuss limitations at study and outcome level, and at review level.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There remains considerable uncertainty regarding the optimal treatment when faced with the decision of fundoplication surgery versus antireflux medications for children with GOR and neurological impairment who are undergoing gastrostomy insertion. There is a need for robust scientific evidence in order to provide data on the comparable risks or benefits of the two interventions.&quot;</span>
The lack of included studies is discussed as a limitation.
[Yes]

P26. Provide a general interpretation of results in the context of other evidence. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review aims to assess the efficacy of fundoplication for neurologically impaired children who are at a high risk of ARP failure compared with medical antireflux treatment. This is clinically important as there is some evidence of poor outcomes from surgery and the uncontrolled studies suggest that PPIs may be a safe, appropriate, cost-effective alternative (Heudebert 1997; Hassall 2000; Cheung 2001).&quot;</span>
The lack of evidence is interpreted in the context of other non-randomized studies.
[Yes]

P27. Describe sources of funding and other support, and the role of funders.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Angharad Vernon-Roberts was funded by Cerebra (Charity for Brain Injured Children and Young People).&quot;</span>
Sources of funding and support are described.
[Yes]

In summary, for the AMSTAR assessment, 10 items were rated "Yes", 1 item was "NA", and no items were rated "No". For the PRISMA assessment, 18 items were rated "Yes", 9 items were "NA", and no items were rated "No". This systematic review without meta-analysis seems to be of good methodological quality based on the AMSTAR and PRISMA tools. The main limitation is the lack of eligible randomized controlled trials for inclusion.</pre>
<p><a name='161'></a></p>
</div>
<div
id="wang-2013-systematic-review-and-meta-analysis-of-studies-comparing-the-perimeatal-based-flap-and-tubularized-incised-plate-techniques-for-primary-hypospadias-repair"
class="section level4">
<h4>161.
<a href='https://doi.org/10.1007/S00383-013-3335-3' title='Open publication'>Wang
2013: <i>Systematic review and meta-analysis of studies comparing the
perimeatal-based flap and tubularized incised-plate techniques for
primary hypospadias repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 99.9%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PubMed, Embase and Cochrane databases were searched using the terms: hypospadias, Snodgrass, TIP*, tubularized incised plate, tubularized incised-plate, Mathieu*, perimeatal-based flap, perimeatal flap, meatal-based flap and meatal based flap.&quot;</span> The review had an a priori design with predefined inclusion criteria and search terms.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The eligibility determination, quality assessment and data extraction for each study were conducted independently by two of the authors (FRW and YHX) and conflicts were resolved by a third author (HJZ).&quot;</span> There was duplicate study selection and data extraction. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The PubMed, Embase and Cochrane databases were searched&quot;</span> [...] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All titles and abstracts were reviewed initially to select studies for full review if they contained results of primary hypospadias repair including both the PBF and TIP techniques. Where the relevance of a study was unclear a review of the full text was undertaken. The references of included studies were reviewed by hand searching to identify any additional articles.&quot;</span> At least two databases were searched along with supplementary hand searching.

A4. [No] The review did not state whether grey literature was searched or used as an inclusion criterion.

A5. [No] The review did not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We extracted data from each study using a predefined data extraction form. The variables assessed included first author, publication year and type, level of evidence, patient age and number, length of follow-up, patient characteristics, surgical techniques and details (coverage of the neo-urethra, suture material and fashion, urinary diversion), and postoperative outcomes (fistula, meatal stenosis, wound dehiscence and cosmesis).&quot;</span> Characteristics of included studies were provided in Tables 1 and 2.

A7. [No] The review did not describe methods for assessing risk of bias of individual studies.

A8. [NA] Risk of bias was not assessed, so using it in formulating conclusions is not applicable.

A9. [NA] There was no quantitative synthesis or meta-analysis performed. 

A10. [NA] Assessment of publication bias is not applicable without a meta-analysis.

A11. [No] Sources of support were not reported for included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Systematic review and meta-analysis of studies comparing the perimeatal-based flap and tubularized incised-plate techniques for primary hypospadias repair&quot;</span> The title identifies the report as a systematic review.

P2. [Yes] The abstract provides a structured summary including objectives, data sources, study eligibility criteria, participants, interventions, results, and conclusions.

P3. [Yes] The introduction describes the rationale and context for the review.

P4. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

conducted a systematic review and meta-analysis of studies comparing the PBF and TIP techniques for primary hypospadias repair and determined whether the two techniques had similar reported outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;To conduct a systematic review and meta-analysis of studies comparing the PBF and TIP techniques for primary hypospadias repair and determine whether the two techniques had similar reported outcomes.&quot;</span> The objectives state the participants, interventions, comparisons, and outcomes. 

P5. [No] The review did not report whether a protocol exists or provide registration information.

P6. [Yes] The methods specify inclusion criteria regarding population, interventions, study design, and outcomes.

P7. [Yes] The methods describe the literature sources searched and date of last search.

P8. [Yes] The full search strategy for PubMed is provided in the Appendix.

P9. [Yes] The methods describe the process of study screening, eligibility, and inclusion. 

P10. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The eligibility determination, quality assessment and data extraction for each study were conducted independently by two of the authors (FRW and YHX) and conflicts were resolved by a third author (HJZ).&quot;</span> Data extraction was done in duplicate.

P11. [Yes] The extracted variables are listed and defined.

P12. [No] Methods for assessing risk of bias were not described.

P13. [NA] Outcome measures are not summarized since no meta-analysis was performed.

P14. [NA] Synthesis methods are not applicable without a meta-analysis. 

P15. [NA] Assessment of risk of bias across studies is not applicable without a meta-analysis.

P16. [NA] Additional analyses are not applicable without a meta-analysis. 

P17. [No] A flow diagram of study selection was provided but numbers excluded at each stage were not given. 

P18. [Yes] Characteristics of included studies were presented in Tables 1 and 2.

P19. [No] Risk of bias within studies was not presented.

P20. [Yes] Results for outcomes were presented for each study in Table 2. 

P21. [NA] Synthesis of results is not applicable without a meta-analysis.

P22. [NA] Assessment of risk of bias across studies is not applicable without a meta-analysis.

P23. [NA] Additional analyses are not applicable without a meta-analysis.

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] Limitations at the study level are discussed.

P26. [Yes] The conclusions provide an interpretation of the results in context of other evidence. 

P27. [No] Sources of funding were not reported.</pre>
<p><a name='162'></a></p>
</div>
<div
id="wayne-2015-what-is-the-ideal-surgical-approach-for-intra-abdominal-testes-a-systematic-review"
class="section level4">
<h4>162.
<a href='https://doi.org/10.1007/S00383-015-3676-1' title='Open publication'>Wayne
2015: <i>What is the ideal surgical approach for intra-abdominal testes?
a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">1 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span>
- The review had predefined objectives, inclusion criteria, and methods as described in the methods section. [Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction. [No]

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span>
- Searched multiple databases. [Yes]  

A4. Was the status of publication used as an inclusion criterion? 
- No mention of including or excluding studies based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows the flow of studies through the review process including the number of studies at each stage. [Yes]

A6. Were the characteristics of the included studies provided?
- Table 1 provides summaries of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- The quality of included studies was assessed using AMSTAR, Cochrane risk of bias tool, and MINORS. [Yes]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
- The conclusions considered the quality assessments, giving more weight to higher quality evidence from systematic reviews. [Yes]

A9. Were the methods used to combine the findings of studies appropriate?
- No quantitative synthesis done due to heterogeneity. [NA]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned. [No] 

A11. Was the conflict of interest included?
- No mention of conflicts of interest. [No]

P1. Identify as a systematic review in title. [Yes]

P2. Structured summary provided. [Yes]

P3. Rationale described. [Yes]  

P4. Objectives stated. [Yes]

P5. Protocol and registration reported. [No]

P6. Eligibility criteria described. [Yes] 

P7. Information sources described. [Yes]

P8. Search strategy provided. [No]

P9. Study selection process described. [Yes] 

P10. Data collection process described. [Yes] 

P11. Data items described. [Yes]

P12. Risk of bias assessment described. [Yes]

P13. Summary measures described. [NA]

P14. Synthesis methods described. [NA] 

P15. Risk of bias across studies assessed. [NA]

P16. Additional analyses described. [NA]

P17. Study selection flow diagram provided. [Yes]

P18. Study characteristics provided. [Yes]

P19. Risk of bias within studies reported. [Yes]

P20. Results of individual studies reported. [Yes]

P21. Results of syntheses reported. [NA] 

P22. Risk of bias across studies reported. [NA]

P23. Results of additional analyses reported. [NA]

P24. Summary of evidence provided. [Yes]

P25. Limitations discussed. [Yes]

P26. Conclusions stated. [Yes]

P27. Funding described. [No]</pre>
<p><a name='163'></a></p>
</div>
<div
id="weih-2012-current-practice-and-future-perspectives-in-the-treatment-of-short-bowel-syndrome-in-childrena-systematic-review"
class="section level4">
<h4>163.
<a href='https://doi.org/10.1007/S00423-011-0874-8' title='Open publication'>Weih
2012: <i>Current practice and future perspectives in the treatment of
short bowel syndrome in childrena systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 99.2%)</i></p>
<pre>
Here are the relevant quotes, explanations, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;A systemic review of Medline-cited studies dealing with current practice and future perspectives in the treatment of short bowel in children was performed.&quot;</span>
Explanation: The review had predefined objectives and criteria.
Response: [Yes]

A2. Was there duplicate study selection and data extraction? 
Quotes: No mention of duplicate study selection or data extraction.
Explanation: The review does not state that there was duplicate study selection or data extraction.
Response: [No] 

A3. Was a comprehensive literature search performed?
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Articles were found using short bowel syndrome, children, therapy, parenteral nutrition, surgical treatment, recirculating loops, reverse segments, Bianchi procedure, STEP, small bowel transplantation, and tissue engineering as search items.&quot;</span>
Explanation: The review searched multiple databases without date restrictions. 
Response: [Yes]

A4. Was the status of publication used as an inclusion criterion?
Quotes: No mention of including or excluding studies based on publication status.
Explanation: The review does not mention searching for or using unpublished studies.
Response: [No]

A5. Was a list of studies (included and excluded) provided?
Quotes: No list of included or excluded studies provided.
Explanation: The review does not provide a list of included or excluded studies.
Response: [No]

A6. Were the characteristics of the included studies provided?
Quotes: No table or description of characteristics of included studies.
Explanation: The review does not provide characteristics of included studies.
Response: [No] 

A7. Was the scientific quality of the included studies assessed and documented?
Quotes: No mention of quality assessment of included studies. 
Explanation: The review does not mention assessing quality of included studies.
Response: [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
Quotes: N/A
Explanation: Quality of studies was not assessed.
Response: [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
Quotes: N/A 
Explanation: No quantitative synthesis performed.
Response: [NA]

A10. Was the likelihood of publication bias assessed?
Quotes: N/A
Explanation: No assessment of publication bias mentioned.  
Response: [NA]

A11. Was the conflict of interest included?
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

Conflicts of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflicts of interest: None.&quot;</span>
Explanation: Conflicts of interest were reported.
Response: [Yes]

P1. Identify the report as a systematic review, meta-analysis, or both.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;REVIEW ARTICLE Current practice and future perspectives in the treatment of short bowel syndrome in childrena systematic review&quot;</span> 
Explanation: The title identifies it as a systematic review.
Response: [Yes]

P2. Structured summary 
Quotes: The abstract provides a structured summary.
Explanation: The abstract has sections for background, objectives, data sources, eligibility criteria, results, conclusions.
Response: [Yes]

P3. Describe rationale for review
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The purpose of this paper was to provide an overview of the established therapeutic approaches together with a discussion of the future perspectives in the treatment of patients with SBS.&quot;</span>
Explanation: The introduction describes the rationale for the review.
Response: [Yes]

P4. Provide objectives with PICOS
Quotes: No PICOS provided in the introduction or objectives.
Explanation: The review does not mention PICOS elements in the objectives.
Response: [No] 

P5. Indicate protocol and registration
Quotes: No mention of a protocol or registration.
Explanation: The review does not mention a protocol or registration.
Response: [No]

P6. Specify study characteristics and eligibility criteria
Quotes: No description of eligibility criteria.
Explanation: The review does not describe eligibility criteria. 
Response: [No]

P7. Describe information sources and dates of coverage
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Articles were found using short bowel syndrome, children, therapy, parenteral nutrition, surgical treatment, recirculating loops, reverse segments, Bianchi procedure, STEP, small bowel transplantation, and tissue engineering as search items. Concerning languages, our analysis included publications in English, German, Spanish, and French.&quot;</span>
Explanation: The review describes the information sources searched without date restrictions.
Response: [Yes] 

P8. Present full electronic search strategy
Quotes: No full search strategy provided.
Explanation: The review does not provide the full search strategy.
Response: [No]

P9. Describe study selection process 
Quotes: No description of study selection process.
Explanation: The review does not describe the study selection process.
Response: [No]

P10. Describe data collection process
Quotes: No description of data collection process. 
Explanation: The review does not describe the data collection process.
Response: [No]

P11. List and define data items sought
Quotes: No list of data items sought.
Explanation: The review does not list or define data items sought.
Response: [No]

P12. Assess risk of bias in individual studies
Quotes: No assessment of risk of bias. 
Explanation: The review does not assess risk of bias.
Response: [No]

P13. State summary measures 
Quotes: N/A
Explanation: No quantitative synthesis performed.
Response: [NA]

P14. Synthesis methods 
Quotes: N/A
Explanation: No quantitative synthesis performed.  
Response: [NA]

P15. Risk of bias across studies
Quotes: N/A
Explanation: No assessment of risk of bias across studies.
Response: [NA] 

P16. Additional analyses
Quotes: N/A
Explanation: No additional analyses conducted.
Response: [NA]

P17. Give numbers of studies at each stage
Quotes: No flow diagram or details on numbers of studies at each stage.
Explanation: The review does not provide a flow diagram or numbers of studies at each stage.
Response: [No]

P18. Study characteristics
Quotes: No table or list of study characteristics. 
Explanation: The review does not provide study characteristics.
Response: [No]

P19. Risk of bias within studies
Quotes: No assessment of risk of bias within studies.
Explanation: The review does not assess risk of bias within studies.
Response: [No]

P20. Results for each study
Quotes: No results presented for individual studies.
Explanation: The review does not present results for each included study. 
Response: [No]

P21. Results of syntheses
Quotes: N/A 
Explanation: No quantitative synthesis performed.
Response: [NA]

P22. Risk of bias across studies
Quotes: N/A
Explanation: No assessment of risk of bias across studies. 
Response: [NA]

P23. Additional analyses
Quotes: N/A
Explanation: No additional analyses conducted.
Response: [NA] 

P24. Summary of evidence
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The treatment of SBS patients remains very complex. It is eminent to find the best therapeutic option for each patient and to individualize and modify the different possible types of applied techniques frequently.&quot;</span>  
Explanation: The discussion summarizes the main findings.
Response: [Yes]

P25. Limitations 
Quotes: No mention of limitations.
Explanation: The review does not discuss limitations.
Response: [No]

P26. Conclusions
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, the treatment of SBS patients remains very complex.&quot;</span>
Explanation: The review provides conclusions.
Response: [Yes]

P27. Funding
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

Conflicts of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflicts of interest: None.&quot;</span>
Explanation: Sources of funding were reported.
Response: [Yes]</pre>
<p><a name='164'></a></p>
</div>
<div
id="wenk-2015-incidence-of-metachronous-contralateral-inguinal-hernias-in-children-following-unilateral-repair-a-meta-analysis-of-prospective-studies"
class="section level4">
<h4>164.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.056' title='Open publication'>Wenk
2015: <i>Incidence of metachronous contralateral inguinal hernias in
children following unilateral repair  A meta-analysis of prospective
studies</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">12 quote(s) from
publication full text</span> (mean similarity 98.9%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Electronic searches restricted to prospective studies with a minimal follow-up of 1 year included MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials.&quot;</span>
The review had predefined eligibility criteria.

A2. "[No]"  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data from selected studies were extracted by two authors (RNV and KW).&quot;</span>
There was no mention of duplicate study selection.

A3. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For MEDLINE search the following search term was used: (InfantORChildORAdolescent) AND (&quot;</span>inguinal Hernia"OR"processus vaginalis<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.9%):

) AND (Incidence' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;) AND (IncidenceOR&quot;</span>Treatment Outcome<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Recurrence OR Laparoscopy OR contralateral OR Surgery OR Examination) AND (english[Language] OR german[Language]).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;ORRecurrenceORLaparoscopyORcontralateralORSurgeryORExamination) AND (english[Language]ORgerman[Language]).&quot;</span>
At least two databases were searched along with supplementary strategies. 

A4. "[No]"
No mention of including or excluding based on publication status.

A5. "[No]"
No list of included/excluded studies provided.

A6. "[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In total 1669 children were included. Of this number 1405 (84%) were male and 264 (16%) were female. Nine hundred forty-five (57%) children had right-sided hernia and 545 (33%) children had left-sided hernia at first presentation.&quot;</span>
Study characteristics were provided in Table 1.

A7. "[No]"
No mention of assessing study quality.

A8. "[NA]"
No meta-analysis performed.

A9. "[NA]" 
No meta-analysis performed.

A10. "[NA]"
No meta-analysis performed. 

A11. "[NA]"
No meta-analysis performed.

P1. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Incidence of metachronous contralateral inguinal hernias in children following unilateral repair  A meta-analysis of prospective studies&quot;</span>
Identified as a systematic review.

P2. "[Yes]" 
Provided structured abstract with background, objectives, eligibility criteria, data sources, synthesis methods, results, conclusions.

P3. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of the present meta-analysis study is to systematically appraise the incidence of metachronous contralateral childhood inguinal hernia following unilateral inguinal hernia repair using data from well-designed prospective studies.&quot;</span>  
Described rationale for review.

P4. "[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i).&quot;</span> 
Provided objectives with PICOS elements.

P5. "[No]"
No protocol registration mentioned.

P6. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Inclusion criteria consisted of prospective observational studies (a), with minimal follow-up time of one year (b), assessing newborns, infants, children, adolescents and young adults, aged from 0 to 19 years (c), without contralateral groin exploration or laparoscopic closure of CPPV (d).&quot;</span>
Specified eligibility criteria.

P7. "[Yes]" 
Detailed search strategies provided in Appendix 1.

P8. "[Yes]"
Provided full search strategy for MEDLINE in Appendix 1. 

P9. "[No]"
No details on study selection process. 

P10. "[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data from selected studies were extracted by two authors (RNV and KW). Extracted data were managed using a preformed Excel data sheet.&quot;</span>
Described data extraction by two authors.

P11. "[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i). Secondary outcomes consisted of incidence of MCIH in male versus female children (ii); in children younger than 1 year of age versus older children (iii); in children with primarily right- versus primarily left-sided inguinal hernia (iv); and in children with open versus cleft versus closed CPPV (v).&quot;</span>
Defined outcomes sought.

P12. "[No]" 
No details on risk of bias assessment.

P13. "[NA]"
No meta-analysis performed.

P14. "[NA]"
No meta-analysis performed.

P15. "[NA]"  
No meta-analysis performed.

P16. "[NA]"
No meta-analysis performed.

P17. "[No]"
No flow diagram of study selection.

P18. "[Yes]"
Provided characteristics of included studies in Table 1.

P19. "[No]"
Did not assess risk of bias in individual studies.

P20. "[Yes]"
Presented summary data and effect estimates for each study in forest plots.

P21. "[NA]" 
No meta-analysis performed.

P22. "[NA]"
No meta-analysis performed. 

P23. "[NA]"
No meta-analysis performed.

P24. "[Yes]"
Summarized main findings and discussed relevance.

P25. "[Yes]" 
Discussed limitations at study and review level.

P26. "[Yes]"
Provided general interpretation of results and implications.

P27. "[Yes]"
Stated no funding received.</pre>
<p><a name='165'></a></p>
</div>
<div
id="wilkinson-2012-outcomes-in-distal-hypospadias-a-systematic-review-of-the-mathieu-and-tubularized-incised-plate-repairs"
class="section level4">
<h4>165.
<a href='https://doi.org/10.1016/J.JPUROL.2010.11.008' title='Open publication'>Wilkinson
2012: <i>Outcomes in distal hypospadias: A systematic review of the
Mathieu and tubularized incised plate repairs</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span style="border-bottom: 1px dashed #2780e3; color: #2780e3;">1
quote(s) from the LLM prompt briefing</span> (mean similarity 100%) -
were instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;[The research question and inclusion criteria should be established before the conduct of the review.]&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The Medline (1990e2009), Embase (1990e2009) and Cochrane databases were searched using the keyword hypospadias&quot;</span> [...] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;There were no other limits applied to the search.]&quot;</span>
"[Yes]"

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction.
"[No]" 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term hypospadias to ensure the broadest capture of relevant papers.]&quot;</span>
"[Yes]"

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status. 
"[No]"

A5. Was a list of studies (included and excluded) provided?
No list of included or excluded studies provided.
"[No]"

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies.
"[Yes]"

A7. Was the scientific quality of the included studies assessed and documented?
No mention of assessing quality of included studies.
"[No]" 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
Did not assess quality of studies (A7), so quality not used in formulating conclusions.
"[No]"

A9. Were the methods used to combine the findings of studies appropriate?
No quantitative synthesis performed.
"[NA]"

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
"[No]"

A11. Was the conflict of interest included?
No mention of conflicts of interest.
"[No]"

P1. Identify the report as a systematic review, meta-analysis, or both.
Title: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Outcomes in distal hypospadias: A systematic review of the Mathieu and tubularized incised plate repairs&quot;</span>
"[Yes]"

P2. Provide a structured summary.
Abstract provides structured summary.
"[Yes]"

P3. Describe the rationale for the review. 
Introduction describes rationale.
"[Yes]"

P4. Provide objectives with PICOS.
Objectives not explicitly stated with PICOS.
"[No]"

P5. Indicate if a review protocol exists and provide registration information.
No mention of a protocol.
"[No]" 

P6. Specify study characteristics used as criteria.
Inclusion and exclusion criteria specify study characteristics.
"[Yes]"

P7. Describe information sources including dates of coverage and date last searched.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;[The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term hypospadias to ensure the broadest capture of relevant papers.]&quot;</span>
"[Yes]"

P8. Present full electronic search strategy for at least one database. 
No full search strategy presented.
"[No]"

P9. State process for selecting studies.
Selection process described in Methods.
"[Yes]"

P10. Describe method of data extraction.
No details provided on data extraction process.
"[No]"

P11. List and define all variables for which data were sought.
Outcomes of fistula, meatal stenosis and urethral stenosis defined. 
"[Yes]"

P12. Describe methods for assessing risk of bias.
No methods described for assessing risk of bias.
"[No]"

P13. State principal summary measures.
No meta-analysis performed.
"[NA]"

P14. Describe methods of handling data and combining results.
No meta-analysis performed.
"[NA]"  

P15. Specify any assessment of risk of bias across studies.
No assessment of risk of bias across studies.
"[No]"

P16. Describe methods of additional analyses.
No additional analyses mentioned.
"[NA]"

P17. Provide study selection results and reasons for exclusions. 
Number of studies screened and included reported, but no reasons given for exclusions.
"[No]"

P18. For each study, present characteristics and provide citations. 
Table 1 provides characteristics and citations for included studies.
"[Yes]"

P19. Present risk of bias assessment for each study.
No risk of bias assessment presented.
"[No]"

P20. For each study, present simple summary data for each intervention group.
Table 1 provides number of fistulas, meatal stenosis cases, and other outcomes by study.
"[Yes]"

P21. Present results of meta-analyses. 
No meta-analysis performed.
"[NA]"

P22. Present assessment of risk of bias across studies.
No assessment of risk of bias across studies.
"[No]"

P23. Give results of additional analyses.
No additional analyses performed.
"[NA]"

P24. Summarize main findings including strength of evidence.
Main findings summarized in Discussion.
"[Yes]"

P25. Discuss limitations at study and outcome level and at review level.
Limitations discussed in Discussion.
"[Yes]"

P26. Provide general interpretation of results in context of other evidence.
Results interpreted in context of other evidence in Discussion.
"[Yes]"

P27. Describe sources of funding and role of funders.
No mention of sources of funding.
"[No]"</pre>
<p><a name='166'></a></p>
</div>
<div
id="wright-2013-effect-of-preoperative-hormonal-stimulation-on-postoperative-complication-rates-after-proximal-hypospadias-repair-a-systematic-review"
class="section level4">
<h4>166.
<a href='https://doi.org/10.1016/J.JURO.2013.02.3234' title='Open publication'>Wright
2013: <i>Effect of Preoperative Hormonal Stimulation on Postoperative
Complication Rates After Proximal Hypospadias Repair: A Systematic
Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">5 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<p><i><span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">23 quote(s)
from the LLM prompt briefing</span> (mean similarity 99.8%) - were
instructions quoted (ok) or examples (unwanted beahviour)?</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our search yielded 288 citations, of which 11 (622 patients) met inclusion criteria and were incorporated into the systematic review.&quot;</span> "[Yes]" The review had predefined inclusion criteria.

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Title and abstract screening was conducted independently by 2 authors to select all citations that might contain comparisons of interest. Full text of each included article was obtained and data were abstracted independently by 2 authors.&quot;</span> "[Yes]" There was duplicate study selection and data extraction.  

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We comprehensively searched the published and unpublished literature between 1990 and 2010. Eligibility criteria were applied.&quot;</span> "[Yes]" Multiple databases were searched along with other supplementary methods.

A4. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.&quot;</span> "[No]" Grey literature was not specifically searched or included.

A5. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;A list of included and excluded studies should be provided.&quot;</span> "[No]" A list of excluded studies was not provided.

A6. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> "[Yes]" Table 1 and 2 provide details on participants, interventions, and outcomes.

A7. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Critical appraisal of the included studies was carried out by 2 independent reviewers using a quality assessment instrument adopted from Elyas et al,14 modified to fit the objectives of this study.&quot;</span> "[Yes]" The methodological quality of included studies was assessed.

A8. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span> "[No]" The quality assessment was not incorporated into the analysis or conclusions.

A9. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span> "[NA]" No quantitative synthesis was performed. 

A10. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span> "[No]" Publication bias was not assessed.

A11. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span> "[No]" Sources of funding were not reported for the included studies.

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Effect of Preoperative Hormonal Stimulation on Postoperative Complication Rates After Proximal Hypospadias Repair: A Systematic Review&quot;</span> "[Yes]" Identified as a systematic review.

P2. <span title='Moderate quote deviation. Best match in prompt (Similarity 94.4%):

Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;The abstract provides relevant background, objectives, data sources, eligibility criteria, interventions, results, conclusions and implications.&quot;</span> "[Yes]" Structured summary provided.

P3. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe the rationale for the review in the context of what is already known.&quot;</span> "[Yes]" Introduction describes the rationale.

P4. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span> "[Yes]" Objectives and inclusion criteria outline the PICOS.

P5. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span> "[No]" A protocol was not referenced.

P6. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span> "[Yes]" The eligibility criteria are detailed. 

P7. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span> "[Yes]" The search methods are described.

P8. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span> "[No]" The search strategy was not presented.

P9. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span> "[Yes]" The study selection process is diagrammed and described.

P10. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span> "[Yes]" Data extraction was done independently and in duplicate. 

P11. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span> "[Yes]" Extracted variables are listed in Tables 1 and 2.

P12. "[NA]" No meta-analysis was performed.

P13. "[NA]" No meta-analysis was performed. 

P14. "[NA]" No meta-analysis was performed.

P15. "[NA]" No meta-analysis was performed.

P16. "[NA]" No meta-analysis was performed.

P17. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span> "[Yes]" The study selection process is diagrammed in Figure 1.

P18. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span> "[Yes]" Study details are presented in Tables 1 and 2.

P19. "[NA]" No meta-analysis was performed. 

P20. "[NA]" No meta-analysis was performed.

P21. "[NA]" No meta-analysis was performed. 

P22. "[NA]" No meta-analysis was performed.

P23. "[NA]" No meta-analysis was performed.

P24. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span> "[Yes]" The findings are summarized in the discussion and conclusion.

P25. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span> "[Yes]" Limitations are described.

P26. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span> "[Yes]" Conclusions are made in context of the current literature.

P27. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span> "[No]" Sources of funding were not reported.</pre>
<p><a name='167'></a></p>
</div>
<div
id="yang-2011-laparoscopic-vs-open-herniorrhaphy-in-the-management-of-pediatric-inguinal-hernia-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>167.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.04.001' title='Open publication'>Yang
2011: <i>Laparoscopic vs open herniorrhaphy in the management of
pediatric inguinal hernia: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">9 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All published studies until July 30, 2010, were searched with the terms laparoscopy, laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases, without lower date limit.&quot;</span>
The review had a comprehensive literature search with no date restrictions.

A2. [No] The review did not mention duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;This review was limited to the published studies, and no contact was made with the authors to obtain unpublished data. The citations, abstracts, or full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (YCL, ZHY, and TQS), and any disagreements were resolved by consensus.&quot;</span> 
At least two electronic databases were searched and supplementary search methods were used.

A4. [No] The review did not mention inclusion or exclusion based on publication status. 

A5. [No] The review did not provide a list of included and excluded studies.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data regarding the following factors were considered: first author, publication date, study method, participant features, intervention characteristics, definition of complications, and outcome measures.&quot;</span> Table 1 provides characteristics of the included studies.

A7. [No] The review did not assess study quality.

A8. [NA] The review did not assess study quality (A7).

A9. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):

Statistical heterogeneity was assessed using the I 2 statistics. If the I 2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I 2 value was 50% or more, then the random effects metaanalysis was used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity was assessed using the I2 statistics. If the I2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I2 value was 50% or more, then the random effects meta-analysis was used.&quot;</span>
Appropriate methods were used to combine study findings. 

A10. [No] The review did not assess publication bias.

A11. [No] The review did not report on sources of support or conflict of interest.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Laparoscopic vs open herniorrhaphy in the management of pediatric inguinal hernia: a systemic review and meta-analysis&quot;</span>
Identifies as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context. 

P4. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of this review was to critique the current literature to determine the efficacy of LH.&quot;</span> 
The objectives relate to PICOS.

P5. [No] The review did not mention a protocol or registration.

P6. [Yes] The methods section specifies eligibility criteria.

P7. [Yes] The methods section describes the information sources and date last searched.

P8. [No] The full search strategy was not provided.

P9. [Yes] The methods section describes the study selection process. 

P10. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Three reviewers (YCL, ZHY, and TQS) independently assessed selected studies, extracted, and tabulated data from each article with a predefined data extraction form.&quot;</span>
The data collection process is described.

P11. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Data regarding the following factors were considered: first author, publication date, study method, participant features, intervention characteristics, definition of complications, and outcome measures.&quot;</span>
The extracted data items are defined.

P12. [NA] The review did not assess individual study bias (meta-analysis only).

P13. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Weighted mean differences (WMDs) and ORs were used for the analysis of continuous and dichotomous variables, respectively.&quot;</span>
Summary measures are stated.

P14. [NA] The review did not combine study results (meta-analysis only). 

P15. [NA] The review did not assess risk of bias across studies (meta-analysis only).

P16. [NA] No additional analyses were done (meta-analysis only).

P17. [Yes] Figure 1 shows the study selection flow diagram. 

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [NA] Individual study bias was not assessed (meta-analysis only).

P20. [NA] Individual study results were not presented (meta-analysis only).

P21. [NA] Results of meta-analyses were not presented (meta-analysis only). 

P22. [NA] Risk of bias across studies was not assessed (meta-analysis only).

P23. [NA] No additional analyses were presented (meta-analysis only).

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] Limitations at the study and outcome level are discussed.

P26. [Yes] The conclusion provides an overall interpretation of results and implications.

P27. [No] Sources of funding were not reported for the review.</pre>
<p><a name='168'></a></p>
</div>
<div
id="yang-2013-postoperative-intussusceptions-in-children-and-infants-a-systematic-review"
class="section level4">
<h4>168.
<a href='https://doi.org/10.1007/S00383-013-3345-1' title='Open publication'>Yang
2013: <i>Postoperative intussusceptions in children and infants: a
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">2 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;MEDLINE electronic database was searched in April 2013 using key words postoperative intussusception. References lists of identified articles were screened for additional publications of interest.&quot;</span>
The review protocol was not registered or published. [No]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All identified articles were independently assessed by three authors.&quot;</span> 
Study selection was done in duplicate. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;MEDLINE electronic database was searched in April 2013 using key words postoperative intussusception. References lists of identified articles were screened for additional publications of interest.&quot;</span>
Only one database was searched. [No]

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Included studies are listed in Table 1. Excluded studies are not listed. [No]

A6. Were the characteristics of the included studies provided? 
Characteristics of included studies are provided in Table 1. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment of included studies. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias. [No]

A11. Was the conflict of interest included?
No statement on conflicts of interest. [No]

P1. Identify as systematic review in title. [Yes]

P2. Structured summary provided. [Yes]

P3. Rationale described. [Yes] 

P4. Objectives stated. [Yes]

P5. Protocol registration not reported. [No] 

P6. Eligibility criteria described. [Yes]

P7. Information sources described. [Yes]

P8. Search strategy not provided. [No]

P9. Study selection process described. [Yes] 

P10. Data collection process not described. [No]

P11. Data items described. [Yes] 

P12. Risk of bias of individual studies not performed. [No]

P13. Summary measures not applicable. [NA]

P14. Synthesis of results not applicable. [NA]

P15. Risk of bias across studies not performed. [NA]

P16. Additional analyses not applicable. [NA]

P17. Study selection process shown in flow diagram. [Yes]

P18. Study characteristics presented. [Yes]

P19. Risk of bias within studies not presented. [No]

P20. Results of individual studies not presented. [No]

P21. Results of syntheses not applicable. [NA] 

P22. Risk of bias across studies not applicable. [NA]

P23. Additional analysis not applicable. [NA]

P24. Summary of evidence provided. [Yes]

P25. Limitations discussed. [Yes]

P26. Conclusions provided. [Yes]

P27. Funding reported. [No]</pre>
<p><a name='169'></a></p>
</div>
<div
id="youssef-2016-flap-versus-fascial-closure-for-gastroschisis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>169.
<a href='https://doi.org/10.1016/J.JPEDSURG.2016.02.010' title='Open publication'>Youssef
2016: <i>Flap versus fascial closure for gastroschisis: a systematic
review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">8 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The protocol of this review was prospectively published in the PROSPERO registry (CRD42015016745) [13].&quot;</span> This indicates that an a priori design was published.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;All of the resulting titles were twice inspected independently; papers were excluded if one of the following exclusion criteria were met: basic science or animal studies, non-comparative studies or case reports, or papers that did not include GS patients.&quot;</span> This indicates that there was duplicate study selection. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Papers with pertinent titles were systematically identified by searching the following sources: AMED, PubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys, Global Health, LLAOS, and Web of Science in November 2014 with no date or language restrictions.&quot;</span> Searching multiple databases indicates a comprehensive search.

A4. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For each of these databases, a search strategy guided by our institution's scientific librarian was established according to the database design (Appendix A). A hand check of reference lists of the included articles was performed to identify any further relevant papers. Gray literature was sought, where appropriate, by probing the abstracts of relevant conferences and contacting the authors for any unpublished results.&quot;</span> Searching for gray literature indicates that publication status was not an inclusion criteria.

A5. [No] A list of included and excluded studies is not provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The characteristics of the included studies are highlighted in Table 1.&quot;</span> Table 1 provides aggregated data on the participants, interventions and outcomes. 

A7. [No] The methodological quality of included studies was assessed using the Newcastle-Ottawa scale, but it is not clear if this was done a priori.

A8. [No] The quality of studies was not incorporated into the analysis or conclusions.

A9. [NA] No quantitative synthesis was performed.

A10. [NA] No assessment of publication bias was performed. 

A11. [No] Sources of support were not reported for the included studies.

P1. [Yes] The title <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Flap versus fascial closure for gastroschisis: a systematic review and meta-analysis&quot;</span> identifies the report as a systematic review and meta-analysis.

P2. [Yes] The abstract provides a structured summary including background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, and conclusions.

P3. [Yes] The introduction describes the rationale for the review in the context of existing knowledge. 

P4. [Yes] The introduction states <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The objective of this investigation was to compare the short-term outcomes of flap closure and fascial closure through a formal systematic literature review and meta-analysis.&quot;</span> This provides the objectives and specifies the participants, interventions, comparisons, and outcomes.

P5. [Yes] The methods state <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The protocol of this review was prospectively published in the PROSPERO registry (CRD42015016745) [13].&quot;</span> This indicates a protocol was registered. 

P6. [Yes] The methods describe the eligibility criteria using PICOS and characteristics such as years considered and language.

P7. [Yes] The methods list the databases searched and date last searched.

P8. [Yes] Appendix A provides the full search strategy for PubMed.

P9. [Yes] The results section describes the study screening, eligibility, and inclusion process, including reasons for exclusion, in a flow diagram. 

P10. [No] The process for data collection is not described.

P11. [No] Variables for which data were sought are not listed.

P12. [No] Methods for assessing risk of bias are not described at the outcome level.

P13. [NA] No quantitative synthesis was performed.

P14. [NA] No quantitative synthesis was performed. 

P15. [NA] No assessment of bias across studies was performed.

P16. [NA] No additional analyses were performed.

P17. [Yes] The flow diagram provides numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions.

P18. [Yes] Table 1 presents relevant characteristics of the included studies. 

P19. [No] Risk of bias within studies is not presented.

P20. [NA] No meta-analysis was performed.

P21. [NA] No meta-analysis was performed.

P22. [NA] No assessment of bias across studies was performed. 

P23. [NA] No additional analyses were performed.

P24. [Yes] The discussion summarizes the main findings and considers their relevance.

P25. [Yes] The discussion describes limitations at the study and outcome level.

P26. [Yes] The conclusion provides an overall interpretation of results and implications for future research.

P27. [Yes] The funding sources are described.</pre>
<p><a name='170'></a></p>
</div>
<div
id="zani-2015-is-single-incision-pediatric-endoscopic-surgery-more-painful-than-standard-laparoscopy-in-children-personal-experience-and-review-of-the-literature."
class="section level4">
<h4>170.
<a href='https://doi.org/pmid:25034218' title='Open publication'>Zani
2015: <i>Is single incision pediatric endoscopic surgery more painful
than standard laparoscopy in children? Personal experience and review of
the literature.</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">7 quote(s) from
publication full text</span> (mean similarity 99.2%)</i></p>
<pre>
Here are the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? 
"[No]"
No protocol or pre-determined objectives are mentioned.

A2. Was there duplicate study selection and data extraction?
"[No]" 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrine Collaboration) were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrane Collaboration) were searched&quot;</span>
Performs search of at least 2 databases plus supplementary strategies.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
"[No]"
Does not mention searching for or including grey literature.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
Does not provide a list of included/excluded studies.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Provides characteristics of included studies in Table II.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
Does not mention assessing quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Since quality of studies was not assessed, this item is not applicable.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]"
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed?
"[No]"
Does not assess publication bias.

A11. Was the conflict of interest included?
"[No]"
Does not report on conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Herein, we compare the postoperative pain in children who underwent SIPES or standard laparoscopy (SL).&quot;</span>

P2. Structured summary 
"[No]"
Does not contain a structured abstract.

P3. Describe rationale for review in context of what is already known.
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

it has been speculated that single incsion pediatnc endoscopic surgery (SIPES) in children could result in more postoperative pain given the device size for a child umbilicus.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;It has been speculated that single incision pediatric endoscopic surgery (SIPES) in children could result in more postoperative pain given the device size for a child umbilicus.&quot;</span>

P4. Provide explicit statement of questions being addressed.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;The aim of our study was to investigate whether children who underwent SIPES suffer from greater postoperative pain than those who underwent SL.&quot;</span>

P5. Indicate if protocol exists and provide registration information.
"[No]"
Does not mention if a protocol exists.

P6. Specify study characteristics used as criteria for eligibility.
"[No]"
Does not describe eligibility criteria.

P7. Describe information sources, search strategy, and dates.
"[Yes]" 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrine Collaboration) were searched using the keywords single port surgery and child. Only compari:tive articles that were published between January 2008 and November 2012 ancl that analysed postoperative pain following SIPES or SL in children were included.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrane Collaboration) were searched using the keywords single port surgery and child. Only comparative articles that were published between January 2008 and November 2012 and that analysed postoperative pain following SIPES or SL in children were included.&quot;</span>

P8. Present full electronic search strategy for at least one database.
"[No]"
Search strategy not provided.

P9. State process for selecting studies.
"[No]"
Selection process not described.

P10. Describe method of data extraction and confirmation. 
"[No]"
Data extraction process not described.

P11. List and define all variables for which data were sought.
"[No]"
Does not list or define data extraction variables.

P12. Describe methods for assessing risk of bias in individual studies.
"[No]" 
Does not describe assessing risk of bias.

P13. State principal summary measures.
"[NA]"
No quantitative synthesis performed.

P14. Describe methods of handling data and combining results.
"[NA]"
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias across studies.
"[NA]"
No quantitative synthesis performed.

P16. Describe methods of additional analyses.
"[NA]"
No additional analyses performed.

P17. Provide numbers of studies screened, assessed, and included, ideally with a flow diagram. 
"[No]"
Does not provide number of studies at each stage or a flow diagram.

P18. For each study, present characteristics and provide citations.
"[Yes]"
Provides characteristics for each included study in Table II and cites studies in text.

P19. Present data on risk of bias for each study. 
"[No]"
Does not present risk of bias results.

P20. For each study, present simple summary data for each intervention group.
"[No]"
Does not present summary data for each study.

P21. Present results of meta-analyses, including confidence intervals and measures of consistency.
"[NA]" 
No meta-analysis performed.

P22. Present results of risk of bias across studies.
"[NA]"
No assessment of risk of bias across studies.

P23. Give results of additional analyses.
"[NA]"
No additional analyses performed. 

P24. Summarize main findings and discuss relevance to key groups.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, the present study suggests that single port laparoscopic surgery in children is feasible, safe and associated with a similar postoperative pain to standard laparoscopy.&quot;</span>

P25. Discuss limitations at study and outcome level and at review level.
"[No]"
Does not discuss limitations.

P26. Provide general interpretation of results in context of other evidence.
"[Yes]" 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Our findings were confirmed by other studies in the literature (Table D.5 According to our systematic review, most of the studies showed no difference or even an advantige of SIPES over SL for postoperative pain.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Our findings were confirmed by other studies in the literature (Table II). According to our systematic review, most of the studies showed no difference or even an advantage of SIPES over SL for postoperative pain.&quot;</span>

P27. Describe sources of funding and role of funders.
"[No]"
Does not describe sources of funding.</pre>
<p><a name='171'></a></p>
</div>
<div
id="zhao-2015-single-incision-versus-conventional-laparoscopic-appendicectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>171.
<a href='https://doi.org/10.1007/S00383-015-3680-5' title='Open publication'>Zhao
2015: <i>Single-incision versus conventional laparoscopic appendicectomy
in children: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">13 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014.&quot;</span>
The review had predefined objectives and criteria.

A2. Was there duplicate study selection and data extraction?
[No] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently extracted data from the list of the included studies, and a third reviewer was required for a final decision in the case of any discrepancies.&quot;</span>
Only two reviewers performed study selection and data extraction.

A3. Was a comprehensive literature search performed?
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014. The search terms single-incision, transumbilical, three-port, conventional, laparoscopic surgery, children and appendectomy were used individually and in combination.&quot;</span>
At least two databases were searched along with supplementary strategies. 

A4. Was the status of publication used as an inclusion criterion?
[No]
The review did not mention searching for or including grey literature.

A5. Was a list of studies (included and excluded) provided?
[No]
A list of included studies was provided in Table 1, but no list of excluded studies.

A6. Were the characteristics of the included studies provided?
[Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Table 1 outlines basic demographic data from each included study, including study style, male:female sex ratio and BMI (kg/m2) or weight (kg) in each group.&quot;</span>

A7. Was the scientific quality of the included studies assessed and documented?
[No]
The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA]
Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?  
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For continuous variables, we calculated mean differences (MDs) with 95 % confidence intervals (CIs). For dichotomous variables, we used odds ratios (ORs). Statistical Heterogeneity was assessed using the Chi square test with significance set at P < 0.10.&quot;</span>
Appropriate methods were used in the meta-analyses.

A10. Was the likelihood of publication bias assessed?
[No]
Publication bias was not assessed.

A11. Was the conflict of interest included?
[No]
Conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Single-incision versus conventional laparoscopic appendicectomy in children: a systematic review and meta-analysis&quot;</span>

P2. Provide a structured summary.
[Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review.  
[Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Although SILA demonstrates some potential advantages over CLA and open appendectomy, some surgeons do not approve this surgical approach. Furthermore, considerable argument still exists regarding the real benefits of SILA over CLA in pediatric patients.&quot;</span>

P4. Provide objectives with PICOS.
[No] 
Objectives are not stated with PICOS.

P5. Indicate if a review protocol exists and provide registration information.
[No]
A protocol is not mentioned.

P6. Specify study characteristics and report characteristics.
[Yes]
Inclusion and exclusion criteria specify study characteristics. 

P7. Describe information sources including dates of coverage.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014.&quot;</span>

P8. Present full electronic search strategy.
[No]
The full search strategy is not presented.

P9. Describe study selection process. 
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Two authors independently extracted data from the list of the included studies, and a third reviewer was required for a final decision in the case of any discrepancies.&quot;</span>

P10. Describe data collection process.
[No] 
The data extraction process is not described in detail.

P11. List and define variables extracted.
[No]
The extracted variables are not defined.

P12. Describe methods for assessing risk of bias.
[No]
Risk of bias methods are not described.

P13. State principal summary measures.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;For continuous variables, we calculated mean differences (MDs) with 95% confidence intervals (CIs). For dichotomous variables, we used odds ratios (ORs).&quot;</span>

P14. Describe synthesis methods.
[Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):

Statistical Heterogeneity was assessed using the Chi square test with significance set at P \ 0.10. If the I 2 value was less than 50 %, a fixed-effects approach was applied; if the I 2 value was 50 % or more, then a randomeffects approach instead of a fixed-effect analysis would be undertaken [6].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical Heterogeneity was assessed using the Chi square test with significance set at P < 0.10. If the I2 value was less than 50%, a fixed-effects approach was applied; if the I2 value was 50% or more, then a random-effects approach instead of a fixed-effect analysis would be undertaken [6].&quot;</span>

P15. Specify assessment of risk of bias across studies.
[NA]
No assessment of risk of bias across studies was performed.

P16. Describe additional analyses.
[NA]
No additional analyses were performed. 

P17. Provide study selection flow diagram. 
[Yes]
Figure 1 shows the study selection flow diagram.

P18. Present study characteristics.
[Yes]
Table 1 presents characteristics of the included studies.

P19. Present risk of bias assessment.
[No]
Risk of bias was not assessed for individual studies.

P20. Present results for each study. 
[Yes] 
Table 2 displays the results for each study.

P21. Present results of syntheses.
[Yes] 
Results of the meta-analyses are presented in forest plots.

P22. Present risk of bias across studies.
[NA]
Risk of bias across studies was not assessed.

P23. Present additional analyses. 
[NA]
No additional analyses were performed.

P24. Summarize evidence.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Our study suggests that SILA is a feasible and safe surgical procedure alternative to CLA for pediatric patients with appendicitis.&quot;</span>

P25. Discuss limitations from study level to review level.
[Yes] 
Limitations at the study and review level are discussed.

P26. Provide general interpretation of results.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;In conclusion, our study suggests that SILA is a feasible and safe surgical procedure alternative to CLA for pediatric patients with appendicitis.&quot;</span> 

P27. Describe sources of funding and role of funders.
[No]
Sources of funding are not reported.</pre>
<p><a name='172'></a></p>
</div>
<div
id="zhu-2016-minimally-invasive-surgery-for-congenital-diaphragmatic-hernia-a-meta-analysis"
class="section level4">
<h4>172.
<a href='https://doi.org/10.1007/S10029-015-1423-0' title='Open publication'>Zhu
2016: <i>Minimally invasive surgery for congenital diaphragmatic hernia:
a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM (Claude-2)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<p><i><span style="border-bottom: 1px dashed black;">4 quote(s) from
publication full text</span> (mean similarity 100%)</i></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We performed a literature search of the PubMed database (National Library of Medicine, Bethesda, MD, USA) that covered the period from 1966 to December 2013.&quot;</span> The review had predefined inclusion criteria.

A2. [No] No mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;We applied the following subject heading or keywords: congenital diaphragmatic hernia (CDH), thoracoscopy, endosurgery, mortality, recurrence, patch, and complications. Two authors (Zhu and Wu) independently performed an electronic database search to identify studies that met the eligibility criteria.&quot;</span> At least two electronic sources were searched. 

A4. [No] No mention of including or excluding based on publication status.

A5. [Yes] Figure 1 shows a flow diagram of included and excluded studies.

A6. [Yes] Table 1 provides characteristics of the included studies. 

A7. [No] No assessment of scientific quality reported.

A8. [NA] Not applicable since A7 is No.

A9. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Heterogeneity among studies was assessed using Cochrans Q statistic to determine whether a fixed (p [ 0.1) or random (p \ 0.1) effect model should be used.&quot;</span> Appropriate tests for combining results were used.

A10. [No] No assessment of publication bias.

A11. [No] No statement about conflicts of interest.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;Minimally invasive surgery for congenital diaphragmatic hernia: a meta-analysis&quot;</span> identifies the report as a meta-analysis.

P2. [Yes] The abstract provides a structured summary.

P3. [Yes] The introduction describes the rationale and context. 

P4. [Yes] The introduction states the objective to compare MIS and open surgery for CDH.

P5. [No] No mention of a review protocol.

P6. [Yes] The methods specify eligibility criteria.

P7. [Yes] The methods describe literature search sources and dates.

P8. [No] The full search strategy is not provided.

P9. [Yes] The methods describe the study selection process. 

P10. [No] No details provided on data collection process. 

P11. [Yes] The methods list data extracted like mortality and recurrence.

P12. [No] No assessment of risk of bias reported.

P13. [Yes] Relative risk is stated as the summary measure.

P14. [Yes] The methods describe using fixed or random effects models based on heterogeneity.

P15. [No] No assessment of risk of bias across studies.

P16. [NA] Not applicable since no additional analyses.

P17. [Yes] The results provide a flow diagram of study selection.

P18. [Yes] Table 1 provides characteristics of included studies.

P19. [No] No assessment of risk of bias for individual studies. 

P20. [Yes] The results provide data on outcomes for each study.

P21. [Yes] The results provide meta-analysis results with CIs and consistency measures. 

P22. [NA] Not applicable since P15 is No.

P23. [NA] Not applicable since P16 is NA.

P24. [Yes] The discussion summarizes the main findings and implications.

P25. [Yes] The discussion considers limitations.

P26. [Yes] The conclusion provides an interpretation in context of other evidence.

P27. [No] No statement about sources of funding.</pre>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
</div>
<div id="formatting-accuracy" class="section level3">
<h3>Formatting accuracy</h3>
<ul>
<li>106 / 112 (94.6%) usable responses with correctly formatted
scores</li>
<li>6 / 112 (5.4%) usable responses with minor fixable score formatting
issues
<ul>
<li>5 with unsolicited-ranges</li>
<li>1 with wrong-response-partial-unclear-etc <br><br></li>
</ul></li>
<li>112 / 112 (100%) publications yielded usable responses on the first
try</li>
</ul>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="quoting-accuracy" class="section level3">
<h3>Quoting accuracy</h3>
<div id="amstar" class="section level4">
<h4>AMSTAR</h4>
<ul>
<li>480 quotes for 110 / 112 (98.2%) publications, median 3.5 (IQR 2-5,
range 1-21)</li>
<li>326 / 480 (67.9%) perfect <span
style="border-bottom: 1px dashed black;">quotes from the publication
full text</span></li>
<li>64 / 480 (13.3%) perfect <span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">quotes from
the LLM prompt briefing</span> - were instructions quoted (ok) or
examples (unwanted beahviour)?</li>
<li>90 / 480 (18.8%) quotes with deviations from source, where the
accuracy was measured by a <a
href="https://maxbachmann.github.io/RapidFuzz/Usage/distance/Levenshtein.html#normalized-similarity">normalized
Levenshtein similarity</a> <span
style="border-bottom: 1px dashed black;"
title="Weights for insertion: 1, deletion: 0.5, substitution: 1.5. Penalizes &quot;positive hallucinations&quot; (insertions) more than omissions of e.g. brackets and references (deletions).">with
custom weights</span>, ranging from 0-100%
<ul>
<li><span style="background-color: #ffe9e2">50 minor</span> deviations
(95%  similarity &lt; 100%); mean: 98.6%</li>
<li><span style="background-color: #ff9e81">17 moderate</span>
deviations (75%  similarity &lt; 95%); mean: 86.3%</li>
<li><span style="background-color: red">23 major</span> deviations
(similarity &lt; 75%); mean: 58.7%</li>
</ul></li>
</ul>
</div>
<div id="prisma" class="section level4">
<h4>PRISMA</h4>
<ul>
<li>557 quotes for 79 / 112 (70.5%) publications, median 5 (IQR 2-9,
range 1-44)</li>
<li>359 / 557 (64.5%) perfect <span
style="border-bottom: 1px dashed black;">quotes from the publication
full text</span></li>
<li>51 / 557 (9.2%) perfect <span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">quotes from
the LLM prompt briefing</span> - were instructions quoted (ok) or
examples (unwanted beahviour)?</li>
<li>147 / 557 (26.4%) quotes with deviations from source, where the
accuracy was measured by a <a
href="https://maxbachmann.github.io/RapidFuzz/Usage/distance/Levenshtein.html#normalized-similarity">normalized
Levenshtein similarity</a> <span
style="border-bottom: 1px dashed black;"
title="Weights for insertion: 1, deletion: 0.5, substitution: 1.5. Penalizes &quot;positive hallucinations&quot; (insertions) more than omissions of e.g. brackets and references (deletions).">with
custom weights</span>, ranging from 0-100%
<ul>
<li><span style="background-color: #ffe9e2">69 minor</span> deviations
(95%  similarity &lt; 100%); mean: 98.3%</li>
<li><span style="background-color: #ff9e81">22 moderate</span>
deviations (75%  similarity &lt; 95%); mean: 85%</li>
<li><span style="background-color: red">56 major</span> deviations
(similarity &lt; 75%); mean: 59%</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-3ef2c918ab759667b6d7" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-3ef2c918ab759667b6d7">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["Healy 2015","Healy 2015","Healy 2015","Healy 2016","Huang 2015","Ishii 2014","Ito 2014","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kunz 2013","Landisch 2015","Landisch 2015","Landisch 2015","Lane 2010","Lansdale 2010","Lansdale 2010","Liang 2011","Livingston 2015","Mauritz 2013","Mauritz 2013","Nagler 2011","Nagler 2011","Narayanan 2013","Narayanan 2013","Narayanan 2013","Nasr 2010","Nicolau 2011","Oliveira 2016","Oomen 2012","Parolini 2016","Peycelon 2014","Puligandla 2015","Romao 2012","Romao 2012","Romao 2012","Romao 2012","Ruttenstock 2010","Ruttenstock 2010","Rynja 2011","Rynja 2011","Scholfield 2016","Scholfield 2016","Scholfield 2016","Sharp 2015","Shawyer 2015","Shawyer 2015","Shawyer 2015","Symeonidis 2016","Terui 2015","Thomson 2015","Thomson 2015","Thomson 2015","Thomson 2015","Thyoka 2013","Thyoka 2013","Thyoka 2013","Thyoka 2013","van Dalen 2015","van Dalen 2015","Wang 2013","Weih 2012","Weih 2012","Wenk 2015","Wenk 2015","Wright 2013","Yang 2011","Zani 2015","Zani 2015","Zani 2015","Zani 2015","Zhao 2015","Aikenhead 2011","Allin 2015","Apelt 2013","Aworanti 2014","Aworanti 2014","Black 2013","Borruto 2010","Castagnetti 2010","Castagnetti 2016","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chen 2013","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cullis 2016","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (Eur J Pediatr Surg)","Ells 2015","Elyas 2010","Elyas 2010","Elyas 2010","Feng 2016","Feng 2016","Feng 2016","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Friedmacher 2012","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Guo 2011","Guo 2011"],["fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","prompt","prompt","prompt","fulltext","fulltext","prompt","fulltext","prompt","fulltext","prompt","fulltext","prompt","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","fulltext","fulltext","fulltext","prompt","prompt","fulltext","fulltext","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","fulltext","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","fulltext","prompt","fulltext","fulltext","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","fulltext","prompt","prompt","fulltext","fulltext","fulltext"],["<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nThis systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\ny was longer. Our article is based upon a group of heterogeneous and mostly retrospective studies and therefore there is little external validity.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;However, our article is based upon a group of heterogeneous and mostly retrospective studies, and therefore there is little external validity.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\nExtracted data comprised details on the following variables: lead author, publication date, study design, inclusion and exclusion criteria, outcomes reported, whether there was a specified primary endpoint, main results, numbers and characteristics of patients, surgical approach, rate of negative appendiceal histology, wound infections, intra-abdominal collections, readmissions, mortality, and length of stay.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Extracted data comprised details on the following variables: lead author, publication date, study design, inclusion and exclusion criteria, outcomes reported, whether there was a specified primary endpoint, main results, numbers and characteristics of patients, surgical approach, rate of negative appendiceal histology, wound infections, intra-abdominal abscesses, readmissions, or mortality, and length of stay.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nConflict of interest The authors declare that they have no conflict of interest.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflict of interest: The authors declare that they have no conflict of interest.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.1%):\n\n. according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu) according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):\n\nA systematic review was conducted using studies identified by a literature search between January 1990 and March 2014.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[This systematic review was conducted using studies identified by a literature search between January 1990 and March 2014.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nAn electronic literature search was systematically performed using databases including PubMed (January1966April 2013), Japana Centra Revuo Medicina (Igaku Chuo Zasshi, January 1983April 2013), CINAHL, and Cochrane Library using the key words ankyloglossia, tongue-tie, frenotomy, and/or breastfeeding in English and the equivalent terms in Japanese.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;An electronic literature search was systematically performed using databases including PubMed (January1966April 2013), Japana Centra Revuo Medicina (Igaku Chuo Zasshi, January 1983April 2013), CINAHL, and Cochrane Library using the key words ankyloglossia, tongue-tie, frenotomy, and/or breastfeeding in English and the equivalent terms in Japanese.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.2%):\n\n? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):\n\ned? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):\n\ned? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.3%):\n\ned? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.5%):\n\ned? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):\n\n? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.4%):\n\nn? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):\n\n? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):\n\nons? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.1%):\n\nTwo independent reviewers conducted all article screening; where consensus on an article could not be reached, a third reviewer was consulted. 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent reviewers conducted all article screening; where consensus on an article could not be reached, a third reviewer was consulted. One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.5%):\n\ned? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):\n\n? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98%):\n\na: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99%):\n\nes: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):\n\nes: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):\n\nes: State the principal summary measures (e.g., risk ratio, difference in means).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] State the principal summary measures (e.g., risk ratio, difference in means).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):\n\n: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nproduce an odds ratio (OR) for morbidity, as this is a categorical variable, and a mean difference (MD) for length of stay, as this is a continuous variable, along with 95% confidence intervals (CIs).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We produced an odds ratio (OR) for morbidity, as this is a categorical variable, and a mean difference (MD) for length of stay, as this is a continuous variable, along with 95% confidence intervals (CIs).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.5%):\n\nn: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.2%):\n\ns: Present results of each meta-analysis done, including confidence intervals and measures of consistency.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Present results of each meta-analysis done, including confidence intervals and measures of consistency.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):\n\ns: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 96.5%):\n\ns: Present results of any assessment of risk of bias across studies (see Item P15).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Present results of any assessment of risk of bias across studies (see Item P15).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.2%):\n\n: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.4%):\n\ns: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Give results of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.8%):\n\nes: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):\n\ns: Provide a general interpretation of the results in the context of other evidence, and implications for future research.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.8%):\n\n: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 95.2%):\n\n: Describe the rationale for the review in the context of what is already known.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe the rationale for the review in the context of what is already known.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.9%):\n\nes: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nWe excluded any studies on nonhuman subjects and those that did not focus on pediatric patients, as well as any studies that were not published in English, owing to resource limitations. We also excluded editorials, case reviews, any studies that did not evaluate postoperative outcomes, and any studies where it was not possible to extract data only on patients who were asymptomatic at birth.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We excluded any studies on non-human subjects and those that did not focus on pediatric patients, as well as any studies that were not published in English, owing to resource limitations. We also excluded editorials, case reviews, any studies that did not evaluate postoperative outcomes, and any studies where it was not possible to extract data only on patients who were asymptomatic at birth.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):\n\nes: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):\n\n: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No] Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98%):\n\ns: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):\n\ns: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.1%):\n\ns: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[NA] Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):\n\n: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):\n\ns: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.8%):\n\ns: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.6%):\n\nn: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):\n\ns: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[Yes] Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 94.5%):\n\n: Identify the report as a systematic review, meta-analysis, or both.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] Identify the report as a systematic review, meta-analysis, or both.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 86.1%):\n\ncript form created by the authors was used to extract study information, including study design, patient characteristics, and reported patient outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;A standard data collection form created by the authors was used to extract study information, including study design, patient characteristics, and reported patient outcomes.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.3%):\n\nTwo independent researchers (R.L. and R.M.) performed the search, critically' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.3%):\n\nTwo independent researchers (R.L. and R.M.) performed the search, critically' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nHeterotaxy syndrome (HS), a consequence of aberrations in left-toright positional signaling in early embryonic development, manifests as cardiac and visceral anatomic malpositioning. Forty percent to 90% of patients with HS also have intestinal rotational abnormalities (IRA) [1]. Improved survival secondary to advances in cardiac surgery and critical care management has led to enhanced prioritization of intestinal abnormalities, namely, prevention of midgut volvulus [2].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Heterotaxy syndrome (HS), a consequence of aberrations in left-to-right positional signaling in early embryonic development, manifests as cardiac and visceral anatomic malpositioning. Forty percent to 90% of patients with HS also have intestinal rotational abnormalities (IRA) [1]. Improved survival secondary to advances in cardiac surgery and critical care management has led to enhanced prioritization of intestinal abnormalities, namely, prevention of midgut volvulus [2].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nCircumcision can be undertaken using a variety of techniques. For the technique to be successful, it should be easy to perform, avoid excessive haemorrhage and achieve a good cosmetic and functional result with minimal postoperative care.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Circumcision can be undertaken using a variety of techniques. For the technique to be successful, it should be easy to perform, avoid excessive haemorrhage and achieve a good cosmetic and functional result with minimal postop-erative care.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nMEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched using the keywords diaphragmatic hernia AND thoracoscopic, diaphragmatic hernia AND laparoscopic, and diaphragmatic hernia AND minimallyinvasive.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;MEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched using the keywords diaphragmatic hernia AND thoracoscopic, diaphragmatic hernia AND laparoscopic, and diaphragmatic hernia AND minimally-invasive.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nNeonatal Endosurgical Congenital Diaphragmatic Hernia Repair A Systematic Review and Meta-Analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Neonatal Endosurgical Congenital Diaphragmatic Hernia Repair: A Systematic Review and Meta-Analysis&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\ns We analyzed possible publication bias by generating funnel plots of the trials used for all of the evaluated comparisons of outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We analyzed possible publication bias by generating funnel plots of the trials used for all of the evaluated comparisons of outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nCAPS Papers Fundoplication and gastrostomy versus percutaneous gastrojejunostomy for gastroesophageal reflux in children with neurologic impairment: A systematic review and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;CAPS Papers: Fundoplication and gastrostomy versus percutaneous gastrojejunostomy for gastroesophageal reflux in children with neurologic impairment: A systematic review and meta-analysis&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 85%):\n\n25 Studies were weighted on sample size and the number of events. Trials with zero events in one arm were included in the analysis by adding a continuity correction of 0.5 to all cells in the two-by-two table for that study. Trials with zero events in both arms were excluded from the meta-analysis. Heterogeneity was calculated using Higgins  2 test ( 2 p value>0.1) 26 and inconsistency in study effects was quantified by I 2 values (I 2 >5' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Results were pooled in meta-analyses and expressed as risk ratios (RRs). Studies were weighted on sample size and the number of events. Trials with zero events in one arm were included in the analysis by adding a continuity correction of 0.5 to all cells in the two-by-two table for that study. Trials with zero events in both arms were excluded from the meta-analysis. Heterogeneity was calculated using Higgins 2 test (2 p value>0.1) and inconsistency in study effects was quantified by I2 values (I2 >50 %).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.9%):\n\nUsing predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD. For PubMed, the following search terms were used: (child*[Title/Abstract] OR infant*[Title/Abstract] OR adolescent*[Title/Abstract] OR pediatric*[Title/Abstract] OR paediatric*[Title/Abstract]) AND (nissen[Title/Abstract] OR toupet[Title/Abstract] OR thal[Title/Abstract] OR antireflux*[Title/Abstract] OR antireflux*[Title/Abstract] OR fundoplication[Title/Abstract] OR fundoplication[MeSH Terms]) AND gastroesophageal reflux[MeSH Terms]. The same search strategy was used in EMBASE (replacing [Title/Abstract] by; ti,ab and [MeSH Terms] by/exp). Human, child and adolescent were used as search limits in both databases. In addition, the Cochrane Library was manually searched.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD. For PubMed, the following search terms were used: (child*[Title/Abstract] OR infant*[Title/Abstract] OR adolescent*[Title/Abstract] OR pediatric*[Title/Abstract] OR paediatric*[Title/Abstract]) AND (nissen[Title/Abstract] OR toupet[Title/Abstract] OR thal[Title/Abstract] OR anti-reflux*[Title/Abstract] OR antireflux*[Title/Abstract] OR fundoplication[Title/Abstract] OR fundoplication[MeSH Terms]) AND gastroesophageal reflux[MeSH Terms]. The same search strategy was used in EMBASE (replacing [Title/Abstract] by; ti,ab and [MeSH Terms] by/exp). Human, child and adolescent were used as search limits in both databases. In addition, the Cochrane Library was manually searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nCompared with no treatment, use of long-term low-dose antibiotics tended to reduce the number of repeat symptomatic and febrile UTIs in children with VUR, but the result was not statistically significant.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Compared with no treatment, use of long-term, low-dose antibiotics tended to reduce the number of repeat symptomatic and febrile UTIs in children with VUR, but the result was not statistically significant.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nA large amount of unexplained heterogeneity in the analysis and inclusion of only one adequately blinded study, makes drawing firm conclusions challenging.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A large amount of unexplained heterogeneity in the analysis and inclusion of only one adequately blinded study, made drawing firm conclusions challenging.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nA Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A Medline, Ovid, Search Medica, Elsevier Clini-calKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nStatistical heterogeneity was assessed using I' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity was assessed using I2.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nA Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A Medline, Ovid, Search Medica, Elsevier Clini-calKey, Google Scholar and the Cochrane library search was performed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nOur objective was to compare both the Nuss and the Ravitch procedure using systematic review and metaanalysis methodology.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Our objective was to compare both the Nuss and the Ravitch procedure using systematic review and meta-analysis methodology.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nn concluzie, dei puin utilizat, dovada fiind i numrul redus de articole publicate, laparoscopia poate fi util la pacienii cu CA atent selectai cu examen clinic i imagistic echivoce n scopul reducerii incidenei laparotomiilor inutile.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In concluzie, dei puin utilizat, dovada fiind i numrul redus de articole publicate, laparoscopia poate fi util la pacienii cu CA atent selectai cu examen clinic i imagistic echivoce n scopul reducerii incidenei laparotomiilor inutile.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nwe selected articles that presented technical alternatives for penile construction in cases of penile dysgenesis, especially aphallia in children and/or adolescents.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[We] selected articles that presented technical alternatives for penile construction in cases of penile dysgenesis, especially aphallia in children and/or adolescents.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nStatistical heterogeneity in the meta-analysis was assessed with the v 2 test and the I 2 index. If I 2 was above 30%, a random-effects approach instead of a fixed-effect analysis would be undertaken. If I 2 was over 60%, we would refrain from meta-analysis.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity in the meta-analysis was assessed with the 2 test and the I2 index. If I2 was above 30%, a random-effects approach instead of a fixed-effect analysis would be undertaken. If I2 was over 60%, we would refrain from meta-analysis.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 83%):\n\nBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;The PubMed database was searched. Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nConclusion MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term followup is mandatory to further delineate objective indications.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conclusion: MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term follow-up is mandatory to further delineate objective indications.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nwe augmented the list by searching the reference list of each selected article to find further papers.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[W]e augmented the list by searching the reference list of each selected article to find further papers.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nWe applied tests for interstudy heterogeneity  2 (Q test) and the I 2 statistic to assess the appropriateness of combining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We applied tests for interstudy heterogeneity 2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\n. If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I 2 statistic), a random effect model was used for meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I2 statistic), a random effect model was used for meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nWe applied tests for interstudy heterogeneity  2 (Q test) and the I 2 statistic to assess the appropriateness of combining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We applied tests for interstudy heterogeneity 2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\n. If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I 2 statistic), a random effect model was used for meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;If the results of these tests showed heterogeneity (cutoff of 0.10 or larger for the Q test or N50% heterogeneity with the I2 statistic), a random effect model was used for meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nThe transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pullthrough operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pull-through operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):\n\nthe fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Considering the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nThe transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pullthrough operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The transanal one-stage pull-through procedure (TERPT) has gained worldwide popularity over open and laparoscopic-assisted one-stage techniques in children with Hirschsprungs disease (HD). It offers the advantages of avoiding laparotomy, laparoscopy, scars, abdominal contamination, and adhesions. However, enterocolitis associated with Hirschsprungs disease (HAEC) still remains to be a potentially life-threatening complication after pull-through operation. The reported incidence of HAEC ranges from 4.6 to 54%. This meta-analysis was designed to evaluate postoperative incidence of HAEC following TERPT procedure.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):\n\nthe fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Considering the fact that the preoperative and postoperative management of HD has been similar over the last decade, it is reasonable to consider the TERPT procedure as a contributor to the observed low rate of postoperative HAEC.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nA systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search, as the first LD pullthrough was described in 1994. 14 Combinations of the key words Hirschsprung disease, Duhamel, pull-through, laparoscopic, minimally invasive and open were used. Reference lists were then manually searched for additional studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search, as the first LD pull-through was described in 1994.14 Combinations of the key words Hirschsprung disease, Duhamel, pull-through, laparoscopic, minimally invasive and open were used. Reference lists were then manually searched for additional studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nDespite the introduction of TERPT, the Duhamel technique still remains a relevant procedure favored by surgeons in both the open Duhamel (OD) and laparoscopic Duhamel (LD) forms, particularly for long segment and redo procedures, 10 Its advantages over the Swenson, Soave, and Rehbein techniques include less pelvic dissection (reducing the risk of damage to surrounding structures), a larger anastomosis (reducing the risk of anastomotic stricture), and the formation of a reservoir, making it a favorable option in infants with longer aganglionic segments.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Despite the introduction of TERPT, the Duhamel technique still remains a relevant procedure favored by surgeons in both the open Duhamel (OD) and laparoscopic Duhamel (LD) forms, particularly for long segment and redo procedures,10. Its advantages over the Swenson, Soave, and Rehbein techniques include less pelvic dissection (reducing the risk of damage to surrounding structures), a larger anastomosis (reducing the risk of anastomotic stricture), and the formation of a reservoir, making it a favorable option in infants with longer aganglionic segments.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nA randomeffects analysis model was used for all outcomes,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A random-effects analysis model was used for all outcomes.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.4%):\n\nWe intend to delineate the best initial treatment for achalasia and synthesize the current body of literature on outcomes Keywords  achalasia  pneumatic dilatation  Heller myotomy' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;We intend to delineate the best initial treatment for achalasia and synthesize the current body of literature on outcomes from initial treatment of pediatric achalasia with pneumatic dilatation (PD) versus surgical Heller esophagomyotomy (HM).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.9%):\n\nes A comprehensive search was conducted of MEDLINE/ PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[We conducted a comprehensive search of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nThe laparoscopically-assisted anorectal pullthrough (LAARP) for recto-bladderneck and recto-prostatic anorectal malformations (RB/RP-ARMs) is believed to improve patient outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The laparoscopically-assisted anorectal pull-through (LAARP) for recto-bladderneck and recto-prostatic anorectal malformations (RB/RP-ARMs) is believed to improve patient outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nWe conducted a systematic review to assess the impact of a laparoscopic repair on rates of mucosal prolapse and defection dysfunction of male children born with RB/RPARMs' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We conducted a systematic review to assess the impact of a laparoscopic repair on rates of mucosal prolapse and defection dysfunction of male children born with RB/RP-ARMs.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nThis systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Review and MetaAnalyses (PRISMA) guidelines [7]; a protocol was agreed beforehand by all authors.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [7]; a protocol was agreed beforehand by all authors.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.7%):\n\nds A systematic literature search was conducted using MEDLINE and the Cochrane Library.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;We conducted a systematic literature search was conducted using MEDLINE and the Cochrane Library.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):\n\nCompeting interests None' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Competing interests: None.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nPROSPERO registryCRD42013005698.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[PROSPERO registry-CRD42013005698].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nWe searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I. MeSH/EMTREE terms used were Hirschsprung disease and laparoscopy. Keyword searches included recto-sigmoid, Hirschsprung*, aganglionosis, colon* resection, pull*through, trans*anal, endo*anal, trans*abdominal, biops*, Soave*, Swenson* and Boley*.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I. MeSH/EMTREE terms used were Hirschsprung disease and laparoscopy. Keyword searches included recto-sigmoid, Hirschsprung*, agan-glionosis, colon* resection, pull*through, trans*anal, endo*anal, trans*abdominal, biops*, Soave*, Swenson* and Boley*.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nFunding MK is funded by a National Institute for Health Research Professorship' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Funding: MK is funded by a National Institute for Health Research Professorship.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\ntotal of 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In total, 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.1%):\n\nOutcomes were success of BD, number of BD sessions, number of oesophageal perforations, need for other surgical interventions and mortality.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Outcomes of interest were success of BD, number of BD sessions, number of oesophageal perforations, need for other surgical interventions and mortality.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\ntotal of 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In total, 139 children (81 [58%] male) were included in this review. In total, 401 balloon dilatation sessions were performed (2.9 dilatations per child). Table 1 shows the characteristics of all the studies included in this review.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nAnastomotic strictures occur in 18 30% of patients following surgery for oesophageal atresia [1]. The most common risk factors for developing anastomotic strictures are a tight anastomosis (gap length) or tension of the suture line at the time of anastomosis, type of suture material used, anastomotic leakage, fistula and associated gastrooesophageal reflux [2].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Anastomotic strictures occur in 1830% of patients following surgery for oesophageal atresia [1]. The most common risk factors for developing anastomotic strictures are a tight anastomosis (gap length) or tension of the suture line at the time of anastomosis, type of suture material used, anastomotic leakage, fistula and associated gastro-oesophageal reflux [2].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nSince no eligible studies were identified, the effects of MIS versus open surgery for the treatment of solid intra-thoracic or intraabdominal neoplasms in children remain unclear.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Since no eligible studies were identified, the effects of MIS versus open surgery for the treatment of solid intra-thoracic or intra-abdominal neoplasms in children remain unclear.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nTo ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intraabdominal or intra-thoracic neoplasms in children. The primary outcomes of interest are OS, EFS, port-site metastases and recurrence rate;' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-abdominal or intra-thoracic neoplasms in children. The primary outcomes of interest are OS, EFS, port-site metastases and recurrence rate.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nconducted a systematic review and meta-analysis of studies comparing the PBF and TIP techniques for primary hypospadias repair and determined whether the two techniques had similar reported outcomes.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;To conduct a systematic review and meta-analysis of studies comparing the PBF and TIP techniques for primary hypospadias repair and determine whether the two techniques had similar reported outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nConflicts of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflicts of interest: None.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nConflicts of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflicts of interest: None.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nRecurrence OR Laparoscopy OR contralateral OR Surgery OR Examination) AND (english[Language] OR german[Language]).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;ORRecurrenceORLaparoscopyORcontralateralORSurgeryORExamination) AND (english[Language]ORgerman[Language]).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.9%):\n\n) AND (Incidence' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;) AND (IncidenceOR&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 94.4%):\n\nAbstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;The abstract provides relevant background, objectives, data sources, eligibility criteria, interventions, results, conclusions and implications.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nStatistical heterogeneity was assessed using the I 2 statistics. If the I 2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I 2 value was 50% or more, then the random effects metaanalysis was used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical heterogeneity was assessed using the I2 statistics. If the I2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I2 value was 50% or more, then the random effects meta-analysis was used.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nScientific databases (PubMed, Medline, OVID, ERIC, and Cochrine Collaboration) were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrane Collaboration) were searched&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nScientific databases (PubMed, Medline, OVID, ERIC, and Cochrine Collaboration) were searched using the keywords single port surgery and child. Only compari:tive articles that were published between January 2008 and November 2012 ancl that analysed postoperative pain following SIPES or SL in children were included.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Scientific databases (PubMed, Medline, OVID, ERIC, and Cochrane Collaboration) were searched using the keywords single port surgery and child. Only comparative articles that were published between January 2008 and November 2012 and that analysed postoperative pain following SIPES or SL in children were included.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nit has been speculated that single incsion pediatnc endoscopic surgery (SIPES) in children could result in more postoperative pain given the device size for a child umbilicus.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;It has been speculated that single incision pediatric endoscopic surgery (SIPES) in children could result in more postoperative pain given the device size for a child umbilicus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nOur findings were confirmed by other studies in the literature (Table D.5 According to our systematic review, most of the studies showed no difference or even an advantige of SIPES over SL for postoperative pain.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Our findings were confirmed by other studies in the literature (Table II). According to our systematic review, most of the studies showed no difference or even an advantage of SIPES over SL for postoperative pain.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nStatistical Heterogeneity was assessed using the Chi square test with significance set at P \\ 0.10. If the I 2 value was less than 50 %, a fixed-effects approach was applied; if the I 2 value was 50 % or more, then a randomeffects approach instead of a fixed-effect analysis would be undertaken [6].' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Statistical Heterogeneity was assessed using the Chi square test with significance set at P < 0.10. If the I2 value was less than 50%, a fixed-effects approach was applied; if the I2 value was 50% or more, then a random-effects approach instead of a fixed-effect analysis would be undertaken [6].&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.5%):\n\nHand-searching of the bibliographies of articles and reviews identified was also conducted to ensure c' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;Hand-searching of the bibliographies of articles and reviews identified was also conducted to ensure completeness of the initial electronic searches.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.7%):\n\nDichotomous outcomes were meta-analysed using MantelHaenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were metaanalysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Dichotomous outcomes were meta-analysed using MantelHaenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were meta-analysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nver, the main limitation of the present study includes the lack of prospective randomized controlled trials (RCT) comparing laparoscopic vs. open reduction of pediatric intussusception.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;However, the main limitation of the present study includes the lack of prospective randomized controlled trials (RCT) comparing laparoscopic vs. open reduction of pediatric intussusception.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91%):\n\nManagement of Recurrent Tracheoesophageal Fistulas: A Systematic Review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Title: Management of Recurrent Tracheoesophageal Fistulas: A Systematic Review&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.4%):\n\ne characteristics of the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;Tables 1 and 2 provide characteristics of included studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nsystematic literature search (19552013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[A] systematic literature search (19552013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nWe first considered all studies that showed a population of 1443 children and adolescents (age, 6-17 years; mean age, 14.62 years) who underwent varicocelectomy by laparoscopic (LS) and open techniques (OS)' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We first considered all studies that showed a population of 1443 children and adolescents (age, 6-17 years; mean age, 14.62 years) who underwent varicocelectomy by laparoscopic (LS) and open techniques (OS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nThree doctors reviewed the abstracts. Articles relevant to the topic of the review were selected by consensu' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Three doctors reviewed the abstracts. Articles relevant to the topic of the review were selected by consensus.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):\n\nA systematic review of the literature published after June 1995 was performed in June 2015 in agreement with the PRISMA statement (3).' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;A systematic review of the literature published after 06/1995 was performed in 06/2015 in agreement with the PRISMA statement (3).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nMinimally invasive versus open repair of Bochdalek hernia: a meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):\n\nMethodological Index for Non-Randomized Studies (MINORS) [5]: We used this index to assess the quality of nonrandomized studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;We used the Methodological Index for Non-Randomized Studies (MINORS) [5] to assess the quality of nonrandomized studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nMinimally invasive versus open repair of Bochdalek hernia: a meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 89.6%):\n\nWe searched all publications from August 1998 to March 2012 in the MEDLINE, EMBASE and Cochrane library databases and the Cochrane Controlled Trials Register using different combinations of the following terms: Hirschsprung&#39;s disease, transanal, perineal approach, transabdominal and pull-through.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Original articles published from 1998 to 2012 were searched from Medline, Embase, and Cochrane databases and the Cochrane Controlled Trials Register using different combinations of the following terms: Hirschsprung's disease, transanal, perineal approach, transabdominal and pull-through.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nhed. Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Yes] Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.2%):\n\nns, Collins 34 found that 4% were reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] Conflicts of interest were not reported.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 79.5%):\n\nthe scientific quality of the included studies used appropriately in formulating conclusions?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] The quality of studies was not discussed in formulating conclusions.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.9%):\n\nnor were any designed to compare those managed conservatively' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] The findings were not combined quantitatively.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 80%):\n\nthe status of publication (i.e. grey literature) used as an inclusion criterion?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] The status of publication was not mentioned as an inclusion criterion.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.5%):\n\nthe scientific quality of the included studies assessed and' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] The quality of included studies was not assessed beyond MINORS criteria applied later.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):\n\n? A list of included and excluded studies should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] A list of included and excluded studies was not provided.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):\n\nTable 2 summarizes the main characteristics of the 19 included studies.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Table 2 summarizes the main characteristics of the 19 included studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.8%):\n\nreview protocol was established.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] The review protocol was not mentioned.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 82.1%):\n\npublication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] Publication bias was not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.4%):\n\nA systematic search of the English language literature was conducted using a keyword algorithm (Supplemental Figure 1, http:// links.lww.com/SLA/A928). The search was conducted using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] A systematic search of the English language literature was conducted using a keyword algorithm (Supplemental Figure 1, http://links.lww.com/SLA/A928). The search was conducted using the indexed databases: CINAHL, EMBASE, Medline, and Cochrane Databases, from inception to January 11, 2015.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.5%):\n\nIntroduction / Rationale: Describe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The introduction describes the rationale in context of existing knowledge.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.2%):\n\nTwo reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] The methods state two reviewers extracted data independently.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61%):\n\nmethods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Methods for assessing risk of bias were not described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 50.9%):\n\nwere any designed to compare those managed conservatively' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Summary measures were not combined quantitatively.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.5%):\n\n) simple summary data for each' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Simple summary data were not presented for each study.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61.7%):\n\nDiscussion / Summary of evidence: Summarize the main findings in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The discussion summarizes main findings and relevance.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.7%):\n\n. Inclusion and Exclusion Criteria' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Inclusion and exclusion criteria are specified in Table 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 61%):\n\nrisk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Risk of bias was not presented for individual studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 78%):\n\nTABLE 2. Characteristics of Included Studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Table 2 presents characteristics of included studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.2%):\n\nMethods / Study selection: State the process for selecti' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The methods section describes the process for study selection.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.2%):\n\nsources of funding for' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Sources of funding were not described.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.4%):\n\nTitle: Identify the report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The title identifies it as a systematic review.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.3%):\n\n, the number of individual patients reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] The number of studies at each stage was not reported.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 81.6%):\n\nAbstract / Structured summary: Provide a structured summary' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The abstract provides a structured summary.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.1%):\n\n(Supplemental Figure 1, http:// links.lww.com/SLA/A928). The search' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Supplemental Figure 1 shows the full search strategy.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 76.6%):\n\nIntroduction / Objectives: Provide an explicit statement of questions being addressed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The introduction states the two questions being addressed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.4%):\n\ns / Data items: List and define' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Data items sought were not explicitly listed and defined.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 80%):\n\n/ Risk of bias across studies: Specify any assess' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[NA] Risk of bias across studies was not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.7%):\n\nassessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] Assessment of risk of bias across studies was not done.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.1%):\n\nlimitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Limitations at the study and review levels are discussed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 87.2%):\n\nDiscussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] The discussion provides an interpretation and implications for research.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.3%):\n\nMethods / Information sources: Describe all information sources (e.g., databases' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] The methods section describes the information sources and dates searched.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.7%):\n\ns (meta-analysis was therefore not' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Meta-analyses were not done.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.9%):\n\nreview protocol was established.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] A review protocol was not mentioned.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.5%):\n\ncombining data in quantitative' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] Data were not combined quantitatively.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.1%):\n\nadditional analyses, if done' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[NA] No additional analyses were done.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\n. Conclusion Meta-analysis of the current literature identifies comparable safety and short-term efficacy for robot-assisted laparoscopic fundoplication when compared to conventional laparoscopic fundoplication in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In conclusion, meta-analysis of the current literature identifies comparable safety and short-term efficacy for robot-assisted laparoscopic fundoplication when compared to conventional laparoscopic fundoplication in children.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nIn the RF group, reasons for conversions were due to intraoperative hypotension and arrhythmia (n = 1) [13], technical difficulty in a redo case (n = 1) [13], and unclear anatomy associated with a hiatus hernia (n = 1) [11]. In the LF group, reasons for conversion were due to gastric perforation (n = 1) [13], incidental discovery of a Morgagni hernia (n = 1) [12], instrument problems (n = 1) [12], and technical difficulty in re-do cases (n = 2) [11]' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;In the RF group, reasons for conversions were due to intraoperative hypotension and arrhythmia (n = 1) [13], technical difficulty in a re-do case (n = 1) [13], and unclear anatomy associated with a hiatus hernia (n = 1) [11]. In the LF group, reasons for conversion were due to gastric perforation (n = 1) [13], incidental discovery of a Morgagni hernia (n = 1) [12], instrument problems (n = 1) [12], and technical difficulty in re-do cases (n = 2) [11].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.6%):\n\nThis meta-analysis has identified no significant difference between robot-assisted and conventional laparoscopic fundoplication for short-term outcomes of intra-operative conversion, length of hospital stay, post-operative complications and total operating time' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;This meta-analysis has identified no significant difference between robot-assisted and conventional laparoscopic fundoplication for short-term outcomes of intra-operative conversion, length of hospital stay, post-operative complications and total operating time.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 79.3%):\n\nThe primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword fundoplication, and 3) abstracts of the Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword fundoplication, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\nd placed no restrictions on the language of publication.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;We placed no restrictions on the language of publication.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.8%):\n\nThe search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; Initial search n = 1807 Non-relevant abstracts and duplicates excluded n = 1660 Grey Literature, conference proceedings, reference lists n = 13 Hard copies of papers and/or abstracts obtained. n = 160 Non-English and non-relevant papers excluded. n = 61 Final exclusion for relevance n = 38 excluded Studies included in review n = 61 Citations underwent review n = 99 Figure 1. Flowchart of excluded and included articles STAGED FOWLER-STEPHENS ORCHIOPEXY 2013 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intraabdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13. This strategy was also used with some modifications for Embase.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-abdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13. This strategy was also used with some modifications for Embase.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nHE surgical approach to the high undescended testis can be quite challenging, since the cord structures might be of insufficient length for a tension-free scrotal placement.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;The surgical approach to the high undescended testis can be quite challenging, since the cord structures might be of insufficient length for a tension-free scrotal placement.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 84%):\n\nFigure 2. Forest plot' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;Figures 2-4. Forest plots&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nFor continuous data, we presented mean differences (MDs) with 95 % confidence intervals (CIs). For dichotomous data, we calculated odds ratios (ORs). Statistical heterogeneity in the meta-analysis was assessed with the v 2 test and the I 2 inde' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;For continuous data, we presented mean differences (MDs) with 95% confidence intervals (CIs). For dichotomous data, we calculated odds ratios (ORs). Statistical heterogeneity in the meta-analysis was assessed with the 2 test and the I2 index.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nTables 2 and 3 outlines the primary and secondary outcome results from each study.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nTables 2 and 3 outlines the primary and secondary outcome results from each study.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 34.2%):\n\ny assessment' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Quality assessment not mentioned.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50%):\n\nSIGLE database, dissertations, conference proceeding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Searched multiple databases and cross-referencing.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.7%):\n\nincluded studies assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Only included studies listed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.5%):\n\n. Conflict of interest' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No] Conflicts of interest not reported.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 55.6%):\n\ncumulative meta-analysis reveal' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Used cumulative meta-analysis and relative risk.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.4%):\n\nassessment of relevant articles was independently performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[NA] Quality assessment not performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70%):\n\npublication (i.e. grey literature) used as an inclusion criteri' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Publication status not mentioned as inclusion criteria.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.2%):\n\n? The research question and inclusion criteria s' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] The research question and inclusion criteria are not explicitly stated.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 41.3%):\n\ns independently performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Two authors independently performed full-text assessment.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):\n\n. Study and patients characteristics are presented in Table 1.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Study characteristics presented in Table 1.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.1%):\n\npublication bias assessed?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No] Publication bias not assessed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 78.6%):\n\n/ Additional analyses:' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[NA] No additional analyses.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.2%):\n\ninclusion criteria as described.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Inclusion criteria described in methods.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.8%):\n\n/ Conclusions: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Yes] Conclusions provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.6%):\n\n, databases with dates' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Databases and dates listed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.9%):\n\ns / Protocol and registration' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Protocol not mentioned.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.4%):\n\n/ Limitations: Discuss' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Limitations described in discussion.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52.6%):\n\nObjectives: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Specific objectives not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.6%):\n\nos / Risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Risk of bias not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.9%):\n\nstudy selection an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Study selection shown in flow diagram.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 48%):\n\ns described.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Outcomes described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.9%):\n\ndata extraction Identified' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Data extraction described.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):\n\n. Study and patients characteristics are presented in Table 1.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Yes] Study characteristics presented in Table 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.7%):\n\n/ Structured summary: Provide' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Structured abstract provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.8%):\n\nsearch strategy should be provided.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Full search strategy not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.6%):\n\n/ Rationale: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Rationale described in introduction.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.4%):\n\nestimates an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Pooled estimates shown.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.7%):\n\ncomplication rates an' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Complication rates shown.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.8%):\n\nnot reported,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No] Funding not reported.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):\n\nmeta-analysis was performed.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[NA] No meta-analysis performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.1%):\n\n: Identify the report as a systematic review, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Identified as meta-analysis in title.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68%):\n\nthe relative risk' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Yes] Used relative risk.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.4%):\n\nmain findings' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Main findings summarized.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.6%):\n\nlection process: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Yes] Selection process described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.2%):\n\nbased on their publication status,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of including or excluding studies based on publication status]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):\n\narticles finally met the inclusion criteria and were analyzed in detail.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[18 articles finally met the inclusion criteria and were analyzed in detail.]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.1%):\n\nassessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No assessment of publication bias mentioned]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.7%):\n\nquality of included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of quality assessment of included studies]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.3%):\n\nduplicate study selection and data extraction?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of duplicate study selection or data extraction]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.5%):\n\nconflict of interest' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of conflicts of interest]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.5%):\n\nData extracted from included articles were study' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Data extracted included study details and patient demographics and outcomes]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.9%):\n\nStudy characteristics: For eac' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Study characteristics described in text and tables]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nOpen Versus Transanal Pull-Through for Hirschsprung Disease: A Systematic Review of Long-Term Outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Open Versus Transanal Pull-Through for Hirschsprung Disease: A Systematic Review of Long-Term Outcome]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.8%):\n\narticles finally met the inclusion criteria' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[18 articles finally met the inclusion criteria]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.9%):\n\nnt full electronic search strategy' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Keywords provided but no full search strategy]&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 76.5%):\n\n/ Additional analyses: Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No additional analyses performed]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):\n\nOdds ratio (OR) with 95% confidence interval (CI) were calculated.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;[Odds ratios with 95% confidence intervals calculated]&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 95.7%):\n\nny assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;[No assessment of risk of bias across studies]&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 92.9%):\n\n/ Risk of bias across studies: Specify any assessment' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[No risk of bias assessment]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.6%):\n\nadditional analyses (e.g., sensi' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No additional analyses mentioned]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 30%):\n\nPresent d' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Pooled odds ratios presented]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 57.7%):\n\nization of the proximal colo' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[No mention of a protocol]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.8%):\n\nnce: Summarize the main findings in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Conclusions summarize main findings and interpretation]&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 85.2%):\n\nbackground; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Abstract with background, objectives, data sources, eligibility criteria, methods, results, limitations, and conclusions]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.8%):\n\nLimitations: Discuss' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Limitations described in discussion]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.8%):\n\nfunding sources)' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No mention of funding sources]&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 93.5%):\n\nIntroduction / Rationale: Describe the rationale for the review in the context' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Introduction describes rationale and context]&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):\n\nConclusions: Provide a general interpretation of the results in the context of other evidence, and implications' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;[Conclusions include overall interpretation and implications]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.9%):\n\nchsprung and outcome. Reference lists' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Described PubMed search and checking reference lists]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.2%):\n\nny assessment of risk of bias that' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[No assessment of risk of bias mentioned]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.5%):\n\nincluded in this study. Exclusion criteria we' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;[Inclusion and exclusion criteria described]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.2%):\n\nStudy selection: State the process' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Flowchart provided of study selection process]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):\n\nresults: Present' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;[Results presented in text and tables]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 77%):\n\nntrolled study evaluating the long-term outcome of OPEN surgery compared with L-TERPT/TERPT.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;[Introduction states examining long-term outcome of OPEN vs L-TERPT/TERPT]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):\n\nConflict of interest None.' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Conflict of interest: None.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\npublications dealing with comparison of LO and OO for the treatment of pediatric NPT were considered to be eligible for inclusion in the analysis. Eleven of these studies were subsequently excluded for only comparing the diagnosis of NPT,' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;Eighteen publications dealing with comparison of LO and OO for the treatment of pediatric NPT were considered to be eligible for inclusion in the analysis. Eleven of these studies were subsequently excluded for only comparing the diagnosis of NPT.&quot;<\/span>"],[99.2481203007519,96.4788732394366,97.8208232445521,98.7654320987654,65.1452282157676,95.9349593495935,99.7214484679666,99.2217898832685,98.7124463519313,99.5245641838352,99.2610837438424,98.5,99.5016611295681,98.3805668016194,98.7951807228916,99.4818652849741,56.078431372549,99.5405819295559,98.8416988416988,98.0392156862745,99.0291262135922,98.2142857142857,97.5903614457831,97.6923076923077,98.5294117647059,97.4842767295598,97.2477064220183,97.9310344827586,96.4705882352941,97.2222222222222,97.3684210526316,98.75,97.6,97.8494623655914,95.2380952380952,98.8636363636364,99.746835443038,99.0909090909091,98.314606741573,97.9865771812081,97.9452054794521,98.0519480519481,98.6885245901639,98.159509202454,97.841726618705,97.5757575757576,98.2954545454545,94.5205479452055,86.1271676300578,65.2542372881356,65.2542372881356,99.7899159663866,99.581589958159,99.6268656716418,98.989898989899,98.4962406015038,99.4652406417112,84.9609375,99.8947368421053,99.5121951219512,99.3506493506494,99.6491228070175,97.9166666666667,99.1379310344828,99.1869918699187,99.5934959349593,99.4011976047904,99.6062992125984,82.962962962963,99.0990990990991,99.0384615384615,98.4615384615385,98.9304812834225,98.4615384615385,98.9304812834225,99.8384491114701,95.2173913043478,99.8384491114701,95.2173913043478,99.7946611909651,99.8207885304659,98.2758620689655,72.4279835390947,91.9463087248322,99.4444444444444,99.4186046511628,99.492385786802,88.659793814433,92.3076923076923,97.1428571428571,99.7706422018349,97.5,99.1379310344828,92.1052631578947,99.1379310344828,99.7252747252747,99.4444444444444,99.625468164794,98.9949748743718,96.4285714285714,96.4285714285714,98.1308411214953,88.8888888888889,94.4444444444444,99.5594713656388,98.9130434782609,99.0536277602524,98.3050847457627,98.1220657276995,99.6621621621622,68.4563758389262,99.6655518394649,97.8835978835979,91.025641025641,64.406779661017,98.6238532110092,99.5169082125604,97.3214285714286,96.9230769230769,98.6842105263158,90.8333333333333,98.6842105263158,89.5973154362416,98.3957219251337,62.2222222222222,79.4520547945205,54.9019607843137,80,49.4505494505495,87.0967741935484,93.5064935064935,62.7906976744186,82.051282051282,63.3898305084746,72.5,67.1641791044776,61.0169491525424,50.9090909090909,52.5423728813559,61.6666666666667,54.6875,61.0169491525424,77.9661016949153,63.2352941176471,51.1627906976744,77.3584905660377,60.3448275862069,81.6326530612245,66.1016949152542,76.5625,48.3870967741936,80,71.6666666666667,65.0793650793651,87.1794871794872,63.2911392405063,72.7272727272727,65.8536585365854,53.4883720930233,71.0526315789474,98.2222222222222,99.562363238512,99.618320610687,79.296875,96.4912280701754,99.8214285714286,99.4252873563218,84,98.7654320987654,97.5609756097561,97.5609756097561,34.2105263157895,50,64.7058823529412,57.5,55.5555555555556,68.4210526315789,70,63.1578947368421,41.2698412698413,91.8367346938776,77.1428571428572,78.5714285714286,65.2173913043478,77.7777777777778,57.5757575757576,67.8571428571429,52.3809523809524,52.6315789473684,51.6129032258064,40.9090909090909,48,71.875,91.8367346938776,65.7142857142857,71.7948717948718,47.6190476190476,41.3793103448276,67.741935483871,53.8461538461538,78.125,65.1162790697674,68,48.3870967741936,70.5882352941176,39.1891891891892,96.1038961038961,71.1111111111111,53.7037037037037,73.3333333333333,59.4594594594595,45.4545454545455,51.9230769230769,99.0291262135922,93.75,48.936170212766,76.4705882352941,96.2962962962963,95.6521739130435,92.8571428571429,70.5882352941176,30,57.6923076923077,51.7857142857143,85.2459016393443,56.7567567567568,54.8387096774194,93.4782608695652,88.5245901639344,51.8518518518519,73.1707317073171,70.4545454545455,53.1914893617021,42.1052631578947,77.027027027027,96.2962962962963,96.7611336032389]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>Author & Year<\/th>\n      <th>Source<\/th>\n      <th>Quote with deviation<\/th>\n      <th>Similarity<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","order":[[3,"desc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 1, 3, \",\", \".\", null);\n  }"},{"visible":false,"targets":1},{"className":"dt-right","targets":3}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
</div>
<div id="llm-prompt" class="section level3">
<h3>LLM prompt</h3>
<ul>
<li>Model: <a
href="https://www.anthropic.com/index/claude-2">Claude-2</a></li>
<li>Temperature: <code>0</code></li>
<li>Briefing derived from: <a
href="https://doi.org/10.1371/journal.pone.0175213">Cullis 2017</a>
Supporting information: <a
href="https://doi.org/10.1371/journal.pone.0175213.s004">S1
Dataset</a></li>
</ul>
<div id="system-prompt" class="section level4">
<h4>System prompt</h4>
<pre>
You are an expert in systematic reviews and are tasked to assess the methodological quality of a systematic review with the AMSTAR tool and its reporting quality with the PRISMA tool based on the full text of its publication. AMSTAR and PRISMA consist of the following items:

&lt;AMSTAR&gt;
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.
A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.
A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.
A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.
A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.
A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies..
&lt;/AMSTAR&gt;
&lt;PRISMA&gt;
P1. Title: Identify the report as a systematic review, meta-analysis, or both.
P2. Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
P3. Introduction / Rationale: Describe the rationale for the review in the context of what is already known.
P4. Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
P5. Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
P6. Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
P7. Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
P8. Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
P9. Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
P10. Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
P11. Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
P12. Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
P13. Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).
P14. Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
P15. Methdos / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
P16. Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
P17. Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
P18. Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
P19. Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
P20. Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
P21. Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.
P22. Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).
P23. Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
P24. Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
P25. Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
P26. Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.
P27. Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
&lt;/PRISMA&gt;

 
</pre>
</div>
<div id="user-prompt" class="section level4">
<h4>User prompt</h4>
<pre>
This is the full text to be assessed:
&lt;FULLTEXT&gt;
%FULLTEXT%
&lt;/FULLTEXT&gt;

For each of the 11 AMSTAR questions (A1 to A11) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond to the question with either "[Yes]" if adequate, "[No]" if inadequate, or "[NA]" if not applicable or not relevant to the text (for example, combining data in quantitative synthesis (A9) or assessing publication bias (A11) in the context of a systematic review without a meta-analysis).

For each of the PRISMA items (P1 to P27) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond with either "[Yes]" if the item was reported, "[No]" if not reported, or "[NA]" if not applicable (for example, items P14, P15, P16, P21, P22, P23 in the context of a systematic review without a meta-analysis).

Before stopping, make sure you've processed all 11 AMSTAR questions and 27 PRISMA items. Do not provide a final summary paragraph in the end.
 
</pre>
</div>
</div>
</div>

</div>

<script>
$(document).ready(function() {
  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed table-sm');

  // initialize mathjax

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460,
    resize_reload: true
  });
  var navbar = $(".navbar").first();
  var body = $("body").first();
  var sidebar = $(".section.sidebar").first();
  function addNavbarPadding() {
    var navHeight = navbar.outerHeight();
    body.css("padding-top", (navHeight + 8) + "px");
    sidebar.css("top", navHeight + "px");
    var resizeEvent = window.document.createEvent("UIEvents");
    resizeEvent.initUIEvent("resize", true, false, window, 0);
    window.dispatchEvent(resizeEvent);
  }
  if (!window.Shiny) setTimeout(addNavbarPadding, 100);
  $(document).on("shiny:idle", function() {
    setTimeout(addNavbarPadding, 50);
  });
});
</script>

</body>
</html>
